<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroimmune Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroimmune Pharmacol</journal-id><journal-title-group><journal-title>Journal of Neuroimmune Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">1557-1890</issn><issn pub-type="epub">1557-1904</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7463108</article-id><article-id pub-id-type="publisher-id">9941</article-id><article-id pub-id-type="doi">10.1007/s11481-020-09941-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Invited Review</subject></subj-group></article-categories><title-group><article-title>Opioid and neuroHIV Comorbidity &#x02013; Current and Future Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fitting</surname><given-names>Sylvia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>McRae</surname><given-names>MaryPeace</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7886-0332</contrib-id><name><surname>Hauser</surname><given-names>Kurt F.</given-names></name><address><email>kurt.hauser@vcuhealth.org</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Department of Psychology and Neuroscience, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, NC 27599-3270 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>Richmond, VA 23298 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Pharmacology and Toxicology, School of Medicine, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>1217 East Marshall Street, Richmond, VA 23298-0613 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Anatomy and Neurobiology, School of Medicine, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>Richmond, VA 23298-0709 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Institute for Drug and Alcohol Studies, </institution><institution>Virginia Commonwealth University, </institution></institution-wrap>203 East Cary Street, Richmond, VA 23298-0059 USA </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>9</month><year>2020</year></pub-date><fpage>1</fpage><lpage>44</lpage><history><date date-type="received"><day>26</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">With the current national opioid crisis, it is critical to examine the mechanisms underlying pathophysiologic interactions between human immunodeficiency virus (HIV) and opioids in the central nervous system (CNS). Recent advances in experimental models, methodology, and our understanding of disease processes at the molecular and cellular levels reveal opioid-HIV interactions with increasing clarity. However, despite the substantial new insight, the unique impact of opioids on the severity, progression, and prognosis of neuroHIV and HIV-associated neurocognitive disorders (HAND) are not fully understood. In this review, we explore, in detail, what is currently known about mechanisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and &#x003bc;-opioid receptor (MOR) and HIV chemokine co-receptor interactions on the comorbidity. Lastly, we present topics that need to be considered in the future to better understand the unique contributions of opioids to the pathophysiology of neuroHIV.</p><p id="Par2"><fig position="anchor" id="Figa"><label>Graphical Abstract</label><caption><p>Blood-brain barrier and the neurovascular unit. With HIV and opiate co-exposure (represented below the dotted line), there is breakdown of tight junction proteins and increased leakage of paracellular compounds into the brain. Despite this, opiate exposure selectively increases the expression of some efflux transporters, thereby restricting brain penetration of specific drugs.</p></caption><graphic position="anchor" xlink:href="11481_2020_9941_Figa_HTML" id="MO1"/></fig></p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antiretroviral therapy</kwd><kwd>Astrocyte</kwd><kwd>Blood-brain barrier</kwd><kwd>Buprenorphine</kwd><kwd>C-C motif chemokine receptor 5 (CCR5) </kwd><kwd>COVID-19</kwd><kwd>Cytochrome P450 3A4 (CYP 3A4)</kwd><kwd>Endogenous opioid system of peptides and receptors</kwd><kwd>Functional selectivity/biased agonism</kwd><kwd>HIV-associated neurocognitive disorders</kwd><kwd>Maladaptive neuroplasticity</kwd><kwd>Methadone</kwd><kwd>Microglia</kwd><kwd>&#x003bc;-Opioid receptor (<italic>OPRM1</italic>) </kwd><kwd>neuroHIV</kwd><kwd>Oligodendroglia</kwd><kwd>P-glycoprotein</kwd><kwd>Pro-brain-derived neurotrophic factor (pro-BDNF) </kwd><kwd>Synaptodendritic degeneration</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>R21 DA045630</award-id><award-id>R01 DA034231</award-id><award-id>R01 DA044855</award-id><award-id>R01 DA045588</award-id><award-id>R01 DA018633</award-id><award-id>R01 DA045596</award-id><award-id>R01 DA044939</award-id><principal-award-recipient><name><surname>Fitting</surname><given-names>Sylvia</given-names></name><name><surname>McRae</surname><given-names>MaryPeace</given-names></name><name><surname>Hauser</surname><given-names>Kurt F.</given-names></name></principal-award-recipient></award-group></funding-group></article-meta></front><body><sec id="Sec1"><title>Overview</title><sec id="Sec2"><title>The Opioid Crisis</title><p id="Par3">Opioid abuse in the United States (U.S.) has reached catastrophic levels. According to the latest World Drug Report, 53.4 million people worldwide used opioids in 2017, which is 56% higher than in the previous year (UNODC <xref ref-type="bibr" rid="CR517">2019a</xref>). North America remains the region with the highest non-medical use of opioids with a staggering 4% of the population aged 15&#x02013;64 using opioids (UNODC <xref ref-type="bibr" rid="CR517">2019a</xref>, <xref ref-type="bibr" rid="CR519">c</xref>). In 2017, the burden of opioid use in the U.S. had accounted for 42 million healthy years of life lost due to premature death and disability (Institute for Health Metrics and Evaluation <xref ref-type="bibr" rid="CR147">2017</xref>; UNODC <xref ref-type="bibr" rid="CR517">2019a</xref>). During 2017, there were 70,237 overdose related deaths, out of which 47,600 (67.8%) were caused by opioids, which was a 12% increase from 2016 (Scholl et al. <xref ref-type="bibr" rid="CR456">2018</xref>; UNODC <xref ref-type="bibr" rid="CR519">2019c</xref>). The Centers of Disease Control and Prevention (CDC) reports that on average 130 Americans die from an opioid overdose each day (CDC <xref ref-type="bibr" rid="CR77">2017</xref>). Due to the constant rise in deaths involving opioids, the U.S. Government declared the opioid crisis/epidemic a public health emergency in 2017 (U.S. Department of Health and Human Services <xref ref-type="bibr" rid="CR459">2017</xref>). Injection drug use increases the likelihood of contracting human immunodeficiency virus (HIV) and drug abuse and HIV have long been described as interrelated epidemics (Swan <xref ref-type="bibr" rid="CR497">1997</xref>; Leshner <xref ref-type="bibr" rid="CR280">1998</xref>; Nath et al. <xref ref-type="bibr" rid="CR359">1999</xref>, <xref ref-type="bibr" rid="CR362">2002</xref>). Despite this understanding, opioid use disorder (OUD) and HIV remain a huge public health concern (Strathdee and Beyrer <xref ref-type="bibr" rid="CR488">2015</xref>; Peters et al. <xref ref-type="bibr" rid="CR391">2016</xref>). In fact, the opioid crisis is seen as a major roadblock in several aspects of public health, including thwarting the goal of eliminating HIV within the next decade (Fauci et al. <xref ref-type="bibr" rid="CR152">2019</xref>; Lerner and Fauci <xref ref-type="bibr" rid="CR279">2019</xref>).</p><p id="Par4">OUD is also likely to exacerbate many negative aspects of the COVID-19 pandemic (Alexander et al. <xref ref-type="bibr" rid="CR5">2020</xref>; Becker and Fiellin <xref ref-type="bibr" rid="CR32">2020</xref>; NIDA <xref ref-type="bibr" rid="CR363">2020</xref>; Wakeman et al. <xref ref-type="bibr" rid="CR532">2020</xref>). Not only are individuals with OUD more vulnerable to SARS-CoV-2 and liable to spread the infection, social-distancing practices create isolation, despair, and economic hardships, heightening opioid abuse (with inherent respiratory depression depending on the amount of tolerance developed) and the probability of overdose (Becker and Fiellin <xref ref-type="bibr" rid="CR32">2020</xref>; Wakeman et al. <xref ref-type="bibr" rid="CR532">2020</xref>). By virtue of its greater safety profile and decreased likelihood for abuse (Bell and Strang <xref ref-type="bibr" rid="CR35">2020</xref>), the use of buprenorphine via telemedicine has become advantageous for managing OUD during the COVID-19 pandemic (Leppla and Gross <xref ref-type="bibr" rid="CR278">2020</xref>; Samuels et al. <xref ref-type="bibr" rid="CR450">2020</xref>) but presents new challenges (Khatri and Perrone <xref ref-type="bibr" rid="CR233">2020</xref>).</p><p id="Par5">The current opioid crisis did not happen quickly; in fact, it has been described as occurring in three phases. The first phase began in the late 1990s with an increase in the number of prescription opioids. This led to overdose deaths that were attributable to natural and semi-synthetic opioids, such as methadone (Kolodyny et al. <xref ref-type="bibr" rid="CR247">2015</xref>; CDC <xref ref-type="bibr" rid="CR77">2017</xref>). The second phase began in 2010 in which heroin took the lead as the principal cause of overdose deaths. The most recent, third wave, began in 2013 in which highly potent synthetic opioids, such as fentanyl and its analogs became the main cause of mortality (Kolodyny et al. <xref ref-type="bibr" rid="CR247">2015</xref>; CDC <xref ref-type="bibr" rid="CR77">2017</xref>). The entry of fentanyl and its analogs into the clandestine market has changed the dynamics of the opioid market in the U.S. The synthetic opioids, such as fentanyl, are several orders of magnitude more potent than morphine, easily smuggled, and frequently and inconsistently mixed with lower quality drugs increasing the probability of overdosing. According to the National Forensic Laboratory Information System of the U.S. Drug Enforcement Administration (DEA), fentanyl accounted for one-third of the illicit opioids seized in 2017 (UNODC <xref ref-type="bibr" rid="CR519">2019c</xref>) and has become a global problem (UNODC <xref ref-type="bibr" rid="CR518">2019b</xref>).</p></sec><sec id="Sec3"><title>The Pathophysiology of Opioid Abuse</title><p id="Par6">The effects of opioid abuse on the central nervous system (CNS) have been extensively examined. Immediate effects of opioids result in decreased levels of consciousness, sedation (Collett <xref ref-type="bibr" rid="CR102">1998</xref>; Thompson <xref ref-type="bibr" rid="CR505">2000</xref>; Indelicato and Portenoy <xref ref-type="bibr" rid="CR220">2002</xref>), drowsiness, and sleep disturbances (Moore and Dimsdale <xref ref-type="bibr" rid="CR344">2002</xref>; Bourne and Mills <xref ref-type="bibr" rid="CR54">2004</xref>; Qureshi and Lee-Chiong <xref ref-type="bibr" rid="CR413">2004</xref>). While acute opioid exposure can impair cognition in healthy subjects (Lawlor <xref ref-type="bibr" rid="CR270">2002</xref>; Ersek et al. <xref ref-type="bibr" rid="CR144">2004</xref>), enduring cognitive and psychomotor deficits occur with chronic opioid use (Sjogren et al. <xref ref-type="bibr" rid="CR470">2000</xref>; Dublin et al. <xref ref-type="bibr" rid="CR121">2015</xref>; Roberts et al. <xref ref-type="bibr" rid="CR430">2018</xref>; Wollman et al. <xref ref-type="bibr" rid="CR544">2019</xref>; Serafini et al. <xref ref-type="bibr" rid="CR460">2020</xref>), including altered pain perception (opioid-induced hyperalgesia), dysregulated reward/saliency processing, hyperkatifeia, and epigenetic changes, which can persist years following abstinence (Ersche et al. <xref ref-type="bibr" rid="CR143">2006</xref>; Browne et al. <xref ref-type="bibr" rid="CR56">2020</xref>). The behavioral changes seen with long-term opioid use are accompanied by lasting structural and epigenetic (e.g., altered DNA methylation and expression of non-coding RNAs) alterations in brain regions implicated in mood, reward, and motivation (Upadhyay et al. <xref ref-type="bibr" rid="CR520">2010</xref>; Dublin et al. <xref ref-type="bibr" rid="CR121">2015</xref>; Volkow and Morales <xref ref-type="bibr" rid="CR529">2015</xref>; Koob and Volkow <xref ref-type="bibr" rid="CR250">2016</xref>; Serafini et al. <xref ref-type="bibr" rid="CR460">2020</xref>).</p><p id="Par7">Up to 90% of post-mortem tissues sampled from opiate abusers display brain edema (Buttner <xref ref-type="bibr" rid="CR64">2011</xref>), astrogliosis and microgliosis especially in the hippocampus (Oehmichen et al. <xref ref-type="bibr" rid="CR374">1996</xref>), white matter, and subcortical regions at autopsy (Tomlinson et al. <xref ref-type="bibr" rid="CR507">1999</xref>; Anthony et al. <xref ref-type="bibr" rid="CR11">2005</xref>; Buttner et al. <xref ref-type="bibr" rid="CR66">2006</xref>; Buttner and Weis <xref ref-type="bibr" rid="CR65">2006</xref>). The reactive gliosis is accompanied by increases in proinflammatory cytokines and inflammatory mediators, including TNF-&#x003b1;, IL-1&#x003b2;, and nitric oxide synthase (NOS) (Dyuizen and Lamash <xref ref-type="bibr" rid="CR126">2009</xref>). Opiates especially drive the enhanced activation of heme-oxygenase, NOS, and cyclic GMP-dependent-protein kinase (Liang and Clark <xref ref-type="bibr" rid="CR287">2004</xref>) and production of reactive nitrogen species (RNS) such as peroxynitrite (Salvemini <xref ref-type="bibr" rid="CR447">2009</xref>), and resultant nitrosative damage (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>). Nitrosative damage is an important endpoint for opiate exposure (Pasternak et al. <xref ref-type="bibr" rid="CR382">1995</xref>; Liang and Clark <xref ref-type="bibr" rid="CR287">2004</xref>; Salvemini <xref ref-type="bibr" rid="CR447">2009</xref>) and key site of convergence for the oxidative stress accompanying HIV protein exposure (Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>; McLane et al. <xref ref-type="bibr" rid="CR328">2018</xref>).</p><p id="Par8">For delayed heroin overdose death after a survival period of 5&#x000a0;h or more, studies report neurovascular disorders, hypoxic ischemic leukoencephalopathy, and region-specific atrophy with neuronal losses that can include the hippocampal formation, the cerebellar Purkinje cell layer and olivary nucleus (Protass <xref ref-type="bibr" rid="CR405">1971</xref>; Ginsberg et al. <xref ref-type="bibr" rid="CR178">1976</xref>; Gosztonyi et al. <xref ref-type="bibr" rid="CR185">1993</xref>), as well as other areas (Buttner <xref ref-type="bibr" rid="CR64">2011</xref>; Cadet et al. <xref ref-type="bibr" rid="CR69">2014</xref>). Loss of neurons and synaptic connections is supported by postmortem reports of smaller mean relative volumes in various brain regions in individuals with OUD, including cortical areas (Danos et al. <xref ref-type="bibr" rid="CR110">1998</xref>; Pezawas et al. <xref ref-type="bibr" rid="CR398">1998</xref>), the basal ganglia (Muller et al. <xref ref-type="bibr" rid="CR348">2015</xref>, <xref ref-type="bibr" rid="CR350">2019</xref>), prefrontal cortex (Cadet et al. <xref ref-type="bibr" rid="CR69">2014</xref>), and hypothalamus (Muller et al. <xref ref-type="bibr" rid="CR349">2018</xref>). Interestingly, leukoencephalopathy, atrophy (Cadet et al. <xref ref-type="bibr" rid="CR69">2014</xref>), and increased hyperphosphorylated tau-containing neurofibrillary tangles are reported with chronic opiate abuse compared to age-matched controls (Ramage et al. <xref ref-type="bibr" rid="CR417">2005</xref>; Anthony et al. <xref ref-type="bibr" rid="CR13">2010</xref>; Kovacs et al. <xref ref-type="bibr" rid="CR252">2015</xref>). Glycogen synthase kinase 3 &#x003b1; or &#x003b2; (GSK-3&#x003b1;/&#x003b2;; the pan antibody used in this study does not discern &#x003b1; from &#x003b2; isoforms) and/or cyclin-dependent kinase-5 (Cdk-5) are increased in the frontal and temporal cortices, the locus coeruleus, and the hippocampus, respectively, and correlate with microgliosis (Anthony et al. <xref ref-type="bibr" rid="CR13">2010</xref>). Further, more prolonged use increases the risk of accelerated age-related and even Alzheimer&#x02019;s-like pathological changes (Ramage et al. <xref ref-type="bibr" rid="CR417">2005</xref>; Anthony et al. <xref ref-type="bibr" rid="CR13">2010</xref>; Kovacs et al. <xref ref-type="bibr" rid="CR252">2015</xref>) and cognitive impairment (Gruber et al. <xref ref-type="bibr" rid="CR191">2007</xref>).</p><p id="Par9">Moreover, heroin use is associated with symmetric T2 and fluid-attenuated inversion recovery (FLAIR) hyperintense white matter lesions of the CNS using magnetic resonance imaging (MRI), which coincide with increased microgliosis and inflammation at the same sites (Upadhyay et al. <xref ref-type="bibr" rid="CR520">2010</xref>; Bora et al. <xref ref-type="bibr" rid="CR52">2012</xref>; Qiu et al. <xref ref-type="bibr" rid="CR412">2013</xref>; Alaee et al. <xref ref-type="bibr" rid="CR3">2014</xref>; Li et al. <xref ref-type="bibr" rid="CR285">2016</xref>; Shrot et al. <xref ref-type="bibr" rid="CR466">2017</xref>). Although a few studies have started to examine opiate-HIV interactions in white matter (see below), we predict that the interactive effects on myelin dysregulation will significantly worsen CNS outcomes.</p><p id="Par10">Preclinical studies indicate opioid-induced neuroimmune signaling alter the saliency of opioid reward and physical dependence (Narita et al. <xref ref-type="bibr" rid="CR355">2006</xref>; Hutchinson et al. <xref ref-type="bibr" rid="CR215">2008</xref>, <xref ref-type="bibr" rid="CR216">2009</xref>). Direct injections of astrocyte-conditioned medium containing cytokines into the nucleus accumbens (NAc) increase morphine conditioned place preference (Narita et al. <xref ref-type="bibr" rid="CR355">2006</xref>). Drugs reported to selectively attenuate glial inflammation block morphine conditioned place preference and attenuate symptoms of opioid withdrawal (Narita et al. <xref ref-type="bibr" rid="CR355">2006</xref>; Hutchinson et al. <xref ref-type="bibr" rid="CR216">2009</xref>; Liu et al. <xref ref-type="bibr" rid="CR292">2010</xref>). &#x003bc; (MOR), &#x003b4; (DOR), and &#x003ba; (KOR) opioid receptors are expressed by subsets of astrocytes and microglia (Stiene-Martin and Hauser <xref ref-type="bibr" rid="CR484">1991</xref>; Eriksson et al. <xref ref-type="bibr" rid="CR142">1992</xref>; Stiene-Martin et al. <xref ref-type="bibr" rid="CR485">1993</xref>; Ruzicka et al. <xref ref-type="bibr" rid="CR443">1995</xref>; Gurwell et al. <xref ref-type="bibr" rid="CR196">1993</xref>; Hauser et al. <xref ref-type="bibr" rid="CR205">1996</xref>; Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR514">2008</xref>; Maduna et al. <xref ref-type="bibr" rid="CR300">2018</xref>) and are involved in opioid tolerance and dependence to varying degrees (Kieffer and Gaveriaux-Ruff <xref ref-type="bibr" rid="CR236">2002</xref>; Berger and Whistler <xref ref-type="bibr" rid="CR41">2010</xref>; Morgan and Christie <xref ref-type="bibr" rid="CR346">2011</xref>). Despite some reports of morphine triggering immune activation via Toll-like receptor 4 (TLR4) (Terashvili et al. <xref ref-type="bibr" rid="CR503">2008</xref>; Hutchinson et al. <xref ref-type="bibr" rid="CR217">2010</xref>; Coller and Hutchinson <xref ref-type="bibr" rid="CR101">2012</xref>; Hutchinson et al. <xref ref-type="bibr" rid="CR218">2012</xref>; Theberge et al. <xref ref-type="bibr" rid="CR504">2013</xref>; Lacagnina et al. <xref ref-type="bibr" rid="CR266">2017</xref>) by binding to a myeloid differentiation protein-2 intermediary (Wang et al. <xref ref-type="bibr" rid="CR536">2012</xref>), this is contrary to the typical actions of opiates, which by themselves (and in the absence of a priming event such as HIV co-exposure) tend to suppress immune function (Eisenstein <xref ref-type="bibr" rid="CR129">2019</xref>). A vast majority of the immune, antinociceptive, and other physiological effects of opioids are mediated by opioid receptors per se and not TLR4 (Hu et al. <xref ref-type="bibr" rid="CR212">2011</xref>; Fukagawa et al. <xref ref-type="bibr" rid="CR166">2013</xref>; Stevens et al. <xref ref-type="bibr" rid="CR483">2013</xref>; Mattioli et al. <xref ref-type="bibr" rid="CR319">2014</xref>; Eisenstein <xref ref-type="bibr" rid="CR129">2019</xref>).</p><p id="Par11">Overall, the findings indicate that immune signaling plays a critical role in the pathophysiology of OUD and associated physical dependence. How opioids effect neuroHIV, as well as how opioid abuse and dependence are altered by neuroHIV or whether opioid-HIV interactions result in a unique disease state are discussed.</p></sec></sec><sec id="Sec4"><title>HIV Neuropathology in the Context of Opioid Use Disorder &#x02013; Clinical and Preclinical Evidence</title><sec id="Sec5"><title>Preclinical and Clinical Findings&#x02014;a Complicated Picture</title><p id="Par12">People infected with HIV (PWH) with OUD have an increased incidence of neuroHIV and CNS complications (Bell et al. <xref ref-type="bibr" rid="CR36">1998</xref>; Nath et al. <xref ref-type="bibr" rid="CR359">1999</xref>, <xref ref-type="bibr" rid="CR360">2000a</xref>, <xref ref-type="bibr" rid="CR362">2002</xref>; Anthony et al. <xref ref-type="bibr" rid="CR12">2008</xref>; Meyer et al. <xref ref-type="bibr" rid="CR336">2013</xref>; Smith et al. <xref ref-type="bibr" rid="CR474">2014</xref>). Injection drug use increases the probability of contracting HIV (Nath et al. <xref ref-type="bibr" rid="CR359">1999</xref>) and opioid drugs intrinsically alter the pathogenesis of HIV. PWH who develop intractable pain syndromes related to peripheral neuropathies often receive opioid drugs for treatment (Mirsattari et al. <xref ref-type="bibr" rid="CR339">1999</xref>; Denis et al. <xref ref-type="bibr" rid="CR113">2019</xref>). PWH who misuse opioids are more likely to undertake risky sexual behavior and are less likely to adhere to combined antiretroviral (ARV) therapy (cART) regimens (Lemons et al. <xref ref-type="bibr" rid="CR276">2019</xref>). Opioid receptors are widely expressed on immune cells and opioids can modulate immune function (Donahoe and Falek <xref ref-type="bibr" rid="CR117">1988</xref>; Plotnikoff <xref ref-type="bibr" rid="CR401">1988</xref>; Rouveix <xref ref-type="bibr" rid="CR437">1992</xref>; Adler et al. <xref ref-type="bibr" rid="CR2">1993</xref>; Carr and Serou <xref ref-type="bibr" rid="CR74">1995</xref>; Carr et al. <xref ref-type="bibr" rid="CR75">1996</xref>; Sheng et al. <xref ref-type="bibr" rid="CR463">1997</xref>; Banerjee et al. <xref ref-type="bibr" rid="CR28">2011</xref>; Purohit et al. <xref ref-type="bibr" rid="CR409">2012</xref>), which typically (but not always) result in immune suppression (Wybran et al. <xref ref-type="bibr" rid="CR548">1979</xref>; McDonough et al. <xref ref-type="bibr" rid="CR325">1980</xref>, <xref ref-type="bibr" rid="CR326">1981</xref>; Donahoe and Falek <xref ref-type="bibr" rid="CR117">1988</xref>; Donahoe et al. <xref ref-type="bibr" rid="CR119">1991</xref>; Falek et al. <xref ref-type="bibr" rid="CR149">1991</xref>; Novick et al. <xref ref-type="bibr" rid="CR372">1991</xref>; Chao et al. <xref ref-type="bibr" rid="CR81">1996a</xref>; Peterson et al. <xref ref-type="bibr" rid="CR395">1998</xref>; Rogers and Peterson <xref ref-type="bibr" rid="CR434">2003</xref>; Stein et al. <xref ref-type="bibr" rid="CR482">2003</xref>; Roy et al. <xref ref-type="bibr" rid="CR438">2006</xref>; Rittner et al. <xref ref-type="bibr" rid="CR425">2008</xref>). The &#x0201c;opiate cofactor hypothesis&#x0201d; proposes opioids contribute directly to the pathogenesis of acquired immune deficiency syndrome (AIDS) (Donahoe and Vlahov <xref ref-type="bibr" rid="CR118">1998</xref>), in part, because MOR activation can increase HIV replication in immune cells (Peterson et al. <xref ref-type="bibr" rid="CR392">1990</xref>, <xref ref-type="bibr" rid="CR393">1992</xref>, <xref ref-type="bibr" rid="CR394">1993</xref>, <xref ref-type="bibr" rid="CR396">1999</xref>; Ho et al. <xref ref-type="bibr" rid="CR211">2003</xref>). Furthermore, MOR and HIV co-receptors, including both CCR5 (El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>; Yuan et al. <xref ref-type="bibr" rid="CR557">2013</xref>; Arnatt et al. <xref ref-type="bibr" rid="CR18">2016</xref>) and CXCR4 (Pitcher et al. <xref ref-type="bibr" rid="CR399">2014</xref>) can interact via convergent downstream signaling and perhaps via direct molecular interactions (Rogers et al. <xref ref-type="bibr" rid="CR435">2000</xref>; Rogers and Peterson <xref ref-type="bibr" rid="CR434">2003</xref>; Steele et al. <xref ref-type="bibr" rid="CR481">2003</xref>; Chen et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Song et al. <xref ref-type="bibr" rid="CR476">2011</xref>; Arnatt et al. <xref ref-type="bibr" rid="CR18">2016</xref>). MOR-CCR5 or CXCR4 interactions are highly contextual and can promote (Guo et al. <xref ref-type="bibr" rid="CR192">2002</xref>; Steele et al. <xref ref-type="bibr" rid="CR481">2003</xref>) or inhibit (Strazza et al. <xref ref-type="bibr" rid="CR489">2014</xref>) HIV expression, depending on the nature and duration of exposure (see Fig.&#x000a0;9; Berman et al. <xref ref-type="bibr" rid="CR42">2006</xref>) and cell type involved (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). Depending on the outcome measure, Tat expression reduces morphine&#x02019;s efficacy and potency (Fitting et al. <xref ref-type="bibr" rid="CR161">2012</xref>, <xref ref-type="bibr" rid="CR164">2016</xref>; Hahn et al. <xref ref-type="bibr" rid="CR200">2016</xref>). Antagonizing CCR5 with maraviroc reinstates morphine potency in an antinociceptive assay and restores physical dependence in Tat exposed, morphine-tolerant mice (Gonek et al. <xref ref-type="bibr" rid="CR183">2018</xref>).</p><p id="Par13">Epidemiological studies suggest OUD can increase AIDS progression (Donahoe and Vlahov <xref ref-type="bibr" rid="CR118">1998</xref>; Dronda et al. <xref ref-type="bibr" rid="CR120">2004</xref>; Meijerink et al. <xref ref-type="bibr" rid="CR332">2014</xref>, <xref ref-type="bibr" rid="CR333">2015</xref>). In the pre-cART era, opiate abuse was found to exacerbate HIV encephalitis (HIVE) (Bell et al. <xref ref-type="bibr" rid="CR36">1998</xref>, <xref ref-type="bibr" rid="CR37">2002</xref>). In Indonesian injection heroin abusers who lacked access to cART, CD4 counts (a measure of HIV progression) were reduced compared to PWH not using heroin (Meijerink et al. <xref ref-type="bibr" rid="CR332">2014</xref>). However, with the introduction of cART, the clinical picture has significantly changed with a 50% decline in the rate of death from AIDS, reduced incidence of opportunistic infections and HIVE, and a 40&#x02013;50% decrease in the incidence of HIV-associated dementia (HAD), the most severe form of HIV-associated neurocognitive disorders (HAND) (Maschke et al. <xref ref-type="bibr" rid="CR313">2000</xref>; McArthur et al. <xref ref-type="bibr" rid="CR321">2010</xref>; Saylor et al. <xref ref-type="bibr" rid="CR454">2016</xref>). Nevertheless, chronic opiate exposure (which almost always is confounded by the use of other illicit and legal drugs) in PWH can worsen neuroHIV (Anthony et al. <xref ref-type="bibr" rid="CR11">2005</xref>; Bell et al. <xref ref-type="bibr" rid="CR38">2006</xref>; Anthony et al. <xref ref-type="bibr" rid="CR12">2008</xref>) and cognitive impairment (Rodriguez Salgado et al. <xref ref-type="bibr" rid="CR432">2006</xref>; Martin-Thormeyer and Paul <xref ref-type="bibr" rid="CR311">2009</xref>; Byrd et al. <xref ref-type="bibr" rid="CR67">2011</xref>; Smith et al. <xref ref-type="bibr" rid="CR474">2014</xref>; Martin et al. <xref ref-type="bibr" rid="CR309">2018</xref>; Rubin et al. <xref ref-type="bibr" rid="CR440">2018</xref>) despite cART, even though some studies fail to show that opioids worsen neuroHIV (Royal et al. <xref ref-type="bibr" rid="CR439">1991</xref>; Applebaum et al. <xref ref-type="bibr" rid="CR16">2010</xref>) or HAND (Martin et al. <xref ref-type="bibr" rid="CR310">2019</xref>). Opiate exposure in cART-treated PWH worsens CD4 counts and viral loads (Ryan et al. <xref ref-type="bibr" rid="CR444">2004</xref>), neuropathology (including increased tauopathy; Smith et al. <xref ref-type="bibr" rid="CR474">2014</xref>), CNS inflammation (Anthony et al. <xref ref-type="bibr" rid="CR11">2005</xref>, <xref ref-type="bibr" rid="CR12">2008</xref>; Smith et al. <xref ref-type="bibr" rid="CR474">2014</xref>), and neurocognition (Applebaum et al. <xref ref-type="bibr" rid="CR15">2009</xref>; Byrd et al. <xref ref-type="bibr" rid="CR67">2011</xref>; Meyer et al. <xref ref-type="bibr" rid="CR336">2013</xref>) including deficits in memory and working memory (Byrd et al. <xref ref-type="bibr" rid="CR67">2011</xref>). Table <xref rid="Tab1" ref-type="table">1</xref> gives an overview on reported interactive effects of HIV and opioids in some of the clinical and preclinical CNS studies referenced in this review.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and preclinical findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Major effects</th><th>HIV pathogen<sup>a</sup></th><th>ARV</th><th>Opioids</th><th>Outcome</th><th>Model system</th><th>Citation(s)</th></tr></thead><tbody><tr><td align="left" colspan="7">Clinical findings (human)</td></tr><tr><td rowspan="3">HIV progression and/or ARV adherence</td><td>HIV</td><td>cART</td><td><p>&#x02022; SUD</p><p>&#x02022; Prescription opioids for pain</p></td><td><p>&#x02022; &#x02191; Viral load with SUD</p><p>&#x02022; &#x02193; ARV adherence</p><p>&#x02022; &#x02191; Frequency of prescription drugs with pain + SUD</p></td><td>Human</td><td>(Denis et al. <xref ref-type="bibr" rid="CR113">2019</xref>)</td></tr><tr><td>HIV</td><td>cART</td><td>OUD</td><td><p>&#x02022; &#x02193; Lasting viral suppression</p><p>&#x02022; &#x02193; Adherence to cART for 3&#x000a0;years</p></td><td>Human</td><td>(Lemons et al. <xref ref-type="bibr" rid="CR276">2019</xref>)</td></tr><tr><td>HIV</td><td>ARV naive</td><td>Injection drug use</td><td>&#x02193; CD4 counts</td><td>Human</td><td>(Meijerink et al. <xref ref-type="bibr" rid="CR332">2014</xref>)</td></tr><tr><td><p>HIV encephalitis (HIVE)</p><p>HIV infection CNS</p></td><td>HIV</td><td>ZDV</td><td>Former drug use (+ OST)</td><td><p>&#x02022; &#x02191; Multinucleated giant cells</p><p>&#x02022; &#x02191; HIV p24</p></td><td>Human, postmortem brain</td><td>(Bell et al. <xref ref-type="bibr" rid="CR36">1998</xref>)</td></tr><tr><td rowspan="4">Microglial activation</td><td>HIV</td><td><p>&#x02022; ARV</p><p>&#x02022; ZDV</p></td><td>OUD</td><td>&#x02191; CD68 microglial activation only in non-OUD HIV+ PWH</td><td>Human, postmortem brain</td><td>(Smith et al. <xref ref-type="bibr" rid="CR474">2014</xref>)</td></tr><tr><td>HIV</td><td><p>&#x02022; ARV</p><p>&#x02022; ZDV, other monotherapies</p></td><td>Injection drug use (+ OST)</td><td>&#x02191; Microglial activation</td><td>Human</td><td>(Bell et al. <xref ref-type="bibr" rid="CR37">2002</xref>)</td></tr><tr><td>HIV</td><td>No info</td><td>Drug use</td><td><p>&#x02022; &#x02191; MHC class II</p><p>&#x02022; &#x02191; CD68</p></td><td>Human, postmortem brain</td><td>(Anthony et al. <xref ref-type="bibr" rid="CR11">2005</xref>)</td></tr><tr><td>HIV</td><td>No info</td><td>OUD (44% methadone, 36% other opiates)</td><td><p>&#x02022; &#x02193; CD68, HLA-D in HIV and HIVE with OUD</p><p>&#x02022; No effect of IDU on CD68</p></td><td>Human, postmortem brain</td><td>(Byrd et al. <xref ref-type="bibr" rid="CR68">2012</xref>)</td></tr><tr><td>Plasma cytokines</td><td>HIV</td><td>cART</td><td>OUD (codeine, fentanyl, morphine)</td><td>&#x02191; sTNF-R2, not sCD14, TNF-&#x003b1;, sTNF-R1, in plasma</td><td>Human</td><td>(Ryan et al. <xref ref-type="bibr" rid="CR444">2004</xref>)</td></tr><tr><td/><td>HIV</td><td>ARV naive</td><td>Reported heroin use</td><td><p>&#x02022; &#x02193; MIP-1&#x003b1;, MIP-1&#x003b2;, MCP-2 in blood after stimulation with LPS</p><p>&#x02022; &#x02191; CCR5 expression in CD4 cells</p></td><td>Human</td><td>(Meijerink et al. <xref ref-type="bibr" rid="CR333">2015</xref>)</td></tr><tr><td>HIVE</td><td>HIV</td><td>No info</td><td>OUD</td><td><p>&#x02022; &#x02191; Parenchymal inflammatory infiltrates</p><p>&#x02022; &#x02191; HIV PCR amplification products</p></td><td>Human, postmortem brain</td><td>(Gosztonyi et al. <xref ref-type="bibr" rid="CR185">1993</xref>)</td></tr><tr><td>Aberrant immune responses</td><td>HIV</td><td>No info</td><td>SUD (opioids, alcohol, marijuana, cocaine) (+ OST)</td><td><p>&#x02022; &#x02191; Autoantibodies and delayed hypersensitivity to neural antigens OUD only</p><p>&#x02022; No HIV effect/interaction</p></td><td>Human</td><td>(Jankovic et al. <xref ref-type="bibr" rid="CR224">1991</xref>)</td></tr><tr><td rowspan="3">Learning-memory</td><td>HIV</td><td>50-70% on cART</td><td>Heroin, crack/cocaine</td><td><p>&#x02022; &#x02193; Total learning; &#x02193; Learning slope</p><p>&#x02022; &#x02193; Delayed recall</p></td><td>Human, female</td><td>(Meyer et al. <xref ref-type="bibr" rid="CR336">2013</xref>)</td></tr><tr><td>HIV</td><td>cART</td><td>Reported heroin use</td><td><p>&#x02022; &#x02193; Recall memory</p><p>&#x02022; &#x02193; Working memory</p></td><td>Human</td><td>(Byrd et al. <xref ref-type="bibr" rid="CR67">2011</xref>)</td></tr><tr><td>HIV</td><td>No info</td><td>SUD (opioids, alcohol, marijuana, cocaine)</td><td><p>&#x02022; &#x02193; Complex figure copy</p><p>&#x02022; &#x02193; Delayed recall</p></td><td>Human</td><td>(Concha et al. <xref ref-type="bibr" rid="CR103">1997</xref>)</td></tr><tr><td>Neuropsychological performance</td><td/><td>cART</td><td>OST (methadone)</td><td>No effect of OST</td><td>Human</td><td>(Applebaum et al. <xref ref-type="bibr" rid="CR16">2010</xref>)</td></tr><tr><td>Cognitive function</td><td>HIV</td><td>cART</td><td>OUD</td><td>&#x02022; &#x02193; Cognitive performance with anticholinergics, but not opioids, anxiolytics, or anticonvulsants</td><td>Human</td><td>(Rubin et al. <xref ref-type="bibr" rid="CR440">2018</xref>)</td></tr><tr><td><p>Memory</p><p>Cognitive function</p></td><td>HIV</td><td>cART</td><td>SUD (alcohol, cocaine, heroin)</td><td><p>&#x02022; &#x02193; Working memory in HIV+</p><p>&#x02022; &#x02193; Spatial and verbal response times in women, irrespective of HIV status</p><p>&#x02022; &#x02191; Response time with cocaine use</p></td><td>Human</td><td>(Martin et al. <xref ref-type="bibr" rid="CR309">2018</xref>)</td></tr><tr><td>Visual and cognitive function</td><td>HIV</td><td>No info</td><td>OUD (+ OST, methadone)</td><td><p>&#x02022; &#x02191; Pattern-shift visual evoked potential delay with methadone</p><p>&#x02022; No HIV effect/interaction</p></td><td>Human</td><td>(Bauer <xref ref-type="bibr" rid="CR31">1998</xref>)</td></tr><tr><td rowspan="2">Transmission risk</td><td>HIV</td><td>No info</td><td>OST</td><td>&#x02193; Frequency of injection drug use</td><td>Human</td><td>(Kwiatkowski and Booth <xref ref-type="bibr" rid="CR265">2001</xref>)</td></tr><tr><td>HIV</td><td>cART</td><td>OST</td><td><p>&#x02022; &#x02193; Frequency of heroin injection</p><p>&#x02022; &#x02191; On ARV</p></td><td>Human</td><td>(Pettes et al. <xref ref-type="bibr" rid="CR397">2010</xref>)</td></tr><tr><td>Motor and visual function</td><td>HIV</td><td>No info</td><td>OST</td><td><p>&#x02022; &#x02193; Digital Finger-Tapping test</p><p>&#x02022; &#x02193; Visual motor pursuit</p></td><td>Human</td><td>(Silberstein et al. <xref ref-type="bibr" rid="CR467">1993</xref>)</td></tr><tr><td>ARV adherence</td><td>HIV</td><td>cART</td><td>OST</td><td>&#x02022; &#x02191; ARV adherence in PWH with OST vs. OUD</td><td>Human</td><td>(Mazhnaya et al. <xref ref-type="bibr" rid="CR320">2018</xref>)</td></tr><tr><td><italic>PENK</italic> expression</td><td>HIV</td><td>Pre- and post-cART</td><td>SUD</td><td><p>&#x02022; &#x02193; <italic>PENK</italic> in HIVE vs. HIV&#x02212;</p><p>&#x02022; &#x02193; <italic>DRD2L</italic> HIV+ vs. HIVE &#x00026; HIV&#x02212;</p><p>&#x02022; &#x02193; <italic>DRD2L</italic> correlates with </p><p>&#x02191; cognitive performance</p></td><td>Human, post mortem brain</td><td>(Gelman et al. <xref ref-type="bibr" rid="CR174">2012</xref>)</td></tr><tr><td rowspan="3"><italic>OPRM1</italic> polymorphisms, splice variants</td><td>HIV</td><td>No info</td><td>SUD</td><td>C17T MOR polymorphism correlates with &#x02191; risk of cocaine, alcohol &#x00026; tobacco (but not opiate) use</td><td>Human</td><td>(Crystal et al. <xref ref-type="bibr" rid="CR107">2012</xref>)</td></tr><tr><td>HIV</td><td>cART</td><td>No</td><td>Some <italic>OPRM1</italic> polymorphisms may alter HIV severity / response to ARV</td><td>Human</td><td>(Proudnikov et al. <xref ref-type="bibr" rid="CR406">2012</xref>)</td></tr><tr><td>HIV</td><td>No info</td><td>MOR-1K expression</td><td><p>&#x02022; &#x02191; MOR-1K in HIVE</p><p>&#x02022; &#x02191; CCL2, CCL6, CCL5, but not CXCR4, CCR5 or CD4 receptor in HIVE</p></td><td>Human, postmortem brain</td><td>(Dever et al. <xref ref-type="bibr" rid="CR115">2014</xref>)</td></tr><tr><td><italic>OPRK</italic> and <italic>PDYN</italic> polymorphisms</td><td>HIV</td><td>cART</td><td>No</td><td>Some <italic>OPRK and PDYN</italic> polymorphisms may alter HIV severity / response to ARV</td><td>Human</td><td>(Proudnikov et al. <xref ref-type="bibr" rid="CR407">2013</xref>)</td></tr><tr><td>Sensory Neuropathy</td><td>HIV</td><td>cART</td><td>SUD</td><td>HIV sensory neuropathy- regardless of SUD (trends, not significant)</td><td>Human</td><td>(Robinson-Papp et al. <xref ref-type="bibr" rid="CR431">2010</xref>)</td></tr><tr><td align="left" colspan="7">Preclinical in vivo findings (animal)</td></tr><tr><td rowspan="2">HIV entry into the brain</td><td>Mixture of SIV<sub>17-EFr</sub>, SHIV<sub>KU_1B,</sub> SHIV<sub>89.6P</sub></td><td>No</td><td>Morphine (5&#x000a0;mg/kg i.m., b.i.d., &#x02264; 56&#x000a0;weeks)</td><td><p>&#x02022; &#x02191; CSF viral load</p><p>&#x02022; &#x02191; Viral migration through BBB for SHIV<sub>KU</sub></p></td><td>Rhesus macaques</td><td>(Kumar et al. <xref ref-type="bibr" rid="CR264">2006</xref>)</td></tr><tr><td>SIV<sub>macR71/17E</sub></td><td>No</td><td>Morphine (3&#x000a0;mg/kg i.m., q.i.d.)</td><td><p>&#x02022; &#x02191; CD4+ and CD8+ T cells</p><p>&#x02022; &#x02191; CSF viral load</p><p>&#x02022; &#x02191; Infiltration of MDMs into the brain</p></td><td>Rhesus macaques</td><td>(Bokhari et al. <xref ref-type="bibr" rid="CR49">2011</xref>).</td></tr><tr><td>Viral load and HIV progression</td><td>Mixture of SIV<sub>17-EFr</sub>, SHIV<sub>KU _1B</sub>, SHIV<sub>89.6P</sub></td><td>No</td><td>Morphine (5&#x000a0;mg/kg, i.m., t.i.d., 20&#x000a0;weeks)</td><td><p>&#x02022; &#x02191; Viral load; &#x02193; CD4 counts</p><p>&#x02022; &#x02191; ROS with morphine + SIV</p></td><td>Rhesus macaques</td><td>(Perez-Casanova et al. <xref ref-type="bibr" rid="CR389">2007</xref>; Perez-Casanova et al. <xref ref-type="bibr" rid="CR390">2008</xref>)</td></tr><tr><td>SIV gene mutation/evolution<italic>tat</italic></td><td rowspan="4">Mixture of SIV<sub>17-EFr</sub>, SHIV<sub>KU _1B</sub>, SHIV<sub>89.6P</sub></td><td rowspan="4">No</td><td rowspan="4"><p>Morphine</p><p>(5&#x000a0;mg/kg, i.m., t.i.d., 20&#x02013;56&#x000a0;weeks)</p></td><td><p>&#x02022; &#x02191; Viral load; &#x02193; CD4 counts</p><p>&#x02022; <italic>tat</italic> evolution&#x02014;inverse correlation with SIV progression</p><p>&#x02022; &#x02193; <italic>tat</italic> diversity with morphine</p></td><td rowspan="4">Rhesus macaques</td><td>(Noel and Kumar <xref ref-type="bibr" rid="CR366">2006</xref>; Noel et al. <xref ref-type="bibr" rid="CR369">2006b</xref>)</td></tr><tr><td><italic>nef</italic></td><td><p>&#x02022; &#x02191; Viral load; &#x02193; CD4 counts</p><p>&#x02022; &#x02193; <italic>nef</italic> evolution; no correlation with SIV progression &#x000b1; morphine</p></td><td>(Noel et al. <xref ref-type="bibr" rid="CR368">2006a</xref>)</td></tr><tr><td><italic>env</italic></td><td><p>&#x02022; &#x02191; Viral load; &#x02193; CD4 counts</p><p>&#x02022; &#x02191; <italic>env</italic> evolution (V4 region) correlates with SIV progression + morphine</p><p>&#x02022; &#x02191; <italic>env</italic> evolution in CSF with morphine</p></td><td>(Rivera-Amill et al. <xref ref-type="bibr" rid="CR427">2007</xref>, <xref ref-type="bibr" rid="CR429">2010b</xref>)</td></tr><tr><td><italic>vpr</italic></td><td><p>&#x02022; &#x02193; <italic>vpr</italic> evolution and/or Vpr R50G mutation&#x02014;inverse correlation with SIV progression/mortality</p><p>&#x02022; &#x02193; <italic>vpr</italic> evolution with morphine</p></td><td>(Noel and Kumar <xref ref-type="bibr" rid="CR367">2007</xref>; Rivera et al. <xref ref-type="bibr" rid="CR426">2013</xref>)</td></tr><tr><td rowspan="3">Neuronal injury, survival, oxidative stress</td><td>gp120 HIV-1<sub>LAV</sub></td><td>No</td><td>Morphine (25&#x000a0;mg pellet, 5&#x02013;7&#x000a0;days)</td><td><p>&#x02022; &#x02191; ROS during withdrawal</p><p>&#x02022; &#x02193; PSD95 during chronic and withdrawal</p><p>&#x02022; &#x02191; Sphingomyelin</p><p>&#x02022; &#x02193; Ceramide</p></td><td>Mouse, gp120 tg<sup>b</sup></td><td>(Bandaru et al. <xref ref-type="bibr" rid="CR26">2011</xref>)</td></tr><tr><td>HIV</td><td>No</td><td>Morphine (37.5&#x000a0;mg&#x000a0;s.c, 5&#x000a0;days)</td><td>&#x02193; neuron survival HIV tg&#x02009;+&#x02009;morphine</td><td>Rat, HIV-1 tg, female</td><td>(Guo et al. <xref ref-type="bibr" rid="CR193">2012</xref>)</td></tr><tr><td><p>SIV</p><p>HIV Tat</p></td><td>No</td><td>Morphine (3&#x000a0;mg/kg i.m., q.i.d., 3&#x000a0;weeks)</td><td><p>&#x02022; &#x02191; miR-29b, &#x02193; PDGF-B mRNA, &#x02191; PDGF-BB with morphine and SIV</p><p>&#x02022; &#x02193; PDGF-B, &#x02193; neuron survival with CM from morphine-treated astrocytes</p></td><td>Rhesus macaques; Rat<sup>b</sup>, primary neurons, astrocytes</td><td>(Hu et al. <xref ref-type="bibr" rid="CR213">2012</xref>)</td></tr><tr><td rowspan="2">Synaptic transmission</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine ex vivo (1&#x000a0;&#x003bc;M) to the bath</td><td>&#x02193; mIPSC frequency</td><td>Mouse, male and female, PFC slices, ex vivo</td><td>(Xu and Fitting <xref ref-type="bibr" rid="CR549">2016</xref>)</td></tr><tr><td><p>SIV<sub>macR71/17E</sub></p><p>Tat</p></td><td>No info</td><td><p>&#x02022; Morphine (escalating doses of 1&#x02013;3&#x000a0;mg/kg i.m., q.i.d., 12&#x000a0;months)</p><p>&#x02022; Morphine in vitro</p></td><td><p>&#x02022; SIV &#x02191; Synaptic protein HSPA5</p><p>&#x02022; Tat &#x02191; HSPA5 mRNA (in vitro)</p></td><td><p>Rhesus macaques;</p><p>Human,</p><p>SH-SY5Y neuroblastoma cells in vitro</p></td><td>(Pendyala et al. <xref ref-type="bibr" rid="CR386">2015</xref>)</td></tr><tr><td>White matter effects</td><td>SIV<sub>macR71/17E</sub></td><td>No</td><td>Morphine (3&#x000a0;mg/kg i.m., q.i.d., &#x02264; 59&#x000a0;weeks)</td><td><p>&#x02022; &#x02191; Focal, demyelinating lesions</p><p>&#x02022; &#x02191; Macrophages in areas of myelin loss</p></td><td>Rhesus macaques</td><td>(Marcario et al. <xref ref-type="bibr" rid="CR306">2008</xref>),</td></tr><tr><td>CNS metabolites</td><td>SIV<sub>smm9</sub></td><td>No info</td><td>Morphine (escalating doses of 1&#x02013;3&#x000a0;mg/kg i.m., q.i.d., &#x02264; 4&#x000a0;years)</td><td><p>&#x02022; &#x02191; Survival time</p><p>&#x02022; &#x02191; Creatine in white matter (SIV&#x02009;+&#x02009;morphine only)</p><p>&#x02022; &#x02191; Myo-inositol in putamen</p></td><td>Rhesus macaques</td><td>(Cloak et al. <xref ref-type="bibr" rid="CR100">2011</xref>)</td></tr><tr><td>Neuroinflammation</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (10&#x000a0;mg/kg&#x000a0;i.p., b.i.d., 5&#x000a0;days)</td><td>&#x02191; Iba1+ 3-NT+ microglia</td><td>Mouse, Tat tg, males</td><td>(Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>)</td></tr><tr><td>Chemokines</td><td><p>Tat<sub>1&#x02013;72</sub></p><p>(25&#x000a0;&#x003bc;g intrastriatal injection)</p></td><td>No</td><td>Morphine (25&#x000a0;mg pellet, 5&#x000a0;days)</td><td><p>&#x02022; &#x02191; CCL2 in astrocytes is regulated by CCR5</p><p>&#x02022; &#x02191; CCL2 in macrophages/microglia</p><p>&#x02022; CCL2-knockout blocks morphine + Tat-induced glial reactivity</p></td><td>Mouse</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>)</td></tr><tr><td>Cytokines, Chemokines</td><td>HIV Tat (10&#x000a0;&#x003bc;g/kg i.v.)</td><td>No</td><td>Morphine (25, 75&#x000a0;mg pellet, 6&#x000a0;days)</td><td><p>&#x02022; Morphine &#x02191; death in Tat&#x02009;+&#x02009;bacterial infection</p><p>&#x02022; &#x02191; TNF&#x003b1;, IL-6, CCL2, </p><p>&#x02022; &#x02191; TLR2, TLR4, TLR9</p></td><td>Mouse, male, in vivo; microglia in vitro</td><td>(Dutta et al. <xref ref-type="bibr" rid="CR125">2012</xref>)</td></tr><tr><td>MOR expression</td><td>HIV-1<sub>IIIB</sub> gp120 (X4)</td><td>No</td><td>MOR</td><td>&#x02191; MOR mRNA</td><td>Rats, HIV-1 tg males</td><td>(Chang et al. <xref ref-type="bibr" rid="CR78">2007</xref>)</td></tr><tr><td>MOR-coupling efficacy to G proteins</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td><p>&#x02022; Morphine (acute, 10&#x000a0;mg/kg&#x000a0;i.p.)</p><p>&#x02022; Morphine, DAMGO (ex vivo)</p></td><td>&#x02193; [<sup>35</sup>S]GTP&#x003b3;S binding in NAc Shell, CPu, amygdala, PFC, but not hippocampus, with morphine in Tat mice</td><td>Mouse, Tat tg, males</td><td>(Hahn et al. <xref ref-type="bibr" rid="CR200">2016</xref>)</td></tr><tr><td>Neuroinflammation; morphine tolerance (antinociception), physical withdrawal, reward</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (75&#x000a0;mg pellet, 5&#x000a0;days)</td><td><p>&#x02022; &#x02191; Tolerance (&#x02193; anti-nociceptive potency and &#x02193; withdrawal symptoms)</p><p>&#x02022; &#x02191; CPP and cytokines (24&#x000a0;h after withdrawal)</p><p>&#x02022; Above effects reduced by CCR5 blockade</p></td><td>Mouse, Tat tg, males</td><td>(Gonek et al. <xref ref-type="bibr" rid="CR183">2018</xref>)</td></tr><tr><td>Neuropathy</td><td>gp120 (0.2&#x000a0;&#x003bc;g), q.d. intrathecally</td><td>No</td><td>Morphine (3&#x000a0;&#x003bc;g, intrathecally, b.i.d., 5&#x000a0;days)</td><td><p>&#x02022; &#x02191; Mechanic allodynia</p><p>&#x02022; &#x02191; Brd4 mRNA</p></td><td>Rat, males, gp120</td><td>(Takahashi et al. <xref ref-type="bibr" rid="CR500">2018</xref>)</td></tr><tr><td>Morphine efficacy, potency</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (acute, 2&#x02013;8&#x000a0;mg/kg&#x000a0;s.c.)</td><td>&#x02193; Antinociceptive potency and efficacy (tail flick)</td><td>Mouse, Tat tg, males</td><td>(Fitting et al. <xref ref-type="bibr" rid="CR161">2012</xref>)</td></tr><tr><td>Morphine tolerance, physical dependence</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (75&#x000a0;mg pellet, 4&#x000a0;days)</td><td><p>&#x02022; &#x02191; Antinociceptive tolerance</p><p>&#x02022; &#x02193; Physical dependence</p></td><td>Mouse, Tat tg, males</td><td>(Fitting et al. <xref ref-type="bibr" rid="CR164">2016</xref>)</td></tr><tr><td rowspan="3">Locomotor function</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Oxycodone (0&#x02013;10&#x000a0;mg/kg, i.p., 15&#x000a0;min prior behavioral assay)</td><td>&#x02191; Locomotor activity, center entries (open field)</td><td>Mouse, Tat tg, females</td><td>(Salahuddin et al. <xref ref-type="bibr" rid="CR446">2020</xref>)</td></tr><tr><td>SIV<sub>macR71/17E</sub></td><td>No</td><td>Morphine (escalating doses of 1&#x02013;2.5&#x000a0;mg/kg i.m., q.i.d., 59&#x000a0;weeks)</td><td>&#x02193; Motor skill</td><td>Rhesus macaques</td><td>(Marcario et al. <xref ref-type="bibr" rid="CR307">2016</xref>)</td></tr><tr><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Oxycodone (acute, 0.1&#x02013;10&#x000a0;mg/kg, i.p.)</td><td>&#x02191; Psychomotor effects</td><td>Mouse, Tat tg, females</td><td>(Paris et al. <xref ref-type="bibr" rid="CR378">2020</xref>)</td></tr><tr><td>BBB integrity</td><td>Tat</td><td>No</td><td>Morphine (25&#x000a0;mg pellet, 5&#x000a0;days)</td><td>&#x02191; Dextran extravasation across the blood-brain barrier</td><td>Mouse, Tat tg females</td><td>(Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>)</td></tr><tr><td>Immune cell trafficking into CNS</td><td>Tat</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; Infiltration of monocytes and T cells into <italic>S. pneumoniae</italic>-infected CNS with morphine </p><p>&#x02022; &#x02191; T cell CXCR4 and CCR5 expression with morphine</p></td><td>Mouse, CNS infection (<italic>S. pneumoniae)</italic>, males</td><td>(Dutta and Roy <xref ref-type="bibr" rid="CR124">2015</xref>)</td></tr><tr><td>ARV accumulation</td><td>Tat</td><td><p>DTG</p><p>ABC</p><p>3TC</p></td><td>Morphine (2&#x000a0;mg/day, s.c.. osmotic pump, 5&#x000a0;days)</td><td>&#x02193; Dolutegravir and abacavir, but no change in lamivudine in brains of morphine-treated animals</td><td>Mouse, Tat tg females</td><td>(Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>)</td></tr><tr><td>Circadian rhythms</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (25&#x000a0;mg pellet, last 5&#x000a0;days)</td><td>&#x02193; Total wheel-running activity</td><td>Mouse, Tat tg, males</td><td>(Duncan et al. <xref ref-type="bibr" rid="CR122">2008</xref>)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>assumed Clade B, unless noted otherwise; <sup>b</sup> sex not reported; <sup>c</sup> authors reported a trend that was not significant</p><p><italic>ABC</italic>, abacavir; <italic>ARV</italic>, antiretroviral(s); <italic>BBB</italic>, blood-brain barrier; <italic>b.i.d.</italic>, twice a day; <italic>Brd4</italic>, Bromodomain-containing protein 4; <italic>CPu</italic>, caudate-putamen; <italic>CNS</italic>, central nervous system; <italic>CPP</italic>, conditioned place preference; <italic>CM</italic>, conditioned medium; <italic>CSF</italic>, cerebrospinal fluid; <italic>DAMGO</italic> [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin; <italic>DRD2L</italic>, type 2 dopamine receptor; <italic>DTG</italic>, dolutegravir; <italic>HIVE</italic>, HIV encephalitis (typically seen pre-cART); <italic>HSPA5</italic>, heat shock 70-kDa protein A 5; <italic>IDU</italic>, injection drug use; <italic>i.m</italic>., intramuscularly; <italic>i.p</italic>., intraperitoneal; <italic>Iba1</italic>, ionized calcium-binding adapter molecule 1; <italic>3TC</italic>, lamivudine; <italic>MHC class II</italic>, major histocompatibility class II; <italic>mIPSC</italic>, miniature inhibitory postsynaptic currents; <italic>MOR</italic>, &#x003bc;-opioid receptor; <italic>No info</italic>, information not provided or uncertain; <italic>OST</italic>, opioid substitution therapy; <italic>OUD</italic>, opioid use disorder; <italic>PFC</italic>, prefrontal cortex; <italic>PENK</italic>, preproenkephalin; <italic>q.d</italic>., once a day; <italic>q.i.d.</italic>, four times a day; <italic>ROS</italic>, reactive oxygen species; <italic>s.c.</italic>, subcutaneous; <italic>SUD</italic>, substance use disorder; <italic>tg</italic>, transgenic; <italic>t.i.d</italic>., three times a day; <italic>ZDV</italic>, zidovudine</p><p>For practicality, Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> are limited to key studies in the CNS with emphasis on neuropathological or neuroimmune rather than psychosocial outcomes. With deference toward the excellent studies we excluded: (1) on opioid and HIV effects on peripheral blood mononuclear cells (PBMCs), or on isolated lymphocytes and monocytes, not directly related to the central nervous system or BBB; (2) on HIV or opioid and ARV interactions in the peripheral nervous system; and (3) studies not directly examining opioid-HIV interactions (irrespective of whether a positive or negative interaction was found)</p></table-wrap-foot></table-wrap></p><p id="Par14">Although translational, &#x0201c;bench-to-bedside&#x0201d;, research is important, reverse-translational approaches and multiple preclinical models are essential to better understand complex disease and improve established therapies (Singer <xref ref-type="bibr" rid="CR468">2019</xref>). Evidence suggests that HIV compartmentalizes within the CNS early during the course of the infection establishing a separate reservoir harboring &#x0201c;intact proviral&#x0201d; HIV (Churchill et al. <xref ref-type="bibr" rid="CR97">2016</xref>; Bruner et al. <xref ref-type="bibr" rid="CR60">2019</xref>) within resident neural cell populations (Bednar et al. <xref ref-type="bibr" rid="CR33">2015</xref>; Sturdevant et al. <xref ref-type="bibr" rid="CR492">2015</xref>; Veenhuis et al. <xref ref-type="bibr" rid="CR523">2019</xref>) and perivascular macrophages (Fischer-Smith et al. <xref ref-type="bibr" rid="CR158">2001</xref>; Burdo et al. <xref ref-type="bibr" rid="CR62">2013</xref>; Rappaport and Volsky <xref ref-type="bibr" rid="CR421">2015</xref>). Preclinical studies assessing opioid interactions with HIV or viral proteins permit mechanistic understanding of how particular CNS cell types, including neurons, astroglia, and microglia are affected and contribute to accentuating effects of opiates on neuroHIV, which are discussed in detail below.</p></sec><sec id="Sec6"><title>Cellular and Molecular Interactions in Astroglia, Microglia, and Neurons</title><p id="Par15">Prior reviews have outlined how opiate drugs likely exacerbate neuroHIV pathology in neurons and glia (Hauser et al. <xref ref-type="bibr" rid="CR206">2005</xref>; Dutta and Roy <xref ref-type="bibr" rid="CR123">2012</xref>; Hauser et al. <xref ref-type="bibr" rid="CR209">2012</xref>; Reddy et al. <xref ref-type="bibr" rid="CR422">2012</xref>; Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>; Liu et al. <xref ref-type="bibr" rid="CR293">2016a</xref>; Murphy et al. <xref ref-type="bibr" rid="CR351">2019</xref>) including in the enteric nervous system (Galligan <xref ref-type="bibr" rid="CR169">2015</xref>; Meng et al. <xref ref-type="bibr" rid="CR334">2015</xref>). Opioid-HIV pathophysiological interactions are complex and differ depending on the timing and duration of co-exposure, the pharmacology of the opioid drug involved, the cell types and brain regions targeted, host and viral genetics, and are highly contextual (Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>, <xref ref-type="bibr" rid="CR202">2018</xref>). A summary of the cellular and molecular interactions in various CNS cell types is also reviewed in detail in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cellular and molecular interactions (in vitro)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Major effects</th><th>HIV pathogen<sup>a</sup></th><th>ARV</th><th>Opioids</th><th>Outcome</th><th>Model system (in vitro)</th><th>Citation(s)</th></tr></thead><tbody><tr><td colspan="7">Mixed-Glia</td></tr><tr><td rowspan="2">HIV expression</td><td>HIV</td><td>No</td><td><p>&#x02022; Dynorphin</p><p>&#x02022; U50,488</p><p>(KOR agonists)</p></td><td><p>&#x02022; &#x02191; HIV-1 expression,</p><p>&#x02022; Dynorphin (KOR agonist) &#x02191; TNF-&#x003b1;, IL-6 mRNA and protein</p></td><td>Human fetal neural cells, HIV-infected promonocyte (U1) line</td><td>(Chao et al. <xref ref-type="bibr" rid="CR80">1995</xref>)</td></tr><tr><td>HIV<sub>SF162</sub></td><td>No</td><td><p>&#x02022; U50,488</p><p>&#x02022; U69,593</p><p>&#x02022; Dynorphin<sub>1&#x02013;17</sub>;</p><p>(KOR agonists)</p><p>&#x02022; Morphine</p></td><td>&#x02022; KOR agonists &#x000b1; TNF-&#x003b1; differentially &#x02193; HIV p24</td><td>Human, primary mixed neurons and glia</td><td>(Chao et al. <xref ref-type="bibr" rid="CR83">1998a</xref>)</td></tr><tr><td rowspan="2">Chemokines</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCL5, CCL2</p><p>&#x02022; &#x02191; [Ca<sup>2+</sup>]<sub>i</sub> (Beclin1 dependent)</p><p>&#x02022; &#x02193; Autophagy</p></td><td>Mouse, primary mixed glia</td><td>(Lapierre et al. <xref ref-type="bibr" rid="CR269">2018</xref>)</td></tr><tr><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; HIV-1 Tat-induced LTR expression</p><p>&#x02022; &#x02191; CCR5 expression (inhibited by bivalent ligand in astrocytes)</p><p>&#x02022; &#x02191; IL-6</p><p>&#x02022; &#x02191; CCL5</p></td><td>Human, primary mixed glia</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>)</td></tr><tr><td>Glial restricted precursors: survival &#x00026; MOR, DOR, KOR expression</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine (acting via DOR and/or KOR)</td><td><p>&#x02022; &#x02191; Caspase-3 activation &#x00026; &#x02191; cell death by Tat or morphine via DOR, KOR</p><p>&#x02022; No opioid-Tat interactions</p></td><td>Mouse, primary glial precursors</td><td>(Buch et al. <xref ref-type="bibr" rid="CR61">2007</xref>)</td></tr><tr><td><p>MOR expression in NPCs;</p><p>NPC survival and developmental fate</p></td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; MOR expressed by subsets of NPCs</p><p>&#x02022; &#x02191; Astrocyte and immature glial death</p></td><td>Mouse, primary mixed glia</td><td>(Khurdayan et al. <xref ref-type="bibr" rid="CR234">2004</xref>)</td></tr><tr><td>MOR and CCR5 interactions</td><td>Tat<sub>1&#x02013;86</sub> (from HIV<sub>IIIB</sub>)</td><td>No</td><td>Morphine</td><td>&#x02022; &#x02193; Neuronal survival via CCR5 activation in glia (rescued by BDNF treatment)</td><td>Mouse, primary neurons and glia</td><td>(Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>)</td></tr><tr><td>HIV infectivity MOR-CCR5 dimerization</td><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td><p>Morphine</p><p>CCR5-MOR bivalent ligand 1b</p></td><td><p>&#x02022; MOR-CCR5 bivalent ligand blocks HIV infection in astroglia, but not microglia, with morphine</p><p>&#x02022; MOR-CCR5 bivalent ligand blocks the fusion of HIV gp160 and CCR5-CD4-expressing HEK cells</p></td><td>Human, primary astrocytes and microglia; HEK-293T cells</td><td>(Yuan et al. <xref ref-type="bibr" rid="CR557">2013</xref>; Arnatt et al. <xref ref-type="bibr" rid="CR18">2016</xref>)</td></tr><tr><td>HIV expression and maturational fate of neurons and astroglia</td><td>HIV<sub>BaL</sub> (R5)</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; HIV p24 and &#x02191; Tat mRNA levels with morphine after 21&#x000a0;days</p><p>&#x02022; &#x02193; Proliferation of neural progenitors; &#x02191; astroglial and &#x02191; neuronal differentiation</p></td><td>Human, neural progenitors</td><td>(Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>)</td></tr><tr><td colspan="7">Astrocytes</td></tr><tr><td>HIV expression</td><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; HIV p24</p><p>&#x02022; &#x02191; CCL2</p></td><td>Human, primary astrocytes</td><td>(Rodriguez et al. <xref ref-type="bibr" rid="CR433">2017</xref>)</td></tr><tr><td>Toll-like receptor (TLR) expression/function</td><td><p>&#x02022; Tat<sub>1&#x02013;72</sub></p><p>&#x02022; gp120</p></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; TLR2 with Tat, Tat&#x02009;+&#x02009;morphine, gp120</p><p>&#x02022; &#x02193; TLR9 with Tat, morphine, gp120</p></td><td>Mouse, primary astrocytes</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR135">2011a</xref>)</td></tr><tr><td rowspan="6">Chemokines</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCL5, CCL2</p><p>&#x02022; &#x02191; IL-6</p><p>&#x02022; &#x02191; [Ca<sup>2+</sup>]<sub>i</sub></p></td><td>Mouse, primary astrocytes</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR130">2005</xref>)</td></tr><tr><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCL2</p><p>&#x02022; &#x02191; CCL5</p><p>&#x02022; &#x02191; Microglial migration</p></td><td>Mouse, primary astrocytes</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR131">2006a</xref>)</td></tr><tr><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCL2, &#x02191; IL-6, &#x02191; TNF-&#x003b1;</p><p>&#x02022; &#x02191; [Ca<sup>2+</sup>]<sub>i</sub></p><p>&#x02022; &#x02191; NF-&#x003ba;B trafficking and transcription</p><p>&#x02022; No interaction / acceleration with morphine</p></td><td>Mouse, primary astrocytes</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR134">2008b</xref>)</td></tr><tr><td>Tat</td><td>No</td><td><p>&#x02022; U50,488 (KOR agonist)</p><p>&#x02022; Nor-BNI (KOR antagonist)</p></td><td><p>&#x02022; U50,488 &#x02193; CCL2</p><p>&#x02022; U50,488 &#x02193; NF-&#x003ba;B</p></td><td>Human, primary astrocytes</td><td>(Sheng et al. <xref ref-type="bibr" rid="CR464">2003</xref>)</td></tr><tr><td>N/A</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCR5, CCR3, CXCR2</p><p>&#x02022; &#x02193; IL-8, CCL4</p></td><td>Human, astrocytoma U87 cell line, primary astrocytes</td><td>(Mahajan et al. <xref ref-type="bibr" rid="CR301">2002</xref>)</td></tr><tr><td><p>&#x02022; Tat<sub>1&#x02013;86</sub></p><p>&#x02022; gp120<sub>IIIB</sub></p></td><td>No</td><td>Morphine</td><td>Regional differences in cytokine and ROS production &#x02014;differed for each insult</td><td>Mouse, primary astrocytes</td><td>(Fitting et al. <xref ref-type="bibr" rid="CR159">2010a</xref>)</td></tr><tr><td>Oxidative stress / damage</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td><p>&#x02022; DPDPE</p><p>&#x02022; SNC-80</p><p>(DOR agonists)</p></td><td>DOR agonists &#x02193; Tat-induced oxidative stress</td><td>Human derived brain cell line (SK-N-SH)</td><td>(Wallace et al. <xref ref-type="bibr" rid="CR533">2006</xref>)</td></tr><tr><td>Inflammation, maturation /plasticity</td><td><p>&#x02022; Tat<sub>86</sub></p><p>&#x02022; Tat<sub>101</sub></p></td><td>No</td><td>Morphine</td><td>&#x02193; &#x003b2;-catenin signaling and variably decreases <italic>TrkB</italic>, <italic>BDNF</italic>, and <italic>NLRP1</italic> mRNA in fetal astrocytes <sup>b</sup></td><td>Human, U87MG and fetal astrocytes</td><td>(Chen et al. <xref ref-type="bibr" rid="CR91">2020</xref>)</td></tr><tr><td colspan="7">Microglia</td></tr><tr><td rowspan="6">HIV replication</td><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td><p>&#x02022; Endomorphin-1</p><p>&#x02022; Endomorphin-2</p><p>(MOR agonists)</p></td><td><p>&#x02022; &#x02191; HIV p24 with endomorphin-1, but not endomorphin-2</p><p>&#x02022; Endomorphin-1 acts via MOR, but not DOR / KOR</p></td><td>Human, primary microglia</td><td>(Peterson et al. <xref ref-type="bibr" rid="CR396">1999</xref>)</td></tr><tr><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td>Morphine</td><td>&#x02191; HIV p24</td><td>Human, primary microglia</td><td>(El-Hage et al. <xref ref-type="bibr" rid="CR138">2014</xref>)</td></tr><tr><td>HIV<sub>SF162</sub> (R5)</td><td>No</td><td><p>&#x02022; U50,488; U69,593 (KOR agonists)</p><p>&#x02022; Dynorphin A<sub>l-13</sub></p></td><td>&#x02193; HIV p24</td><td>Human, primary microglia</td><td>(Chao et al. <xref ref-type="bibr" rid="CR82">1996b</xref>)</td></tr><tr><td><p>&#x02022; HIV<sub>JR-FL</sub> (R5)</p><p>&#x02022; gp120</p></td><td>No</td><td>&#x003b2;-endorphin</td><td><p>&#x02022; &#x02191; HIV expression</p><p>&#x02022; &#x02191; HIV p24 (14-day post infection)</p><p>&#x02022; gp120 &#x02191; IL-1, TNF, IL-6</p></td><td>Human, fetal microglia</td><td>(Sundar et al. <xref ref-type="bibr" rid="CR493">1995</xref>)</td></tr><tr><td>HIV<sub>SF162</sub></td><td>No</td><td><p>&#x02022; 8-CAC, U50,488 (KOR agonists)</p><p>&#x02022; Cocaine</p></td><td><p>&#x02022; KOR agonist &#x02193; p24; blocked by KOR antagonists</p><p>&#x02022; KOR agonist negates cocaine-induced &#x02191; HIV</p></td><td>Human, fetal brain microglia</td><td>(Gekker et al. <xref ref-type="bibr" rid="CR173">2004</xref>)</td></tr><tr><td>HIV<sub>SF162</sub></td><td>No</td><td><p><italic>OPRL1</italic> antisense</p><p>Nociceptin / orphanin FQ (OPRL1 agonist)</p></td><td><p>&#x02022; <italic>OPRL1</italic> antisense (<italic>and sense</italic>) &#x02193; p24</p><p>&#x02022; Nociceptin, no effect on p24</p></td><td>Human, fetal brain microglia and mixed neurons/glia</td><td>(Chao et al. <xref ref-type="bibr" rid="CR84">1998b</xref>)</td></tr><tr><td>HIV expression</td><td><p>&#x02022; HIV<sub>SF162</sub></p><p>&#x02022; Tat</p></td><td>ZDV</td><td>U50,488 (KOR agonist)</td><td><p>&#x02022; &#x02193; p24 on day 14 with U50,488</p><p>&#x02022; &#x02193; Neurotoxicity (U50,488)</p><p>&#x02022; &#x02193; Quinolinate by microglia</p></td><td>Human, fetal microglia and neural cells</td><td>(Chao et al. <xref ref-type="bibr" rid="CR85">2000</xref>)</td></tr><tr><td>Chemokines and Cytokines</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; CCR5</p><p>&#x02022; &#x02191; CD11b, &#x02191; CD40</p><p>&#x02022; &#x02191; TNF-&#x003b1;, &#x02191; IL-6, &#x02191; IP-10</p><p>&#x02022; &#x02191; iNOS</p></td><td>Mouse, BV-2 and primary microglia</td><td>(Bokhari et al. <xref ref-type="bibr" rid="CR48">2009</xref>)</td></tr><tr><td>MOR signaling</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; MOR (intracellular)</p><p>&#x02022; &#x02191; MOR mRNA</p></td><td>Mouse, N9 and primary microglia</td><td>(Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR514">2008</xref>)</td></tr><tr><td>Oxidative Stress</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; ROS [O<sub>2</sub><sup>&#x02212;</sup> (DHE), &#x02191; HO<sub>2</sub><sup>&#x02022;</sup>, H<sub>2</sub>O<sub>2</sub> (DCF)]</p><p>&#x02022; &#x02191; Protein carbonyls</p></td><td>Mouse, N9 and primary microglia</td><td>(Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>)</td></tr><tr><td>Glutamate release</td><td>Tat<sub>1&#x02013;72</sub></td><td>No</td><td>Morphine</td><td>&#x02191; Glutamate release via &#x02191; x<sub>c</sub><sup>&#x02212;</sup> cystine-glutamate antiporter expression/function</td><td>Mouse, primary microglia</td><td>(Gupta et al. <xref ref-type="bibr" rid="CR195">2010</xref>)</td></tr><tr><td colspan="7">Neurons</td></tr><tr><td>HIV expression</td><td>HIV</td><td>No</td><td>Morphine</td><td>&#x02191; HIV expression</td><td>Human derived, SH-SY5Y neuroblastoma cells</td><td>(Squinto et al. <xref ref-type="bibr" rid="CR479">1990</xref>)</td></tr><tr><td>Homeostasis and Injury</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; [Ca<sup>2+</sup>]<sub>i,</sub></p><p>&#x02022; &#x02191; [Na<sup>+</sup>]<sub>i</sub></p><p>&#x02022; &#x02193; &#x00394;<sub>&#x003a8;m</sub> (mitochondrial) instability</p><p>&#x02022; &#x02191; Dendritic degeneration</p></td><td>Mouse, primary neurons</td><td>(Fitting et al. <xref ref-type="bibr" rid="CR162">2014a</xref>)</td></tr><tr><td>Mitochondrial inner membrane potential and ROS</td><td><p>&#x02022; Tat<sub>1&#x02013;86</sub>, Tat<sub>1&#x02013;72</sub></p><p>&#x02022; gp120</p></td><td>No</td><td>Morphine</td><td>&#x02191; &#x00394;<sub>&#x003a8;m</sub> instability and oxidative stress &#x02191; with Tat&#x02009;+&#x02009;morphine, &#x02191; neuroprotection with allopregnanolone</td><td>Human, primary neurons ; mouse, striatal medium spiny neurons; mouse, striatal medium spiny neurons, SH-SY5Y neuroblastoma cells</td><td>(Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR513">2006</xref>; Paris et al. <xref ref-type="bibr" rid="CR378">2020</xref>)</td></tr><tr><td rowspan="3">Neuronal survival</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02193; Neuronal survival from Tat&#x02009;+&#x02009;morphine and &#x02193; glial CX<sub>3</sub>CL1 rescued by CX<sub>3</sub>CL</p><p>&#x02022; CX<sub>3</sub>CL1 (fractalkine) regulates microglial motility</p></td><td>Mouse, primary neurons and mixed glia</td><td>(Suzuki et al. <xref ref-type="bibr" rid="CR496">2011</xref>)</td></tr><tr><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02193; Proliferation</p><p>&#x02022; &#x02191; ERK1/2 activation</p><p>&#x02022; &#x02191; p53 and p21</p><p>&#x02022; &#x02193; Cyclin D1 and Akt levels</p></td><td>Human, neuronal precursors</td><td>(Malik et al. <xref ref-type="bibr" rid="CR305">2014</xref>)</td></tr><tr><td>Tat<sub>1&#x02013;72</sub>, Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02193; Neuronal survival</p><p>&#x02022; &#x02191; Neuronal survival with ibudilast (AV411) (inhibiting glial NF-&#x003ba;B blocks Tat&#x02009;&#x000b1;&#x02009;morphine neurotoxicity)</p></td><td>Mouse, primary neurons and mixed glia</td><td>(Gurwell et al. <xref ref-type="bibr" rid="CR197">2001</xref>; El-Hage et al. <xref ref-type="bibr" rid="CR138">2014</xref>)</td></tr><tr><td colspan="7">White matter/oligodendroglial pathology</td></tr><tr><td>Changes in OL survival and morphology</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine (25&#x000a0;mg pellet, 7&#x000a0;days); morphine (in vitro)</td><td><p>&#x02022; &#x02191; Degeneration of OLs</p><p>&#x02022; &#x02191; TUNEL reactivity</p><p>&#x02022; &#x02191; Caspase-3 activation</p></td><td>Mouse, Tat tg; primary OLs</td><td>(Hauser et al. <xref ref-type="bibr" rid="CR208">2009</xref>)</td></tr><tr><td colspan="7">Blood-brain barrier and the neurovascular unit</td></tr><tr><td>BBB model integrity and function</td><td>Tat<sub>1&#x02013;86</sub></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02191; TNF-&#x003b1;</p><p>&#x02022; &#x02191; IL-8</p><p>&#x02022; &#x02193;TEER</p><p>&#x02022; &#x02191; JAM-2 expression</p><p>&#x02022; &#x02191; Monocyte transmigration with CCL5</p></td><td>Human, using primary BMVEC and primary astrocytes</td><td>(Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>)</td></tr><tr><td>ARV accumulation</td><td>Tat<sub>1&#x02013;86</sub></td><td><p>DTG</p><p>FTC</p><p>TFV</p></td><td>Morphine</td><td>&#x02022; &#x02193; Intracellular ARV concentrations</td><td>Human, primary astrocytes</td><td>(Patel et al. <xref ref-type="bibr" rid="CR384">2019</xref>)</td></tr><tr><td colspan="7">HIV-1 strain differences</td></tr><tr><td rowspan="2">Neuronal Survival</td><td>Tat<sub>1&#x02013;86</sub> (clades B &#x00026; C)</td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02193; Neuronal survival via MOR on mixed glia</p><p>&#x02022; &#x02191; ROS in astrocytes</p><p>&#x02022; &#x02191; Iba1 and 3-NT microglia with morphine</p></td><td>Mouse, primary neurons and mixed glia</td><td>(Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>)</td></tr><tr><td><p>&#x02022; gp120<sub>IIIB</sub></p><p>&#x02022; gp120<sub>MN</sub> (X4)</p><p>&#x02022; gp120<sub>ADA</sub> (R5)</p></td><td>No</td><td>Morphine</td><td>&#x02193; Neuronal survival in presence of glia with gp120<sub>MN</sub> and transiently with gp120<sub>IIIB</sub> (X4), not R5-tropic gp120, in combination with morphine</td><td>Mouse, primary neurons and mixed glia</td><td>(Podhaizer et al. <xref ref-type="bibr" rid="CR402">2012</xref>)</td></tr><tr><td>Proliferation and maturational fate of neural progenitors and oligodendroglia</td><td><p>&#x02022; HIV<sub>SF162</sub> (R5)</p><p>&#x02022; HIV<sub>IIIB</sub> (X4)</p></td><td>No</td><td>Morphine</td><td><p>&#x02022; &#x02193; Proliferation of immature neural and OL progenitors with Tat&#x02009;+&#x02009;morphine</p><p>&#x02022; &#x02193; NPC DNA synthesis with R5-tropic HIV&#x02009;+&#x02009;morphine</p><p>&#x02022; &#x02191; NPC DNA synthesis with X4-tropic HIV&#x02009;+&#x02009;morphine</p></td><td>Mouse, Tat tg; Mouse, Human, primary neural progenitors</td><td>(Hahn et al. <xref ref-type="bibr" rid="CR199">2012</xref>)</td></tr><tr><td>GABA function</td><td><p>&#x02022; HIV<sub>BaL</sub> (R5)</p><p>&#x02022; gp120 <sub>(ADA, MN, and IIIB)</sub></p><p>&#x02022; Tat<sub>1&#x02013;86</sub></p></td><td>No</td><td>Morphine</td><td><p>&#x02022; Tat or morphine &#x02193; KCC2 levels via CCR5</p><p>&#x02022; &#x02191; KCC2 prevents Tat and R5 HIV, gp120, but not X4, gp120 neurotoxicity &#x000b1; morphine</p></td><td>Human, primary neurons, hNPCs</td><td>(Barbour et al. <xref ref-type="bibr" rid="CR30">2020</xref>)</td></tr><tr><td>Astroglial CCL5 and neuroprotection</td><td><p>&#x02022; gp120<sub>IIIB</sub> (X4)</p><p>&#x02022; gp120<sub>BaL</sub> (R5)</p></td><td>No</td><td><p>&#x02022; Morphine (10&#x000a0;&#x003bc;M)</p><p>&#x02022; DAMGO</p></td><td><p>&#x02022; Morphine &#x02191; astroglial CCL5 blocking gp120<sub>BaL</sub> neurotoxicity</p><p>&#x02022; Morphine (or CXCL12) does not block gp120<sub>IIIB</sub> neurotoxicity</p></td><td>Rat, mixed neurons and glia; isolated neurons, astrocytes and microglia</td><td>(Avdoshina et al. <xref ref-type="bibr" rid="CR21">2010</xref>)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>assumed Clade B, unless noted otherwise, <sup>b</sup> statistical findings for some results are unclear</p><p><italic>ARV</italic>, antiretroviral(s); <italic>BMVEC</italic>, brain vascular endothelial cells; <italic>[Ca</italic><sup><italic>2+</italic></sup><italic>]</italic><sub>i</sub> intracellular calcium concentration; <italic>8-CAC</italic>, 8-carboxamidocyclazocine; <italic>DAMGO</italic>, D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin; <italic>DCF</italic>, dihydro-dichlorofluorescein; <italic>DOR</italic>, &#x003b4;-opioid receptor; <italic>DHE</italic>, dihydroethidium; <italic>DTG</italic>, dolutegravir; <italic>DPDPE</italic>, [D-Pen<sup>2</sup>,D-Pen<sup>5</sup>]enkephalin; <italic>FTC</italic>, emtricitabine; <italic>GABA</italic>, &#x003b3;-aminobutyric acid; <italic>Iba1</italic>, ionized calcium-binding adapter molecule 1; <italic>JAM-1</italic>, junctional adhesion molecule-1; <italic>KCC2</italic>, K<sup>+</sup>-Cl<sup>&#x02212;</sup> cotransporter 2; <italic>KOR</italic>, &#x003ba;-opioid receptor; <italic>LTR</italic>, long terminal repeat; <italic>&#x00394;</italic><sub><italic>&#x003a8;m</italic></sub>, mitochondrial inner membrane potential; <italic>MOR</italic>, &#x003bc;-opioid receptor; <italic>[Na</italic><sup><italic>+</italic></sup><italic>]</italic><sub>i</sub>, intracellular sodium concentration; <italic>nor-BNI</italic>, nor-binaltorphimine; <italic>NPCs</italic>, neural progenitor cells; <italic>OLs</italic>, oligodendroglia; <italic>ROS</italic>, reactive oxygen species; <italic>TEER</italic>, transendothelial electrical resistance; <italic>TFV</italic>, tenofovir; <italic>TUNEL</italic>, terminal deoxynucleotidyl transferase dUTP nick end labeling; <italic>ZDV</italic>, zidovudine</p><p>For practicality, the table is limited to key studies in the CNS with emphasis on neuropathological or neuroimmune rather than psychosocial outcomes. With deference toward the excellent studies we excluded: (1) on opioid and HIV effects on PBMCs, or on isolated lymphocytes and monocytes, not directly related to the central nervous system or BBB; (2) on HIV or opioid and ARV interactions in the peripheral nervous system; and (3) studies not directly examining opioid-HIV interactions (irrespective of whether a positive or negative interaction was found)</p></table-wrap-foot></table-wrap></p><sec id="Sec7"><title>Opioid and HIV Interactive Pathology in Astroglia</title><p id="Par16">Although the extent to which astroglia display productive infection is debated (Russell et al. <xref ref-type="bibr" rid="CR441">2017</xref>; Ko et al. <xref ref-type="bibr" rid="CR244">2019</xref>), there is nevertheless considerable evidence of proviral integration in the CNS of PWH (Gorry et al. <xref ref-type="bibr" rid="CR184">2003</xref>; Churchill et al. <xref ref-type="bibr" rid="CR96">2009</xref>), infectious animal models (Eugenin et al. <xref ref-type="bibr" rid="CR146">2011</xref>), and/or cultured human fetal astrocytes (Tornatore et al. <xref ref-type="bibr" rid="CR508">1994</xref>; Liu et al. <xref ref-type="bibr" rid="CR290">2004</xref>; Do et al. <xref ref-type="bibr" rid="CR116">2014</xref>; Narasipura et al. <xref ref-type="bibr" rid="CR354">2014</xref>; Li et al. <xref ref-type="bibr" rid="CR284">2015</xref>; Nath <xref ref-type="bibr" rid="CR358">2015</xref>; Li et al. <xref ref-type="bibr" rid="CR286">2020</xref>). Integrated HIV sequences have been identified in astrocytes in HIV-infected CNS tissue by laser capture microdissection (Churchill et al. <xref ref-type="bibr" rid="CR95">2006</xref>). Astroglia appear to infect via non-classical, CD4-independent mechanisms, that can have the appearance of virologic synapses, adding to the debate (Liu et al. <xref ref-type="bibr" rid="CR290">2004</xref>; Do et al. <xref ref-type="bibr" rid="CR116">2014</xref>; Li et al. <xref ref-type="bibr" rid="CR284">2015</xref>; Nath <xref ref-type="bibr" rid="CR358">2015</xref>; Al-Harthi et al. <xref ref-type="bibr" rid="CR6">2019</xref>; Li et al. <xref ref-type="bibr" rid="CR286">2020</xref>).</p><p id="Par17">Irrespective of whether they become infected, MOR-expressing, HIV or HIV protein-exposed astrocytes release greater amounts of inflammatory cytokines and dysfunction sufficient to harm bystander neurons upon treatment with opiates (El-Hage et al. <xref ref-type="bibr" rid="CR130">2005</xref>, <xref ref-type="bibr" rid="CR134">2008b</xref>; Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>; El-Hage et al. <xref ref-type="bibr" rid="CR138">2014</xref>). MOR-expressing subsets of glia, especially microglia and astroglia, are prominent in driving the interactive opioid and HIV neuropathogenesis (Hauser et al. <xref ref-type="bibr" rid="CR207">2007</xref>, <xref ref-type="bibr" rid="CR209">2012</xref>; Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>; Liu et al. <xref ref-type="bibr" rid="CR293">2016a</xref>; Chilunda et al. <xref ref-type="bibr" rid="CR92">2019</xref>; Murphy et al. <xref ref-type="bibr" rid="CR351">2019</xref>). When MOR is deleted from glia (astrocytes and microglia), morphine no longer increases the death of Tat-exposed striatal medium spiny neurons (MSNs) (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>). Conversely, if MOR is deleted from MSNs, morphine exacerbates the neurotoxic effects of Tat in MSNs (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>). The proinflammatory effects of Tat alone or in combination with morphine on glia are mediated through a Beclin-1-dependent autophagy pathway (Rodriguez et al. <xref ref-type="bibr" rid="CR433">2017</xref>; Lapierre et al. <xref ref-type="bibr" rid="CR269">2018</xref>). Drugs with selective glial anti-inflammatory activity (i.e., ibudilast or AV411) attenuated the deleterious effects of HIV and opiate exposure, including HIV-1 replication, cytokine release, and neurotoxicity in vitro (El-Hage et al. <xref ref-type="bibr" rid="CR138">2014</xref>). Thus, the observed neuronal death is largely mediated by MOR-expressing glia (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>), including astroglia (El-Hage et al. <xref ref-type="bibr" rid="CR130">2005</xref>, <xref ref-type="bibr" rid="CR134">2008b</xref>) and microglia (Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR514">2008</xref>; Bokhari et al. <xref ref-type="bibr" rid="CR48">2009</xref>; Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>; Gupta et al. <xref ref-type="bibr" rid="CR195">2010</xref>).</p><p id="Par18">The direct contributions of astrocytes to opioid and HIV interactions have been discussed previously (Dutta and Roy <xref ref-type="bibr" rid="CR123">2012</xref>; Hauser et al. <xref ref-type="bibr" rid="CR209">2012</xref>; Reddy et al. <xref ref-type="bibr" rid="CR422">2012</xref>; Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>). Subsets of astroglia can express MOR, DOR and KOR (Stiene-Martin and Hauser <xref ref-type="bibr" rid="CR484">1991</xref>; Eriksson et al. <xref ref-type="bibr" rid="CR142">1992</xref>; Ruzicka et al. <xref ref-type="bibr" rid="CR443">1995</xref>; Gurwell et al. <xref ref-type="bibr" rid="CR196">1996</xref>; Hauser et al. <xref ref-type="bibr" rid="CR205">1996</xref>; Peterson et al. <xref ref-type="bibr" rid="CR395">1998</xref>; Stiene-Martin et al. <xref ref-type="bibr" rid="CR486">1998</xref>, <xref ref-type="bibr" rid="CR487">2001</xref>), as well as endogenous opioid peptides (Vilijn et al. <xref ref-type="bibr" rid="CR527">1988</xref>; Shinoda et al. <xref ref-type="bibr" rid="CR465">1989</xref>; Spruce et al. <xref ref-type="bibr" rid="CR478">1990</xref>; Hauser et al. <xref ref-type="bibr" rid="CR203">1990</xref>; Low et al. <xref ref-type="bibr" rid="CR296">1992</xref>). It appears that the &#x02018;early&#x02019; events triggering the release of proinflammatory cytokines (i.e., TNF-&#x003b1; and IL-1&#x003b2;) from astroglia can be mediated by HIV Tat exposure alone (El-Hage et al. <xref ref-type="bibr" rid="CR130">2005</xref>, <xref ref-type="bibr" rid="CR131">2006a</xref>, <xref ref-type="bibr" rid="CR132">b</xref>, <xref ref-type="bibr" rid="CR133">2008a</xref>). Opioids enhance HIV-1-induced inflammation later during the inflammatory cascade by exacerbating the sustained release of CCL5 from astrocytes, which subsequently triggers the release of CCL2 thereby enhancing the recruitment and activation of macrophages/microglia (El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This is caused by the morphine-dependent exacerbation of Tat-induced increases in intracellular calcium concentration ([Ca<sup>2+</sup>]<sub>i</sub>) in astroglia (El-Hage et al. <xref ref-type="bibr" rid="CR130">2005</xref>)<sub>,</sub> which accelerates the trafficking of NF-&#x003ba;B p65 (RelA) subunits to the nucleus and sustained CCL2, CCL5, and IL-6 transcription in astrocytes (El-Hage et al. <xref ref-type="bibr" rid="CR134">2008b</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Opioids exacerbate HIV-1-induced CNS inflammation, in part, by augmenting CCL5-dependent increases in CCL2&#x02014;key sites of opioid-HIV convergent interactions in glial inflammatory signaling cascades. Subpopulations of striatal glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in wildtype mice normally express CCR2 immunoreactivity (<bold>a-b</bold>; <italic>arrows</italic>), CCL2 (<bold>c</bold>; <italic>arrow</italic>), or &#x003bc;-opioid receptor (MOR) (<bold>d</bold>; <italic>arrows</italic>) immunoreactivity (scale bars <bold>a-b</bold>&#x000a0;=&#x02009;25&#x000a0;&#x003bc;m; <bold>c-d</bold>&#x000a0;=&#x02009;15&#x000a0;&#x003bc;m). CCR2 deletion (&#x02212;/&#x02212;) significantly reduces HIV-1 Tat&#x02009;&#x000b1;&#x02009;morphine-induced increases in GFAP+ astroglia (<bold>e</bold>) and F4/80+ macrophages/microglia (<bold>f</bold>) compared to wild type (+/+) mice at sites near (300&#x02009;&#x000b1;&#x02009;100&#x000a0;&#x003bc;m) the site of Tat injection (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. wild type mice) (see, El-Hage et al. <xref ref-type="bibr" rid="CR131">2006a</xref>). In wild-type mice, Tat&#x02009;&#x000b1;&#x02009;morphine administration markedly increases the proportion of CCL2 immunoreactive astrocytes (<bold>g</bold>) or macrophages/microglia (<bold>h</bold>) [*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. other groups in wild-type or CCL5(&#x02212;/&#x02212;) mice; <sup>b</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. vehicle- or Tat plus morphine-treated wild-type mice; <sup>#</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. equivalent treatment in wild-type mice], while in CCL5 null mice, significant increases in CCL2 immunoreactivity were only seen in macrophages/microglia co-exposed to Tat and morphine (<sup>&#x000a7;</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. vehicle injected CCL5 knockout mice) (see, El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>). CCL5 expression in striatal GFAP-immunoreactive astrocytes (<italic>arrows</italic>) increases following Tat injections (<bold>i, j</bold>) compared to wild-type control mice (<italic>not shown</italic>) (El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>). Opioids exacerbate HIV-1-induced CNS inflammation, in part, by increasing CCL5 and augmenting CCR5-dependent increases in CCL2 production by astrocytes resulting in the activation and recruitment of microglia/macrophages and spiraling inflammation (<bold>k</bold>). Additional factors likely mediate the proinflammatory cascade, but these are less well substantiated (<italic>?</italic>). Moreover, autocrine and reciprocal paracrine (<italic>astroglial &#x02194; macrophage/microglial</italic>) intercellular, feedback amplification mechanisms from macrophages/microglia are likely to be operative (<italic>dashed red arrow</italic>) (also see, Kang and Hebert <xref ref-type="bibr" rid="CR229">2011</xref>) and occur elsewhere within the cascade (<italic>not shown</italic>); effects of HIV-1 Tat/HIV, <italic>red arrows</italic>; sites of opioid convergence, <italic>blue arrows</italic>; pro-BDNF:mature BDNF (mBDNF) ratio (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). (<bold>a-f</bold>) Modified and reprinted with permission from El-Hage et al. (<xref ref-type="bibr" rid="CR131">2006a</xref>). (<bold>g-k</bold>) Modified and reprinted with permission from El-Hage et al. (<xref ref-type="bibr" rid="CR133">2008a</xref>)</p></caption><graphic xlink:href="11481_2020_9941_Fig1_HTML" id="MO2"/></fig></p></sec><sec id="Sec8"><title>Opioid and HIV Interactive Pathology in Microglia</title><p id="Par19">Unlike in astrocytes, opiate and HIV interactions in microglia tend to be self-limiting (Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>). Opiates initially trigger large increases in the production of proinflammatory cytokines (Hauser, unpublished), reactive oxygen (ROS) and nitrogen (RNS) species (Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>), and the release of glutamate (Gupta et al. <xref ref-type="bibr" rid="CR195">2010</xref>) and ATP (Sorrell and Hauser <xref ref-type="bibr" rid="CR477">2014</xref>) extracellularly in Tat-exposed microglia. The release of glutamate is mediated by the catalytic subunit of the cystine-glutamate antiporter x<sub>c</sub><sup>&#x02212;</sup> (xCT) (Gupta et al. <xref ref-type="bibr" rid="CR195">2010</xref>). Interestingly, following acute increases in the release of cytokines (e.g., TNF-&#x003b1;; unpublished), morphine no longer increases Tat-induced cytokine levels at 24&#x000a0;h; instead, their levels are reduced by opiate-dependent proteasome inhibition. The proteasome inhibitor, MG115, mimics the effects of morphine in decreasing proteasome activity at 24&#x000a0;h and blocks TNF&#x003b1;, IL-6, and CCL2 release from microglia, but does not increase ROS or RNS production (Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>). The ubiquitin proteasome system (UPS) is typically viewed as contributing to opiate tolerance and physical dependence by modulating MOR downregulation (Massaly et al. <xref ref-type="bibr" rid="CR314">2014</xref>; Caputi et al. <xref ref-type="bibr" rid="CR73">2019</xref>), rather than MOR activity constraining the UPS. Thus, while HIV-exposed, MOR-expressing microglia show a burst of ROS and proinflammatory cytokine production in response to morphine, the cytokine release collapses within 24&#x000a0;h seemingly because sustained opiate exposure inhibits the UPS thereby preventing degradation of the I&#x003ba;B subunit and nuclear translocation of NF-&#x003ba;B (Turchan-Cholewo et al. <xref ref-type="bibr" rid="CR515">2009</xref>).</p><p id="Par20">While neither astroglia nor microglia alone mimic the full inflammatory profile seen with opiates and HIV in the CNS; in combination, the neuroimmune signature more accurately mimics that seen in neuroHIV. Accordingly, we have proposed that opioids promote positive feedback through separate actions in astroglia and microglia in neuroHIV&#x02014;resulting in spiraling inflammation and cytotoxicity (Hauser et al. <xref ref-type="bibr" rid="CR206">2005</xref>, <xref ref-type="bibr" rid="CR207">2007</xref>).</p></sec><sec id="Sec9"><title>Opioid and HIV Interactive Pathology in Neurons</title><p id="Par21">Besides accentuating HIV-induced neurotoxicity via glial-mediated mechanisms, morphine appears to converge with HIV Tat to dysregulate ion homeostasis and dendritic injury through potential direct actions on neurons, even though some contributions of glia cannot be excluded in this study (Fitting et al. <xref ref-type="bibr" rid="CR162">2014a</xref>). Combined morphine and Tat exposure accelerates the formation of Tat-induced focal dendritic varicosities/swelling via a MOR-related mechanism that was caused by focal increases in Na<sup>+</sup> influx and [Ca<sup>2+</sup>]<sub>i</sub>, an overload of Na<sup>+</sup>/K<sup>+</sup>-ATPase, ATP depletion, and a collapse in mitochondrial inner membrane potential (Fitting et al. <xref ref-type="bibr" rid="CR162">2014a</xref>). Importantly, morphine&#x02019;s additive effects were mediated via a MOR-related mechanism, as the exacerbating effects of morphine were absent in neurons from MOR knockout mice, thus excluding TLR4 involvement (Fitting et al. <xref ref-type="bibr" rid="CR162">2014a</xref>). Further, morphine exacerbated Tat-dependent focal losses in ion homeostasis by mobilizing [Ca<sup>2+</sup>]<sub>i</sub> through ryanodine-2 (RyR2)-sensitive sites (Fitting et al. <xref ref-type="bibr" rid="CR162">2014a</xref>) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Although morphine typically acts via MOR in an inhibitory manner by activating G<sub>i/o</sub>-proteins (Sharma et al. <xref ref-type="bibr" rid="CR462">1977</xref>; Moises et al. <xref ref-type="bibr" rid="CR343">1994</xref>; Al-Hasani and Bruchas <xref ref-type="bibr" rid="CR7">2011</xref>), MOR-dependent stimulation of PI3-kinase and Ca<sup>2+</sup> mobilization (Leopoldt et al. <xref ref-type="bibr" rid="CR277">1998</xref>) in neurons via the G&#x003b2;&#x003b3; protein subunit (Mathews et al. <xref ref-type="bibr" rid="CR317">2008</xref>) is presumed operative here (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Morphine exacerbates the excitotoxic effects of HIV Tat by mobilizing Ca<sup>2+</sup> from ryanodine (RyR)-sensitive internal stores. (<bold>a</bold>) Tat-induced increases in [Ca<sup>2+</sup>]<sub>i</sub> were not attenuated by ryanodine, whereas ryanodine and pyruvate attenuate combined Tat and morphine-induced increases in [Ca<sup>2+</sup>]<sub>i</sub>. Nimodipine (L-type Ca<sup>2+</sup> channel blocker) and dantrolene did not show any effects. (<bold>b</bold>) Average [Ca<sup>2+</sup>]<sub>i</sub> over 10&#x000a0;min indicated ryanodine significantly blocked combined Tat and morphine-induced increases in [Ca<sup>2+</sup>]<sub>i</sub>, whereas no effects were noted for nimodipine, dantrolene, or pyruvate. *<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. control, <sup>#</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. Tat 50 nM, <sup>&#x000a7;</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. TM, TM: Tat 50&#x000a0;nM&#x02009;+&#x02009;Morphine 500&#x000a0;nM. (<bold>c</bold>) Summary of HIV-1 Tat and morphine interactive neuronal injury in striatal medium spiny neurons. Combined Tat and morphine promotes structural and functional defects in dendrites via &#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), <italic>N</italic>-methyl-D-aspartic acid receptors (NMDAR), and MOR, causing influxes of Na<sup>+</sup> and/or Ca<sup>2+</sup>, compensatory increases in Na<sup>+</sup>/K<sup>+</sup>-dependent ATPase activity, and a rapid loss in ATP mobilization with an inability to extrude excess Na<sup>+</sup> via Na<sup>+</sup>/K<sup>+</sup>-ATPase caused by mitochondrial hyperpolarization. Dysregulation of [Ca<sup>2+</sup>]<sub>i</sub> homeostasis by combined Tat and morphine appears to be mediated downstream of [Na<sup>+</sup>]<sub>i</sub> at the level of calcium mobilization, which in turn appears to be regulated via ryanodine (RyR)-sensitive sites, and enhanced by morphine exposure likely via MOR-dependent stimulation of PI3-kinase and Ca<sup>2+</sup> mobilization via the G&#x003b2;&#x003b3; protein subunit. (<bold>a-b</bold>) Modified and reprinted with permission from Fitting et al. (<xref ref-type="bibr" rid="CR162">2014a</xref>)</p></caption><graphic xlink:href="11481_2020_9941_Fig2_HTML" id="MO3"/></fig></p><p id="Par22">Glial-derived neuronal injury is not unidirectional. Neuronal damage-associated molecular patterns (DAMPs) and dysfunction can trigger both infected and uninfected glia to become reactive, resulting in further neuronal damage and escalating pathology. Neuronal injury can reactivate HIV in latently infected microglia (Alvarez-Carbonell et al. <xref ref-type="bibr" rid="CR9">2019</xref>). While the events underlying the disruption of neuronal-microglial activation that trigger the emergence of latent HIV are unclear, the induction of HIV expression appears to involve the production of DAMPs by injured neurons and can be turned &#x0201c;on&#x0201d;, e.g., by methamphetamine-induced sigma-1 (&#x003c3;1) receptor activation, TNF-&#x003b1; and IL-1&#x003b2;, and TLR3 activation can be turned &#x0201c;off&#x0201d; by CX3CL1/fractalkine or glucocorticoid receptor activation (Alvarez-Carbonell et al. <xref ref-type="bibr" rid="CR8">2017</xref>, <xref ref-type="bibr" rid="CR9">2019</xref>).</p></sec></sec><sec id="Sec10"><title>Neural Systems Selectively Disrupted by Opiate and HIV Interactions</title><sec id="Sec11"><title>Blood-Brain Barrier and the Neurovascular Unit</title><p id="Par23">Despite growing evidence on how opiates and HIV interact to impact the neuropathology of HIV, little is known about their interactive effects on the blood-brain barrier (BBB). BBB integrity and function are critical for maintaining CNS homeostasis, and mediating neuroimmune interactions with the periphery and drug delivery into the CNS. HIV and many individual HIV proteins can breakdown the BBB disrupting tight junction proteins (Dallasta et al. <xref ref-type="bibr" rid="CR109">1999</xref>; Boven et al. <xref ref-type="bibr" rid="CR55">2000</xref>; Andras et al. <xref ref-type="bibr" rid="CR10">2003</xref>; Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Banerjee et al. <xref ref-type="bibr" rid="CR27">2010</xref>; Gandhi et al. <xref ref-type="bibr" rid="CR172">2010</xref>; Xu et al. <xref ref-type="bibr" rid="CR550">2012</xref>; Patel et al. <xref ref-type="bibr" rid="CR383">2017</xref>) and decreasing transendothelial electrical resistance (TEER) (an in vitro measure of barrier integrity) (Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Gandhi et al. <xref ref-type="bibr" rid="CR172">2010</xref>; Mishra and Singh <xref ref-type="bibr" rid="CR340">2014</xref>; Patel et al. <xref ref-type="bibr" rid="CR383">2017</xref>), with resultant paracellular &#x0201c;leakage&#x0201d; of compounds/current between compromised barrier endothelial cells (Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Gandhi et al. <xref ref-type="bibr" rid="CR172">2010</xref>; Wen et al. <xref ref-type="bibr" rid="CR537">2011</xref>; McLane et al. <xref ref-type="bibr" rid="CR327">2014</xref>; Leibrand et al. <xref ref-type="bibr" rid="CR273">2017</xref>, <xref ref-type="bibr" rid="CR274">2019</xref>). Although opioids can also impair the BBB through alterations in tight junction proteins and/or increased paracellular flux (Baba et al. <xref ref-type="bibr" rid="CR23">1988</xref>; Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Wen et al. <xref ref-type="bibr" rid="CR537">2011</xref>; Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>), others have found that it is morphine withdrawal, not the continued exposure to morphine, that most greatly disrupts BBB integrity (Sharma and Ali <xref ref-type="bibr" rid="CR461">2006</xref>). In addition to perturbing paracellular dynamics, morphine may also alter the expression and/or function of drug efflux proteins, such as P-glycoprotein (P-gp). Sub-chronic and chronic morphine exposure is reported to increase P-gp expression and/or function (Aquilante et al. <xref ref-type="bibr" rid="CR17">2000</xref>; Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Yousif et al. <xref ref-type="bibr" rid="CR555">2008</xref>; Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>). Alternatively, other investigators report no changes in P-gp with chronic exposure (Chaves et al. <xref ref-type="bibr" rid="CR88">2016</xref>), while some see increases upon morphine withdrawal (Yousif et al. <xref ref-type="bibr" rid="CR556">2012</xref>; Chaves et al. <xref ref-type="bibr" rid="CR88">2016</xref>). Alterations in drug transport proteins would impact the central accumulation and efficacy of therapeutic drugs that are their substrates.</p><p id="Par24">Using a primary human brain microvascular endothelial cell (BMEC) and astrocyte co-culture model, Mahajan et al. (<xref ref-type="bibr" rid="CR303">2008</xref>) were among the first to demonstrate that co-exposure to morphine and HIV-1 Tat resulted in greater increases in TNF-&#x003b1; and IL-8 levels and decreases in barrier tightness (measured by TEER) than either morphine or Tat alone. Morphine and Tat co-exposure also additively increased JAM-2, while zonula occludens-1 (ZO-1) levels were decreased by morphine or by Tat individually, and occludin protein levels were decreased by morphine alone but not Tat (Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>). Using the inducible Tat transgenic mouse model, Leibrand et al. (<xref ref-type="bibr" rid="CR274">2019</xref>), also demonstrated that HIV-1 Tat and morphine act independently to disrupt BBB integrity. In these studies, morphine, and to a lesser extent Tat, exposure increased the leakage of fluorescently labeled dextrans from the circulation into the brain (Leibrand et al. <xref ref-type="bibr" rid="CR273">2017</xref>, <xref ref-type="bibr" rid="CR274">2019</xref>) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Morphine exposure decreased the penetration of select ARVs in the brain, in a region-specific manner (Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Morphine exposure also resulted in increased expression and function of the drug efflux transport protein, P-gp, suggesting a mechanism by which morphine decreased the ARV concentrations (Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>). This finding suggests that morphine exposure could impact the efficient delivery of any therapeutic drug that is a substrate of P-gp into the CNS. Future research should also investigate morphine&#x02019;s impact on other drug transport proteins important for ARV delivery to the brain.<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of HIV-1 Tat and morphine on BBB leakiness and on antiretroviral brain concentrations. After 14 days of Tat induction, there was a significant increase in the 10&#x000a0;kDa (Cascade Blue&#x000ae;) tracer leakage into the brain in Tat&#x02009;+&#x02009;placebo as compared to Tat&#x02009;&#x02212;&#x02009;placebo mice (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05) and in Tat&#x02009;&#x02212;&#x02009;mouse brains upon exposure to morphine as compared to Tat&#x02009;&#x02212;&#x02009;placebo mice (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05) (<bold>a</bold>). There was a significant main effect of morphine, resulting in reduced integrity of the BBB and increased leakage of the higher molecular weight (40&#x000a0;kDa and 70&#x000a0;kDa) tracers in morphine-exposed groups as compared to the those groups (Tat&#x02009;+&#x02009;and Tat&#x02009;&#x02212;&#x02009;together) not exposed to morphine (placebo) (<sup>#</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05; significant main effect of morphine) (<bold>b, c</bold>). Data represent the fold change in mean fluorescence intensity &#x000b1; SEM; <italic>n</italic>&#x000a0;=&#x02009;8 Tat&#x02212;/placebo, <italic>n</italic>&#x000a0;=&#x02009;6 Tat+/placebo, <italic>n</italic>&#x000a0;=&#x02009;9 Tat&#x02212;/morphine, and <italic>n</italic>&#x000a0;=&#x02009;7 Tat+/morphine mice. Additionally, morphine exposure increased horseradish peroxidase (HRP) extravasation from the vasculature into the perivascular space and/or parenchyma in the striatum (<bold>d, e</bold>). HRP antigenicity was detected by indirect immunofluorescence (red) in tissue sections counterstained with Hoechst 33342 (blue) to reveal cell nuclei and visualized by differential interference contrast (DIC)-enhanced confocal microscopy. HRP extravasation into the striatal perivascular space/parenchyma was especially prevalent in morphine-exposed mice (arrowheads; left-hand panels in <bold>e</bold> versus <bold>d</bold>). The dotted lines (&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;&#x000b7;) indicate the approximate edge of the capillaries/post-capillary venules; while intermittent dotted lines (&#x000b7; &#x000b7; &#x000b7; &#x000b7; &#x000b7; &#x000b7; &#x000b7;) indicate the approximate edge of a partly sectioned blood vessel that appears partially outside the plane of section. The asterisks (*) indicate white matter tracts within the striatum. Representative samples from &#x02265; <italic>n</italic> = 4 mice per group. All images are the same magnification. Scale bar = 10 &#x003bc;m. Antiretroviral tissue-to-plasma ratios in striatum (<bold>f&#x02013;g</bold>). Irrespective of Tat exposure, morphine significantly reduced the levels of dolutegravir (<bold>f</bold>) and abacavir (<bold>g</bold>), but not lamivudine (<bold>h</bold>), within the striatum, as compared to placebo. (* <italic>p</italic> &#x0003c; 0.05; main effect for morphine). Data represent the tissue-to-plasma ratios &#x000b1; SEM sampled from <italic>n</italic> = 9 Tat&#x02212;/placebo, <italic>n</italic> = 9 Tat+/placebo, <italic>n</italic> = 6 Tat&#x02212;/morphine, and <italic>n</italic> = 8 Tat+/morphine mice. (<bold>a&#x02013;h</bold>) Modified and reprinted with permission from Leibrand et al. (<xref ref-type="bibr" rid="CR274">2019</xref>)</p></caption><graphic xlink:href="11481_2020_9941_Fig3_HTML" id="MO4"/></fig></p><p id="Par25">HIV, HIV-1 viral proteins, and opiate-induced barrier dysfunction is associated with increased infiltration of monocyte-derived macrophages (MDMs) into the brain. Enhanced influx of peripheral (infected) macrophages into the brain can serve to replenish viral reservoirs and further promote neuroinflammation. Several studies have examined the individual impact of HIV, Tat, or morphine on monocyte adhesion or migration into the CNS (Nottet et al. <xref ref-type="bibr" rid="CR371">1996</xref>; Wu et al. <xref ref-type="bibr" rid="CR545">2000</xref>; Fischer-Smith et al. <xref ref-type="bibr" rid="CR158">2001</xref>; Pello et al. <xref ref-type="bibr" rid="CR385">2006</xref>; Williams et al. <xref ref-type="bibr" rid="CR539">2013a</xref>, <xref ref-type="bibr" rid="CR541">2014</xref>; Strazza et al. <xref ref-type="bibr" rid="CR490">2016</xref>; Leibrand et al. <xref ref-type="bibr" rid="CR273">2017</xref>; Chilunda et al. <xref ref-type="bibr" rid="CR92">2019</xref>). However, fewer studies have examined the combined effects of HIV/Tat and opiates. Co-exposure of HIV-1 Tat and morphine on astrocytes increases the production of chemoattractants, primarily CCL2 and CCL5, and increases microglial migration. These effects were inhibited by MOR blockade (El-Hage et al. <xref ref-type="bibr" rid="CR132">2006b</xref>). Co-exposure of Tat and morphine or buprenorphine to a BBB model increases monocyte transmigration in response to CCL5 and other chemokines (Mahajan et al. <xref ref-type="bibr" rid="CR303">2008</xref>; Jaureguiberry-Bravo et. al. <xref ref-type="bibr" rid="CR225">2016</xref>). In <italic>S. pneumoniae</italic>-infected mice, morphine and/or Tat exposure significantly enhances immune cell trafficking into the brain via actions at TLR2 and TLR4 (Dutta and Roy <xref ref-type="bibr" rid="CR124">2015</xref>).</p><p id="Par26">Taken together, BBB damage from HIV and/or opiates can disrupt the homeostasis within the brain. Breakdown of paracellular processes, through decreases in tight junction proteins and increased cellular adhesion proteins, increased leakage of circulating molecules into the brain and increased monocyte/MDM adhesion and transmigration into the brain, which if infected, can serve to replenish viral reservoirs within the CNS. Furthermore, alterations in drug transport proteins within the brain can decrease ARV efficacy by decreasing drug concentrations. Collectively, these changes serve to maintain HIV infection within the brain (see Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref><bold>;</bold> Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Schematic representation of the blood-brain barrier and other components of the neurovascular unit. Under normal conditions (represented above the dotted line), tight junctions are intact which restricts the leakage of paracellular, typically small hydrophilic, compounds, across the barrier and into the brain. Additionally, there is a basal expression of efflux transporters, such as P-glycoprotein (P-gp), which effluxes substrates out of the brain, serving to restrict overall accumulation within the brain. In the setting of HIV and opiate exposure (represented below the dotted line), there is a breakdown of the tight junction proteins and increased leakage of paracellular compounds into the brain. Additionally, opiate exposure increases efflux transporter expression, including P-gp and potentially breast cancer resistance protein (Bcrp), thereby restricting overall brain penetration of drugs (like many antiretroviral drugs) which are substrates for these transporters and in response to HIV and/or opioid exposure.</p></caption><graphic xlink:href="11481_2020_9941_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec12"><title>White Matter/Oligodendroglial Pathology</title><p id="Par27">HIV can cause white matter damage (Gosztonyi et al. <xref ref-type="bibr" rid="CR186">1994</xref>; Langford et al. <xref ref-type="bibr" rid="CR268">2002</xref>; Xuan et al. <xref ref-type="bibr" rid="CR554">2013</xref>) even with less severe forms of HAND (Chen et al. <xref ref-type="bibr" rid="CR90">2009</xref>; Leite et al. <xref ref-type="bibr" rid="CR275">2013</xref>; Correa et al. <xref ref-type="bibr" rid="CR104">2015</xref>). Diffusion tensor magnetic resonance imaging (DTI) demonstrates white matter damage early in HAND (Ragin et al. <xref ref-type="bibr" rid="CR415">2004</xref>; Stubbe-Drger et al. <xref ref-type="bibr" rid="CR491">2012</xref>; Leite et al. <xref ref-type="bibr" rid="CR275">2013</xref>; Correa et al. <xref ref-type="bibr" rid="CR104">2015</xref>). White matter deficits are associated with cognitive impairment, including shortfalls in memory (Ragin et al. <xref ref-type="bibr" rid="CR416">2005</xref>), executive function (Correa et al. <xref ref-type="bibr" rid="CR104">2015</xref>), motor speed (Wu et al. <xref ref-type="bibr" rid="CR546">2006</xref>; Stubbe-Drger et al. <xref ref-type="bibr" rid="CR491">2012</xref>), and perhaps depression (Schmaal and van Velzen <xref ref-type="bibr" rid="CR455">2019</xref>). Preclinical studies in simian immunodeficiency virus- (SIV-) infected rhesus macaques (Marcario et al. <xref ref-type="bibr" rid="CR306">2008</xref>) and HIV-infected humanized mice (Boska et al. <xref ref-type="bibr" rid="CR53">2014</xref>) support the clinical findings. Injury to oligodendrocytes (OLs) can occur very early in the disease (see review, Liu et al. <xref ref-type="bibr" rid="CR294">2016b</xref>). Viral proteins, including Tat, gp120, and Nef, have been implicated in OL injury in vitro (Kimura-Kuroda et al. <xref ref-type="bibr" rid="CR238">1994</xref>; Bernardo et al. <xref ref-type="bibr" rid="CR43">1997</xref>; Radja et al. <xref ref-type="bibr" rid="CR414">2003</xref>; Nukuzuma et al. <xref ref-type="bibr" rid="CR373">2012</xref>; Zou et al. <xref ref-type="bibr" rid="CR561">2015</xref>), and in animal models in vivo (Radja et al. <xref ref-type="bibr" rid="CR414">2003</xref>; Hauser et al. <xref ref-type="bibr" rid="CR208">2009</xref>; Zou et al. <xref ref-type="bibr" rid="CR561">2015</xref>). Importantly, Tat has been detected in OLs in the brains of AIDS patients (Del Valle et al. <xref ref-type="bibr" rid="CR112">2000</xref>).</p><p id="Par28">HIV likely damages OLs through both direct and indirect actions. OLs lack CD4, and reports of OL infection by HIV are variable (Esiri et al. <xref ref-type="bibr" rid="CR145">1991</xref>; Albright et al. <xref ref-type="bibr" rid="CR4">1996</xref>; Wohlschlaeger et al. <xref ref-type="bibr" rid="CR543">2009</xref>); thus, HIV infection of OLs is unlikely a major avenue of OL or white matter damage (discussed below). Alternatively, bystander damage to OLs through the production of &#x0201c;virotoxins&#x0201d; and &#x0201c;cellular toxins&#x0201d; (Nath <xref ref-type="bibr" rid="CR357">1999</xref>) by infected neighboring cells is more likely to be operative (Hauser et al. <xref ref-type="bibr" rid="CR208">2009</xref>; Zou et al. <xref ref-type="bibr" rid="CR561">2015</xref>; Jensen et al. <xref ref-type="bibr" rid="CR228">2019</xref>; Zou et al. <xref ref-type="bibr" rid="CR562">2019</xref>). ARVs also contribute to OL cytotoxicity (Jensen et al. <xref ref-type="bibr" rid="CR227">2015</xref>; Festa et al. <xref ref-type="bibr" rid="CR156">2019</xref>; Jensen et al. <xref ref-type="bibr" rid="CR228">2019</xref>). HIV-1 Tat directly induces damage in isolated OLs through &#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/<italic>N</italic>-methyl-D-aspartic acid (NMDA) receptor-dependent mechanisms (Zou et al. <xref ref-type="bibr" rid="CR561">2015</xref>) and is also associated with abnormal Kv1.3 activity (Liu et al. <xref ref-type="bibr" rid="CR295">2017</xref>). Immature OLs are preferentially targeted by Tat compared to differentiated OLs (Khurdayan et al. <xref ref-type="bibr" rid="CR234">2004</xref>; Hahn et al. <xref ref-type="bibr" rid="CR199">2012</xref>; Zou et al. <xref ref-type="bibr" rid="CR561">2015</xref>, <xref ref-type="bibr" rid="CR562">2019</xref>). While the reasons why immature OLs are more susceptible to Tat are unclear, unlike mature OLs, Tat preferentially upregulates GSK-3&#x003b2; signaling in undifferentiated OLs by inhibiting Ca<sup>2+</sup>/calmodulin-dependent protein kinase II &#x003b2; (CaMKII&#x003b2;) (Zou et al. <xref ref-type="bibr" rid="CR562">2019</xref>).</p><p id="Par29">Opioid abuse by itself can result in demyelination, leukoencephalopathy, and lesions in white matter (Offiah and Hall <xref ref-type="bibr" rid="CR375">2008</xref>; Eran and Barak <xref ref-type="bibr" rid="CR141">2009</xref>; Morales Odia et al. <xref ref-type="bibr" rid="CR345">2010</xref>; Bora et al. <xref ref-type="bibr" rid="CR52">2012</xref>; Li et al. <xref ref-type="bibr" rid="CR283">2013</xref>), and the degree of myelin disruption correlates with the duration of opiate dependence (Ivers et al. <xref ref-type="bibr" rid="CR221">2018</xref>). Chronic oxycodone exposure in rats causes some axonopathies and reduces the size of axonal fascicles, decreases myelin basic protein levels, and causes the accumulation of amyloid-&#x003b2; precursor protein (APP) (Fan et al. <xref ref-type="bibr" rid="CR151">2018</xref>). Most preclinical studies have examined the effects of opioids and opioid receptor blockade on OL maturation and/or the timing of myelination (Hauser et al. <xref ref-type="bibr" rid="CR204">1993</xref>; Knapp et al. <xref ref-type="bibr" rid="CR241">1998</xref>; Stiene-Martin et al. <xref ref-type="bibr" rid="CR487">2001</xref>; Sanchez et al. <xref ref-type="bibr" rid="CR451">2008</xref>; Knapp et al. <xref ref-type="bibr" rid="CR243">2009</xref>; Vestal-Laborde et al. <xref ref-type="bibr" rid="CR526">2014</xref>). OLs can transiently express MORs and other opioid receptor types (Knapp et al. <xref ref-type="bibr" rid="CR241">1998</xref>; Tryoen-Toth et al. <xref ref-type="bibr" rid="CR512">2000</xref>; Knapp et al. <xref ref-type="bibr" rid="CR242">2001</xref>; Stiene-Martin et al. <xref ref-type="bibr" rid="CR487">2001</xref>). Selective MOR and possibly KOR activation can directly modulate the growth of OLs in vitro (Knapp and Hauser <xref ref-type="bibr" rid="CR240">1996</xref>; Knapp et al. <xref ref-type="bibr" rid="CR241">1998</xref>, <xref ref-type="bibr" rid="CR242">2001</xref>).</p><p id="Par30">Despite long-standing evidence of white matter damage early during the infection even in asymptomatic PWH (Price et al. <xref ref-type="bibr" rid="CR404">1988</xref>; Gray et al. <xref ref-type="bibr" rid="CR187">1996</xref>; Chen et al. <xref ref-type="bibr" rid="CR90">2009</xref>; Stubbe-Drger et al. <xref ref-type="bibr" rid="CR491">2012</xref>; Jensen et al. <xref ref-type="bibr" rid="CR228">2019</xref>), few studies have examined how opiate exposure affects OLs and myelin in neuroHIV (Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Increased demyelination is reported in SIV-infected rhesus macaques chronically treated with morphine (4&#x000d7; daily, up to 59&#x000a0;weeks) (Marcario et al. <xref ref-type="bibr" rid="CR306">2008</xref>). Specifically, morphine-treated SIV macaques developed more subtle, focal, dysmyelinating lesions, with accumulations of macrophages in areas of myelin loss (Marcario et al. <xref ref-type="bibr" rid="CR306">2008</xref>), as well as accompanying gliosis (Marcario et al. <xref ref-type="bibr" rid="CR306">2008</xref>; Rivera-Amill et al. <xref ref-type="bibr" rid="CR428">2010a</xref>; Bokhari et al. <xref ref-type="bibr" rid="CR49">2011</xref>). Morphine exposure increased degeneration of OLs in Tat+&#x02009;mice, which was accompanied by elevations in caspase-3 activation and TUNEL reactivity in OLs and reversible by naloxone or naltrexone, respectively (Hauser et al. <xref ref-type="bibr" rid="CR208">2009</xref>). Although OLs can express MOR both in vivo (Stiene-Martin et al. <xref ref-type="bibr" rid="CR487">2001</xref>) and in vitro (Hauser et al. <xref ref-type="bibr" rid="CR208">2009</xref>), it remains unclear the extent to which MOR activation in OLs directly mediates HIV pathogenesis.</p></sec><sec id="Sec13"><title>Neural Progenitors as an HIV Reservoir and Target for Opioids</title><p id="Par31">Even though neural progenitors (Krathwohl and Kaiser <xref ref-type="bibr" rid="CR254">2004</xref>; Lawrence et al. <xref ref-type="bibr" rid="CR271">2004</xref>; Rothenaigner et al. <xref ref-type="bibr" rid="CR436">2007</xref>; Schwartz et al. <xref ref-type="bibr" rid="CR458">2007</xref>; Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>), neuroblast cell lines (Ensoli et al. <xref ref-type="bibr" rid="CR140">1994</xref>; Rothenaigner et al. <xref ref-type="bibr" rid="CR436">2007</xref>), and/or immature astroglia (Atwood et al. <xref ref-type="bibr" rid="CR20">1993</xref>; Tornatore et al. <xref ref-type="bibr" rid="CR508">1994</xref>; Barat et al. <xref ref-type="bibr" rid="CR29">2018</xref>) can harbor HIV infection (reviewed by Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>; Putatunda et al. <xref ref-type="bibr" rid="CR411">2019</xref>), the degree to which they are a source of active infection or serve as a latent viral reservoir (Blankson et al. <xref ref-type="bibr" rid="CR44">2002</xref>; Bruner et al. <xref ref-type="bibr" rid="CR60">2019</xref>) by retaining intact proviral DNA within incipient macroglial progeny is uncertain. In fact, spurious reports of HIV-infected adult neurons (Torres-Munoz et al. <xref ref-type="bibr" rid="CR509">2001</xref>; Canto-Nogues et al. <xref ref-type="bibr" rid="CR72">2005</xref>) may result from the retention of proviral genes that integrated into pluripotent neural progenitors or neuroblasts at earlier stages during maturation. Importantly, prolonged exposure to opioids can increase the production of HIV in human neural progenitor cells (hNPCs). Exposure of R5-tropic HIV<sub>BaL</sub>-infected hNPCs to morphine continuously for 21 d increased viral production compared to HIV<sub>BaL</sub> infection alone in vitro (Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>).</p><p id="Par32">Besides being able to infect hNPCs, HIV may also affect their maturation and the fate of neural stem cells. That HIV or gp120 can inhibit adult neurogenesis (Okamoto et al. <xref ref-type="bibr" rid="CR376">2007</xref>; Lee et al. <xref ref-type="bibr" rid="CR272">2013</xref>; Putatunda et al. <xref ref-type="bibr" rid="CR410">2018</xref>) has been the topic of past reviews (Schwartz and Major <xref ref-type="bibr" rid="CR457">2006</xref>; Venkatesan et al. <xref ref-type="bibr" rid="CR524">2007</xref>; Peng et al. <xref ref-type="bibr" rid="CR387">2008</xref>, <xref ref-type="bibr" rid="CR388">2011</xref>; Ferrell and Giunta <xref ref-type="bibr" rid="CR154">2014</xref>; Hauser and Knapp <xref ref-type="bibr" rid="CR201">2014</xref>; Putatunda et al. <xref ref-type="bibr" rid="CR411">2019</xref>). How HIV inhibits the self-renewal, tripotential differentiation, and survival of neural progenitors/stem cells or the genesis of adult neurons in the subgranular zone (SGZ) of the dentate gyrus is uncertain. HIV and gp120 [via actions at the same chemokine receptor(s) (Tran and Miller <xref ref-type="bibr" rid="CR510">2005</xref>; Li and Ransohoff <xref ref-type="bibr" rid="CR281">2008</xref>)] are proposed to modulate the adult neurogenesis via Notch (Fan et al. <xref ref-type="bibr" rid="CR150">2016</xref>), by obstructing a cell cycle checkpoint via the activation MAPK-activated protein kinase 2 and Cdc25B/C (Okamoto et al. <xref ref-type="bibr" rid="CR376">2007</xref>), or through signaling by platelet-derived growth factor BB (Chao et al. <xref ref-type="bibr" rid="CR86">2014</xref>) or BDNF (Lee et al. <xref ref-type="bibr" rid="CR272">2013</xref>). The extent that HIV regulates the genesis of neural progenitors within the subventricular zone of the developing CNS through similar mechanisms as in the adult SGZ of the dentate gyrus is uncertain&#x02014;even though HIV disrupts the generation of neurons and glia during maturation or in adults. For example, MAPK/ERK1/2 enhances p53- and p21-dependent downregulation of cyclin D1 hindering progression through the G<sub>1</sub> phase of the cell cycle in hNPCs (Mishra et al. <xref ref-type="bibr" rid="CR342">2010</xref>; Malik et al. <xref ref-type="bibr" rid="CR305">2014</xref>). Importantly, opioids too can affect the genesis of neurons and glia during maturation or in the adult directly via convergent pathways (Hauser and Knapp <xref ref-type="bibr" rid="CR202">2018</xref>; Kibaly et al. <xref ref-type="bibr" rid="CR235">2018</xref>) suggesting yet another site of opioid and HIV interactions in dysregulating the creation and fate of new neurons and glia.</p><p id="Par33">Few studies have examined the interplay between opioids, neural progenitors and HIV/HIV proteins. Sustained exposure (4 d) to morphine (500&#x000a0;nM) and Tat<sub>1&#x02013;72</sub> (100&#x000a0;nM) decreased the viability of MOR-expressing striatal glial precursors, and to a lesser extent astrocytes, and this coincided with caspase-3 activation (Khurdayan et al. <xref ref-type="bibr" rid="CR234">2004</xref>). By contrast, comparably administered morphine or Tat alone was sufficient to decrease the viability of immature glia/glial progenitors in spinal cord cultures, while Tat and morphine failed to interact (Buch et al. <xref ref-type="bibr" rid="CR61">2007</xref>). Collectively, these findings were the first to indicate that opioid and/or Tat could enhance programmed cell death in subpopulations of glial precursors in a developmentally regulated and region-dependent manner (Khurdayan et al. <xref ref-type="bibr" rid="CR234">2004</xref>; Buch et al. <xref ref-type="bibr" rid="CR61">2007</xref>). In human glial progenitors, co-administering morphine (500&#x000a0;nM) increased the antiproliferative effects of Tat (12&#x02013;48&#x000a0;h) or conditioned medium from HIV-1<sub>SF162</sub>-infected MDMs (12&#x000a0;h), while paradoxically reversing the antiproliferative effects from HIV-1<sub>IIIB</sub> conditioned medium (12&#x000a0;h) (Hahn et al. <xref ref-type="bibr" rid="CR199">2012</xref>). In these studies, Tat or HIV exposure reduced the proliferation of Sox2+ and Olig2+ undifferentiated glial and oligodendroglial progenitors, respectively, while progenitor viability was unchanged (Hahn et al. <xref ref-type="bibr" rid="CR199">2012</xref>). In human neural progenitor cells (hNPCs), sustained infection with R5-tropic HIV<sub>BaL</sub> increased the proliferation and premature differentiation of hNPCs into both neurons and astrocytes, and both measures were significantly enhanced by morphine co-exposure (Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>). Importantly, immunoneutralizing antibodies (Hahn et al. <xref ref-type="bibr" rid="CR199">2012</xref>) or the selective antagonist, maraviroc (Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>), were able to significantly attenuate the consequences of R5-tropic HIV infection on hNPC differentiation and fate confirming a direct role of CCR5 in these processes. Lastly, decreases in the proliferation of hNPCs seen with morphine and Tat are, in part, regulated by ERK1/2-dependent increases in p53 and p21 expression (Malik et al. <xref ref-type="bibr" rid="CR305">2014</xref>) and can be modulated by PDGF BB suggesting a possible therapeutic target (Malik et al. <xref ref-type="bibr" rid="CR304">2011</xref>). Thus, morphine can exaggerate R5-tropic HIV-induced alterations in the maturation and fate of human and rodent NPCs, thereby further disrupting the balance of neural cell types and CNS function.</p></sec></sec></sec><sec id="Sec14"><title>Matters Needing Further Consideration in Opioid and HIV Comorbidity</title><p id="Par34">The interplay of complex host and viral genetic differences is likely to play a huge role in determining pathologic outcomes in PWH. For example, differences in HIV strains/variants (Rao et al. <xref ref-type="bibr" rid="CR420">2013</xref>) and human/host genetic variability (Proudnikov et al. <xref ref-type="bibr" rid="CR406">2012</xref>), pharmacokinetics (Kuhlman et al. <xref ref-type="bibr" rid="CR263">1996</xref>; Eap et al. <xref ref-type="bibr" rid="CR127">2002</xref>; Elkader and Sproule <xref ref-type="bibr" rid="CR139">2005</xref>; Kharasch <xref ref-type="bibr" rid="CR232">2017</xref>; Kringen et al. <xref ref-type="bibr" rid="CR261">2017</xref>), and sex (Zubieta et al. <xref ref-type="bibr" rid="CR563">2002</xref>; Taylor and Davies <xref ref-type="bibr" rid="CR501">2010</xref>; Venuto et al. <xref ref-type="bibr" rid="CR525">2014</xref>; Marinho et al. <xref ref-type="bibr" rid="CR308">2019</xref>) all contribute to variability in responsiveness. The following subsections will focus on key factors affecting opioid and HIV comorbidity.</p><sec id="Sec15"><title>HIV-1 Genetics</title><p id="Par35">Genetic differences among HIV-1 variants have a significant impact on HIV transmission, disease progression, as well as the response to ARV therapy (see reviews, Geretti <xref ref-type="bibr" rid="CR177">2006</xref>; Taylor et al. <xref ref-type="bibr" rid="CR502">2008</xref>; Tyor et al. <xref ref-type="bibr" rid="CR516">2013</xref>; Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Pre-cART studies provide substantial evidence that HIV clade differences can influence HAND (Gupta et al. <xref ref-type="bibr" rid="CR194">2007</xref>; Sacktor et al. <xref ref-type="bibr" rid="CR445">2009</xref>; Boivin et al. <xref ref-type="bibr" rid="CR47">2010</xref>; McArthur et al. <xref ref-type="bibr" rid="CR321">2010</xref>; Rao et al. <xref ref-type="bibr" rid="CR420">2013</xref>), with HAND severity being highest for clade D and B strains, followed by C and A clades (Tyor et al. <xref ref-type="bibr" rid="CR516">2013</xref>). These findings are supported by preclinical studies in which clade B or clade C HIV-infected macrophages were intracranially injected into severe combined immunodeficient mice (SCID) mice. Exposure to clade B isolates induced more severe memory deficits, as well as greater astrogliosis and neuronal damage (Rao et al. <xref ref-type="bibr" rid="CR419">2008</xref>, <xref ref-type="bibr" rid="CR420">2013</xref>). In another example, the Tat dicysteine motif (CC) at positions 30 and 31, which is commonly found in clade B isolates, appears to worsen HAND (Mishra et al. <xref ref-type="bibr" rid="CR341">2008</xref>; Rao et al. <xref ref-type="bibr" rid="CR420">2013</xref>) and has been studied extensively in vitro (Ranga et al. <xref ref-type="bibr" rid="CR418">2004</xref>; Rao et al. <xref ref-type="bibr" rid="CR419">2008</xref>; Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>; Krishnan and Chatterjee <xref ref-type="bibr" rid="CR262">2015</xref>). Clade B Tat is more intrinsically cytotoxic to primary neurons in vitro than clade C Tat (Li et al. <xref ref-type="bibr" rid="CR282">2008</xref>; Campbell et al. <xref ref-type="bibr" rid="CR71">2011</xref>; Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>), resulting in increased proinflammatory cytokine production (e.g., IL-6 and TNF-&#x003b1;) (Gandhi et al. <xref ref-type="bibr" rid="CR170">2009</xref>) and monocyte recruitment/migration into the brain (Ranga et al. <xref ref-type="bibr" rid="CR418">2004</xref>; Rao et al. <xref ref-type="bibr" rid="CR419">2008</xref>), and increased disruption of the BBB (Gandhi et al. <xref ref-type="bibr" rid="CR172">2010</xref>). Similarly, the production of the inflammatory mediators prostaglandin E<sub>2</sub> and the thromboxane A<sub>2</sub> receptor by astrocytes is more significantly increased by clade B than clade C gp120 (Samikkannu et al. <xref ref-type="bibr" rid="CR448">2011</xref>). Sequence and structural alterations in gp120 have been demonstrated between clades B and C (Gnanakaran et al. <xref ref-type="bibr" rid="CR181">2007</xref>) and potentially contribute to these observed differences.</p><p id="Par36">When considering effects of HIV clade variants in the presence of opioids, the overall toxicity in MSNs seen with clade C Tat (30% neuronal losses)&#x02009;was considerably less than with clade B (70% losses) (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>). Although clade B HIV predominates in Western countries, future clinical longitudinal studies are necessary that employ HIV clade testing in HIV-1 infected opioid users to confirm the hypothesis that opioid interactive effects on HAND pathogenesis depend on the HIV clade assessed.</p><p id="Par37">Besides HIV genetic diversity, differences in HIV tropism add another level of complexity. Morphine interactions can differ significantly between X4 and R5-tropic gp120 variants depending on the outcome measure (El-Hage et al. <xref ref-type="bibr" rid="CR136">2011b</xref>; Podhaizer et al. <xref ref-type="bibr" rid="CR402">2012</xref>; Balinang et al. <xref ref-type="bibr" rid="CR25">2017</xref>; Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). Increased infectivity in the presence of morphine was noted for the R5-tropic HIV-1<sub>SF162</sub> strain in a human hepatoma Huh7.5.1 cell line model, whereas the infectivity rate with the X4-tropic HIV-1<sub>LAI/IIIB</sub> strain was unaffected by morphine (El-Hage et al. <xref ref-type="bibr" rid="CR136">2011b</xref>).</p><p id="Par38">To date, no clinical studies have assessed whether opioid interactions with R5- or R4-preferring HIV strains differentially impact the severity of HAND. However, the findings from preclinical studies indicate that HIV-1 strain-specific differences are critical determinants in shaping both the timing and pattern of neurotoxic interactions with opioid drugs.</p></sec><sec id="Sec16"><title>Host Genetics</title><p id="Par39">Host genetic variability can be a major determinant in individual susceptibility to HIV infectivity and may influence neuroHIV progression in the context of opiate co-exposure. The importance of CCR5 for HIV infectivity and polymorphisms in this gene are well established. Individuals who are homozygous in the CCR5 gene (CCR5&#x00394;32) are highly resistant to infection by CCR5- (R5-) tropic HIV as demonstrated by individuals heterozygous for CCR5&#x00394;32 who display partial resistance to infection and slower disease progression (Huang et al. <xref ref-type="bibr" rid="CR214">1996</xref>; Liu et al. <xref ref-type="bibr" rid="CR288">1996</xref>; van Rij et al. <xref ref-type="bibr" rid="CR522">1999</xref>). Besides CCR5, polymorphisms of other chemokine co-receptors and/or their cognate ligands have been implicated in HIV infectivity, including CCR2 (Smith et al. <xref ref-type="bibr" rid="CR473">1997</xref>; Kostrikis et al. <xref ref-type="bibr" rid="CR251">1998</xref>), CCL5 (Liu et al. <xref ref-type="bibr" rid="CR289">1999</xref>; McDermott et al. <xref ref-type="bibr" rid="CR324">2000</xref>), and CXCL12 (Winkler et al. <xref ref-type="bibr" rid="CR542">1998</xref>). Authoritative reviews on other gene polymorphisms that modify HIV infectivity and disease progression have been published (Lama and Planelles <xref ref-type="bibr" rid="CR267">2007</xref>; Singh and Spector <xref ref-type="bibr" rid="CR469">2009</xref>; Chatterjee <xref ref-type="bibr" rid="CR87">2010</xref>; Aouizerat et al. <xref ref-type="bibr" rid="CR14">2011</xref>).</p><p id="Par40">Gene polymorphisms of opioid (<italic>OPRM1</italic> and <italic>OPRK1</italic>) and non-opioid (e.g., <italic>DRD1</italic> and <italic>DRD2</italic>) drug/neurotransmitter receptor genes are associated with altered HIV infectivity, viral loads and CD4+ cell counts (Proudnikov et al. <xref ref-type="bibr" rid="CR406">2012</xref>; Regan et al. <xref ref-type="bibr" rid="CR423">2012</xref>; Jacobs et al. <xref ref-type="bibr" rid="CR223">2013</xref>; Proudnikov et al. <xref ref-type="bibr" rid="CR407">2013</xref>; Dever et al. <xref ref-type="bibr" rid="CR115">2014</xref>). Not only do MORs mediate the behavioral consequences of opiate abuse (Bond et al. <xref ref-type="bibr" rid="CR51">1998</xref>; Szeto et al. <xref ref-type="bibr" rid="CR499">2001</xref>; Ikeda et al. <xref ref-type="bibr" rid="CR219">2005</xref>; Kreek et al. <xref ref-type="bibr" rid="CR260">2005</xref>; Xu et al. <xref ref-type="bibr" rid="CR552">2014b</xref>), but the ability of MOR to modulate HIV chemokine co-receptor signaling through cross desensitization or through direct molecular interactions suggest MOR may influence HIV infectivity at multiple levels. The unique ability of MOR to modulate HIV co-receptor function, prompted inquiry regarding whether variants of the <italic>OPRM1</italic> gene (polymorphisms or splicing variants) might differentially effect HIV infectivity and/or opiate addictive behaviors. In a sample of 1031 HIV-1-infected women, 18 <italic>OPRM1</italic> polymorphisms were significantly associated with decreases or increases in HIV infectivity and responsiveness to cART (Proudnikov et al. <xref ref-type="bibr" rid="CR406">2012</xref>). Other gene polymorphisms, such as enzymes affecting drug metabolism (Meyer and Zanger <xref ref-type="bibr" rid="CR335">1997</xref>; Benowitz et al. <xref ref-type="bibr" rid="CR40">2006</xref>) and other neurochemical systems (Herman and Balogh <xref ref-type="bibr" rid="CR210">2012</xref>; Koob and Volkow <xref ref-type="bibr" rid="CR250">2016</xref>) can also affect drug dependence. The A118G variant of <italic>OPRM1</italic> alters the regulation of proinflammatory cytokine secretion (i.e., TNF-&#x003b1;, IL-10, IFN-&#x003b3;) from peripheral immune cells (Matsunaga et al. <xref ref-type="bibr" rid="CR318">2009</xref>). Overall, these findings suggest that polymorphisms in MOR ligands/genes (<italic>OPRM1</italic>) can influence the pathophysiology of HIV-1.</p><p id="Par41">Nineteen different <italic>OPRM1</italic> spliced variants have been described in humans (Pasternak <xref ref-type="bibr" rid="CR379">2004</xref>, <xref ref-type="bibr" rid="CR380">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR551">2014a</xref>; Lu et al. <xref ref-type="bibr" rid="CR298">2015</xref>). <italic>OPRM1</italic> alternative splicing may also influence susceptibility to HIV-1 infection (Dever et al. <xref ref-type="bibr" rid="CR114">2012</xref>, <xref ref-type="bibr" rid="CR115">2014</xref>). Although many variants are thought to be non-functional and fail to traffic from the endoplasmic reticulum, increasing evidence suggests they may oligomerize other G Protein-coupled receptors or bind chaperones to assist in trafficking to the plasma membrane (Samoshkin et al. <xref ref-type="bibr" rid="CR449">2015</xref>; Zhu et al. <xref ref-type="bibr" rid="CR559">2019</xref>). Quantitative and qualitative differences in human MOR splice variant expression levels have been noted across different CNS cell types following exposure to HIV (Dever et al. <xref ref-type="bibr" rid="CR114">2012</xref>, <xref ref-type="bibr" rid="CR115">2014</xref>). Interestingly, an excitatory, MOR-1&#x000a0;K splice variant, that couples to G&#x003b1;<sub>S</sub> (Gris et al. <xref ref-type="bibr" rid="CR190">2010</xref>) is preferentially expressed in human astroglia (Dever et al. <xref ref-type="bibr" rid="CR114">2012</xref>) and has been shown to correlate with HIVE and cognitive impairment (Dever et al. <xref ref-type="bibr" rid="CR114">2012</xref>, <xref ref-type="bibr" rid="CR115">2014</xref>).</p></sec><sec id="Sec17"><title>MOR and Chemokine Receptor Interactions (CCR5, CXCR4)</title><p id="Par42">The ability of opiates to modulate HIV infection and HIV neuropathogenesis/disease progression may be partly due to the interactive effects seen between the opioid and chemokine receptors, specifically MOR and CCR5 or CXCR4 (Rogers and Peterson <xref ref-type="bibr" rid="CR434">2003</xref>; Steele et al. <xref ref-type="bibr" rid="CR481">2003</xref>; Szabo et al. <xref ref-type="bibr" rid="CR498">2003</xref>; Festa and Meucci <xref ref-type="bibr" rid="CR155">2012</xref>). The potential mechanisms for this interaction can include heterologous cross-desensitization via downstream signaling (Rogers et al. <xref ref-type="bibr" rid="CR435">2000</xref>; Steele et al. <xref ref-type="bibr" rid="CR480">2002</xref>; Song et al. <xref ref-type="bibr" rid="CR476">2011</xref>) and/or potentially via direct opioid-chemokine receptor dimeric or heteromeric interactions (Suzuki et al. <xref ref-type="bibr" rid="CR495">2002</xref>; Chen et al. <xref ref-type="bibr" rid="CR89">2004</xref>; Nash and Meucci <xref ref-type="bibr" rid="CR356">2014</xref>). MOR and DOR activation can heterologously desensitize CCR5 responsiveness to CCL3, CCL4, and CCL5 in monocytes (Grimm et al. <xref ref-type="bibr" rid="CR189">1998</xref>; Szabo et al. <xref ref-type="bibr" rid="CR498">2003</xref>; Chen et al. <xref ref-type="bibr" rid="CR89">2004</xref>). The cross-desensitization appears to be regulated by MOR-dependent PKC&#x003b6; activation and CCR5 phosphorylation and downregulation (Song et al. <xref ref-type="bibr" rid="CR476">2011</xref>). Alternatively, MOR-induced downregulation of CCL2 and CCL4 mRNA reciprocally upregulates the expression of their associated receptors, CCR2b, CCR3, and CCR5 (Mahajan et al. <xref ref-type="bibr" rid="CR302">2005</xref>). A previous study reported significant upregulation of CCR5 and CXCR4 expression in CD14 monocytes with [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol]-enkephalin (DAMGO), a MOR ligand, exposure with enhanced replication of both X4- and R5-tropic viral strains of HIV (Steele et al. <xref ref-type="bibr" rid="CR481">2003</xref>). For CXCR4, bidirectional heterologous desensitization is less evident with MOR but has been reported for KOR, with Ca<sup>2+</sup> signaling experiments suggesting that cross-desensitization occurs within seconds of KOR or CXCR4 activation in a concentration-dependent manner (Finley et al. <xref ref-type="bibr" rid="CR157">2008</xref>). Thus, opiates acting at different opioid receptors in the presence of HIV appear to activate chemokine receptor signaling and can contribute to the synergistic effects of HIV and opioid drug co-exposure seen in neuroHIV progression.</p><p id="Par43">The ability of opiates to modulate CCR5 expression in the CNS has been demonstrated to occur in various cell types, including microglia (Bokhari et al. <xref ref-type="bibr" rid="CR48">2009</xref>), and astrocytes (Mahajan et al. <xref ref-type="bibr" rid="CR301">2002</xref>). Specifically, in astrocytes MOR activation enhanced CCR5 and additional HIV-1 entry co-receptor (CCR3 and CXCR2) expression, whereas local production of HIV-1 protective chemokines (IL-8, CCL4) was inhibited (Mahajan et al. <xref ref-type="bibr" rid="CR301">2002</xref>). Deletion of CCR5 significantly attenuates morphine-induced increases in astrocyte CCL2 immunoreactivity in Tat transgenic mice (El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Interestingly, the proportion of CCL2 immunoreactive macrophages/microglia in CCL5(&#x02212;/&#x02212;) mice after Tat and morphine co-administration still showed a significant upregulation, suggesting CCL5 regulates Tat and morphine-induced increases in CCL2 in astrocytes, but not in microglia (El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par44">The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Interestingly, maraviroc&#x02019;s antiviral effects are completely negated in both astrocytes and microglia when morphine is present suggesting that maraviroc therapy may not be effective with opiate co-exposure. Importantly, unlike maraviroc, the bivalent compound blocked HIV entry in astrocytes irrespective of morphine treatment, while exacerbating HIV infectivity in morphine co-exposed microglia and revealing fundamental differences in the regulation of MOR and CCR5 expression in these glial types. Whereas, MOR and CCR5 expression appear to be similarly regulated in astrocytes, their expression patterns in microglia appear to be inversely correlated upon HIV and/or morphine exposure, with CCR5 being expressed at much higher levels than MOR (see El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>). The differential effects of the bivalent ligand in astrocytes compared to microglia might be due to the fact that the expression levels of MOR and CCR5 are differentially regulated by HIV in each of the cell types (El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>; Yuan et al. <xref ref-type="bibr" rid="CR557">2013</xref>; Arnatt et al. <xref ref-type="bibr" rid="CR18">2016</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (<bold>a</bold>) Construction of a MOR-CCR5 heterodimer model in a membrane (<italic>gray</italic>), and aqueous surrounds (<italic>red</italic>) system. The green protein represents MOR and the blue protein represents CCR5, while the bivalent ligand is colored in yellow. (<bold>b</bold>) Different binding pocket (green) for the triazole moiety of the bivalent ligand yellow) at 0&#x000a0;ns and 6.0&#x000a0;ns. (<bold>c</bold>) Construction of a chemical probe that interacts with both the MOR and CCR5 receptors simultaneously. To monitor HIV-1 infection (<bold>d</bold>) astrocytes and (<bold>e</bold>) microglia were transfected with a pBlue3&#x02032;LTR-luc reporter sensitive to Tat expression and luciferase activity was measured. Data indicate that maraviroc&#x02019;s antiviral effects are completely negated in both astrocytes and microglia when morphine is present (<italic>red bars</italic>). Interestingly, unlike maraviroc, the bivalent compound blocked HIV entry in astrocytes irrespective of morphine treatment. By contrast, the bivalent antagonist exacerbated HIV infectivity in microglia in the presence of morphine (<italic>red bars</italic>). The findings reveal fundamental differences in co-regulation of MOR and CCR5 expression in astroglia and microglia upon HIV and/or morphine exposure (see El-Hage et al. <xref ref-type="bibr" rid="CR137">2013</xref>). Values are luminescence intensity &#x000b1; SEM from 3 to 5 independent experiments at 18&#x000a0;h post-infection (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.005 vs. un-infected cells; <sup>$</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. R5 HIV-1; <sup>#</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. R5&#x02009;+&#x02009;morphine (M); <sup>&#x000b6;</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. R5&#x02009;+&#x02009;maraviroc (MVC); <sup>&#x000a7;</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. R5&#x02009;+&#x02009;M&#x02009;+&#x02009;MVC; <sup>&#x000a5;</sup><italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. R5&#x02009;+&#x02009;M&#x02009;+&#x02009;MVC&#x02009;+&#x02009;naltrexone). (<bold>a&#x02013;b</bold>) Modified and reprinted with permission from Arnatt et al. (<xref ref-type="bibr" rid="CR18">2016</xref>). (<bold>c&#x02013;e</bold>) Modified and reprinted with permission from El-Hage et al. (<xref ref-type="bibr" rid="CR137">2013</xref>)</p></caption><graphic xlink:href="11481_2020_9941_Fig5_HTML" id="MO6"/></fig></p><p id="Par45">The importance of CCR5 activation in glia, but not neurons, in mediating the neurotoxic effects of morphine-dependent MOR activation is further supported in a recent study demonstrating that the loss of CCR5 from glia (but not neurons) eliminated neurotoxicity due to Tat and morphine interactions (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). Similarly, short-duration (5 d) maraviroc pre-treatment also eliminated neurotoxicity and attenuated neuronal increases in [Ca<sup>2+</sup>]<sub>i</sub> caused by Tat&#x02009;&#x000b1;&#x02009;morphine (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). Selectively deleting either CCR5 (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>) or MOR (Zou et al. <xref ref-type="bibr" rid="CR560">2011</xref>) from glia completely protects MSNs from morphine&#x02019;s ability to exacerbate Tat neurotoxicity. However, deleting CCR5 from glia only revealed a paradoxical neuroprotective effect of morphine on Tat toxicity that is mediated by opioid receptors and appears to involve alterations in BDNF processing and signaling (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>).</p><sec id="FPar1"><title>Enhanced Mature BDNF (mBDNF) Produced by CCR5 Deficient Glia is Neuroprotective</title><p id="Par46">Mature BDNF (mBDNF) activates tyrosine receptor kinase B (TrkB) and is neuroprotective, while the precursor to BDNF, pro-BDNF, binds p75<sup>NTR</sup> and can activate cell death pathways. Based on findings of significant, reversible reductions in glially produced BDNF after exposure to HIV-infected cell supernatant &#x000b1; morphine (Masvekar et al. <xref ref-type="bibr" rid="CR315">2014</xref>), altered BDNF processing in lymphocytes from PWH (Avdoshina et al. <xref ref-type="bibr" rid="CR22">2011</xref>), and following exposure to HIV-1 gp120 (Bachis et al. <xref ref-type="bibr" rid="CR24">2012</xref>), the pro-BDNF:mBDNF ratio was analyzed in supernatants from wild-type vs. CCR5-null striatal glial cultures exposed to Tat&#x02009;&#x000b1;&#x02009;morphine for 6 or 24&#x000a0;h (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>) <bold>(</bold>Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref><bold>)</bold>. CCR5-deficiency reduced this ratio by over 2-fold in cells treated with Tat and morphine after 6&#x000a0;h <bold>(</bold>Fig. <xref rid="Fig6" ref-type="fig">6</xref><bold>)</bold>, indicating a relative increase in mBDNF that may partially protect neurons in the CCR5-deficient glial environment.<fig id="Fig6"><label>Fig. 6</label><caption><p>Role of CCR5 and BDNF in mediating HIV-1 Tat and morphine-induced interactive cytotoxicity in striatal medium spiny neurons (MSNs). A proportion of glial fibrillary acidic protein (GFAP)-immunolabeled striatal astrocytes display punctate patterns of &#x003bc;-opioid receptor (MOR) (<bold>a</bold>) and CCR5 (<bold>b</bold>) (43.8&#x02009;&#x000b1;&#x02009;2.4%) immunofluorescence&#x02014;with some faint immunoreactivity extending into the cell processes; scale bars&#x02009;=&#x02009;10&#x000a0;&#x003bc;m (<bold>a-b</bold>). HIV-1 Tat and morphine are no longer toxic to MSNs when CCR5 is deleted from glia (<bold>c-f</bold>). In C57BL/J wild-type mixed glia-MSN co-cultures, Tat is neurotoxic (*<italic>p</italic>&#x000a0;=&#x02009;0.001 vs. controls), and co-exposure to morphine enhanced Tat-induced toxicity over a 72-h period (**<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001 vs. controls, <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05 vs. Tat) and antagonized by naloxone (<bold>c</bold>). Naloxone or morphine by themselves had no effect on neuronal survival (<bold>c</bold>). In co-cultures with CCR5-deficit glia and wild-type neurons, exposure to Tat by itself is significantly toxic (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001 vs. controls); however, the enhanced toxicity seen with combined morphine exposure was eliminated (<bold>d</bold>). Unexpectedly, morphine co-treatment entirely abolished the toxic effects of Tat, restoring MSN survival to control levels. Pre-treatment with naloxone re-established Tat toxicity, suggesting that the paradoxical protective effects of morphine are mediated by MOR (or perhaps another opioid receptor type) (<bold>d</bold>) (see Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). The neurotoxic patterns seen in CCR5-deficient MSNs and wild-type glial co-cultures are similar to wild-type co-cultures (<bold>e</bold>). Co-cultures in which MSNs and glia are both deficient in CCR5 are similar to those in which CCR5 is only deficient in glia (<bold>f</bold>). CCR5 deletion alters the expression and processing of BDNF precursor (pro-BDNF) to mature (mBDNF) by mixed-glial cultures (<bold>g</bold>). BDNF is expressed by both astroglia and microglia; mBDNF is neuroprotective, while pro-BDNF can promote programmed cell death. mBDNF and pro-BDNF levels were analyzed in conditioned media from wild-type or CCR5-deficient mixed glia treated with Tat&#x02009;&#x000b1;&#x02009;morphine after 6&#x000a0;h or 24&#x000a0;h to assess pro-BDNF and mBDNF levels. The proportion of pro-BDNF/mBDNF levels was significantly higher in wild-type compared to CCR5-null glia at 24&#x000a0;h (<italic>lower row;</italic>
<bold>g</bold>), suggesting reduced neuronal support. Although morphine significantly decreased pro-BDNF in CCR5-deficient glia at both 6&#x000a0;h and 24&#x000a0;h compared to control levels (<italic>not shown</italic>), the pro-BDNF/mBDNF ratios were unaltered (<italic>upper and lower rows;</italic>
<bold>g</bold>). By contrast, combined Tat and morphine significantly decreased the pro-BDNF/mBDNF ratio at 6&#x000a0;h, suggesting transient protection with CCR5 deficiency that was not fully sustained at 24&#x000a0;h (<italic>p</italic>&#x000a0;=&#x02009;0.17) (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05, wild-type vs. CCR5-null) (<bold>g</bold>). Exogenous mBDNF is neuroprotective against combined Tat and morphine treatment (<bold>h</bold>). Wild-type, mixed glial-MSN co-cultures were treated with mBDNF and Tat, or combined Tat and morphine (represented by dotted survival curves). Tat alone was neurotoxic (*<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05), and Tat was significantly worsened by co-exposing MSNs to morphine (**<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001). The addition of mBDNF (50&#x000a0;ng/ml; 72&#x000a0;h) fully protected MSNs against combined Tat and morphine toxicity, but only tended to protect (albeit not significantly) MSNs treated with Tat alone (<sup>#</sup>)(<bold>h</bold>). Overall, the results in <bold>c-h</bold> suggest (1) an important role for glial CCR5 in mediating HIV-1 and opiate neurotoxic interactions, (2) that CCR5 deficiency influences signaling through MOR, and (3) that CCR5 (and perhaps MOR) act via a BDNF intermediary to promote or obstruct neuronal survival (Kim et al. <xref ref-type="bibr" rid="CR237">2018</xref>). (<bold>a-b</bold>) Modified and reprinted with permission from Podhaizer et al. (<xref ref-type="bibr" rid="CR402">2012</xref>). (<bold>c-h</bold>) Modified and reprinted from Kim et al. (<xref ref-type="bibr" rid="CR237">2018</xref>), which is an open access article distributed under the terms of the <italic>Creative Commons CC BY license</italic></p></caption><graphic xlink:href="11481_2020_9941_Fig6_HTML" id="MO7"/></fig></p><p id="Par47">Exogenous mBDNF treatment has been found to mimic the pro-survival effect of glial CCR5 deficiency against Tat&#x02009;&#x000b1;&#x02009;morphine, and its neuroprotective effects have been supported in other neurodegenerative disease models (Cai et al. <xref ref-type="bibr" rid="CR70">2014</xref>; Xu et al. <xref ref-type="bibr" rid="CR553">2018</xref>). Collectively, the findings suggest that the loss of CCR5 may fundamentally change MOR signaling in HIV-exposed glia in a BDNF-dependent manner. Thus, overall the interaction of opioid and chemokine receptors, specifically MOR and CCR5, may alter the neuropathogenesis of HIV in a qualitatively unique manner not seen with either disorder alone.</p></sec></sec><sec id="Sec18"><title>Does HIV Alter the Endogenous Opioid System?</title><p id="Par48">Little is known about the effects of HIV on the endogenous opioid system and the extent to which HIV might disrupt the expression and function of opioid peptides and receptors, and vice versa. Because opiate drugs act exclusively by mimicking endogenous peptides and engaging opioid receptors, it is likely that endogenous opioids also interact with HIV to some extent to affect the pathogenesis of neuroHIV.</p><p id="Par49">The endogenous opioid system comprises three originally described opioid receptors, MOR, KOR, and DOR and endogenous opioid peptide-expressing genes proopiomelanocortin (<italic>POMC</italic>), prodynorphin (<italic>PDYN</italic>), and proenkephalin (<italic>PENK</italic>) (Brownstein <xref ref-type="bibr" rid="CR57">1993</xref>; Trescot et al. <xref ref-type="bibr" rid="CR511">2008</xref>; Bodnar <xref ref-type="bibr" rid="CR45">2010</xref>; Pasternak and Pan <xref ref-type="bibr" rid="CR381">2013</xref>), as well as a fourth receptor (<italic>OPRN1</italic>) and peptide (nociceptin/orphanin FQ) family member. The endogenous opioid system has a fundamental role in pain regulation and has been implicated in the pathophysiology of various neurologic diseases (Nandhu et al. <xref ref-type="bibr" rid="CR353">2010</xref>; Sauriyal et al. <xref ref-type="bibr" rid="CR453">2011</xref>; Benarroch <xref ref-type="bibr" rid="CR39">2012</xref>) and in pain management (Bruehl et al. <xref ref-type="bibr" rid="CR59">2013</xref>).</p><p id="Par50">Postmortem clinical studies indicate the endogenous opioid system is disrupted in neuroHIV (Gelman et al. <xref ref-type="bibr" rid="CR174">2012</xref>; Yuferov et al. <xref ref-type="bibr" rid="CR558">2014</xref>). Specifically, <italic>OPRK1</italic> mRNA is significantly upregulated in PWH (Yuferov et al. <xref ref-type="bibr" rid="CR558">2014</xref>) and in transgenic neuroHIV rodent models (Chang et al. <xref ref-type="bibr" rid="CR78">2007</xref>; Fitting et al. <xref ref-type="bibr" rid="CR160">2010b</xref>) potentially as a compensatory neuroprotective function in response to inflammatory processes in the presence of HIV infection (Yuferov et al. <xref ref-type="bibr" rid="CR558">2014</xref>). The upregulation of mRNA coding <italic>OPRK1</italic> is triggered by factors released by activated macrophages and glia and is supported by mechanistic studies in dorsal root ganglia (Puehler et al. <xref ref-type="bibr" rid="CR408">2006</xref>; Gabrilovac et al. <xref ref-type="bibr" rid="CR167">2012</xref>). Since leukocytes, including macrophages, can express &#x003b2;-endorphin and enkephalins, it is important to consider the potential influence of leukocyte-derived endogenous opioid peptides in neuroinflammation (Rittner et al. <xref ref-type="bibr" rid="CR424">2001</xref>). Granulocytes express about 10-fold higher levels of &#x003b2;-endorphin, a preferential MOR and lower affinity KOR endogenous ligand, than lymphocytes (Pallinger and Csaba <xref ref-type="bibr" rid="CR377">2008</xref>). Increases in &#x003b2;-endorphin expression by peripheral blood mononuclear cells (PBMCs) (Gironi et al. <xref ref-type="bibr" rid="CR179">2000</xref>; Gironi et al. <xref ref-type="bibr" rid="CR180">2003</xref>), coincide with inflammation and relapse in multiple sclerosis. Moreover, increases in inflammatory cytokines, such as interleukin-1&#x003b2; (IL-1&#x003b2;), have been demonstrated to differentially increase the expression of proenkephalin transcripts in primary astrocytes cultured from different brain regions (Ruzicka and Akil <xref ref-type="bibr" rid="CR442">1997</xref>) and increase IL-10-stimulated &#x003b2;-endorphin expression in cultured primary microglia (Wu et al. <xref ref-type="bibr" rid="CR547">2017</xref>). Interestingly, <italic>OPRM1</italic> mRNA levels do not differ between HIV+&#x02009;and HIV&#x02212; subjects (Yuferov et al. <xref ref-type="bibr" rid="CR558">2014</xref>).</p><p id="Par51"><italic>PENK</italic> was downregulated in brain samples from 446 PWH compared to 67 HIV negative patients (Gelman et al. <xref ref-type="bibr" rid="CR174">2012</xref>). The subjects with HIV also expressed higher levels of interferon regulatory factor 1 (<italic>IRF1</italic>) transcripts. The idea that higher opioid peptide expression levels are neuroprotective has been supported in human studies and experimental animal models (Solbrig and Koob <xref ref-type="bibr" rid="CR475">2004</xref>; Sarkisyan et al. <xref ref-type="bibr" rid="CR452">2015</xref>; Nam et al. <xref ref-type="bibr" rid="CR352">2019</xref>) suggesting the reductions in <italic>PENK</italic> expression are deleterious.</p><p id="Par52">The effects of HIV Tat on expression levels of opioid peptide and receptor levels depend on the individual CNS region involved as well as levels of <italic>tat</italic> transgene expression (Fitting et al. <xref ref-type="bibr" rid="CR160">2010b</xref>). For example, while <italic>PDYN</italic> mRNA levels were significantly reduced in the hippocampus and striatum of Tat-expressing mice, <italic>POMC</italic> was only significantly reduced by Tat induction in the striatum and <italic>PENK</italic> mRNA levels in the hippocampus were affected by chronic (but not acute) Tat exposure (Fitting et al. <xref ref-type="bibr" rid="CR160">2010b</xref>). Thus, HIV may alter the endogenous opioid system by modifying the expression of opioid peptides and their receptors in a brain- and cell-type specific manner. The consequences of HIV-1-dependent alterations in the endogenous opioid system to HAND are uncertain.</p></sec></sec><sec id="Sec19"><title>Questions Remaining &#x02013; Future Directions</title><sec id="Sec20"><title>Modeling the Pharmacology of Opioid Self-Administration</title><p id="Par53">Opiate self-administration as seen with addiction can have different CNS consequences than &#x0201c;steady-state&#x0201d; (e.g., continuous via a pump or time-release drug implant) exposure to the same drug (Kreek <xref ref-type="bibr" rid="CR256">1987</xref>, <xref ref-type="bibr" rid="CR257">2001</xref>; Kreek et al. <xref ref-type="bibr" rid="CR259">2002</xref>), and we predict the pharmacokinetic differences in opiate exposure will markedly impact neuroHIV progression. Differential effects based on &#x0201c;on-off&#x0201d; and &#x0201c;steady-state&#x0201d; drug administration schedules have been reported for the stress-responsive hypothalamic-pituitary-adrenal (HPA) axis, the endogenous opioid system, and the dopamine system (Kreek <xref ref-type="bibr" rid="CR255">1973</xref>; Kreek et al. <xref ref-type="bibr" rid="CR259">2002</xref>; George et al. <xref ref-type="bibr" rid="CR176">2012</xref>). Acute opiate exposure typically activates the HPA axis, corticotropin releasing factor, and peripheral steroidogenesis in a species-dependent manner (Koob and Kreek <xref ref-type="bibr" rid="CR249">2007</xref>; Cleck and Blendy <xref ref-type="bibr" rid="CR99">2008</xref>). Alternatively, chronic self-administration of short-acting opiates suppresses diurnal cortisol rhythmicity (Facchinetti et al. <xref ref-type="bibr" rid="CR148">1984</xref>; Vuong et al. <xref ref-type="bibr" rid="CR531">2010</xref>), while opiate withdrawal typically evokes HPA activation (Culpepper-Morgan and Kreek <xref ref-type="bibr" rid="CR108">1997</xref>; Kreek <xref ref-type="bibr" rid="CR258">2007</xref>; Paris et al. <xref ref-type="bibr" rid="CR378">2020</xref>). The daily, repeated bouts of relative withdrawal seen with opiate addiction cause sustained HPA activation, stress (Koob and Kreek <xref ref-type="bibr" rid="CR249">2007</xref>; Koob <xref ref-type="bibr" rid="CR248">2020</xref>), and immune suppression (Eisenstein <xref ref-type="bibr" rid="CR129">2019</xref>). Importantly, maintenance therapy with the long-acting drug methadone achieves steady-dose opiate levels and normalization of the HPA axis (Kreek <xref ref-type="bibr" rid="CR255">1973</xref>). Further, it is known that HIV infection significantly alters the HPA axis, due to CNS toxicity and cytokine production (Costa et al. <xref ref-type="bibr" rid="CR105">2000</xref>; George and Bhangoo <xref ref-type="bibr" rid="CR175">2013</xref>; Chrousos and Zapanti <xref ref-type="bibr" rid="CR94">2014</xref>).</p><p id="Par54">Additionally, the nature of opiate exposure in the context of neuroHIV needs to be considered as it may induce different outcomes on neurotransmitter metabolism and gene expression. Specifically, the NAc shell demonstrates molecular and structural changes associated with intravenous heroin self-administration (Jacobs et al. <xref ref-type="bibr" rid="CR222">2005</xref>). Moreover, earlier studies have reported differential alterations in the turnover rates of various neurotransmitters for active versus passive morphine administration, including dopamine, serotonin, &#x003b3;-aminobutyric acid (GABA), acetylcholine, aspartate, and glutamate during exposure to morphine (Smith et al. <xref ref-type="bibr" rid="CR471">1982</xref>, <xref ref-type="bibr" rid="CR472">1984</xref>). The disruptions were noticed specifically in brain regions involved in reinforcement processes, including the NAc, frontal cortex, and striatum, and encompassed increased dopamine and norepinephrine levels and turnover, which are central in opiate reward processes (Smith et al. <xref ref-type="bibr" rid="CR471">1982</xref>). Heroin abuse is known to downregulate dopaminergic activity in the NAc and may reflect a compensatory reduction in of dopamine biosynthesis in response to excessive dopaminergic stimulation resulting from chronic opiate exposure (Kish et al. <xref ref-type="bibr" rid="CR239">2001</xref>). Additionally, HIV is known to interfere with dopamine neurotransmission (Nath et al. <xref ref-type="bibr" rid="CR361">2000b</xref>; Gaskill et al. <xref ref-type="bibr" rid="CR171">2017</xref>) causing reductions in presynaptic dopamine terminals and dopamine transport in the striatum (Wang et al. <xref ref-type="bibr" rid="CR535">2004</xref>; Chang et al. <xref ref-type="bibr" rid="CR79">2008</xref>; Midde et al. <xref ref-type="bibr" rid="CR337">2012</xref>, <xref ref-type="bibr" rid="CR338">2015</xref>). The decline in dopamine function may exacerbate opioid abuse tendencies and drug-seeking behaviors as the rewarding effects of opioids are discounted by neuroHIV.</p></sec><sec id="Sec21"><title>Opioid Substitution Therapies and the Role of Selective/Biased Agonism in neuroHIV Pathogenesis</title><p id="Par55">Although morphine, methadone, and buprenorphine all activate MOR, each can impart different signals through MOR, related to the nature and timing of their coupling to G&#x003b1;, G&#x003b2;&#x003b3;, &#x003b2;-arrestin and/or regulators of G protein signaling (RGS), since each downstream effector couples into unique cell functions. Functional selectivity occurs at each opioid receptor type, and for most endogenous opioid peptides at all three receptor types (Gomes et al. <xref ref-type="bibr" rid="CR182">2020</xref>). Moreover, opioid receptors can be expressed on a subset of virtually every cell type in the CNS&#x02014;with second messenger coupling to each opioid receptor type potentially being unique, cell-type specific, and context dependent. Thus, the &#x0201c;pluridimensional&#x0201d; (Galandrin and Bouvier <xref ref-type="bibr" rid="CR168">2006</xref>; Kenakin <xref ref-type="bibr" rid="CR230">2011</xref>; Costa-Neto et al. <xref ref-type="bibr" rid="CR106">2016</xref>) actions of any opiate at MOR are sufficiently complicated that it is not possible to predict whether, e.g., morphine, methadone or buprenorphine, would similarly effect any aspect of neuroHIV pathology without empirical testing. Despite their significant use as medication-assisted therapies for treating opioid addiction, few studies have directly compared commonly used opiate substitution therapies (Bell and Strang <xref ref-type="bibr" rid="CR35">2020</xref>), especially in relation to HIV (Khalsa et al. <xref ref-type="bibr" rid="CR231">2006</xref>; Choi et al. <xref ref-type="bibr" rid="CR93">2020</xref>).</p><p id="Par56">Opioid substitution therapies significantly reduce the frequency of injection drug use (Kwiatkowski and Booth <xref ref-type="bibr" rid="CR265">2001</xref>; Pettes et al. <xref ref-type="bibr" rid="CR397">2010</xref>), decrease HIV transmission risk (MacArthur et al. <xref ref-type="bibr" rid="CR299">2012</xref>; Platt et al. <xref ref-type="bibr" rid="CR400">2016</xref>), and reduce drug-related mortality (Mathers et al. <xref ref-type="bibr" rid="CR316">2013</xref>) and the risk of opioid overdose (Volkow et al. <xref ref-type="bibr" rid="CR530">2014</xref>). Further, improved ARV outcomes among PWH have been reported with opioid substitution therapies, including the uptake and retention on ARV, medication adherence rates, and viral suppression (Low et al. <xref ref-type="bibr" rid="CR297">2016</xref>; Mukandavire et al. <xref ref-type="bibr" rid="CR347">2017</xref>). The two main medications used for opioid substitution therapy include methadone, a MOR full agonist, and buprenorphine, a MOR partial agonist and partial antagonist of KOR (Noble and Marie <xref ref-type="bibr" rid="CR365">2018</xref>). In comparison to methadone, buprenorphine has been shown to have fewer pharmacodynamic interactions with ARVs and causes less opioid withdrawal symptoms potentially due to its partial agonism on MOR, but also due to its high affinity and long duration of MOR binding (Walsh et al. <xref ref-type="bibr" rid="CR534">1994</xref>; McCance-Katz <xref ref-type="bibr" rid="CR322">2005</xref>; Whelan and Remski <xref ref-type="bibr" rid="CR538">2012</xref>). Further, differential proinflammatory and neurotoxic effects have been noted for various opioid treatments (Boland et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Fitting et al. <xref ref-type="bibr" rid="CR163">2014b</xref>; Carvallo et al. <xref ref-type="bibr" rid="CR76">2015</xref>; Dutta and Roy <xref ref-type="bibr" rid="CR124">2015</xref>). In primary astrocytes, agonist-selective actions at MOR and KOR can be clearly demonstrated (Bohn et al. <xref ref-type="bibr" rid="CR46">2000</xref>; Belcheva et al. <xref ref-type="bibr" rid="CR34">2003</xref>; McLennan et al. <xref ref-type="bibr" rid="CR329">2008</xref>; Hahn et al. <xref ref-type="bibr" rid="CR198">2010</xref>), and we found that morphine, methadone, and buprenorphine differentially increase ROS and [Ca<sup>2+</sup>]<sub>i</sub> alone or following Tat co-exposure (Fitting et al. <xref ref-type="bibr" rid="CR163">2014b</xref>). Morphine can enhance HIV-1-induced production of cytokines and specifically chemokines (El-Hage et al. <xref ref-type="bibr" rid="CR133">2008a</xref>; Dave <xref ref-type="bibr" rid="CR111">2012</xref>; El-Hage et al. <xref ref-type="bibr" rid="CR138">2014</xref>), while other opioids including methadone, oxycodone, buprenorphine, and DAMGO can decrease inflammatory function and decrease monocyte migration (Boland et al. <xref ref-type="bibr" rid="CR50">2014</xref>; Carvallo et al. <xref ref-type="bibr" rid="CR76">2015</xref>; Jaureguiberry-Bravo et al. <xref ref-type="bibr" rid="CR225">2016</xref>; Chilunda et al. <xref ref-type="bibr" rid="CR92">2019</xref>).</p><p id="Par57">As most opiate drugs preferentially act via MOR, a potential explanation for differential interactive effects of opioids in the context of neuroHIV is the phenomenon of selective or &#x0201c;biased agonism&#x0201d;, such that different agonists can trigger distinct signaling events at the same receptor (Hauser et al. <xref ref-type="bibr" rid="CR209">2012</xref>). For example, coupling of MOR to G&#x003b1;, G&#x003b2;&#x003b3;, and/or &#x003b2;-arrestin have been noted to differ depending on the MOR agonists involved (McPherson et al. <xref ref-type="bibr" rid="CR330">2010</xref>; Thompson et al. <xref ref-type="bibr" rid="CR506">2015</xref>; Burgueno et al. <xref ref-type="bibr" rid="CR63">2017</xref>). Physiologic outcomes of MOR activation in any cell type are determined by a bias for specific signaling pathways, the initial step of which is activation of G proteins and/or &#x003b2;-arrestin (Williams et al. <xref ref-type="bibr" rid="CR540">2013b</xref>; Violin et al. <xref ref-type="bibr" rid="CR528">2014</xref>; Suomivuori et al. <xref ref-type="bibr" rid="CR494">2020</xref>). The subcellular organization of GPCR signaling transduced by heterotrimeric G proteins and &#x003b2;-arrestin has been recently reviewed in detail (Eichel and von Zastrow <xref ref-type="bibr" rid="CR128">2018</xref>).</p><p id="Par58">In the context of HIV, it has been shown that selective MOR agonists such as endomorphin-1, but not DAMGO or morphine, significantly increase HIV-1 replication in infected microglia (Peterson et al. <xref ref-type="bibr" rid="CR396">1999</xref>). This effect might be due to an apparent bias of endomorphin-1 towards arrestin recruitment and receptor phosphorylation, which was significantly correlated with agonist-induced internalization of MOR (McPherson et al. <xref ref-type="bibr" rid="CR330">2010</xref>). It is suggested that ligands that display bias towards G protein-mediated pathways and away from &#x003b2;-arrestin 2 recruitment may have improved therapeutic profiles against the development of tolerance and dependence/addiction (McPherson et al. <xref ref-type="bibr" rid="CR330">2010</xref>).</p></sec><sec id="Sec22"><title>Opioid Effects on Antiretroviral Efficacy within the CNS and Vice Versa</title><p id="Par59">Opioid misuse has been linked to poor adherence to cART (Jeevanjee et al. <xref ref-type="bibr" rid="CR226">2014</xref>). However, adherence to ARV therapy improves after initiation of opioid substitution therapy (Nosyk et al. <xref ref-type="bibr" rid="CR370">2015</xref>; Low et al. <xref ref-type="bibr" rid="CR297">2016</xref>; Adams et al. <xref ref-type="bibr" rid="CR1">2020</xref>). Although better adherence can improve therapeutic outcomes in PWH, little information is currently available on the interaction between opioids or opioid substitution therapies and cART specifically within the CNS.</p><p id="Par60">There are several known drug-drug interactions between opioids and ARVs that affect systemic concentrations. The partial opioid agonist, buprenorphine, is metabolized primarily by cytochrome P450 (CYP) 3A4 and 2C8. Both buprenorphine and its active metabolite, norbuprenorphine, are glucuronidated by UDP-glucuronosyltransferase (UGT) 1A1 and then excreted in bile. Several ARVs inhibit or induce these metabolic pathways. However, not all interactions are clinically relevant. The boosted protease inhibitor combination, atazanavir/ritonavir, inhibits CYP 3A4 and UGT 1A1, leading to increases in overall systemic exposure of buprenorphine and norbuprenorphine and also results in symptoms of opioid excess, such as increased sedation and impaired cognition (McCance-Katz et al. <xref ref-type="bibr" rid="CR323">2007</xref>). Dose adjustments of buprenorphine are recommended when initiating therapy with atazanavir to avoid symptoms of opioid excess. Methadone is a full opioid substrate with multiple metabolic pathways, including CYP 3A4, 2B6, 2C19, 2C9, and 2D6. Several pharmacokinetic interactions are reported between methadone and protease inhibitors. However, withdrawal symptoms are rare, and therefore, dose adjustments are not recommended (Bruce et al. <xref ref-type="bibr" rid="CR58">2006</xref>; Meemken et al. <xref ref-type="bibr" rid="CR331">2015</xref>). In contrast, efavirenz and nevirapine induce CYP 3A4, resulting in decreased systemic concentrations of methadone and the development of opioid withdrawal symptoms. To avoid opioid withdrawal, increased methadone dosing is recommended when either efavirenz or nevirapine therapy is initiated (Marzolini et al. <xref ref-type="bibr" rid="CR312">2000</xref>; Clarke et al. <xref ref-type="bibr" rid="CR98">2001</xref>; Meemken et al. <xref ref-type="bibr" rid="CR331">2015</xref>). Oxycodone metabolism is inhibited by lopinavir/ritonavir, increasing oxycodone concentrations as well as the self-reported drug effects (Nieminen et al. <xref ref-type="bibr" rid="CR364">2010</xref>; Feng et al. <xref ref-type="bibr" rid="CR153">2017</xref>).</p><p id="Par61">The pharmacokinetic studies above focused on overall systemic exposure of drugs. Plasma concentrations, however, are not always accurate indicators of tissue exposure. Similarly, CNS drug exposure is often estimated based on drug concentrations within the CSF. However, CSF drug levels may not accurately predict brain concentrations. For many drugs with high efflux activities (e.g., substrates of P-gp), CSF tends to over-predict brain tissue concentrations (Liu et al. <xref ref-type="bibr" rid="CR291">2006</xref>; Friden et al. <xref ref-type="bibr" rid="CR165">2009</xref>; Kodaira et al. <xref ref-type="bibr" rid="CR245">2011</xref>, <xref ref-type="bibr" rid="CR246">2014</xref>). This could be due, in part, to differential expression of transporters at the blood-CSF barrier vs. BBB. In a study of the ARV drug amprenavir, concentrations of [<sup>14</sup>C]-amprenavir in CSF versus brain were 23.3&#x02009;&#x000b1;&#x02009;11.2 and 3.33&#x02009;&#x000b1;&#x02009;0.6 nCi/g, respectively, demonstrating overprediction of brain concentrations by CSF (Polli et al. <xref ref-type="bibr" rid="CR403">1999</xref>). These studies illustrate the high likelihood of misinterpreting drug brain penetration when using CSF as the surrogate marker. Therefore, direct measurement of brain tissue concentrations in animal models are likely to be more predictive of the interactive effects of ARVs and opioids on ARV and/or opioid brain exposure.</p><p id="Par62">A few studies have investigated the impact of opioids and ARV administration on drug concentrations within the brain. One study investigated the impact of 5 d continuous exposure to morphine on ARV brain concentrations (dolutegravir, lamivudine and abacavir) and demonstrated that morphine exposure resulted in regionally specific decreases in the concentrations of select ARV drugs (Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>) and, furthermore, that the decreases in ARV concentrations (dolutegravir and abacavir) were likely due to increased efflux by the drug efflux transport protein, P-gp (Leibrand et al. <xref ref-type="bibr" rid="CR274">2019</xref>). Morphine alterations in P-gp within the brain could have wide reaching impact on other CNS active drugs.</p><p id="Par63">HIV preferentially infects microglia and perivascular macrophages within the brain, although BMECs, astrocytes, and pericytes can also be infected (Kramer-Hammerle et al. <xref ref-type="bibr" rid="CR253">2005</xref>). Achieving optimal intracellular ARV concentrations are essential to suppress the infection. Few studies have examined whether ARV drugs differentially accumulate within different neural cell types and especially within cells of the neurovascular unit. Although nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are efficacious in inhibiting viral replication within monocyte-derived macrophages, only a few drugs within each ARV class can effectively inhibit viral replication within astrocytes (Gray et al. <xref ref-type="bibr" rid="CR188">2013</xref>), which could be a result of poor intracellular accumulation within astrocytes. In vitro studies have demonstrated darunavir and raltegravir intracellular concentrations to be approximately 100-fold lower (with higher EC<sub>50</sub> values) in microglia than in PBMCs (Asahchop et al. <xref ref-type="bibr" rid="CR19">2017</xref>).</p><p id="Par64">Another study measured intracellular concentrations of dolutegravir, tenofovir and emtricitabine in primary human astrocytes, microglia, pericytes and BMECs (Patel et al. <xref ref-type="bibr" rid="CR384">2019</xref>). Intracellular ARV concentrations were typically significantly higher in BMECs than in the other brain cell types. Dolutegravir achieved the highest relative concentrations within each cell type, whereas tenofovir accumulated the least (Patel et al. <xref ref-type="bibr" rid="CR384">2019</xref>). Furthermore, 24&#x000a0;h treatment with morphine significantly decreased intracellular accumulation of composite ARV concentrations, but only in astrocytes. In contrast, morphine exposure significantly increased the net accumulation of drugs within BMECs compared to controls. BMECs may sequester ARV drugs as a protective mechanism (Patel et al. <xref ref-type="bibr" rid="CR384">2019</xref>).</p><p id="Par65">Using experimental data from SIV-infected, morphine-addicted macaques, mathematical modeling suggests that morphine exposure increases the proportion of cells with high susceptibility to SIV infection, at least in part, because of increased co-receptor expression (Vaidya et al. <xref ref-type="bibr" rid="CR521">2016</xref>). In addition to promoting a higher steady state viral loads and larger CD4 count declines, the model also predicts that morphine exposure results in the need for more efficacious ARV treatment than would be necessary for animals not exposed to morphine (Vaidya et al. <xref ref-type="bibr" rid="CR521">2016</xref>). Although the direct impact of morphine on ARV concentrations was not investigated, the study provides evidence supporting morphine&#x02019;s negative impact on ARV efficacy.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Portions of this review were initially presented at the Satellite Symposium of the 25th SNIP Scientific Conference entitled, &#x0201c;Unraveling NeuroAIDS in the Presence of Substance Use Disorder&#x0201d; that was sponsored and organized by NIH/NIDA. Co-Chairs: Yu (Woody) Lin and Roger Sorensen (April 10, 2019)</p></ack><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Institute on Drug Abuse: R01 DA034231 (KFH), R01 DA044855 (KFH), R01 DA045588 (KFH), R01 DA018633 (KFH), R21 DA045630 (MM), and R01 DA045596 (SF).</p></notes><notes><title>Compliance with Ethical Standards</title><notes id="FPar2" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par67">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JW</given-names></name><name><surname>Marshall</surname><given-names>BDL</given-names></name><name><surname>Mohd Salleh</surname><given-names>NA</given-names></name><name><surname>Barrios</surname><given-names>R</given-names></name><name><surname>Nolan</surname><given-names>S</given-names></name><name><surname>Milloy</surname><given-names>MJ</given-names></name></person-group><article-title>Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs</article-title><source>Drug Alcohol Depend</source><year>2020</year><volume>206</volume><fpage>107670</fpage><?supplied-pmid 31711873?><pub-id pub-id-type="pmid">31711873</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>MW</given-names></name><name><surname>Geller</surname><given-names>EB</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Henderson</surname><given-names>EE</given-names></name><name><surname>Eisenstein</surname><given-names>TK</given-names></name></person-group><article-title>Opioids, receptors, and immunity</article-title><source>Adv Exp Med Biol</source><year>1993</year><volume>335</volume><fpage>13</fpage><lpage>20</lpage><?supplied-pmid 8237587?><pub-id pub-id-type="pmid">8237587</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alaee</surname><given-names>A</given-names></name><name><surname>Zarghami</surname><given-names>M</given-names></name><name><surname>Farnia</surname><given-names>S</given-names></name><name><surname>Khademloo</surname><given-names>M</given-names></name><name><surname>Khoddad</surname><given-names>T</given-names></name></person-group><article-title>Comparison of brain white matter hyperintensities in methamphetamine and methadone dependent patients and healthy controls</article-title><source>Iran J Radiol</source><year>2014</year><volume>11</volume><fpage>e14275</fpage><?supplied-pmid 25035700?><pub-id pub-id-type="pmid">25035700</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albright</surname><given-names>AV</given-names></name><name><surname>Strizki</surname><given-names>J</given-names></name><name><surname>Harouse</surname><given-names>JM</given-names></name><name><surname>Lavi</surname><given-names>E</given-names></name><name><surname>O'Connor</surname><given-names>M</given-names></name><name><surname>Gonzalez-Scarano</surname><given-names>F</given-names></name></person-group><article-title>HIV-1 infection of cultured human adult oligodendrocytes</article-title><source>Virology</source><year>1996</year><volume>217</volume><fpage>211</fpage><lpage>219</lpage><?supplied-pmid 8599205?><pub-id pub-id-type="pmid">8599205</pub-id></element-citation></ref><ref id="CR5"><mixed-citation publication-type="other">Alexander GC, Stoller KB, Haffajee RL, Saloner B (2020) An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med 173:57&#x02013;58</mixed-citation></ref><ref id="CR6"><mixed-citation publication-type="other">Al-Harthi L, Joseph J, Nath A (2019) Correction to: astrocytes as an HIV CNS reservoir: highlights and reflections of an NIMH-sponsored symposium. J Neurovirol 25:616</mixed-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Hasani</surname><given-names>R</given-names></name><name><surname>Bruchas</surname><given-names>MR</given-names></name></person-group><article-title>Molecular mechanisms of opioid receptor-dependent signaling and behavior</article-title><source>Anesthesiology</source><year>2011</year><volume>115</volume><fpage>1363</fpage><lpage>1381</lpage><?supplied-pmid 22020140?><pub-id pub-id-type="pmid">22020140</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Carbonell</surname><given-names>D</given-names></name><name><surname>Garcia-Mesa</surname><given-names>Y</given-names></name><name><surname>Milne</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>B</given-names></name><name><surname>Dobrowolski</surname><given-names>C</given-names></name><name><surname>Rojas</surname><given-names>R</given-names></name><name><surname>Karn</surname><given-names>J</given-names></name></person-group><article-title>Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells</article-title><source>Retrovirology</source><year>2017</year><volume>14</volume><fpage>9</fpage><?supplied-pmid 28166799?><pub-id pub-id-type="pmid">28166799</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Carbonell</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Ramanath</surname><given-names>N</given-names></name><name><surname>Garcia-Mesa</surname><given-names>Y</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Karn</surname><given-names>J</given-names></name></person-group><article-title>Cross-talk between microglia and neurons regulates HIV latency</article-title><source>PLoS Pathog</source><year>2019</year><volume>15</volume><fpage>e1008249</fpage><?supplied-pmid 31887215?><pub-id pub-id-type="pmid">31887215</pub-id></element-citation></ref><ref id="CR10"><mixed-citation publication-type="other">Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 74:255&#x02013;265</mixed-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>IC</given-names></name><name><surname>Ramage</surname><given-names>SN</given-names></name><name><surname>Carnie</surname><given-names>FW</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name></person-group><article-title>Does drug abuse alter microglial phenotype and cell turnover in the context of advancing HIV infection?</article-title><source>Neuropathol Appl Neurobiol</source><year>2005</year><volume>31</volume><fpage>325</fpage><lpage>338</lpage><?supplied-pmid 15885069?><pub-id pub-id-type="pmid">15885069</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>IC</given-names></name><name><surname>Arango</surname><given-names>JC</given-names></name><name><surname>Stephens</surname><given-names>B</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name></person-group><article-title>The effects of illicit drugs on the HIV infected brain</article-title><source>Front Biosci</source><year>2008</year><volume>13</volume><fpage>1294</fpage><lpage>1307</lpage><?supplied-pmid 17981630?><pub-id pub-id-type="pmid">17981630</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anthony</surname><given-names>IC</given-names></name><name><surname>Norrby</surname><given-names>KE</given-names></name><name><surname>Dingwall</surname><given-names>T</given-names></name><name><surname>Carnie</surname><given-names>FW</given-names></name><name><surname>Millar</surname><given-names>T</given-names></name><name><surname>Arango</surname><given-names>JC</given-names></name><name><surname>Robertson</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name></person-group><article-title>Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>3685</fpage><lpage>3698</lpage><?supplied-pmid 21126996?><pub-id pub-id-type="pmid">21126996</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aouizerat</surname><given-names>BE</given-names></name><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Miaskowski</surname><given-names>C</given-names></name></person-group><article-title>The search for host genetic factors of HIV/AIDS pathogenesis in the post-genome era: progress to date and new avenues for discovery</article-title><source>Curr HIV/AIDS Rep</source><year>2011</year><volume>8</volume><fpage>38</fpage><lpage>44</lpage><?supplied-pmid 21221856?><pub-id pub-id-type="pmid">21221856</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Applebaum</surname><given-names>AJ</given-names></name><name><surname>Reilly</surname><given-names>LC</given-names></name><name><surname>Gonzalez</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>MA</given-names></name><name><surname>Leveroni</surname><given-names>CL</given-names></name><name><surname>Safren</surname><given-names>SA</given-names></name></person-group><article-title>The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients</article-title><source>AIDS Patient Care STDs</source><year>2009</year><volume>23</volume><fpage>455</fpage><lpage>462</lpage><?supplied-pmid 19519229?><pub-id pub-id-type="pmid">19519229</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Applebaum</surname><given-names>AJ</given-names></name><name><surname>Otto</surname><given-names>MW</given-names></name><name><surname>Richardson</surname><given-names>MA</given-names></name><name><surname>Safren</surname><given-names>SA</given-names></name></person-group><article-title>Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients</article-title><source>J Clin Exp Neuropsychol</source><year>2010</year><volume>32</volume><fpage>579</fpage><lpage>589</lpage><?supplied-pmid 19890760?><pub-id pub-id-type="pmid">19890760</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquilante</surname><given-names>CL</given-names></name><name><surname>Letrent</surname><given-names>SP</given-names></name><name><surname>Pollack</surname><given-names>GM</given-names></name><name><surname>Brouwer</surname><given-names>KL</given-names></name></person-group><article-title>Increased brain P-glycoprotein in morphine tolerant rats</article-title><source>Life Sci</source><year>2000</year><volume>66</volume><fpage>PL47</fpage><lpage>PL51</lpage><?supplied-pmid 10665989?><pub-id pub-id-type="pmid">10665989</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnatt</surname><given-names>CK</given-names></name><name><surname>Falls</surname><given-names>BA</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Raborg</surname><given-names>TJ</given-names></name><name><surname>Masvekar</surname><given-names>RR</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Selley</surname><given-names>DE</given-names></name><name><surname>Nicola</surname><given-names>AV</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization</article-title><source>Bioorg Med Chem</source><year>2016</year><volume>24</volume><fpage>5969</fpage><lpage>5987</lpage><?supplied-pmid 27720326?><pub-id pub-id-type="pmid">27720326</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahchop</surname><given-names>EL</given-names></name><name><surname>Meziane</surname><given-names>O</given-names></name><name><surname>Mamik</surname><given-names>MK</given-names></name><name><surname>Chan</surname><given-names>WF</given-names></name><name><surname>Branton</surname><given-names>WG</given-names></name><name><surname>Resch</surname><given-names>L</given-names></name><name><surname>Gill</surname><given-names>MJ</given-names></name><name><surname>Haddad</surname><given-names>E</given-names></name><name><surname>Guimond</surname><given-names>JV</given-names></name><name><surname>Wainberg</surname><given-names>MA</given-names></name><name><surname>Baker</surname><given-names>GB</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name><name><surname>Power</surname><given-names>C</given-names></name></person-group><article-title>Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain</article-title><source>Retrovirology</source><year>2017</year><volume>14</volume><fpage>47</fpage><?supplied-pmid 29037245?><pub-id pub-id-type="pmid">29037245</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atwood</surname><given-names>WJ</given-names></name><name><surname>Tornatore</surname><given-names>CS</given-names></name><name><surname>Meyers</surname><given-names>K</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name></person-group><article-title>HIV-1 mRNA transcripts from persistently infected human fetal astrocytes</article-title><source>Ann N Y Acad Sci</source><year>1993</year><volume>693</volume><fpage>324</fpage><lpage>325</lpage><?supplied-pmid 8267293?><pub-id pub-id-type="pmid">8267293</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdoshina</surname><given-names>V</given-names></name><name><surname>Biggio</surname><given-names>F</given-names></name><name><surname>Palchik</surname><given-names>G</given-names></name><name><surname>Campbell</surname><given-names>LA</given-names></name><name><surname>Mocchetti</surname><given-names>I</given-names></name></person-group><article-title>Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120</article-title><source>Glia</source><year>2010</year><volume>58</volume><fpage>1630</fpage><lpage>1639</lpage><?supplied-pmid 20578038?><pub-id pub-id-type="pmid">20578038</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avdoshina</surname><given-names>V</given-names></name><name><surname>Garzino-Demo</surname><given-names>A</given-names></name><name><surname>Bachis</surname><given-names>A</given-names></name><name><surname>Monaco</surname><given-names>MC</given-names></name><name><surname>Maki</surname><given-names>PM</given-names></name><name><surname>Tractenberg</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name><name><surname>Mocchetti</surname><given-names>I</given-names></name></person-group><article-title>HIV-1 decreases the levels of neurotrophins in human lymphocytes</article-title><source>AIDS</source><year>2011</year><volume>25</volume><fpage>1126</fpage><lpage>1128</lpage><?supplied-pmid 21422985?><pub-id pub-id-type="pmid">21422985</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Oishi</surname><given-names>R</given-names></name><name><surname>Saeki</surname><given-names>K</given-names></name></person-group><article-title>Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation of mu opioid receptors in mice</article-title><source>Naunyn Schmiedeberg's Arch Pharmacol</source><year>1988</year><volume>337</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">2841613</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachis</surname><given-names>A</given-names></name><name><surname>Avdoshina</surname><given-names>V</given-names></name><name><surname>Zecca</surname><given-names>L</given-names></name><name><surname>Parsadanian</surname><given-names>M</given-names></name><name><surname>Mocchetti</surname><given-names>I</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>9477</fpage><lpage>9484</lpage><?supplied-pmid 22787033?><pub-id pub-id-type="pmid">22787033</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balinang</surname><given-names>JM</given-names></name><name><surname>Masvekar</surname><given-names>RR</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Productive infection of human neural progenitor cells by R5 tropic HIV-1: opiate co-exposure heightens infectivity and functional vulnerability</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>753</fpage><lpage>764</lpage><?supplied-pmid 28099189?><pub-id pub-id-type="pmid">28099189</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandaru</surname><given-names>VV</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Ewaleifoh</surname><given-names>O</given-names></name><name><surname>Haughey</surname><given-names>NJ</given-names></name></person-group><article-title>A failure to normalize biochemical and metabolic insults during morphine withdrawal disrupts synaptic repair in mice transgenic for HIV-gp120</article-title><source>J NeuroImmune Pharmacol</source><year>2011</year><volume>6</volume><fpage>640</fpage><lpage>649</lpage><?supplied-pmid 21748284?><pub-id pub-id-type="pmid">21748284</pub-id></element-citation></ref><ref id="CR27"><mixed-citation publication-type="other">Banerjee A, Zhang X, Manda KR, Banks WA, Ercal N (2010) HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med 48:1388&#x02013;1398</mixed-citation></ref><ref id="CR28"><mixed-citation publication-type="other">Banerjee A, Strazza M, Wigdahl B, Pirrone V, Meucci O, Nonnemacher MR (2011) Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 17:291&#x02013;302</mixed-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barat</surname><given-names>C</given-names></name><name><surname>Proust</surname><given-names>A</given-names></name><name><surname>Deshiere</surname><given-names>A</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><name><surname>Drouin</surname><given-names>J</given-names></name><name><surname>Tremblay</surname><given-names>MJ</given-names></name></person-group><article-title>Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency</article-title><source>Glia</source><year>2018</year><volume>66</volume><fpage>1363</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">29464785</pub-id></element-citation></ref><ref id="CR30"><mixed-citation publication-type="other">Barbour AJ, Hauser KF, McQuiston AR, Knapp PE (2020) HIV and opiates dysregulate K<sup>+</sup>-Cl cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice. Neurobiol Dis 141: 104878</mixed-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>LO</given-names></name></person-group><article-title>Effects of chronic opioid dependence and HIV-1 infection on pattern shift visual evoked potentials</article-title><source>Drug Alcohol Depend</source><year>1998</year><volume>50</volume><fpage>147</fpage><lpage>155</lpage><?supplied-pmid 9649966?><pub-id pub-id-type="pmid">9649966</pub-id></element-citation></ref><ref id="CR32"><mixed-citation publication-type="other">Becker WC, Fiellin DA (2020) When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med 173: 59-60</mixed-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednar</surname><given-names>MM</given-names></name><name><surname>Sturdevant</surname><given-names>CB</given-names></name><name><surname>Tompkins</surname><given-names>LA</given-names></name><name><surname>Arrildt</surname><given-names>KT</given-names></name><name><surname>Dukhovlinova</surname><given-names>E</given-names></name><name><surname>Kincer</surname><given-names>LP</given-names></name><name><surname>Swanstrom</surname><given-names>R</given-names></name></person-group><article-title>Compartmentalization, viral evolution, and viral latency of HIV in the CNS</article-title><source>Curr HIV/AIDS Rep</source><year>2015</year><volume>12</volume><fpage>262</fpage><lpage>271</lpage><?supplied-pmid 25914150?><pub-id pub-id-type="pmid">25914150</pub-id></element-citation></ref><ref id="CR34"><mixed-citation publication-type="other">Belcheva MM, Tan Y, Heaton VM, Clark AL, Coscia CJ (2003) &#x003bc;-Opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol 64:1391&#x02013;1401</mixed-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Strang</surname><given-names>J</given-names></name></person-group><article-title>Medication treatment of opioid use disorder</article-title><source>Biol Psychiatry</source><year>2020</year><volume>87</volume><fpage>82</fpage><lpage>88</lpage><?supplied-pmid 31420089?><pub-id pub-id-type="pmid">31420089</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Brettle</surname><given-names>RP</given-names></name><name><surname>Chiswick</surname><given-names>A</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name></person-group><article-title>HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement</article-title><source>Brain</source><year>1998</year><volume>121</volume><issue>Pt 11</issue><fpage>2043</fpage><lpage>2052</lpage><?supplied-pmid 9827765?><pub-id pub-id-type="pmid">9827765</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Arango</surname><given-names>JC</given-names></name><name><surname>Robertson</surname><given-names>R</given-names></name><name><surname>Brettle</surname><given-names>RP</given-names></name><name><surname>Leen</surname><given-names>C</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name></person-group><article-title>HIV and drug misuse in the Edinburgh cohort</article-title><source>J Acquir Immune Defic Syndr</source><year>2002</year><volume>31</volume><issue>Suppl 2</issue><fpage>S35</fpage><lpage>S42</lpage><?supplied-pmid 12394781?><pub-id pub-id-type="pmid">12394781</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Arango</surname><given-names>JC</given-names></name><name><surname>Anthony</surname><given-names>IC</given-names></name></person-group><article-title>Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs</article-title><source>J NeuroImmune Pharmacol</source><year>2006</year><volume>1</volume><fpage>182</fpage><lpage>191</lpage><?supplied-pmid 18040783?><pub-id pub-id-type="pmid">18040783</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benarroch</surname><given-names>EE</given-names></name></person-group><article-title>Endogenous opioid systems: current concepts and clinical correlations</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>807</fpage><lpage>814</lpage><?supplied-pmid 22915176?><pub-id pub-id-type="pmid">22915176</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>3rd</suffix></name><name><surname>Lessov-Schlaggar</surname><given-names>CN</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group><article-title>CYP2A6 genotype and the metabolism and disposition kinetics of nicotine</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>80</volume><fpage>457</fpage><lpage>467</lpage><?supplied-pmid 17112802?><pub-id pub-id-type="pmid">17112802</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Whistler</surname><given-names>JL</given-names></name></person-group><article-title>How to design an opioid drug that causes reduced tolerance and dependence</article-title><source>Ann Neurol</source><year>2010</year><volume>67</volume><fpage>559</fpage><lpage>569</lpage><?supplied-pmid 20437553?><pub-id pub-id-type="pmid">20437553</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>JW</given-names></name><etal/></person-group><article-title>NeuroAIDS, drug abuse, and inflammation: building collaborative research activities</article-title><source>J NeuroImmune Pharmacol</source><year>2006</year><volume>1</volume><fpage>351</fpage><lpage>399</lpage><?supplied-pmid 18040811?><pub-id pub-id-type="pmid">18040811</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>A</given-names></name><name><surname>Agresti</surname><given-names>C</given-names></name><name><surname>Levi</surname><given-names>G</given-names></name></person-group><article-title>HIV-gp120 affects the functional activity of oligodendrocytes and their susceptibility to complement</article-title><source>J Neurosci Res</source><year>1997</year><volume>50</volume><fpage>946</fpage><lpage>957</lpage><?supplied-pmid 9452009?><pub-id pub-id-type="pmid">9452009</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blankson</surname><given-names>JN</given-names></name><name><surname>Persaud</surname><given-names>D</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>The challenge of viral reservoirs in HIV-1 infection</article-title><source>Annu Rev Med</source><year>2002</year><volume>53</volume><fpage>557</fpage><lpage>593</lpage><?supplied-pmid 11818490?><pub-id pub-id-type="pmid">11818490</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodnar</surname><given-names>RJ</given-names></name></person-group><article-title>Endogenous opiates and behavior: 2009</article-title><source>Peptides</source><year>2010</year><volume>31</volume><fpage>2325</fpage><lpage>2359</lpage><?supplied-pmid 20875476?><pub-id pub-id-type="pmid">20875476</pub-id></element-citation></ref><ref id="CR46"><mixed-citation publication-type="other">Bohn LM, Belcheva MM, Coscia CJ (2000) &#x003bc;-Opioid agonist inhibition of &#x003ba;-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells. J Neurochem 74:574&#x02013;581</mixed-citation></ref><ref id="CR47"><mixed-citation publication-type="other">Boivin MJ, Ruel TD, Boal HE, Bangirana P, Cao H, Eller LA, Charlebois E, Havlir DV, Kamya MR, Achan J, Akello C, Wong JK (2010) HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS 24:1163&#x02013;1170</mixed-citation></ref><ref id="CR48"><mixed-citation publication-type="other">Bokhari SM, Yao H, Bethel-Brown C, Fuwang P, Williams R, Dhillon NK, Hegde R, Kumar A, Buch SJ (2009) Morphine enhances tat-induced activation in murine microglia. J Neurovirol 15:219&#x02013;228</mixed-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokhari</surname><given-names>SM</given-names></name><name><surname>Hegde</surname><given-names>R</given-names></name><name><surname>Callen</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Adany</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Pinson</surname><given-names>D</given-names></name><name><surname>Yeh</surname><given-names>HW</given-names></name><name><surname>Cheney</surname><given-names>PD</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name></person-group><article-title>Morphine potentiates neuropathogenesis of SIV infection in rhesus macaques</article-title><source>J NeuroImmune Pharmacol</source><year>2011</year><volume>6</volume><fpage>626</fpage><lpage>639</lpage><?supplied-pmid 21431470?><pub-id pub-id-type="pmid">21431470</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>JW</given-names></name><name><surname>Foulds</surname><given-names>GA</given-names></name><name><surname>Ahmedzai</surname><given-names>SH</given-names></name><name><surname>Pockley</surname><given-names>AG</given-names></name></person-group><article-title>A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function</article-title><source>BMJ Support Palliat Care</source><year>2014</year><volume>4</volume><fpage>357</fpage><lpage>367</lpage><?supplied-pmid 24644198?><pub-id pub-id-type="pmid">24644198</pub-id></element-citation></ref><ref id="CR51"><mixed-citation publication-type="other">Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters &#x003b2;-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608&#x02013;9613</mixed-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bora</surname><given-names>E</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Pantelis</surname><given-names>C</given-names></name><name><surname>Harrison</surname><given-names>BJ</given-names></name><name><surname>Cocchi</surname><given-names>L</given-names></name><name><surname>Pell</surname><given-names>G</given-names></name><name><surname>Lubman</surname><given-names>DI</given-names></name></person-group><article-title>White matter microstructure in opiate addiction</article-title><source>Addict Biol</source><year>2012</year><volume>17</volume><fpage>141</fpage><lpage>148</lpage><?supplied-pmid 21070508?><pub-id pub-id-type="pmid">21070508</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boska</surname><given-names>MD</given-names></name><name><surname>Dash</surname><given-names>PK</given-names></name><name><surname>Knibbe</surname><given-names>J</given-names></name><name><surname>Epstein</surname><given-names>AA</given-names></name><name><surname>Akhter</surname><given-names>SP</given-names></name><name><surname>Fields</surname><given-names>N</given-names></name><name><surname>High</surname><given-names>R</given-names></name><name><surname>Makarov</surname><given-names>E</given-names></name><name><surname>Bonasera</surname><given-names>S</given-names></name><name><surname>Gelbard</surname><given-names>HA</given-names></name><name><surname>Poluektova</surname><given-names>LY</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Gorantla</surname><given-names>S</given-names></name></person-group><article-title>Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice</article-title><source>Mol Neurodegener</source><year>2014</year><volume>9</volume><fpage>58</fpage><?supplied-pmid 25523827?><pub-id pub-id-type="pmid">25523827</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>RS</given-names></name><name><surname>Mills</surname><given-names>GH</given-names></name></person-group><article-title>Sleep disruption in critically ill patients--pharmacological considerations</article-title><source>Anaesthesia</source><year>2004</year><volume>59</volume><fpage>374</fpage><lpage>384</lpage><?supplied-pmid 15023109?><pub-id pub-id-type="pmid">15023109</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boven</surname><given-names>LA</given-names></name><name><surname>Middel</surname><given-names>J</given-names></name><name><surname>Verhoef</surname><given-names>J</given-names></name><name><surname>De Groot</surname><given-names>CJ</given-names></name><name><surname>Nottet</surname><given-names>HS</given-names></name></person-group><article-title>Monocyte infiltration is highly associated with loss of the tight junction protein zonula occludens in HIV-1-associated dementia</article-title><source>Neuropathol Appl Neurobiol</source><year>2000</year><volume>26</volume><fpage>356</fpage><lpage>360</lpage><?supplied-pmid 10931369?><pub-id pub-id-type="pmid">10931369</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>CJ</given-names></name><name><surname>Godino</surname><given-names>A</given-names></name><name><surname>Salery</surname><given-names>M</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><article-title>Epigenetic mechanisms of opioid addiction</article-title><source>Biol Psychiatry</source><year>2020</year><volume>87</volume><fpage>22</fpage><lpage>33</lpage><?supplied-pmid 31477236?><pub-id pub-id-type="pmid">31477236</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownstein</surname><given-names>MJ</given-names></name></person-group><article-title>A brief history of opiates, opioid peptides, and opioid receptors</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>5391</fpage><lpage>5393</lpage><?supplied-pmid 8390660?><pub-id pub-id-type="pmid">8390660</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>RD</given-names></name><name><surname>McCance-Katz</surname><given-names>E</given-names></name><name><surname>Kharasch</surname><given-names>ED</given-names></name><name><surname>Moody</surname><given-names>DE</given-names></name><name><surname>Morse</surname><given-names>GD</given-names></name></person-group><article-title>Pharmacokinetic interactions between buprenorphine and antiretroviral medications</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><issue>Suppl 4</issue><fpage>S216</fpage><lpage>S223</lpage><?supplied-pmid 17109308?><pub-id pub-id-type="pmid">17109308</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruehl</surname><given-names>S</given-names></name><name><surname>Apkarian</surname><given-names>AV</given-names></name><name><surname>Ballantyne</surname><given-names>JC</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Borsook</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>WG</given-names></name><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Haythornthwaite</surname><given-names>JA</given-names></name><name><surname>Horn</surname><given-names>SD</given-names></name><name><surname>Iadarola</surname><given-names>MJ</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name><name><surname>Lao</surname><given-names>L</given-names></name><name><surname>Mackey</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Sawczuk</surname><given-names>A</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name><name><surname>Witter</surname><given-names>J</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name><name><surname>Zubieta</surname><given-names>JK</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name></person-group><article-title>Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges</article-title><source>The journal of pain : official journal of the American Pain Society</source><year>2013</year><volume>14</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">23374939</pub-id></element-citation></ref><ref id="CR60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruner</surname><given-names>KM</given-names></name><etal/></person-group><article-title>A quantitative approach for measuring the reservoir of latent HIV-1 proviruses</article-title><source>Nature</source><year>2019</year><volume>566</volume><fpage>120</fpage><lpage>125</lpage><?supplied-pmid 30700913?><pub-id pub-id-type="pmid">30700913</pub-id></element-citation></ref><ref id="CR61"><mixed-citation publication-type="other">Buch SK, Khurdayan VK, Lutz SE, Knapp PE, El-Hage N, Hauser KF (2007) Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro. Neuroscience 146:1546&#x02013;1554</mixed-citation></ref><ref id="CR62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdo</surname><given-names>TH</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>KC</given-names></name></person-group><article-title>Monocyte/macrophages and their role in HIV neuropathogenesis</article-title><source>Immunol Rev</source><year>2013</year><volume>254</volume><fpage>102</fpage><lpage>113</lpage><?supplied-pmid 23772617?><pub-id pub-id-type="pmid">23772617</pub-id></element-citation></ref><ref id="CR63"><mixed-citation publication-type="other">Burgueno J, Pujol M, Monroy X, Roche D, Varela MJ, Merlos M, Giraldo J (2017) A complementary scale of biased agonism for agonists with differing maximal responses. Sci Rep 7:15389</mixed-citation></ref><ref id="CR64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttner</surname><given-names>A</given-names></name></person-group><article-title>Review: the neuropathology of drug abuse</article-title><source>Neuropathol Appl Neurobiol</source><year>2011</year><volume>37</volume><fpage>118</fpage><lpage>134</lpage><?supplied-pmid 20946118?><pub-id pub-id-type="pmid">20946118</pub-id></element-citation></ref><ref id="CR65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buttner</surname><given-names>A</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>Neuropathological alterations in drug abusers : the involvement of neurons, glial, and vascular systems</article-title><source>Forensic Sci Med Pathol</source><year>2006</year><volume>2</volume><fpage>115</fpage><lpage>126</lpage><?supplied-pmid 25868590?><pub-id pub-id-type="pmid">25868590</pub-id></element-citation></ref><ref id="CR66"><mixed-citation publication-type="other">Buttner A, Rohrmoser K, Mall G, Penning R, Weis S (2006) Widespread axonal damage in the brain of drug abusers as evidenced by accumulation of &#x003b2;-amyloid precursor protein (&#x003b2;-APP): an immunohistochemical investigation. Addiction 101:1339&#x02013;1346</mixed-citation></ref><ref id="CR67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd</surname><given-names>DA</given-names></name><name><surname>Fellows</surname><given-names>RP</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Franklin</surname><given-names>D</given-names></name><name><surname>Heaton</surname><given-names>RK</given-names></name><name><surname>Deutsch</surname><given-names>R</given-names></name><name><surname>Atkinson</surname><given-names>JH</given-names></name><name><surname>Clifford</surname><given-names>DB</given-names></name><name><surname>Collier</surname><given-names>AC</given-names></name><name><surname>Marra</surname><given-names>CM</given-names></name><name><surname>Gelman</surname><given-names>B</given-names></name><name><surname>McCutchan</surname><given-names>JA</given-names></name><name><surname>Duarte</surname><given-names>NA</given-names></name><name><surname>Simpson</surname><given-names>DM</given-names></name><name><surname>McArthur</surname><given-names>J</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name></person-group><article-title>Neurocognitive impact of substance use in HIV infection</article-title><source>J Acquir Immune Defic Syndr</source><year>2011</year><volume>58</volume><fpage>154</fpage><lpage>162</lpage><?supplied-pmid 21725250?><pub-id pub-id-type="pmid">21725250</pub-id></element-citation></ref><ref id="CR68"><mixed-citation publication-type="other">Byrd D, Murray J, Safdieh G, Morgello S (2012) Impact of opiate addiction on neuroinflammation in HIV. J Neurovirol 18:364&#x02013;373</mixed-citation></ref><ref id="CR69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadet</surname><given-names>JL</given-names></name><name><surname>Bisagno</surname><given-names>V</given-names></name><name><surname>Milroy</surname><given-names>CM</given-names></name></person-group><article-title>Neuropathology of substance use disorders</article-title><source>Acta Neuropathol</source><year>2014</year><volume>127</volume><fpage>91</fpage><lpage>107</lpage><?supplied-pmid 24292887?><pub-id pub-id-type="pmid">24292887</pub-id></element-citation></ref><ref id="CR70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Potential therapeutic effects of neurotrophins for acute and chronic neurological diseases</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>601084</fpage><?supplied-pmid 24818146?><pub-id pub-id-type="pmid">24818146</pub-id></element-citation></ref><ref id="CR71"><mixed-citation publication-type="other">Campbell GR, Watkins JD, Loret EP, Spector SA (2011) Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C Tat proteins. AIDS Res Hum Retrovir 27:647&#x02013;654</mixed-citation></ref><ref id="CR72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canto-Nogues</surname><given-names>C</given-names></name><name><surname>Sanchez-Ramon</surname><given-names>S</given-names></name><name><surname>Alvarez</surname><given-names>S</given-names></name><name><surname>Lacruz</surname><given-names>C</given-names></name><name><surname>Munoz-Fernandez</surname><given-names>MA</given-names></name></person-group><article-title>HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children</article-title><source>J Mol Neurosci</source><year>2005</year><volume>27</volume><fpage>79</fpage><lpage>89</lpage><?supplied-pmid 16055948?><pub-id pub-id-type="pmid">16055948</pub-id></element-citation></ref><ref id="CR73"><mixed-citation publication-type="other">Caputi FF, Rullo L, Stamatakos S, Candeletti S, Romualdi P (2019) Interplay between the endogenous opioid system and proteasome complex: beyond signaling. International Journal of Molecular Sciences 20: 1441</mixed-citation></ref><ref id="CR74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>DJJ</given-names></name><name><surname>Serou</surname><given-names>M</given-names></name></person-group><article-title>Exogenous and endogenous opioids as biological response modifiers</article-title><source>Immunopharmacology</source><year>1995</year><volume>31</volume><fpage>59</fpage><lpage>71</lpage><?supplied-pmid 8655291?><pub-id pub-id-type="pmid">8655291</pub-id></element-citation></ref><ref id="CR75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>DJ</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Weber</surname><given-names>RJ</given-names></name></person-group><article-title>The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis</article-title><source>Proc Soc Exp Biol Med</source><year>1996</year><volume>213</volume><fpage>248</fpage><lpage>257</lpage><?supplied-pmid 8985308?><pub-id pub-id-type="pmid">8985308</pub-id></element-citation></ref><ref id="CR76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvallo</surname><given-names>L</given-names></name><name><surname>Lopez</surname><given-names>L</given-names></name><name><surname>Che</surname><given-names>FY</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Eugenin</surname><given-names>EA</given-names></name><name><surname>Williams</surname><given-names>DW</given-names></name><name><surname>Nieves</surname><given-names>E</given-names></name><name><surname>Calderon</surname><given-names>TM</given-names></name><name><surname>Madrid-Aliste</surname><given-names>C</given-names></name><name><surname>Fiser</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>L</given-names></name><name><surname>Angeletti</surname><given-names>RH</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><fpage>3246</fpage><lpage>3258</lpage><?supplied-pmid 25716997?><pub-id pub-id-type="pmid">25716997</pub-id></element-citation></ref><ref id="CR77"><mixed-citation publication-type="other">CDC (2017) Understanding the epidemic. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/drugoverdose/epidemic/index.html">https://www.cdc.gov/drugoverdose/epidemic/index.html</ext-link></mixed-citation></ref><ref id="CR78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>SL</given-names></name><name><surname>Beltran</surname><given-names>JA</given-names></name><name><surname>Swarup</surname><given-names>S</given-names></name></person-group><article-title>Expression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat model</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>8406</fpage><lpage>8411</lpage><?supplied-pmid 17553897?><pub-id pub-id-type="pmid">17553897</pub-id></element-citation></ref><ref id="CR79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name></person-group><article-title>Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse</article-title><source>NeuroImage</source><year>2008</year><volume>42</volume><fpage>869</fpage><lpage>878</lpage><?supplied-pmid 18579413?><pub-id pub-id-type="pmid">18579413</pub-id></element-citation></ref><ref id="CR80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Sheng</surname><given-names>WS</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Portoghese</surname><given-names>PS</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1</article-title><source>Adv Exp Med Biol</source><year>1995</year><volume>373</volume><fpage>65</fpage><lpage>72</lpage><?supplied-pmid 7668162?><pub-id pub-id-type="pmid">7668162</pub-id></element-citation></ref><ref id="CR81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>Opiates, glia, and neurotoxicity</article-title><source>Adv Exp Med Biol</source><year>1996</year><volume>402</volume><fpage>29</fpage><lpage>33</lpage><?supplied-pmid 8787640?><pub-id pub-id-type="pmid">8787640</pub-id></element-citation></ref><ref id="CR82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>WS</given-names></name><name><surname>Shark</surname><given-names>KB</given-names></name><name><surname>Bu</surname><given-names>DF</given-names></name><name><surname>Archer</surname><given-names>S</given-names></name><name><surname>Bidlack</surname><given-names>JM</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>&#x003ba; opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>8051</fpage><lpage>8056</lpage><?supplied-pmid 8755601?><pub-id pub-id-type="pmid">8755601</pub-id></element-citation></ref><ref id="CR83"><mixed-citation publication-type="other">Chao CC, Gekker G, Hu S, Kravitz F, Peterson PK (1998a) &#x003ba;-Opioid potentiation of tumor necrosis factor-&#x003b1;-induced anti-HIV-1 activity in acutely infected human brain cell cultures. Biochem Pharmacol 56:397&#x02013;404</mixed-citation></ref><ref id="CR84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Sheng</surname><given-names>WS</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Loh</surname><given-names>HH</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>Orphan opioid receptor oligonucleotides inhibit HIV-1 expression in human brain cells</article-title><source>Adv Exp Med Biol</source><year>1998</year><volume>437</volume><fpage>83</fpage><lpage>90</lpage><?supplied-pmid 9666260?><pub-id pub-id-type="pmid">9666260</pub-id></element-citation></ref><ref id="CR85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>CC</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Lokensgard</surname><given-names>JR</given-names></name><name><surname>Heyes</surname><given-names>MP</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression</article-title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>150</fpage><lpage>160</lpage><?supplied-pmid 10665828?><pub-id pub-id-type="pmid">10665828</pub-id></element-citation></ref><ref id="CR86"><mixed-citation publication-type="other">Chao J, Yang L, Yao H, Buch S (2014) Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis: role of GSK-3&#x003b2;/&#x003b2;-catenin. J NeuroImmune Pharmacol 9:259&#x02013;268</mixed-citation></ref><ref id="CR87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>K</given-names></name></person-group><article-title>Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS</article-title><source>J Genet</source><year>2010</year><volume>89</volume><fpage>109</fpage><lpage>116</lpage><?supplied-pmid 20505255?><pub-id pub-id-type="pmid">20505255</pub-id></element-citation></ref><ref id="CR88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaves</surname><given-names>C</given-names></name><name><surname>Gomez-Zepeda</surname><given-names>D</given-names></name><name><surname>Auvity</surname><given-names>S</given-names></name><name><surname>Menet</surname><given-names>MC</given-names></name><name><surname>Crete</surname><given-names>D</given-names></name><name><surname>Labat</surname><given-names>L</given-names></name><name><surname>Remiao</surname><given-names>F</given-names></name><name><surname>Cisternino</surname><given-names>S</given-names></name><name><surname>Decleves</surname><given-names>X</given-names></name></person-group><article-title>Effect of subchronic intravenous morphine infusion and naloxone-precipitated morphine withdrawal on P-gp and Bcrp at the rat blood-brain barrier</article-title><source>J Pharm Sci</source><year>2016</year><volume>105</volume><fpage>350</fpage><lpage>358</lpage><?supplied-pmid 26554626?><pub-id pub-id-type="pmid">26554626</pub-id></element-citation></ref><ref id="CR89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Bot</surname><given-names>G</given-names></name><name><surname>Szabo</surname><given-names>I</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Liu-Chen</surname><given-names>LY</given-names></name></person-group><article-title>Heterodimerization and cross-desensitization between the &#x003bc;-opioid receptor and the chemokine CCR5 receptor</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>483</volume><fpage>175</fpage><lpage>186</lpage><?supplied-pmid 14729105?><pub-id pub-id-type="pmid">14729105</pub-id></element-citation></ref><ref id="CR90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Stone</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>JK</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Bullitt</surname><given-names>E</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name></person-group><article-title>White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients</article-title><source>NeuroImage</source><year>2009</year><volume>47</volume><fpage>1154</fpage><lpage>1162</lpage><?supplied-pmid 19376246?><pub-id pub-id-type="pmid">19376246</pub-id></element-citation></ref><ref id="CR91"><mixed-citation publication-type="other">Chen K, Phan T, Lin A, Sardo L, Mele AR, Nonnemacher MR, Klase Z (2020) Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes. PLoS One 15:e0230563</mixed-citation></ref><ref id="CR92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chilunda</surname><given-names>V</given-names></name><name><surname>Calderon</surname><given-names>TM</given-names></name><name><surname>Martinez-Aguado</surname><given-names>P</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era</article-title><source>Brain Res</source><year>2019</year><volume>1724</volume><fpage>146426</fpage><?supplied-pmid 31473221?><pub-id pub-id-type="pmid">31473221</pub-id></element-citation></ref><ref id="CR93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Yerneni</surname><given-names>R</given-names></name><name><surname>Healy</surname><given-names>S</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>Neighbors</surname><given-names>CJ</given-names></name></person-group><article-title>Predictors of medication utilization for opioid use disorder among medicaid-insured HIV patients in New York</article-title><source>The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions</source><year>2020</year><volume>29</volume><fpage>151</fpage><lpage>154</lpage></element-citation></ref><ref id="CR94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrousos</surname><given-names>GP</given-names></name><name><surname>Zapanti</surname><given-names>ED</given-names></name></person-group><article-title>Hypothalamic-pituitary-adrenal axis in HIV infection and disease</article-title><source>Endocrinol Metab Clin N Am</source><year>2014</year><volume>43</volume><fpage>791</fpage><lpage>806</lpage></element-citation></ref><ref id="CR95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>MJ</given-names></name><name><surname>Gorry</surname><given-names>PR</given-names></name><name><surname>Cowley</surname><given-names>D</given-names></name><name><surname>Lal</surname><given-names>L</given-names></name><name><surname>Sonza</surname><given-names>S</given-names></name><name><surname>Purcell</surname><given-names>DF</given-names></name><name><surname>Thompson</surname><given-names>KA</given-names></name><name><surname>Gabuzda</surname><given-names>D</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>Wesselingh</surname><given-names>SL</given-names></name></person-group><article-title>Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues</article-title><source>J Neuro-Oncol</source><year>2006</year><volume>12</volume><fpage>146</fpage><lpage>152</lpage></element-citation></ref><ref id="CR96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>MJ</given-names></name><name><surname>Wesselingh</surname><given-names>SL</given-names></name><name><surname>Cowley</surname><given-names>D</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Brew</surname><given-names>BJ</given-names></name><name><surname>Gorry</surname><given-names>PR</given-names></name></person-group><article-title>Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia</article-title><source>Ann Neurol</source><year>2009</year><volume>66</volume><fpage>253</fpage><lpage>258</lpage><?supplied-pmid 19743454?><pub-id pub-id-type="pmid">19743454</pub-id></element-citation></ref><ref id="CR97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>MJ</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name><name><surname>Swanstrom</surname><given-names>R</given-names></name></person-group><article-title>HIV reservoirs: what, where and how to target them</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><fpage>55</fpage><lpage>60</lpage><?supplied-pmid 26616417?><pub-id pub-id-type="pmid">26616417</pub-id></element-citation></ref><ref id="CR98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>SM</given-names></name><name><surname>Mulcahy</surname><given-names>FM</given-names></name><name><surname>Tjia</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>HE</given-names></name><name><surname>Gibbons</surname><given-names>SE</given-names></name><name><surname>Barry</surname><given-names>MG</given-names></name><name><surname>Back</surname><given-names>DJ</given-names></name></person-group><article-title>The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz</article-title><source>Br J Clin Pharmacol</source><year>2001</year><volume>51</volume><fpage>213</fpage><lpage>217</lpage><?supplied-pmid 11298066?><pub-id pub-id-type="pmid">11298066</pub-id></element-citation></ref><ref id="CR99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleck</surname><given-names>JN</given-names></name><name><surname>Blendy</surname><given-names>JA</given-names></name></person-group><article-title>Making a bad thing worse: adverse effects of stress on drug addiction</article-title><source>J Clin Invest</source><year>2008</year><volume>118</volume><fpage>454</fpage><lpage>461</lpage><?supplied-pmid 18246196?><pub-id pub-id-type="pmid">18246196</pub-id></element-citation></ref><ref id="CR100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloak</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>O'Neil</surname><given-names>SP</given-names></name><name><surname>Ernst</surname><given-names>TM</given-names></name><name><surname>Anderson</surname><given-names>DC</given-names></name><name><surname>Donahoe</surname><given-names>RM</given-names></name></person-group><article-title>Neurometabolite abnormalities in simian immunodeficiency virus-infected macaques with chronic morphine administration</article-title><source>J NeuroImmune Pharmacol</source><year>2011</year><volume>6</volume><fpage>371</fpage><lpage>380</lpage><?supplied-pmid 20938808?><pub-id pub-id-type="pmid">20938808</pub-id></element-citation></ref><ref id="CR101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coller</surname><given-names>JK</given-names></name><name><surname>Hutchinson</surname><given-names>MR</given-names></name></person-group><article-title>Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence</article-title><source>Pharmacol Ther</source><year>2012</year><volume>134</volume><fpage>219</fpage><lpage>245</lpage><?supplied-pmid 22316499?><pub-id pub-id-type="pmid">22316499</pub-id></element-citation></ref><ref id="CR102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collett</surname><given-names>BJ</given-names></name></person-group><article-title>Opioid tolerance: the clinical perspective</article-title><source>Br J Anaesth</source><year>1998</year><volume>81</volume><fpage>58</fpage><lpage>68</lpage><?supplied-pmid 9771273?><pub-id pub-id-type="pmid">9771273</pub-id></element-citation></ref><ref id="CR103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concha</surname><given-names>M</given-names></name><name><surname>Selnes</surname><given-names>OA</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Nance-Sproson</surname><given-names>T</given-names></name><name><surname>Updike</surname><given-names>M</given-names></name><name><surname>Royal</surname><given-names>W</given-names></name><name><surname>Palenicek</surname><given-names>J</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group><article-title>Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men</article-title><source>Neuroepidemiology</source><year>1997</year><volume>16</volume><fpage>78</fpage><lpage>85</lpage><?supplied-pmid 9057169?><pub-id pub-id-type="pmid">9057169</pub-id></element-citation></ref><ref id="CR104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>DG</given-names></name><name><surname>Zimmermann</surname><given-names>N</given-names></name><name><surname>Doring</surname><given-names>TM</given-names></name><name><surname>Wilner</surname><given-names>NV</given-names></name><name><surname>Leite</surname><given-names>SC</given-names></name><name><surname>Cabral</surname><given-names>RF</given-names></name><name><surname>Fonseca</surname><given-names>RP</given-names></name><name><surname>Bahia</surname><given-names>PR</given-names></name><name><surname>Gasparetto</surname><given-names>EL</given-names></name></person-group><article-title>Diffusion tensor MR imaging of white matter integrity in HIV-positive patients with planning deficit</article-title><source>Neuroradiology</source><year>2015</year><volume>57</volume><fpage>475</fpage><lpage>482</lpage><?supplied-pmid 25604843?><pub-id pub-id-type="pmid">25604843</pub-id></element-citation></ref><ref id="CR105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>A</given-names></name><name><surname>Nappi</surname><given-names>RE</given-names></name><name><surname>Polatti</surname><given-names>F</given-names></name><name><surname>Poma</surname><given-names>A</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name></person-group><article-title>Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: involvement of nitric oxide</article-title><source>Exp Neurol</source><year>2000</year><volume>166</volume><fpage>376</fpage><lpage>384</lpage><?supplied-pmid 11085902?><pub-id pub-id-type="pmid">11085902</pub-id></element-citation></ref><ref id="CR106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Neto</surname><given-names>CM</given-names></name><name><surname>Parreiras</surname><given-names>ESLT</given-names></name><name><surname>Bouvier</surname><given-names>M</given-names></name></person-group><article-title>A pluridimensional view of biased Agonism</article-title><source>Mol Pharmacol</source><year>2016</year><volume>90</volume><fpage>587</fpage><lpage>595</lpage><?supplied-pmid 27638872?><pub-id pub-id-type="pmid">27638872</pub-id></element-citation></ref><ref id="CR107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crystal</surname><given-names>HA</given-names></name><name><surname>Hamon</surname><given-names>S</given-names></name><name><surname>Randesi</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Anastos</surname><given-names>K</given-names></name><name><surname>Lazar</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Pearce</surname><given-names>L</given-names></name><name><surname>Golub</surname><given-names>E</given-names></name><name><surname>Valcour</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>KM</given-names></name><name><surname>Holman</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women</article-title><source>Addict Biol</source><year>2012</year><volume>17</volume><fpage>181</fpage><lpage>191</lpage><?supplied-pmid 21070507?><pub-id pub-id-type="pmid">21070507</pub-id></element-citation></ref><ref id="CR108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culpepper-Morgan</surname><given-names>JA</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal</article-title><source>Metab Clin Exp</source><year>1997</year><volume>46</volume><fpage>130</fpage><lpage>134</lpage><?supplied-pmid 9030816?><pub-id pub-id-type="pmid">9030816</pub-id></element-citation></ref><ref id="CR109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallasta</surname><given-names>LM</given-names></name><name><surname>Pisarov</surname><given-names>LA</given-names></name><name><surname>Esplen</surname><given-names>JE</given-names></name><name><surname>Werley</surname><given-names>JV</given-names></name><name><surname>Moses</surname><given-names>AV</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name><name><surname>Achim</surname><given-names>CL</given-names></name></person-group><article-title>Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>1915</fpage><lpage>1927</lpage><?supplied-pmid 10595922?><pub-id pub-id-type="pmid">10595922</pub-id></element-citation></ref><ref id="CR110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danos</surname><given-names>P</given-names></name><name><surname>Van Roos</surname><given-names>D</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Bromel</surname><given-names>T</given-names></name><name><surname>Broich</surname><given-names>K</given-names></name><name><surname>Krappel</surname><given-names>C</given-names></name><name><surname>Solymosi</surname><given-names>L</given-names></name><name><surname>Moller</surname><given-names>HJ</given-names></name></person-group><article-title>Enlarged cerebrospinal fluid spaces in opiate-dependent male patients: a stereological CT study</article-title><source>Neuropsychobiology</source><year>1998</year><volume>38</volume><fpage>80</fpage><lpage>83</lpage><?supplied-pmid 9732207?><pub-id pub-id-type="pmid">9732207</pub-id></element-citation></ref><ref id="CR111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>RS</given-names></name></person-group><article-title>Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages</article-title><source>FEMS Immunol Med Microbiol</source><year>2012</year><volume>64</volume><fpage>228</fpage><lpage>236</lpage><?supplied-pmid 22066570?><pub-id pub-id-type="pmid">22066570</pub-id></element-citation></ref><ref id="CR112"><mixed-citation publication-type="other">Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K (2000) Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 6:221&#x02013;228</mixed-citation></ref><ref id="CR113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denis</surname><given-names>CM</given-names></name><name><surname>Morales</surname><given-names>KH</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Metzger</surname><given-names>DS</given-names></name><name><surname>Cheatle</surname><given-names>MD</given-names></name></person-group><article-title>Association between diagnoses of chronic noncancer pain, substance use disorder, and HIV-related outcomes in people living with HIV</article-title><source>J Acquir Immune Defic Syndr</source><year>2019</year><volume>82</volume><issue>Suppl 2</issue><fpage>S142</fpage><lpage>S147</lpage><?supplied-pmid 31658202?><pub-id pub-id-type="pmid">31658202</pub-id></element-citation></ref><ref id="CR114"><mixed-citation publication-type="other">Dever SM, Xu R, Fitting S, Knapp PE, Hauser KF (2012) Differential expression and HIV-1 regulation of &#x003bc;-opioid receptor splice variants across human central nervous system cell types. J Neurovirol 18:181&#x02013;190</mixed-citation></ref><ref id="CR115"><mixed-citation publication-type="other">Dever SM, Costin BN, Xu R, El-Hage N, Balinang J, Samoshkin A, O'Brien MA, McRae M, Diatchenko L, Knapp PE, Hauser KF (2014) Differential expression of the alternatively spliced <italic>OPRM1</italic> isoform &#x003bc;-opioid receptor-1K in HIV-infected individuals. AIDS 28:19&#x02013;30</mixed-citation></ref><ref id="CR116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>T</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Earl</surname><given-names>LA</given-names></name><name><surname>Del Prete</surname><given-names>GQ</given-names></name><name><surname>Grandinetti</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>GH</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Rao</surname><given-names>P</given-names></name><name><surname>Trubey</surname><given-names>CM</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Spector</surname><given-names>J</given-names></name><name><surname>Bliss</surname><given-names>D</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name></person-group><article-title>Three-dimensional imaging of HIV-1 virological synapses reveals membrane architectures involved in virus transmission</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>10327</fpage><lpage>10339</lpage><?supplied-pmid 24965444?><pub-id pub-id-type="pmid">24965444</pub-id></element-citation></ref><ref id="CR117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahoe</surname><given-names>RM</given-names></name><name><surname>Falek</surname><given-names>A</given-names></name></person-group><article-title>Neuroimmunomodulation by opiates and other drugs of abuse: relationship to HIV infection and AIDS</article-title><source>Adv Biochem Psychopharmacol</source><year>1988</year><volume>44</volume><fpage>145</fpage><lpage>158</lpage><?supplied-pmid 3041744?><pub-id pub-id-type="pmid">3041744</pub-id></element-citation></ref><ref id="CR118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahoe</surname><given-names>RM</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name></person-group><article-title>Opiates as potential cofactors in progression of HIV-1 infections to AIDS</article-title><source>J Neuroimmunol</source><year>1998</year><volume>83</volume><fpage>77</fpage><lpage>87</lpage><?supplied-pmid 9610676?><pub-id pub-id-type="pmid">9610676</pub-id></element-citation></ref><ref id="CR119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donahoe</surname><given-names>RM</given-names></name><name><surname>Falek</surname><given-names>A</given-names></name><name><surname>Madden</surname><given-names>JJ</given-names></name><name><surname>Nicholson</surname><given-names>JK</given-names></name><name><surname>Bokos</surname><given-names>P</given-names></name><name><surname>Gallegos</surname><given-names>K</given-names></name><name><surname>Veit</surname><given-names>R</given-names></name></person-group><article-title>Effects of cocaine and other drugs of abuse on immune function</article-title><source>Adv Exp Med Biol</source><year>1991</year><volume>288</volume><fpage>143</fpage><lpage>150</lpage><?supplied-pmid 1950728?><pub-id pub-id-type="pmid">1950728</pub-id></element-citation></ref><ref id="CR120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dronda</surname><given-names>F</given-names></name><name><surname>Zamora</surname><given-names>J</given-names></name><name><surname>Moreno</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>A</given-names></name><name><surname>Casado</surname><given-names>JL</given-names></name><name><surname>Muriel</surname><given-names>A</given-names></name><name><surname>Perez-Elias</surname><given-names>MJ</given-names></name><name><surname>Antela</surname><given-names>A</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Quereda</surname><given-names>C</given-names></name></person-group><article-title>CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use</article-title><source>AIDS</source><year>2004</year><volume>18</volume><fpage>2210</fpage><lpage>2212</lpage><?supplied-pmid 15577659?><pub-id pub-id-type="pmid">15577659</pub-id></element-citation></ref><ref id="CR121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dublin</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>RL</given-names></name><name><surname>Gray</surname><given-names>SL</given-names></name><name><surname>Hubbard</surname><given-names>RA</given-names></name><name><surname>Anderson</surname><given-names>ML</given-names></name><name><surname>Yu</surname><given-names>O</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name></person-group><article-title>Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study</article-title><source>J Am Geriatr Soc</source><year>2015</year><volume>63</volume><fpage>1519</fpage><lpage>1526</lpage><?supplied-pmid 26289681?><pub-id pub-id-type="pmid">26289681</pub-id></element-citation></ref><ref id="CR122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MJ</given-names></name><name><surname>Bruce-Keller</surname><given-names>AJ</given-names></name><name><surname>Conner</surname><given-names>C</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Effects of chronic expression of the HIV-induced protein, transactivator of transcription, on circadian activity rhythms in mice, with or without morphine</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2008</year><volume>295</volume><fpage>R1680</fpage><lpage>R1687</lpage><?supplied-pmid 18784333?><pub-id pub-id-type="pmid">18784333</pub-id></element-citation></ref><ref id="CR123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>R</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>Mechanism(s) involved in opioid drug abuse modulation of HAND</article-title><source>Curr HIV Res</source><year>2012</year><volume>10</volume><fpage>469</fpage><lpage>477</lpage><?supplied-pmid 22591371?><pub-id pub-id-type="pmid">22591371</pub-id></element-citation></ref><ref id="CR124"><mixed-citation publication-type="other">Dutta R, Roy S (2015) Chronic morphine and HIV-1 Tat promote differential central nervous system trafficking of CD3+ and Ly6C+ immune cells in a murine <italic>Streptococcus pneumoniae</italic> infection model. J Neuroinflammation 12:120</mixed-citation></ref><ref id="CR125"><mixed-citation publication-type="other">Dutta R, Krishnan A, Meng J, Das S, Ma J, Banerjee S, Wang J, Charboneau R, Prakash O, Barke RA, Roy S (2012) Morphine modulation of toll-like receptors in microglial cells potentiates neuropathogenesis in a HIV-1 model of coinfection with pneumococcal pneumoniae. J Neurosci 32:9917&#x02013;9930</mixed-citation></ref><ref id="CR126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyuizen</surname><given-names>I</given-names></name><name><surname>Lamash</surname><given-names>NE</given-names></name></person-group><article-title>Histo- and immunocytochemical detection of inducible NOS and TNF-&#x003b1; in the locus coeruleus of human opiate addicts</article-title><source>J Chem Neuroanat</source><year>2009</year><volume>37</volume><fpage>65</fpage><lpage>70</lpage><?supplied-pmid 19038328?><pub-id pub-id-type="pmid">19038328</pub-id></element-citation></ref><ref id="CR127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eap</surname><given-names>CB</given-names></name><name><surname>Buclin</surname><given-names>T</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name></person-group><article-title>Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence</article-title><source>Clin Pharmacokinet</source><year>2002</year><volume>41</volume><fpage>1153</fpage><lpage>1193</lpage><?supplied-pmid 12405865?><pub-id pub-id-type="pmid">12405865</pub-id></element-citation></ref><ref id="CR128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichel</surname><given-names>K</given-names></name><name><surname>von Zastrow</surname><given-names>M</given-names></name></person-group><article-title>Subcellular organization of GPCR signaling</article-title><source>Trends Pharmacol Sci</source><year>2018</year><volume>39</volume><fpage>200</fpage><lpage>208</lpage><?supplied-pmid 29478570?><pub-id pub-id-type="pmid">29478570</pub-id></element-citation></ref><ref id="CR129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenstein</surname><given-names>TK</given-names></name></person-group><article-title>The role of opioid receptors in immune system function</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2904</fpage><?supplied-pmid 31921165?><pub-id pub-id-type="pmid">31921165</pub-id></element-citation></ref><ref id="CR130"><mixed-citation publication-type="other">El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF (2005) Synergistic increases in intracellular Ca<sup>2+</sup>, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50:91&#x02013;106</mixed-citation></ref><ref id="CR131"><mixed-citation publication-type="other">El-Hage N, Wu G, Ambati J, Bruce-Keller AJ, Knapp PE, Hauser KF (2006a) CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 178:9&#x02013;16</mixed-citation></ref><ref id="CR132"><mixed-citation publication-type="other">El-Hage N, Wu G, Wang J, Ambati J, Knapp PE, Reed JL, Bruce-Keller AJ, Hauser KF (2006b) HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53:132&#x02013;146</mixed-citation></ref><ref id="CR133"><mixed-citation publication-type="other">El-Hage N, Bruce-Keller AJ, Knapp PE, Hauser KF (2008a) CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice. J NeuroImmune Pharmacol 3:275&#x02013;285</mixed-citation></ref><ref id="CR134"><mixed-citation publication-type="other">El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, Hauser KF (2008b) Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca<sup>2+</sup>] , NF-&#x003ba;B trafficking and transcription. PLoS One 3:e4093</mixed-citation></ref><ref id="CR135"><mixed-citation publication-type="other">El-Hage N, Podhaizer EM, Sturgill J, Hauser KF (2011a) Toll-like receptor expression and activation in astroglia: differential regulation by HIV-1 Tat, gp120, and morphine. Immunol Investig 40:498&#x02013;522</mixed-citation></ref><ref id="CR136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Dever</surname><given-names>SM</given-names></name><name><surname>Fitting</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>T</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses</article-title><source>J Virol</source><year>2011</year><volume>85</volume><fpage>11601</fpage><lpage>11614</lpage><?supplied-pmid 21900165?><pub-id pub-id-type="pmid">21900165</pub-id></element-citation></ref><ref id="CR137"><mixed-citation publication-type="other">El-Hage N, Dever SM, Podhaizer EM, Arnatt CK, Zhang Y, Hauser KF (2013) A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-&#x003bc;-opioid receptor interactions between human astroglia and microglia. AIDS 27:2181&#x02013;2190</mixed-citation></ref><ref id="CR138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Rodriguez</surname><given-names>M</given-names></name><name><surname>Podhaizer</surname><given-names>EM</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Dever</surname><given-names>SM</given-names></name><name><surname>Snider</surname><given-names>SE</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Beardsley</surname><given-names>PM</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>1409</fpage><lpage>1419</lpage><?supplied-pmid 24732776?><pub-id pub-id-type="pmid">24732776</pub-id></element-citation></ref><ref id="CR139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkader</surname><given-names>A</given-names></name><name><surname>Sproule</surname><given-names>B</given-names></name></person-group><article-title>Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>661</fpage><lpage>680</lpage><?supplied-pmid 15966752?><pub-id pub-id-type="pmid">15966752</pub-id></element-citation></ref><ref id="CR140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ensoli</surname><given-names>F</given-names></name><name><surname>Ensoli</surname><given-names>B</given-names></name><name><surname>Thiele</surname><given-names>CJ</given-names></name></person-group><article-title>HIV-1 gene expression and replication in neuronal and glial cell lines with immature phenotype: effects of nerve growth factor</article-title><source>Virology</source><year>1994</year><volume>200</volume><fpage>668</fpage><lpage>676</lpage><?supplied-pmid 8178451?><pub-id pub-id-type="pmid">8178451</pub-id></element-citation></ref><ref id="CR141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eran</surname><given-names>A</given-names></name><name><surname>Barak</surname><given-names>M</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome after combined general and spinal anesthesia with intrathecal morphine</article-title><source>Anesth Analg</source><year>2009</year><volume>108</volume><fpage>609</fpage><lpage>612</lpage><?supplied-pmid 19151296?><pub-id pub-id-type="pmid">19151296</pub-id></element-citation></ref><ref id="CR142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>PS</given-names></name><name><surname>Hansson</surname><given-names>E</given-names></name><name><surname>Ronnback</surname><given-names>L</given-names></name></person-group><article-title>Delta and kappa opiate receptors in primary astroglial cultures. Part II: receptor sets in cultures from various brain regions and interactions with beta-receptor activated cyclic AMP</article-title><source>Neurochem Res</source><year>1992</year><volume>17</volume><fpage>545</fpage><lpage>551</lpage><?supplied-pmid 1318509?><pub-id pub-id-type="pmid">1318509</pub-id></element-citation></ref><ref id="CR143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersche</surname><given-names>KD</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>London</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Profile of executive and memory function associated with amphetamine and opiate dependence</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>1036</fpage><lpage>1047</lpage><?supplied-pmid 16160707?><pub-id pub-id-type="pmid">16160707</pub-id></element-citation></ref><ref id="CR144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersek</surname><given-names>M</given-names></name><name><surname>Cherrier</surname><given-names>MM</given-names></name><name><surname>Overman</surname><given-names>SS</given-names></name><name><surname>Irving</surname><given-names>GA</given-names></name></person-group><article-title>The cognitive effects of opioids</article-title><source>Pain Manag Nurs</source><year>2004</year><volume>5</volume><fpage>75</fpage><lpage>93</lpage><?supplied-pmid 15297954?><pub-id pub-id-type="pmid">15297954</pub-id></element-citation></ref><ref id="CR145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esiri</surname><given-names>MM</given-names></name><name><surname>Morris</surname><given-names>CS</given-names></name><name><surname>Millard</surname><given-names>PR</given-names></name></person-group><article-title>Fate of oligodendrocytes in HIV-1 infection</article-title><source>AIDS</source><year>1991</year><volume>5</volume><fpage>1081</fpage><lpage>1088</lpage><?supplied-pmid 1657038?><pub-id pub-id-type="pmid">1657038</pub-id></element-citation></ref><ref id="CR146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugenin</surname><given-names>EA</given-names></name><name><surname>Clements</surname><given-names>JE</given-names></name><name><surname>Zink</surname><given-names>MC</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>9456</fpage><lpage>9465</lpage><?supplied-pmid 21715610?><pub-id pub-id-type="pmid">21715610</pub-id></element-citation></ref><ref id="CR147"><mixed-citation publication-type="other">Evaluation - Institute for Health Metrics and Evaluation (2017) Global burden of disease study. Global Health Data Exchange. <ext-link ext-link-type="uri" xlink:href="http://www.healthdata.org/gbd/gbd-2017-resources">http://www.healthdata.org/gbd/gbd-2017-resources</ext-link>.</mixed-citation></ref><ref id="CR148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Facchinetti</surname><given-names>F</given-names></name><name><surname>Grasso</surname><given-names>A</given-names></name><name><surname>Petraglia</surname><given-names>F</given-names></name><name><surname>Parrini</surname><given-names>D</given-names></name><name><surname>Volpe</surname><given-names>A</given-names></name><name><surname>Genazzani</surname><given-names>AR</given-names></name></person-group><article-title>Impaired circadian rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in heroin addicts</article-title><source>Acta Endocrinol</source><year>1984</year><volume>105</volume><fpage>149</fpage><lpage>155</lpage><?supplied-pmid 6320568?><pub-id pub-id-type="pmid">6320568</pub-id></element-citation></ref><ref id="CR149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falek</surname><given-names>A</given-names></name><name><surname>Donahoe</surname><given-names>RM</given-names></name><name><surname>Madden</surname><given-names>JJ</given-names></name><name><surname>Shafer</surname><given-names>DA</given-names></name></person-group><article-title>Opiates as immunosuppressive and genotoxic agents</article-title><source>Drugs of Abuse, Immunity, and Immunodeficiency</source><year>1991</year><volume>288</volume><fpage>189</fpage><lpage>201</lpage></element-citation></ref><ref id="CR150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>JJ</given-names></name></person-group><article-title>HIV tat impairs neurogenesis through functioning as a notch ligand and activation of notch signaling pathway</article-title><source>J Neurosci</source><year>2016</year><volume>36</volume><fpage>11362</fpage><lpage>11373</lpage><?supplied-pmid 27807176?><pub-id pub-id-type="pmid">27807176</pub-id></element-citation></ref><ref id="CR151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>R</given-names></name><name><surname>Schrott</surname><given-names>LM</given-names></name><name><surname>Arnold</surname><given-names>T</given-names></name><name><surname>Snelling</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Cornelius</surname><given-names>A</given-names></name><name><surname>Korneeva</surname><given-names>NL</given-names></name></person-group><article-title>Chronic oxycodone induces axonal degeneration in rat brain</article-title><source>BMC Neurosci</source><year>2018</year><volume>19</volume><fpage>15</fpage><?supplied-pmid 29571287?><pub-id pub-id-type="pmid">29571287</pub-id></element-citation></ref><ref id="CR152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Redfield</surname><given-names>RR</given-names></name><name><surname>Sigounas</surname><given-names>G</given-names></name><name><surname>Weahkee</surname><given-names>MD</given-names></name><name><surname>Giroir</surname><given-names>BP</given-names></name></person-group><article-title>Ending the HIV epidemic: a plan for the United States</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>844</fpage><lpage>845</lpage><?supplied-pmid 30730529?><pub-id pub-id-type="pmid">30730529</pub-id></element-citation></ref><ref id="CR153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>XQ</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management</article-title><source>J Pain Res</source><year>2017</year><volume>10</volume><fpage>1225</fpage><lpage>1239</lpage><?supplied-pmid 28579821?><pub-id pub-id-type="pmid">28579821</pub-id></element-citation></ref><ref id="CR154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrell</surname><given-names>D</given-names></name><name><surname>Giunta</surname><given-names>B</given-names></name></person-group><article-title>The impact of HIV-1 on neurogenesis: implications for HAND</article-title><source>Cellular and molecular life sciences : CMLS</source><year>2014</year><volume>71</volume><fpage>4387</fpage><lpage>4392</lpage><?supplied-pmid 25134912?><pub-id pub-id-type="pmid">25134912</pub-id></element-citation></ref><ref id="CR155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festa</surname><given-names>L</given-names></name><name><surname>Meucci</surname><given-names>O</given-names></name></person-group><article-title>Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism</article-title><source>Curr HIV Res</source><year>2012</year><volume>10</volume><fpage>453</fpage><lpage>462</lpage><?supplied-pmid 22591369?><pub-id pub-id-type="pmid">22591369</pub-id></element-citation></ref><ref id="CR156"><mixed-citation publication-type="other">Festa L, Roth LM, B KJ, Geiger JD, Jordan-Sciutto KL, Grinspan JB (2019) Protease inhibitors, saquinavir and darunavir, inhibit oligodendrocyte maturation: Implications for Lysosomal Stress. J Neuroimmune Pharmacol. 10.1007/s11481-019-09893-8.</mixed-citation></ref><ref id="CR157"><mixed-citation publication-type="other">Finley MJ, Chen X, Bardi G, Davey P, Geller EB, Zhang L, Adler MW, Rogers TJ (2008) Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the &#x003ba;-opioid receptor. J Neuroimmunol 197:114&#x02013;123</mixed-citation></ref><ref id="CR158"><mixed-citation publication-type="other">Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG, Richardson MW, Amini S, Morgello S, Khalili K, Rappaport J (2001) CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 7:528&#x02013;541</mixed-citation></ref><ref id="CR159"><mixed-citation publication-type="other">Fitting S, Zou S, Chen W, Vo P, Hauser KF, Knapp PE (2010a) Regional heterogeneity and diversity in cytokine and chemokine production by astroglia: differential responses to HIV-1 Tat, gp120, and morphine revealed by multiplex analysis. J Proteome Res 9:1795&#x02013;1804</mixed-citation></ref><ref id="CR160"><mixed-citation publication-type="other">Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser KF (2010b) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177:1397&#x02013;1410</mixed-citation></ref><ref id="CR161"><mixed-citation publication-type="other">Fitting S, Scoggins KL, Xu R, Dever SM, Knapp PE, Dewey WL, Hauser KF (2012) Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice. Eur J Pharmacol 689:96&#x02013;103</mixed-citation></ref><ref id="CR162"><mixed-citation publication-type="other">Fitting S, Knapp PE, Zou S, Marks WD, Bowers MS, Akbarali HI, Hauser KF (2014a) Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na<sup>+</sup> influx, mitochondrial instability, and Ca<sup>2+</sup> overload. J Neurosci 34:12850&#x02013;12864</mixed-citation></ref><ref id="CR163"><mixed-citation publication-type="other">Fitting S, Zou S, El-Hage N, Suzuki M, Paris JJ, Schier CJ, Rodriguez JW, Rodriguez M, Knapp PE, Hauser KF (2014b) Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca<sup>2+</sup>]<sub>i</sub> oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. Curr HIV Res 12:424&#x02013;434</mixed-citation></ref><ref id="CR164"><mixed-citation publication-type="other">Fitting S, Stevens DL, Khan FA, Scoggins KL, Enga RM, Beardsley PM, Knapp PE, Dewey WL, Hauser KF (2016) Morphine tolerance and physical dependence are altered in conditional HIV-1 Tat transgenic mice. J Pharmacol Exp Ther 356:96&#x02013;105</mixed-citation></ref><ref id="CR165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friden</surname><given-names>M</given-names></name><name><surname>Winiwarter</surname><given-names>S</given-names></name><name><surname>Jerndal</surname><given-names>G</given-names></name><name><surname>Bengtsson</surname><given-names>O</given-names></name><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Bredberg</surname><given-names>U</given-names></name><name><surname>Hammarlund-Udenaes</surname><given-names>M</given-names></name><name><surname>Antonsson</surname><given-names>M</given-names></name></person-group><article-title>Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids</article-title><source>J Med Chem</source><year>2009</year><volume>52</volume><fpage>6233</fpage><lpage>6243</lpage><?supplied-pmid 19764786?><pub-id pub-id-type="pmid">19764786</pub-id></element-citation></ref><ref id="CR166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukagawa</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>T</given-names></name><name><surname>Kakuyama</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>K</given-names></name></person-group><article-title>Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4</article-title><source>J Anesth</source><year>2013</year><volume>27</volume><fpage>93</fpage><lpage>97</lpage><?supplied-pmid 22926420?><pub-id pub-id-type="pmid">22926420</pub-id></element-citation></ref><ref id="CR167"><mixed-citation publication-type="other">Gabrilovac J, Cupic B, Zapletal E, Brozovic A (2012) IFN-&#x003b3; up-regulates &#x003ba; opioid receptors (KOR) on murine macrophage cell line J774. J Neuroimmunol 245:56&#x02013;65</mixed-citation></ref><ref id="CR168"><mixed-citation publication-type="other">Galandrin S, Bouvier M (2006) Distinct signaling profiles of &#x003b2;1 and &#x003b2;2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70:1575&#x02013;1584</mixed-citation></ref><ref id="CR169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galligan</surname><given-names>JJ</given-names></name></person-group><article-title>HIV, opiates, and enteric neuron dysfunction</article-title><source>Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society</source><year>2015</year><volume>27</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">25817054</pub-id></element-citation></ref><ref id="CR170"><mixed-citation publication-type="other">Gandhi N, Saiyed Z, Thangavel S, Rodriguez J, Rao KV, Nair MP (2009) Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retrovir 25:691&#x02013;699</mixed-citation></ref><ref id="CR171"><mixed-citation publication-type="other">Gaskill PJ, Miller DR, Gamble-George J, Yano H, Khoshbouei H (2017) HIV, Tat and dopamine transmission. Neurobiol Dis 105:51&#x02013;73</mixed-citation></ref><ref id="CR172"><mixed-citation publication-type="other">Gandhi N, Saiyed ZM, Napuri J, Samikkannu T, Reddy PVB, Agudelo M, Khatavkar P, Saxena SK, Nair MPN (2010) Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: Implications for HIV-1&#x02013;associated neurocognitive disorder. J Neurovirol 16(4):294&#x02013;305</mixed-citation></ref><ref id="CR173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Wentland</surname><given-names>MP</given-names></name><name><surname>Bidlack</surname><given-names>JM</given-names></name><name><surname>Lokensgard</surname><given-names>JR</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells</article-title><source>J Pharmacol Exp Ther</source><year>2004</year><volume>309</volume><fpage>600</fpage><lpage>606</lpage><?supplied-pmid 14757849?><pub-id pub-id-type="pmid">14757849</pub-id></element-citation></ref><ref id="CR174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>BB</given-names></name><name><surname>Lisinicchia</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>KM</given-names></name><name><surname>Jennings</surname><given-names>K</given-names></name><name><surname>Freeman</surname><given-names>DH</given-names><suffix>Jr</suffix></name><name><surname>Soukup</surname><given-names>VM</given-names></name></person-group><article-title>Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis</article-title><source>J NeuroImmune Pharmacol</source><year>2012</year><volume>7</volume><fpage>686</fpage><lpage>700</lpage><?supplied-pmid 22391864?><pub-id pub-id-type="pmid">22391864</pub-id></element-citation></ref><ref id="CR175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>MM</given-names></name><name><surname>Bhangoo</surname><given-names>A</given-names></name></person-group><article-title>Human immune deficiency virus (HIV) infection and the hypothalamic pituitary adrenal axis</article-title><source>Rev Endocr Metab Disord</source><year>2013</year><volume>14</volume><fpage>105</fpage><lpage>112</lpage><?supplied-pmid 23728720?><pub-id pub-id-type="pmid">23728720</pub-id></element-citation></ref><ref id="CR176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>O</given-names></name><name><surname>Le Moal</surname><given-names>M</given-names></name><name><surname>Koob</surname><given-names>GF</given-names></name></person-group><article-title>Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems</article-title><source>Physiol Behav</source><year>2012</year><volume>106</volume><fpage>58</fpage><lpage>64</lpage><?supplied-pmid 22108506?><pub-id pub-id-type="pmid">22108506</pub-id></element-citation></ref><ref id="CR177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geretti</surname><given-names>AM</given-names></name></person-group><article-title>HIV-1 subtypes: epidemiology and significance for HIV management</article-title><source>Curr Opin Infect Dis</source><year>2006</year><volume>19</volume><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 16374210?><pub-id pub-id-type="pmid">16374210</pub-id></element-citation></ref><ref id="CR178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>MD</given-names></name><name><surname>Hedley-Whyte</surname><given-names>ET</given-names></name><name><surname>Richardson</surname><given-names>EP</given-names><suffix>Jr</suffix></name></person-group><article-title>Hypoxic-ischemic leukoencephalopathy in man</article-title><source>Arch Neurol</source><year>1976</year><volume>33</volume><fpage>5</fpage><lpage>14</lpage><?supplied-pmid 1247396?><pub-id pub-id-type="pmid">1247396</pub-id></element-citation></ref><ref id="CR179"><mixed-citation publication-type="other">Gironi M, Martinelli V, Brambilla E, Furlan R, Panerai AE, Comi G, Sacerdote P (2000) &#x003b2;-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis: effects of treatment with interferon beta. Arch Neurol 57:1178&#x02013;1181</mixed-citation></ref><ref id="CR180"><mixed-citation publication-type="other">Gironi M, Furlan R, Rovaris M, Comi G, Filippi M, Panerai AE, Sacerdote P (2003) &#x003b2; endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry 74:495&#x02013;497</mixed-citation></ref><ref id="CR181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnanakaran</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Daniels</surname><given-names>M</given-names></name><name><surname>Bhattacharya</surname><given-names>T</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Korber</surname><given-names>B</given-names></name></person-group><article-title>Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>4886</fpage><lpage>4891</lpage><?supplied-pmid 17166900?><pub-id pub-id-type="pmid">17166900</pub-id></element-citation></ref><ref id="CR182"><mixed-citation publication-type="other">Gomes I, Sierra S, Lueptow L, Gupta A, Gouty S, Margolis EB, Cox BM, Devi LA (2020) Biased signaling by endogenous opioid peptides. Proc Natl Acad Sci USA 117:11820-11828</mixed-citation></ref><ref id="CR183"><mixed-citation publication-type="other">Gonek M, McLane VD, Stevens DL, Lippold K, Akbarali HI, Knapp PE, Dewey WL, Hauser KF, Paris JJ (2018) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun 69:124&#x02013;138</mixed-citation></ref><ref id="CR184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorry</surname><given-names>PR</given-names></name><name><surname>Ong</surname><given-names>C</given-names></name><name><surname>Thorpe</surname><given-names>J</given-names></name><name><surname>Bannwarth</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>KA</given-names></name><name><surname>Gatignol</surname><given-names>A</given-names></name><name><surname>Vesselingh</surname><given-names>SL</given-names></name><name><surname>Purcell</surname><given-names>DF</given-names></name></person-group><article-title>Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia</article-title><source>Curr HIV Res</source><year>2003</year><volume>1</volume><fpage>463</fpage><lpage>473</lpage><?supplied-pmid 15049431?><pub-id pub-id-type="pmid">15049431</pub-id></element-citation></ref><ref id="CR185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosztonyi</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>V</given-names></name><name><surname>Nickel</surname><given-names>R</given-names></name><name><surname>Rothschild</surname><given-names>MA</given-names></name><name><surname>Camacho</surname><given-names>S</given-names></name><name><surname>Siegel</surname><given-names>G</given-names></name><name><surname>Zill</surname><given-names>E</given-names></name><name><surname>Pauli</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>V</given-names></name></person-group><article-title>Neuropathologic analysis of postmortal brain samples of HIV-seropositive and -seronegative i.v. drug addicts</article-title><source>Forensic Sci Int</source><year>1993</year><volume>62</volume><fpage>101</fpage><lpage>105</lpage><?supplied-pmid 8300019?><pub-id pub-id-type="pmid">8300019</pub-id></element-citation></ref><ref id="CR186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosztonyi</surname><given-names>G</given-names></name><name><surname>Artigas</surname><given-names>J</given-names></name><name><surname>Lamperth</surname><given-names>L</given-names></name><name><surname>Webster</surname><given-names>HD</given-names></name></person-group><article-title>Human immunodeficiency virus (HIV) distribution in HIV encephalitis: study of 19 cases with combined use of in situ hybridization and immunocytochemistry</article-title><source>J Neuropathol Exp Neurol</source><year>1994</year><volume>53</volume><fpage>521</fpage><lpage>534</lpage><?supplied-pmid 8083694?><pub-id pub-id-type="pmid">8083694</pub-id></element-citation></ref><ref id="CR187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Scaravilli</surname><given-names>F</given-names></name><name><surname>Everall</surname><given-names>I</given-names></name><name><surname>Chretien</surname><given-names>F</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Boche</surname><given-names>D</given-names></name><name><surname>Adle-Biassette</surname><given-names>H</given-names></name><name><surname>Wingertsmann</surname><given-names>L</given-names></name><name><surname>Durigon</surname><given-names>M</given-names></name><name><surname>Hurtrel</surname><given-names>B</given-names></name><name><surname>Chiodi</surname><given-names>F</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Lantos</surname><given-names>P</given-names></name></person-group><article-title>Neuropathology of early HIV-1 infection</article-title><source>Brain Pathol</source><year>1996</year><volume>6</volume><fpage>1</fpage><lpage>15</lpage><?supplied-pmid 8866743?><pub-id pub-id-type="pmid">8866743</pub-id></element-citation></ref><ref id="CR188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>LR</given-names></name><name><surname>Tachedjian</surname><given-names>G</given-names></name><name><surname>Ellett</surname><given-names>AM</given-names></name><name><surname>Roche</surname><given-names>MJ</given-names></name><name><surname>Cheng</surname><given-names>WJ</given-names></name><name><surname>Guillemin</surname><given-names>GJ</given-names></name><name><surname>Brew</surname><given-names>BJ</given-names></name><name><surname>Turville</surname><given-names>SG</given-names></name><name><surname>Wesselingh</surname><given-names>SL</given-names></name><name><surname>Gorry</surname><given-names>PR</given-names></name><name><surname>Churchill</surname><given-names>MJ</given-names></name></person-group><article-title>The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e62196</fpage><?supplied-pmid 23614033?><pub-id pub-id-type="pmid">23614033</pub-id></element-citation></ref><ref id="CR189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>MC</given-names></name><name><surname>Ben-Baruch</surname><given-names>A</given-names></name><name><surname>Taub</surname><given-names>DD</given-names></name><name><surname>Howard</surname><given-names>OM</given-names></name><name><surname>Resau</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Richardson</surname><given-names>R</given-names></name><name><surname>Snyderman</surname><given-names>R</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name></person-group><article-title>Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>317</fpage><lpage>325</lpage><?supplied-pmid 9670044?><pub-id pub-id-type="pmid">9670044</pub-id></element-citation></ref><ref id="CR190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gris</surname><given-names>P</given-names></name><name><surname>Gauthier</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Gibson</surname><given-names>DG</given-names></name><name><surname>Gris</surname><given-names>D</given-names></name><name><surname>Laur</surname><given-names>O</given-names></name><name><surname>Pierson</surname><given-names>J</given-names></name><name><surname>Wentworth</surname><given-names>S</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name><name><surname>Maixner</surname><given-names>W</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name></person-group><article-title>A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism</article-title><source>Mol Pain</source><year>2010</year><volume>6</volume><fpage>33</fpage><?supplied-pmid 20525224?><pub-id pub-id-type="pmid">20525224</pub-id></element-citation></ref><ref id="CR191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber</surname><given-names>SA</given-names></name><name><surname>Silveri</surname><given-names>MM</given-names></name><name><surname>Yurgelun-Todd</surname><given-names>DA</given-names></name></person-group><article-title>Neuropsychological consequences of opiate use</article-title><source>Neuropsychol Rev</source><year>2007</year><volume>17</volume><fpage>299</fpage><lpage>315</lpage><?supplied-pmid 17690984?><pub-id pub-id-type="pmid">17690984</pub-id></element-citation></ref><ref id="CR192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C-J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Douglas</surname><given-names>SD</given-names></name><name><surname>Ho</surname><given-names>W-Z</given-names></name></person-group><article-title>Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of &#x003b2;-chemokines and CCR5 receptor</article-title><source>J Investig Med</source><year>2002</year><volume>50</volume><fpage>435</fpage><lpage>442</lpage><?supplied-pmid 12425430?><pub-id pub-id-type="pmid">12425430</pub-id></element-citation></ref><ref id="CR193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Sultana</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>O</given-names></name><name><surname>Royal</surname><given-names>W</given-names><suffix>3rd</suffix></name></person-group><article-title>Effects of vitamin a deficiency and opioids on parvalbumin + interneurons in the hippocampus of the HIV-1 transgenic rat</article-title><source>Curr HIV Res</source><year>2012</year><volume>10</volume><fpage>463</fpage><lpage>468</lpage><?supplied-pmid 22591370?><pub-id pub-id-type="pmid">22591370</pub-id></element-citation></ref><ref id="CR194"><mixed-citation publication-type="other">Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, Ownby R, Subbakrishna DK, Desai A, Kamat A, Ravi V, Rao BS, Satish KS, Kumar M (2007) Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 13:195&#x02013;202</mixed-citation></ref><ref id="CR195"><mixed-citation publication-type="other">Gupta S, Knight AG, Gupta S, Knapp PE, Hauser KF, Keller JN, Bruce-Keller AJ (2010) HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antiporter. Neurosci Lett 485:233&#x02013;236</mixed-citation></ref><ref id="CR196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurwell</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>MJ</given-names></name><name><surname>Maderspach</surname><given-names>K</given-names></name><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Elde</surname><given-names>RP</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>&#x003ba;-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca<sup>2+</sup> mobilization, development, and the antiproliferative effect of opioids</article-title><source>Brain Res</source><year>1996</year><volume>737</volume><fpage>175</fpage><lpage>187</lpage><?supplied-pmid 8930364?><pub-id pub-id-type="pmid">8930364</pub-id></element-citation></ref><ref id="CR197"><mixed-citation publication-type="other">Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF (2001) Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 102(3):555&#x02013;563</mixed-citation></ref><ref id="CR198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>JW</given-names></name><name><surname>Jagwani</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Rendell</surname><given-names>VR</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Ezerskiy</surname><given-names>LA</given-names></name><name><surname>Wesselschmidt</surname><given-names>R</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name><name><surname>Belcheva</surname><given-names>MM</given-names></name></person-group><article-title>Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases</article-title><source>J Neurochem</source><year>2010</year><volume>112</volume><fpage>1431</fpage><lpage>1441</lpage><?supplied-pmid 19895666?><pub-id pub-id-type="pmid">19895666</pub-id></element-citation></ref><ref id="CR199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>YK</given-names></name><name><surname>Podhaizer</surname><given-names>EM</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation</article-title><source>Glia</source><year>2012</year><volume>60</volume><fpage>1871</fpage><lpage>1887</lpage><?supplied-pmid 22865725?><pub-id pub-id-type="pmid">22865725</pub-id></element-citation></ref><ref id="CR200"><mixed-citation publication-type="other">Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE (2016) Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered &#x003bc;-opioid receptor-mediated G-protein activation and &#x003b2;-arrestin 2 activity in the forebrain. Neurobiol Dis 92(PtB):124-136</mixed-citation></ref><ref id="CR201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors</article-title><source>Int Rev Neurobiol</source><year>2014</year><volume>118</volume><fpage>231</fpage><lpage>313</lpage><?supplied-pmid 25175867?><pub-id pub-id-type="pmid">25175867</pub-id></element-citation></ref><ref id="CR202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Opiate drugs with abuse liability hijack the endogenous opioid system to disrupt neuronal and glial maturation in the central nervous system</article-title><source>Front Pediatr</source><year>2018</year><volume>5</volume><fpage>294</fpage><?supplied-pmid 29410949?><pub-id pub-id-type="pmid">29410949</pub-id></element-citation></ref><ref id="CR203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Osborne</surname><given-names>JG</given-names></name><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Melner</surname><given-names>MH</given-names></name></person-group><article-title>Cellular localization of proenkephalin mRNA and enkephalin peptide products in cultured astrocytes</article-title><source>Brain Res</source><year>1990</year><volume>522</volume><fpage>347</fpage><lpage>353</lpage><?supplied-pmid 2224534?><pub-id pub-id-type="pmid">2224534</pub-id></element-citation></ref><ref id="CR204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Gurwell</surname><given-names>JA</given-names></name><name><surname>Bhat</surname><given-names>NR</given-names></name></person-group><article-title>Endogenous opioid systems and the growth of oligodendrocyte progenitors: paradoxical increases in oligodendrogenesis as an indirect mechanism of opioid action</article-title><source>Glia</source><year>1993</year><volume>9</volume><fpage>157</fpage><lpage>162</lpage><?supplied-pmid 8244536?><pub-id pub-id-type="pmid">8244536</pub-id></element-citation></ref><ref id="CR205"><mixed-citation publication-type="other">Hauser KF, Stiene-Martin A, Mattson MP, Elde RP, Ryan SE, Godleske CC (1996) &#x003bc;-Opioid receptor-induced Ca<sup>2+</sup> mobilization and astroglial development: morphine inhibits DNA synthesis and stimulates cellular hypertrophy through a Ca<sup>2+</sup> -dependent mechanism. Brain Res 720:191&#x02013;203</mixed-citation></ref><ref id="CR206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>JR</given-names></name><name><surname>Tyor</surname><given-names>WR</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Bruce-Keller</surname><given-names>AJ</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Molecular targets of opiate drug abuse in neuroAIDS</article-title><source>Neurotox Res</source><year>2005</year><volume>8</volume><fpage>63</fpage><lpage>80</lpage><?supplied-pmid 16260386?><pub-id pub-id-type="pmid">16260386</pub-id></element-citation></ref><ref id="CR207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Maragos</surname><given-names>WF</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Persidsky</surname><given-names>Y</given-names></name><name><surname>Volsky</surname><given-names>DJ</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse</article-title><source>J Neurochem</source><year>2007</year><volume>100</volume><fpage>567</fpage><lpage>586</lpage><?supplied-pmid 17173547?><pub-id pub-id-type="pmid">17173547</pub-id></element-citation></ref><ref id="CR208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Hahn</surname><given-names>YK</given-names></name><name><surname>Adjan</surname><given-names>VV</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Buch</surname><given-names>SK</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Bruce-Keller</surname><given-names>AJ</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>HIV-1 tat and morphine have interactive effects on oligodendrocyte survival and morphology</article-title><source>Glia</source><year>2009</year><volume>57</volume><fpage>194</fpage><lpage>206</lpage><?supplied-pmid 18756534?><pub-id pub-id-type="pmid">18756534</pub-id></element-citation></ref><ref id="CR209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Fitting</surname><given-names>S</given-names></name><name><surname>Dever</surname><given-names>SM</given-names></name><name><surname>Podhaizer</surname><given-names>EM</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Opiate drug use and the pathophysiology of neuroAIDS</article-title><source>Curr HIV Res</source><year>2012</year><volume>10</volume><fpage>435</fpage><lpage>452</lpage><?supplied-pmid 22591368?><pub-id pub-id-type="pmid">22591368</pub-id></element-citation></ref><ref id="CR210"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>AI</given-names></name><name><surname>Balogh</surname><given-names>KN</given-names></name></person-group><article-title>Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse</article-title><source>Subst Abus Rehabil</source><year>2012</year><volume>3</volume><fpage>49</fpage><lpage>57</lpage></element-citation></ref><ref id="CR211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>WZ</given-names></name><name><surname>Guo</surname><given-names>CJ</given-names></name><name><surname>Yuan</surname><given-names>CS</given-names></name><name><surname>Douglas</surname><given-names>SD</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name></person-group><article-title>Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes</article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>307</volume><fpage>1158</fpage><lpage>1162</lpage><?supplied-pmid 14560041?><pub-id pub-id-type="pmid">14560041</pub-id></element-citation></ref><ref id="CR212"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>WS</given-names></name><name><surname>Rock</surname><given-names>RB</given-names></name></person-group><article-title>Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis</article-title><source>J NeuroImmune Pharmacol</source><year>2011</year><volume>6</volume><fpage>528</fpage><lpage>539</lpage><?supplied-pmid 21850403?><pub-id pub-id-type="pmid">21850403</pub-id></element-citation></ref><ref id="CR213"><mixed-citation publication-type="other">Hu G, Yao H, Chaudhuri AD, Duan M, Yelamanchili SV, Wen H, Cheney PD, Fox HS, Buch S (2012) Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. Cell Death Dis 3:e381</mixed-citation></ref><ref id="CR214"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Paxton</surname><given-names>WA</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Ceradini</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K</given-names></name><name><surname>Kunstman</surname><given-names>K</given-names></name><name><surname>Erickson</surname><given-names>D</given-names></name><name><surname>Dragon</surname><given-names>E</given-names></name><name><surname>Landau</surname><given-names>NR</given-names></name><name><surname>Phair</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name></person-group><article-title>The role of a mutant CCR5 allele in HIV-1 transmission and disease progression</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>1240</fpage><lpage>1243</lpage><?supplied-pmid 8898752?><pub-id pub-id-type="pmid">8898752</pub-id></element-citation></ref><ref id="CR215"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Northcutt</surname><given-names>AL</given-names></name><name><surname>Chao</surname><given-names>LW</given-names></name><name><surname>Kearney</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Berkelhammer</surname><given-names>DL</given-names></name><name><surname>Loram</surname><given-names>LC</given-names></name><name><surname>Rozeske</surname><given-names>RR</given-names></name><name><surname>Bland</surname><given-names>ST</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Gleeson</surname><given-names>TT</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><article-title>Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia</article-title><source>Brain Behav Immun</source><year>2008</year><volume>22</volume><fpage>1248</fpage><lpage>1256</lpage><?supplied-pmid 18706994?><pub-id pub-id-type="pmid">18706994</pub-id></element-citation></ref><ref id="CR216"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Lewis</surname><given-names>SS</given-names></name><name><surname>Coats</surname><given-names>BD</given-names></name><name><surname>Skyba</surname><given-names>DA</given-names></name><name><surname>Crysdale</surname><given-names>NY</given-names></name><name><surname>Berkelhammer</surname><given-names>DL</given-names></name><name><surname>Brzeski</surname><given-names>A</given-names></name><name><surname>Northcutt</surname><given-names>A</given-names></name><name><surname>Vietz</surname><given-names>CM</given-names></name><name><surname>Judd</surname><given-names>CM</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name></person-group><article-title>Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)</article-title><source>Brain Behav Immun</source><year>2009</year><volume>23</volume><fpage>240</fpage><lpage>250</lpage><?supplied-pmid 18938237?><pub-id pub-id-type="pmid">18938237</pub-id></element-citation></ref><ref id="CR217"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Evidence that opioids may have toll-like receptor 4 and MD-2 effects</article-title><source>Brain Behav Immun</source><year>2010</year><volume>24</volume><fpage>83</fpage><lpage>95</lpage><?supplied-pmid 19679181?><pub-id pub-id-type="pmid">19679181</pub-id></element-citation></ref><ref id="CR218"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Opioid activation of toll-like receptor 4 contributes to drug reinforcement</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>11187</fpage><lpage>11200</lpage><?supplied-pmid 22895704?><pub-id pub-id-type="pmid">22895704</pub-id></element-citation></ref><ref id="CR219"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Ide</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Hayashida</surname><given-names>M</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name><name><surname>Sora</surname><given-names>I</given-names></name></person-group><article-title>How individual sensitivity to opiates can be predicted by gene analyses</article-title><source>Trends Pharmacol Sci</source><year>2005</year><volume>26</volume><fpage>311</fpage><lpage>317</lpage><?supplied-pmid 15925706?><pub-id pub-id-type="pmid">15925706</pub-id></element-citation></ref><ref id="CR220"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Indelicato</surname><given-names>RA</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name></person-group><article-title>Opioid rotation in the management of refractory cancer pain</article-title><source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source><year>2002</year><volume>20</volume><fpage>348</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">11773191</pub-id></element-citation></ref><ref id="CR221"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivers</surname><given-names>JH</given-names></name><name><surname>Fitzgerald</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>C</given-names></name><name><surname>Sweeney</surname><given-names>B</given-names></name><name><surname>Keenan</surname><given-names>E</given-names></name><name><surname>Fagan</surname><given-names>A</given-names></name><name><surname>McMarrow</surname><given-names>J</given-names></name><name><surname>Meany</surname><given-names>J</given-names></name><name><surname>Barry</surname><given-names>J</given-names></name><name><surname>Frodl</surname><given-names>T</given-names></name></person-group><article-title>Progressive white matter impairment as a predictor of outcome in a cohort of opioid-dependent patient's post-detoxification</article-title><source>Addict Biol</source><year>2018</year><volume>23</volume><fpage>304</fpage><lpage>312</lpage><?supplied-pmid 27739172?><pub-id pub-id-type="pmid">27739172</pub-id></element-citation></ref><ref id="CR222"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>EH</given-names></name><name><surname>Smit</surname><given-names>AB</given-names></name><name><surname>de Vries</surname><given-names>TJ</given-names></name><name><surname>Schoffelmeer</surname><given-names>AN</given-names></name></person-group><article-title>Long-term gene expression in the nucleus accumbens following heroin administration is subregion-specific and depends on the nature of drug administration</article-title><source>Addict Biol</source><year>2005</year><volume>10</volume><fpage>91</fpage><lpage>100</lpage><?supplied-pmid 15849023?><pub-id pub-id-type="pmid">15849023</pub-id></element-citation></ref><ref id="CR223"><mixed-citation publication-type="other">Jacobs MM, Murray J, Byrd DA, Hurd YL, Morgello S (2013) HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations. J Neurovirol 19:495&#x02013;504</mixed-citation></ref><ref id="CR224"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>BD</given-names></name><name><surname>Horvat</surname><given-names>J</given-names></name><name><surname>Djordjijevic</surname><given-names>D</given-names></name><name><surname>Ramah</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>V</given-names></name><name><surname>Spahic</surname><given-names>O</given-names></name></person-group><article-title>Brain-associated autoimmune features in heroin addicts: correlation to HIV infection and dementia</article-title><source>The International journal of neuroscience</source><year>1991</year><volume>58</volume><fpage>113</fpage><lpage>126</lpage><?supplied-pmid 1938173?><pub-id pub-id-type="pmid">1938173</pub-id></element-citation></ref><ref id="CR225"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaureguiberry-Bravo</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Carvallo</surname><given-names>L</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>Opioids and opioid maintenance therapies: their impact on monocyte-mediated HIV Neuropathogenesis</article-title><source>Curr HIV Res</source><year>2016</year><volume>14</volume><fpage>417</fpage><lpage>430</lpage><?supplied-pmid 27009099?><pub-id pub-id-type="pmid">27009099</pub-id></element-citation></ref><ref id="CR226"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeevanjee</surname><given-names>S</given-names></name><name><surname>Penko</surname><given-names>J</given-names></name><name><surname>Guzman</surname><given-names>D</given-names></name><name><surname>Miaskowski</surname><given-names>C</given-names></name><name><surname>Bangsberg</surname><given-names>DR</given-names></name><name><surname>Kushel</surname><given-names>MB</given-names></name></person-group><article-title>Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco</article-title><source>AIDS Behav</source><year>2014</year><volume>18</volume><fpage>1352</fpage><lpage>1358</lpage><?supplied-pmid 24077929?><pub-id pub-id-type="pmid">24077929</pub-id></element-citation></ref><ref id="CR227"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>BK</given-names></name><name><surname>Monnerie</surname><given-names>H</given-names></name><name><surname>Mannell</surname><given-names>MV</given-names></name><name><surname>Gannon</surname><given-names>PJ</given-names></name><name><surname>Espinoza</surname><given-names>CA</given-names></name><name><surname>Erickson</surname><given-names>MA</given-names></name><name><surname>Bruce-Keller</surname><given-names>AJ</given-names></name><name><surname>Gelman</surname><given-names>BB</given-names></name><name><surname>Briand</surname><given-names>LA</given-names></name><name><surname>Pierce</surname><given-names>RC</given-names></name><name><surname>Jordan-Sciutto</surname><given-names>KL</given-names></name><name><surname>Grinspan</surname><given-names>JB</given-names></name></person-group><article-title>Altered oligodendrocyte maturation and myelin maintenance: the role of Antiretrovirals in HIV-associated neurocognitive disorders</article-title><source>J Neuropathol Exp Neurol</source><year>2015</year><volume>74</volume><fpage>1093</fpage><lpage>1118</lpage><?supplied-pmid 26469251?><pub-id pub-id-type="pmid">26469251</pub-id></element-citation></ref><ref id="CR228"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>BK</given-names></name><name><surname>Roth</surname><given-names>LM</given-names></name><name><surname>Grinspan</surname><given-names>JB</given-names></name><name><surname>Jordan-Sciutto</surname><given-names>KL</given-names></name></person-group><article-title>White matter loss and oligodendrocyte dysfunction in HIV: a consequence of the infection, the antiretroviral therapy or both?</article-title><source>Brain Res</source><year>2019</year><volume>1724</volume><fpage>146397</fpage><?supplied-pmid 31442414?><pub-id pub-id-type="pmid">31442414</pub-id></element-citation></ref><ref id="CR229"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Hebert</surname><given-names>JM</given-names></name></person-group><article-title>Signaling pathways in reactive astrocytes, a genetic perspective</article-title><source>Mol Neurobiol</source><year>2011</year><volume>43</volume><fpage>147</fpage><lpage>154</lpage><?supplied-pmid 21234816?><pub-id pub-id-type="pmid">21234816</pub-id></element-citation></ref><ref id="CR230"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><article-title>Functional selectivity and biased receptor signaling</article-title><source>J Pharmacol Exp Ther</source><year>2011</year><volume>336</volume><fpage>296</fpage><lpage>302</lpage><?supplied-pmid 21030484?><pub-id pub-id-type="pmid">21030484</pub-id></element-citation></ref><ref id="CR231"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalsa</surname><given-names>J</given-names></name><name><surname>Vocci</surname><given-names>F</given-names></name><name><surname>Altice</surname><given-names>F</given-names></name><name><surname>Fiellin</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name></person-group><article-title>Buprenorphine and HIV primary care: new opportunities for integrated treatment</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><issue>Suppl 4</issue><fpage>S169</fpage><lpage>S172</lpage><?supplied-pmid 17109302?><pub-id pub-id-type="pmid">17109302</pub-id></element-citation></ref><ref id="CR232"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharasch</surname><given-names>ED</given-names></name></person-group><article-title>Current concepts in methadone metabolism and transport</article-title><source>Clin Pharmacol Drug Dev</source><year>2017</year><volume>6</volume><fpage>125</fpage><lpage>134</lpage><?supplied-pmid 28263461?><pub-id pub-id-type="pmid">28263461</pub-id></element-citation></ref><ref id="CR233"><mixed-citation publication-type="other">Khatri UG, Perrone J (2020) Opioid use disorder and COVID-19: crashing of the crises. J Addict Med 14:e6&#x02013;e7. 10.1097/ADM.0000000000000684</mixed-citation></ref><ref id="CR234"><mixed-citation publication-type="other">Khurdayan VK, Buch S, El-Hage N, Lutz SE, Goebel SM, Singh IN, Knapp PE, Turchan-Cholewo J, Nath A, Hauser KF (2004) Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure <italic>in vitro</italic>. Eur J Neurosci 19:3171&#x02013;3182</mixed-citation></ref><ref id="CR235"><mixed-citation publication-type="other">Kibaly C, Xu C, Cahill CM, Evans CJ, Law P-Y (2018) Non-nociceptive roles of opioids in the CNS: opioids&#x02019; effects on neurogenesis, learning, memory and affect. Nat Rev Neurosci 20:5-18</mixed-citation></ref><ref id="CR236"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieffer</surname><given-names>BL</given-names></name><name><surname>Gaveriaux-Ruff</surname><given-names>C</given-names></name></person-group><article-title>Exploring the opioid system by gene knockout</article-title><source>Prog Neurobiol</source><year>2002</year><volume>66</volume><fpage>285</fpage><lpage>306</lpage><?supplied-pmid 12015197?><pub-id pub-id-type="pmid">12015197</pub-id></element-citation></ref><ref id="CR237"><mixed-citation publication-type="other">Kim S, Hahn YK, Podhaizer EM, McLane VD, Zou S, Hauser KF, Knapp PE (2018) A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates. J Neuroinflammation 15:285</mixed-citation></ref><ref id="CR238"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura-Kuroda</surname><given-names>J</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Yasui</surname><given-names>K</given-names></name></person-group><article-title>Inhibition of myelin formation by HIV-1 gp120 in rat cerebral cortex culture</article-title><source>Arch Virol</source><year>1994</year><volume>137</volume><fpage>81</fpage><lpage>99</lpage><?supplied-pmid 7526826?><pub-id pub-id-type="pmid">7526826</pub-id></element-citation></ref><ref id="CR239"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kish</surname><given-names>SJ</given-names></name><name><surname>Kalasinsky</surname><given-names>KS</given-names></name><name><surname>Derkach</surname><given-names>P</given-names></name><name><surname>Schmunk</surname><given-names>GA</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Ang</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>V</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Haycock</surname><given-names>JW</given-names></name></person-group><article-title>Striatal dopaminergic and serotonergic markers in human heroin users</article-title><source>Neuropsychopharmacology</source><year>2001</year><volume>24</volume><fpage>561</fpage><lpage>567</lpage><?supplied-pmid 11282256?><pub-id pub-id-type="pmid">11282256</pub-id></element-citation></ref><ref id="CR240"><mixed-citation publication-type="other">Knapp PE, Hauser KF (1996) &#x003bc;-Opioid receptor activation enhances DNA synthesis in immature oligodendrocytes. Brain Res 743:341&#x02013;345</mixed-citation></ref><ref id="CR241"><mixed-citation publication-type="other">Knapp PE, Maderspach K, Hauser KF (1998) Endogenous opioid system in developing normal and jimpy oligodendrocytes: &#x003bc; and &#x003ba; opioid receptors mediate differential mitogenic and growth responses. Glia 22:189&#x02013;201</mixed-citation></ref><ref id="CR242"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Itkis</surname><given-names>OS</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Spruce</surname><given-names>BA</given-names></name><name><surname>Bakalkin</surname><given-names>G</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Endogenous opioids and oligodendroglial function: possible autocrine/paracrine effects on cell survival and development</article-title><source>Glia</source><year>2001</year><volume>35</volume><fpage>156</fpage><lpage>165</lpage><?supplied-pmid 11460271?><pub-id pub-id-type="pmid">11460271</pub-id></element-citation></ref><ref id="CR243"><mixed-citation publication-type="other">Knapp PE, Adjan VV, Hauser KF (2009) Cell-specific loss of &#x003ba;-opioid receptors in oligodendrocytes of the dysmyelinating jimpy mouse. Neurosci Lett 451:114&#x02013;118</mixed-citation></ref><ref id="CR244"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>G</given-names></name><name><surname>Hattler</surname><given-names>JB</given-names></name><name><surname>Galadima</surname><given-names>HI</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>WK</given-names></name></person-group><article-title>Macrophages but not Astrocytes Harbor HIV DNA in the brains of HIV-1-infected Aviremic individuals on suppressive antiretroviral therapy</article-title><source>J NeuroImmune Pharmacol</source><year>2019</year><volume>14</volume><fpage>110</fpage><lpage>119</lpage><?supplied-pmid 30194646?><pub-id pub-id-type="pmid">30194646</pub-id></element-citation></ref><ref id="CR245"><mixed-citation publication-type="other">Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y (2011) Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 339:935&#x02013;944</mixed-citation></ref><ref id="CR246"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodaira</surname><given-names>H</given-names></name><name><surname>Kusuhara</surname><given-names>H</given-names></name><name><surname>Fuse</surname><given-names>E</given-names></name><name><surname>Ushiki</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><fpage>983</fpage><lpage>989</lpage><?supplied-pmid 24644297?><pub-id pub-id-type="pmid">24644297</pub-id></element-citation></ref><ref id="CR247"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolodyny</surname><given-names>A</given-names></name><name><surname>Courtwright</surname><given-names>DT</given-names></name><name><surname>Hwang</surname><given-names>CS</given-names></name><name><surname>Kreiner</surname><given-names>P</given-names></name><name><surname>Eadie</surname><given-names>JL</given-names></name><name><surname>Clark</surname><given-names>TW</given-names></name><name><surname>Alexander</surname><given-names>GC</given-names></name></person-group><article-title>The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction</article-title><source>Annu Rev Public Health</source><year>2015</year><volume>36</volume><fpage>559</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">25581144</pub-id></element-citation></ref><ref id="CR248"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koob</surname><given-names>GF</given-names></name></person-group><article-title>Neurobiology of opioid addiction: opponent process, Hyperkatifeia, and negative reinforcement</article-title><source>Biol Psychiatry</source><year>2020</year><volume>87</volume><fpage>44</fpage><lpage>53</lpage><?supplied-pmid 31400808?><pub-id pub-id-type="pmid">31400808</pub-id></element-citation></ref><ref id="CR249"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koob</surname><given-names>G</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Stress, dysregulation of drug reward pathways, and the transition to drug dependence</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>1149</fpage><lpage>1159</lpage><?supplied-pmid 17671276?><pub-id pub-id-type="pmid">17671276</pub-id></element-citation></ref><ref id="CR250"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koob</surname><given-names>GF</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Neurobiology of addiction: a neurocircuitry analysis</article-title><source>Lancet Psychiatry</source><year>2016</year><volume>3</volume><fpage>760</fpage><lpage>773</lpage><?supplied-pmid 27475769?><pub-id pub-id-type="pmid">27475769</pub-id></element-citation></ref><ref id="CR251"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostrikis</surname><given-names>LG</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Deutsch</surname><given-names>L</given-names></name><name><surname>Phair</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>AU</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>350</fpage><lpage>353</lpage><?supplied-pmid 9500612?><pub-id pub-id-type="pmid">9500612</pub-id></element-citation></ref><ref id="CR252"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Horvath</surname><given-names>MC</given-names></name><name><surname>Majtenyi</surname><given-names>K</given-names></name><name><surname>Lutz</surname><given-names>MI</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name></person-group><article-title>Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>3100</fpage><lpage>3107</lpage><?supplied-pmid 26254956?><pub-id pub-id-type="pmid">26254956</pub-id></element-citation></ref><ref id="CR253"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer-Hammerle</surname><given-names>S</given-names></name><name><surname>Rothenaigner</surname><given-names>I</given-names></name><name><surname>Wolff</surname><given-names>H</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Brack-Werner</surname><given-names>R</given-names></name></person-group><article-title>Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus</article-title><source>Virus Res</source><year>2005</year><volume>111</volume><fpage>194</fpage><lpage>213</lpage><?supplied-pmid 15885841?><pub-id pub-id-type="pmid">15885841</pub-id></element-citation></ref><ref id="CR254"><mixed-citation publication-type="other">Krathwohl MD, Kaiser JL (2004) HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis 190:216&#x02013;226</mixed-citation></ref><ref id="CR255"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Medical safety and side effects of methadone in tolerant individuals</article-title><source>JAMA</source><year>1973</year><volume>223</volume><fpage>665</fpage><lpage>668</lpage><?supplied-pmid 4739193?><pub-id pub-id-type="pmid">4739193</pub-id></element-citation></ref><ref id="CR256"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Tolerance and dependence: implications for the pharmacological treatment of addiction</article-title><source>NIDA Res Monogr</source><year>1987</year><volume>76</volume><fpage>53</fpage><lpage>62</lpage><?supplied-pmid 3125471?><pub-id pub-id-type="pmid">3125471</pub-id></element-citation></ref><ref id="CR257"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Drug addictions. Molecular and cellular endpoints</article-title><source>Ann N Y Acad Sci</source><year>2001</year><volume>937</volume><fpage>27</fpage><lpage>49</lpage><?supplied-pmid 11458539?><pub-id pub-id-type="pmid">11458539</pub-id></element-citation></ref><ref id="CR258"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Opioids, dopamine, stress, and the addictions</article-title><source>Dialogues Clin Neurosci</source><year>2007</year><volume>9</volume><fpage>363</fpage><lpage>378</lpage><?supplied-pmid 18286797?><pub-id pub-id-type="pmid">18286797</pub-id></element-citation></ref><ref id="CR259"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name><name><surname>LaForge</surname><given-names>KS</given-names></name><name><surname>Butelman</surname><given-names>E</given-names></name></person-group><article-title>Pharmacotherapy of addictions</article-title><source>Nat Rev Drug Discov</source><year>2002</year><volume>1</volume><fpage>710</fpage><lpage>726</lpage><?supplied-pmid 12209151?><pub-id pub-id-type="pmid">12209151</pub-id></element-citation></ref><ref id="CR260"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name><name><surname>Bart</surname><given-names>G</given-names></name><name><surname>Lilly</surname><given-names>C</given-names></name><name><surname>LaForge</surname><given-names>KS</given-names></name><name><surname>Nielsen</surname><given-names>DA</given-names></name></person-group><article-title>Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments</article-title><source>Pharmacol Rev</source><year>2005</year><volume>57</volume><fpage>1</fpage><lpage>26</lpage><?supplied-pmid 15734726?><pub-id pub-id-type="pmid">15734726</pub-id></element-citation></ref><ref id="CR261"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kringen</surname><given-names>MK</given-names></name><name><surname>Chalabianloo</surname><given-names>F</given-names></name><name><surname>Bernard</surname><given-names>JP</given-names></name><name><surname>Bramness</surname><given-names>JG</given-names></name><name><surname>Molden</surname><given-names>E</given-names></name><name><surname>Hoiseth</surname><given-names>G</given-names></name></person-group><article-title>Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment</article-title><source>Ther Drug Monit</source><year>2017</year><volume>39</volume><fpage>550</fpage><lpage>555</lpage><?supplied-pmid 28723731?><pub-id pub-id-type="pmid">28723731</pub-id></element-citation></ref><ref id="CR262"><mixed-citation publication-type="other">Krishnan G, Chatterjee N (2015) Differential immune mechanism to HIV-1 Tat variants and its regulation by AEA [corrected]. Sci Rep 5:9887</mixed-citation></ref><ref id="CR263"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhlman</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Lalani</surname><given-names>S</given-names></name><name><surname>Magluilo</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Darwin</surname><given-names>WD</given-names></name></person-group><article-title>Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine</article-title><source>J Anal Toxicol</source><year>1996</year><volume>20</volume><fpage>369</fpage><lpage>378</lpage><?supplied-pmid 8889672?><pub-id pub-id-type="pmid">8889672</pub-id></element-citation></ref><ref id="CR264"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Orsoni</surname><given-names>S</given-names></name><name><surname>Norman</surname><given-names>L</given-names></name><name><surname>Verma</surname><given-names>AS</given-names></name><name><surname>Tirado</surname><given-names>G</given-names></name><name><surname>Giavedoni</surname><given-names>LD</given-names></name><name><surname>Staprans</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>GM</given-names></name><name><surname>Buch</surname><given-names>SJ</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques</article-title><source>Virology</source><year>2006</year><volume>354</volume><fpage>192</fpage><lpage>206</lpage><?supplied-pmid 16876224?><pub-id pub-id-type="pmid">16876224</pub-id></element-citation></ref><ref id="CR265"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowski</surname><given-names>CF</given-names></name><name><surname>Booth</surname><given-names>RE</given-names></name></person-group><article-title>Methadone maintenance as HIV risk reduction with street-recruited injecting drug users</article-title><source>J Acquir Immune Defic Syndr</source><year>2001</year><volume>26</volume><fpage>483</fpage><lpage>489</lpage><?supplied-pmid 11391170?><pub-id pub-id-type="pmid">11391170</pub-id></element-citation></ref><ref id="CR266"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacagnina</surname><given-names>MJ</given-names></name><name><surname>Rivera</surname><given-names>PD</given-names></name><name><surname>Bilbo</surname><given-names>SD</given-names></name></person-group><article-title>Glial and neuroimmune mechanisms as critical modulators of drug use and abuse</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><fpage>156</fpage><lpage>177</lpage><?supplied-pmid 27402494?><pub-id pub-id-type="pmid">27402494</pub-id></element-citation></ref><ref id="CR267"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lama</surname><given-names>J</given-names></name><name><surname>Planelles</surname><given-names>V</given-names></name></person-group><article-title>Host factors influencing susceptibility to HIV infection and AIDS progression</article-title><source>Retrovirology</source><year>2007</year><volume>4</volume><fpage>52</fpage><?supplied-pmid 17651505?><pub-id pub-id-type="pmid">17651505</pub-id></element-citation></ref><ref id="CR268"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>TD</given-names></name><name><surname>Letendre</surname><given-names>SL</given-names></name><name><surname>Marcotte</surname><given-names>TD</given-names></name><name><surname>Ellis</surname><given-names>RJ</given-names></name><name><surname>JA</surname><given-names>MC</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Mallory</surname><given-names>ME</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Archibald</surname><given-names>S</given-names></name><name><surname>Jernigan</surname><given-names>T</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><collab>Group H</collab></person-group><article-title>Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy</article-title><source>AIDS</source><year>2002</year><volume>16</volume><fpage>1019</fpage><lpage>1029</lpage><?supplied-pmid 11953468?><pub-id pub-id-type="pmid">11953468</pub-id></element-citation></ref><ref id="CR269"><mixed-citation publication-type="other">Lapierre J, Rodriguez M, Ojha CR, El-Hage N (2018) Critical role of Beclin1 in HIV Tat and morphine-induced inflammation and calcium release in glial cells from autophagy deficient mouse. J NeuroImmune Pharmacol 13:355&#x02013;370</mixed-citation></ref><ref id="CR270"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawlor</surname><given-names>PG</given-names></name></person-group><article-title>The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>1836</fpage><lpage>1853</lpage><?supplied-pmid 11920548?><pub-id pub-id-type="pmid">11920548</pub-id></element-citation></ref><ref id="CR271"><mixed-citation publication-type="other">Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO (2004) Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 78:7319&#x02013;7328</mixed-citation></ref><ref id="CR272"><mixed-citation publication-type="other">Lee MH, Amin ND, Venkatesan A, Wang T, Tyagi R, Pant HC, Nath A (2013) Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation. J Neurovirol 19:418&#x02013;431</mixed-citation></ref><ref id="CR273"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibrand</surname><given-names>CR</given-names></name><name><surname>Paris</surname><given-names>JJ</given-names></name><name><surname>Ghandour</surname><given-names>MS</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Kim</surname><given-names>WK</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>McRae</surname><given-names>M</given-names></name></person-group><article-title>HIV-1 tat disrupts blood-brain barrier integrity and increases phagocytic perivascular macrophages and microglia in the dorsal striatum of transgenic mice</article-title><source>Neurosci Lett</source><year>2017</year><volume>640</volume><fpage>136</fpage><lpage>143</lpage><?supplied-pmid 28057474?><pub-id pub-id-type="pmid">28057474</pub-id></element-citation></ref><ref id="CR274"><mixed-citation publication-type="other">Leibrand CR, Paris JJ, Jones AM, Masuda QN, Halquist MS, Kim WK, Knapp PE, Kashuba ADM, Hauser KF, McRae M (2019) HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. J Neurovirol 25:560&#x02013;577</mixed-citation></ref><ref id="CR275"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>SC</given-names></name><name><surname>Correa</surname><given-names>DG</given-names></name><name><surname>Doring</surname><given-names>TM</given-names></name><name><surname>Kubo</surname><given-names>TT</given-names></name><name><surname>Netto</surname><given-names>TM</given-names></name><name><surname>Ferracini</surname><given-names>R</given-names></name><name><surname>Ventura</surname><given-names>N</given-names></name><name><surname>Bahia</surname><given-names>PR</given-names></name><name><surname>Gasparetto</surname><given-names>EL</given-names></name></person-group><article-title>Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients</article-title><source>J Magn Reson Imaging</source><year>2013</year><volume>38</volume><fpage>1488</fpage><lpage>1493</lpage><?supplied-pmid 23559497?><pub-id pub-id-type="pmid">23559497</pub-id></element-citation></ref><ref id="CR276"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemons</surname><given-names>A</given-names></name><name><surname>DeGroote</surname><given-names>N</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Craw</surname><given-names>J</given-names></name><name><surname>Nyaku</surname><given-names>M</given-names></name><name><surname>Broz</surname><given-names>D</given-names></name><name><surname>Mattson</surname><given-names>CL</given-names></name><name><surname>Beer</surname><given-names>L</given-names></name></person-group><article-title>Opioid misuse among HIV-positive adults in medical care: results from the medical monitoring project, 2009-2014</article-title><source>J Acquir Immune Defic Syndr</source><year>2019</year><volume>80</volume><fpage>127</fpage><lpage>134</lpage><?supplied-pmid 30383590?><pub-id pub-id-type="pmid">30383590</pub-id></element-citation></ref><ref id="CR277"><mixed-citation publication-type="other">Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B (1998) G&#x003b2;&#x003b3; stimulates phosphoinositide 3-kinase-&#x003b3; by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 273:7024&#x02013;7029</mixed-citation></ref><ref id="CR278"><mixed-citation publication-type="other">Leppla IE, Gross MS (2020) Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2). J Addict Med 14:e1&#x02013;e3. 10.1097/ADM.0000000000000678.</mixed-citation></ref><ref id="CR279"><mixed-citation publication-type="other">Lerner AM, Fauci AS (2019) Opioid injection in rural areas of the United States: a potential obstacle to ending the HIV epidemic. JAMA 322:1041&#x02013;1042. 10.1001/jama.2019.10657.</mixed-citation></ref><ref id="CR280"><mixed-citation publication-type="other">Leshner AI (1998) HIV prevention with drug using populations. Current status and future prospects. Public Health Rep 113 Suppl 1:1-3</mixed-citation></ref><ref id="CR281"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><article-title>Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology</article-title><source>Prog Neurobiol</source><year>2008</year><volume>84</volume><fpage>116</fpage><lpage>131</lpage><?supplied-pmid 18177992?><pub-id pub-id-type="pmid">18177992</pub-id></element-citation></ref><ref id="CR282"><mixed-citation publication-type="other">Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden TA, Shankar SK, Mahadevan A, Satishchandra P, Nath A (2008) NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 28:12190&#x02013;12198</mixed-citation></ref><ref id="CR283"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>White matter impairment in chronic heroin dependence: a quantitative DTI study</article-title><source>Brain Res</source><year>2013</year><volume>1531</volume><fpage>58</fpage><lpage>64</lpage><?supplied-pmid 23895765?><pub-id pub-id-type="pmid">23895765</pub-id></element-citation></ref><ref id="CR284"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GH</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Jaeger</surname><given-names>L</given-names></name><name><surname>Do</surname><given-names>T</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Cell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4</article-title><source>AIDS</source><year>2015</year><volume>29</volume><fpage>755</fpage><lpage>766</lpage><?supplied-pmid 25985398?><pub-id pub-id-type="pmid">25985398</pub-id></element-citation></ref><ref id="CR285"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Methadone-induced damage to white matter integrity in methadone maintenance patients: a longitudinal self-control DTI study</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>19662</fpage><?supplied-pmid 26794650?><pub-id pub-id-type="pmid">26794650</pub-id></element-citation></ref><ref id="CR286"><mixed-citation publication-type="other">Li GH, Maric D, Major EO, Nath A (2020) Productive HIV infection in astrocytes can be established via a non-classical mechanism. AIDS 34:963&#x02013;978</mixed-citation></ref><ref id="CR287"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>DY</given-names></name><name><surname>Clark</surname><given-names>JD</given-names></name></person-group><article-title>Modulation of the NO/CO-cGMP signaling cascade during chronic morphine exposure in mice</article-title><source>Neurosci Lett</source><year>2004</year><volume>365</volume><fpage>73</fpage><lpage>77</lpage><?supplied-pmid 15234476?><pub-id pub-id-type="pmid">15234476</pub-id></element-citation></ref><ref id="CR288"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Paxton</surname><given-names>WA</given-names></name><name><surname>Choe</surname><given-names>S</given-names></name><name><surname>Ceradini</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Horuk</surname><given-names>R</given-names></name><name><surname>MacDonald</surname><given-names>ME</given-names></name><name><surname>Stuhlmann</surname><given-names>H</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Landau</surname><given-names>NR</given-names></name></person-group><article-title>Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection</article-title><source>Cell</source><year>1996</year><volume>86</volume><fpage>367</fpage><lpage>377</lpage><?supplied-pmid 8756719?><pub-id pub-id-type="pmid">8756719</pub-id></element-citation></ref><ref id="CR289"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>4581</fpage><lpage>4585</lpage><?supplied-pmid 10200305?><pub-id pub-id-type="pmid">10200305</pub-id></element-citation></ref><ref id="CR290"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>BO</given-names></name><name><surname>Gattone</surname><given-names>VH</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Blum</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>JJ</given-names></name></person-group><article-title>CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>4120</fpage><lpage>4133</lpage><?supplied-pmid 15047828?><pub-id pub-id-type="pmid">15047828</pub-id></element-citation></ref><ref id="CR291"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Callegari</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cianfrogna</surname><given-names>J</given-names></name><name><surname>Doran</surname><given-names>AC</given-names></name><name><surname>Doran</surname><given-names>SD</given-names></name><name><surname>Gibbs</surname><given-names>JP</given-names></name><name><surname>Hosea</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>FR</given-names></name><name><surname>Szewc</surname><given-names>MA</given-names></name><name><surname>Van Deusen</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration</article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><fpage>1443</fpage><lpage>1447</lpage><?supplied-pmid 16760229?><pub-id pub-id-type="pmid">16760229</pub-id></element-citation></ref><ref id="CR292"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WT</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>YP</given-names></name><name><surname>Song</surname><given-names>AA</given-names></name><name><surname>Barnes</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>XJ</given-names></name></person-group><article-title>Spinal matrix metalloproteinase-9 contributes to physical dependence on morphine in mice</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>7613</fpage><lpage>7623</lpage><?supplied-pmid 20519536?><pub-id pub-id-type="pmid">20519536</pub-id></element-citation></ref><ref id="CR293"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>SJ</given-names></name></person-group><article-title>Interactions of opioids and HIV infection in the pathogenesis of chronic pain</article-title><source>Front Microbiol</source><year>2016</year><volume>7</volume><fpage>103</fpage><?supplied-pmid 26903982?><pub-id pub-id-type="pmid">26903982</pub-id></element-citation></ref><ref id="CR294"><mixed-citation publication-type="other">Liu H, Xu E, Liu J, Xiong H (2016b) Oligodendrocyte injury and pathogenesis of HIV-1-associated neurocognitive disorders. Brain Sci 6:23</mixed-citation></ref><ref id="CR295"><mixed-citation publication-type="other">Liu H, Liu J, Xu E, Tu G, Guo M, Liang S, Xiong H (2017) Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K<sup>+</sup> current conducted by K<sub>V</sub>1.3. Neurobiol Dis 97:1&#x02013;10</mixed-citation></ref><ref id="CR296"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>KG</given-names></name><name><surname>Allen</surname><given-names>RG</given-names></name><name><surname>Melner</surname><given-names>MH</given-names></name></person-group><article-title>Differential regulation of proenkephalin expression in astrocytes by cytokines</article-title><source>Endocrinology</source><year>1992</year><volume>131</volume><fpage>1908</fpage><lpage>1914</lpage><?supplied-pmid 1396335?><pub-id pub-id-type="pmid">1396335</pub-id></element-citation></ref><ref id="CR297"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>AJ</given-names></name><name><surname>Mburu</surname><given-names>G</given-names></name><name><surname>Welton</surname><given-names>NJ</given-names></name><name><surname>May</surname><given-names>MT</given-names></name><name><surname>Davies</surname><given-names>CF</given-names></name><name><surname>French</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>KM</given-names></name><name><surname>Looker</surname><given-names>KJ</given-names></name><name><surname>Christensen</surname><given-names>H</given-names></name><name><surname>McLean</surname><given-names>S</given-names></name><name><surname>Rhodes</surname><given-names>T</given-names></name><name><surname>Platt</surname><given-names>L</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name><name><surname>Guise</surname><given-names>A</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name></person-group><article-title>Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis</article-title><source>Clin Infect Dis</source><year>2016</year><volume>63</volume><fpage>1094</fpage><lpage>1104</lpage><?supplied-pmid 27343545?><pub-id pub-id-type="pmid">27343545</pub-id></element-citation></ref><ref id="CR298"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Rossi</surname><given-names>GC</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Pan</surname><given-names>YX</given-names></name></person-group><article-title>Mediation of opioid analgesia by a truncated 6-transmembrane GPCR</article-title><source>J Clin Invest</source><year>2015</year><volume>125</volume><fpage>2626</fpage><lpage>2630</lpage><?supplied-pmid 26011641?><pub-id pub-id-type="pmid">26011641</pub-id></element-citation></ref><ref id="CR299"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>GJ</given-names></name><name><surname>Minozzi</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>N</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name><name><surname>Deren</surname><given-names>S</given-names></name><name><surname>Bruneau</surname><given-names>J</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name></person-group><article-title>Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e5945</fpage><?supplied-pmid 23038795?><pub-id pub-id-type="pmid">23038795</pub-id></element-citation></ref><ref id="CR300"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maduna</surname><given-names>T</given-names></name><name><surname>Audouard</surname><given-names>E</given-names></name><name><surname>Dembele</surname><given-names>D</given-names></name><name><surname>Mouzaoui</surname><given-names>N</given-names></name><name><surname>Reiss</surname><given-names>D</given-names></name><name><surname>Massotte</surname><given-names>D</given-names></name><name><surname>Gaveriaux-Ruff</surname><given-names>C</given-names></name></person-group><article-title>Microglia express mu opioid receptor: insights from transcriptomics and fluorescent reporter mice</article-title><source>Frontiers in psychiatry</source><year>2018</year><volume>9</volume><fpage>726</fpage><?supplied-pmid 30662412?><pub-id pub-id-type="pmid">30662412</pub-id></element-citation></ref><ref id="CR301"><mixed-citation publication-type="other">Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP, Nair MP (2002) Morphine regulates gene expression of &#x003b1;- and &#x003b2;-chemokines and their receptors on astroglial cells via the opioid &#x003bc; receptor. J Immunol 169:3589&#x02013;3599</mixed-citation></ref><ref id="CR302"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>SD</given-names></name><name><surname>Schwartz</surname><given-names>SA</given-names></name><name><surname>Aalinkeel</surname><given-names>R</given-names></name><name><surname>Chawda</surname><given-names>RP</given-names></name><name><surname>Sykes</surname><given-names>DE</given-names></name><name><surname>Nair</surname><given-names>MP</given-names></name></person-group><article-title>Morphine modulates chemokine gene regulation in normal human astrocytes</article-title><source>Clin Immunol</source><year>2005</year><volume>115</volume><fpage>323</fpage><lpage>332</lpage><?supplied-pmid 15893700?><pub-id pub-id-type="pmid">15893700</pub-id></element-citation></ref><ref id="CR303"><mixed-citation publication-type="other">Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Fernandez SF, Chawda R, Shanahan TC, Schwartz SA (2008) Tight junction regulation by morphine and HIV-1 Tat modulates blood-brain barrier permeability. J Clin Immunol 28:528&#x02013;541</mixed-citation></ref><ref id="CR304"><mixed-citation publication-type="other">Malik S, Khalique H, Buch S, Seth P (2011) A growth factor attenuates HIV-1 Tat and morphine induced damage to human neurons: implication in HIV/AIDSdrug abuse cases. PLoS One 6:e18116</mixed-citation></ref><ref id="CR305"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>R</given-names></name><name><surname>Seth</surname><given-names>P</given-names></name></person-group><article-title>Involvement of extracellular signal-regulated kinase (ERK1/2)-p53-p21 axis in mediating neural stem/progenitor cell cycle arrest in co-morbid HIV-drug abuse exposure</article-title><source>J NeuroImmune Pharmacol</source><year>2014</year><volume>9</volume><fpage>340</fpage><lpage>353</lpage><?supplied-pmid 24469921?><pub-id pub-id-type="pmid">24469921</pub-id></element-citation></ref><ref id="CR306"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcario</surname><given-names>JK</given-names></name><name><surname>Riazi</surname><given-names>M</given-names></name><name><surname>Adany</surname><given-names>I</given-names></name><name><surname>Kenjale</surname><given-names>H</given-names></name><name><surname>Fleming</surname><given-names>K</given-names></name><name><surname>Marquis</surname><given-names>J</given-names></name><name><surname>Nemon</surname><given-names>O</given-names></name><name><surname>Mayo</surname><given-names>MS</given-names></name><name><surname>Yankee</surname><given-names>T</given-names></name><name><surname>Narayan</surname><given-names>O</given-names></name><name><surname>Cheney</surname><given-names>PD</given-names></name></person-group><article-title>Effect of morphine on the neuropathogenesis of SIVmac infection in Indian rhesus macaques</article-title><source>J NeuroImmune Pharmacol</source><year>2008</year><volume>3</volume><fpage>12</fpage><lpage>25</lpage><?supplied-pmid 18247128?><pub-id pub-id-type="pmid">18247128</pub-id></element-citation></ref><ref id="CR307"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcario</surname><given-names>JK</given-names></name><name><surname>Pendyala</surname><given-names>G</given-names></name><name><surname>Riazi</surname><given-names>M</given-names></name><name><surname>Fleming</surname><given-names>K</given-names></name><name><surname>Marquis</surname><given-names>J</given-names></name><name><surname>Callen</surname><given-names>S</given-names></name><name><surname>Lisco</surname><given-names>SJ</given-names></name><name><surname>Fowler</surname><given-names>SC</given-names></name><name><surname>Cheney</surname><given-names>PD</given-names></name><name><surname>Buch</surname><given-names>SJ</given-names></name></person-group><article-title>Effects of morphine on behavioral task performance in SIV-infected rhesus macaques</article-title><source>J NeuroImmune Pharmacol</source><year>2016</year><volume>11</volume><fpage>348</fpage><lpage>357</lpage><?supplied-pmid 27039332?><pub-id pub-id-type="pmid">27039332</pub-id></element-citation></ref><ref id="CR308"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinho</surname><given-names>AT</given-names></name><name><surname>Miranda</surname><given-names>JP</given-names></name><name><surname>Caixas</surname><given-names>U</given-names></name><name><surname>Charneira</surname><given-names>C</given-names></name><name><surname>Goncalves-Dias</surname><given-names>C</given-names></name><name><surname>Marques</surname><given-names>MM</given-names></name><name><surname>Monteiro</surname><given-names>EC</given-names></name><name><surname>Antunes</surname><given-names>AMM</given-names></name><name><surname>Pereira</surname><given-names>SA</given-names></name></person-group><article-title>Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity</article-title><source>Drug Metab Rev</source><year>2019</year><volume>51</volume><fpage>76</fpage><lpage>90</lpage><?supplied-pmid 30712401?><pub-id pub-id-type="pmid">30712401</pub-id></element-citation></ref><ref id="CR309"><mixed-citation publication-type="other">Martin E, Keutmann MK, Fogel JS, Maki PM, Gonzalez R, Vassileva J, Rubin LH, Hardy D (2018) Verbal and spatial working memory among drug-using HIVinfected men and women. J NeuroVirol 24:488&#x02013;497</mixed-citation></ref><ref id="CR310"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>EM</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Vassileva</surname><given-names>J</given-names></name><name><surname>Bechara</surname><given-names>A</given-names></name></person-group><article-title>Double dissociation of HIV and substance use disorder effects on neurocognitive tasks dependent on striatal integrity</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>1863</fpage><lpage>1870</lpage><?supplied-pmid 31259761?><pub-id pub-id-type="pmid">31259761</pub-id></element-citation></ref><ref id="CR311"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Thormeyer</surname><given-names>EM</given-names></name><name><surname>Paul</surname><given-names>RH</given-names></name></person-group><article-title>Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features</article-title><source>Neuropsychol Rev</source><year>2009</year><volume>19</volume><fpage>215</fpage><lpage>231</lpage><?supplied-pmid 19468837?><pub-id pub-id-type="pmid">19468837</pub-id></element-citation></ref><ref id="CR312"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzolini</surname><given-names>C</given-names></name><name><surname>Troillet</surname><given-names>N</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Decosterd</surname><given-names>LA</given-names></name><name><surname>Eap</surname><given-names>CB</given-names></name></person-group><article-title>Efavirenz decreases methadone blood concentrations</article-title><source>AIDS</source><year>2000</year><volume>14</volume><fpage>1291</fpage><lpage>1292</lpage><?supplied-pmid 10894303?><pub-id pub-id-type="pmid">10894303</pub-id></element-citation></ref><ref id="CR313"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maschke</surname><given-names>M</given-names></name><name><surname>Kastrup</surname><given-names>O</given-names></name><name><surname>Esser</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>B</given-names></name><name><surname>Hengge</surname><given-names>U</given-names></name><name><surname>Hufnagel</surname><given-names>A</given-names></name></person-group><article-title>Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2000</year><volume>69</volume><fpage>376</fpage><lpage>380</lpage><?supplied-pmid 10945813?><pub-id pub-id-type="pmid">10945813</pub-id></element-citation></ref><ref id="CR314"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massaly</surname><given-names>N</given-names></name><name><surname>Frances</surname><given-names>B</given-names></name><name><surname>Mouledous</surname><given-names>L</given-names></name></person-group><article-title>Roles of the ubiquitin proteasome system in the effects of drugs of abuse</article-title><source>Front Mol Neurosci</source><year>2014</year><volume>7</volume><fpage>99</fpage><?supplied-pmid 25610367?><pub-id pub-id-type="pmid">25610367</pub-id></element-citation></ref><ref id="CR315"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masvekar</surname><given-names>RR</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name></person-group><article-title>Morphine enhances HIV-1<sub>SF162</sub>-mediated neuron death and delays recovery of injured neurites</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e100196</fpage><?supplied-pmid 24949623?><pub-id pub-id-type="pmid">24949623</pub-id></element-citation></ref><ref id="CR316"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>BM</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Bucello</surname><given-names>C</given-names></name><name><surname>Lemon</surname><given-names>J</given-names></name><name><surname>Wiessing</surname><given-names>L</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name></person-group><article-title>Mortality among people who inject drugs: a systematic review and meta-analysis</article-title><source>Bull World Health Organ</source><year>2013</year><volume>91</volume><fpage>102</fpage><lpage>123</lpage><?supplied-pmid 23554523?><pub-id pub-id-type="pmid">23554523</pub-id></element-citation></ref><ref id="CR317"><mixed-citation publication-type="other">Mathews JL, Smrcka AV, Bidlack JM (2008) A novel G&#x003b2;&#x003b3;-subunit inhibitor selectively modulates &#x003bc;-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. J Neurosci 28:12183&#x02013;12189</mixed-citation></ref><ref id="CR318"><mixed-citation publication-type="other">Matsunaga M, Isowa T, Murakami H, Kasugai K, Yoneda M, Kaneko H, Ohira H (2009) Association of polymorphism in the human mu-opioid receptor <italic>OPRM1</italic> gene with proinflammatory cytokine levels and health perception. Brain Behav Immun 23:931&#x02013;935</mixed-citation></ref><ref id="CR319"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattioli</surname><given-names>TA</given-names></name><name><surname>Leduc-Pessah</surname><given-names>H</given-names></name><name><surname>Skelhorne-Gross</surname><given-names>G</given-names></name><name><surname>Nicol</surname><given-names>CJ</given-names></name><name><surname>Milne</surname><given-names>B</given-names></name><name><surname>Trang</surname><given-names>T</given-names></name><name><surname>Cahill</surname><given-names>CM</given-names></name></person-group><article-title>Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e97361</fpage><?supplied-pmid 24824631?><pub-id pub-id-type="pmid">24824631</pub-id></element-citation></ref><ref id="CR320"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazhnaya</surname><given-names>A</given-names></name><name><surname>Marcus</surname><given-names>R</given-names></name><name><surname>Bojko</surname><given-names>MJ</given-names></name><name><surname>Zelenev</surname><given-names>A</given-names></name><name><surname>Makarenko</surname><given-names>I</given-names></name><name><surname>Pykalo</surname><given-names>I</given-names></name><name><surname>Filippovych</surname><given-names>S</given-names></name><name><surname>Dvoriak</surname><given-names>S</given-names></name><name><surname>Altice</surname><given-names>FL</given-names></name></person-group><article-title>Opioid agonist treatment and improved outcomes at each stage of the HIV treatment cascade in people who inject drugs in Ukraine</article-title><source>J Acquir Immune Defic Syndr</source><year>2018</year><volume>79</volume><fpage>288</fpage><lpage>295</lpage><?supplied-pmid 30312275?><pub-id pub-id-type="pmid">30312275</pub-id></element-citation></ref><ref id="CR321"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Human immunodeficiency virus-associated neurocognitive disorders: mind the gap</article-title><source>Ann Neurol</source><year>2010</year><volume>67</volume><fpage>699</fpage><lpage>714</lpage><?supplied-pmid 20517932?><pub-id pub-id-type="pmid">20517932</pub-id></element-citation></ref><ref id="CR322"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCance-Katz</surname><given-names>EF</given-names></name></person-group><article-title>Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><issue>Suppl 1</issue><fpage>S89</fpage><lpage>S95</lpage><?supplied-pmid 16265622?><pub-id pub-id-type="pmid">16265622</pub-id></element-citation></ref><ref id="CR323"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCance-Katz</surname><given-names>EF</given-names></name><name><surname>Moody</surname><given-names>DE</given-names></name><name><surname>Morse</surname><given-names>GD</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>DiFrancesco</surname><given-names>R</given-names></name><name><surname>Friedland</surname><given-names>G</given-names></name><name><surname>Pade</surname><given-names>P</given-names></name><name><surname>Rainey</surname><given-names>PM</given-names></name></person-group><article-title>Interaction between buprenorphine and atazanavir or atazanavir/ritonavir</article-title><source>Drug Alcohol Depend</source><year>2007</year><volume>91</volume><fpage>269</fpage><lpage>278</lpage><?supplied-pmid 17643869?><pub-id pub-id-type="pmid">17643869</pub-id></element-citation></ref><ref id="CR324"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname><given-names>DH</given-names></name><name><surname>Beecroft</surname><given-names>MJ</given-names></name><name><surname>Kleeberger</surname><given-names>CA</given-names></name><name><surname>Al-Sharif</surname><given-names>FM</given-names></name><name><surname>Ollier</surname><given-names>WE</given-names></name><name><surname>Zimmerman</surname><given-names>PA</given-names></name><name><surname>Boatin</surname><given-names>BA</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><name><surname>Hajeer</surname><given-names>AH</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the multicenter AIDS cohort study</article-title><source>AIDS</source><year>2000</year><volume>14</volume><fpage>2671</fpage><lpage>2678</lpage><?supplied-pmid 11125885?><pub-id pub-id-type="pmid">11125885</pub-id></element-citation></ref><ref id="CR325"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonough</surname><given-names>RJ</given-names></name><name><surname>Madden</surname><given-names>JJ</given-names></name><name><surname>Falek</surname><given-names>A</given-names></name><name><surname>Shafer</surname><given-names>DA</given-names></name><name><surname>Pline</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Bokos</surname><given-names>P</given-names></name><name><surname>Kuehnle</surname><given-names>JC</given-names></name><name><surname>Mendelson</surname><given-names>J</given-names></name></person-group><article-title>Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes</article-title><source>J Immunol</source><year>1980</year><volume>125</volume><fpage>2539</fpage><lpage>2543</lpage><?supplied-pmid 6253568?><pub-id pub-id-type="pmid">6253568</pub-id></element-citation></ref><ref id="CR326"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonough</surname><given-names>RJ</given-names></name><name><surname>Madden</surname><given-names>JJ</given-names></name><name><surname>Rosman</surname><given-names>HS</given-names></name><name><surname>Falek</surname><given-names>A</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Shafer</surname><given-names>DA</given-names></name><name><surname>Bokos</surname><given-names>PJ</given-names></name><name><surname>Kuehnle</surname><given-names>JC</given-names></name><name><surname>Mendelson</surname><given-names>JH</given-names></name></person-group><article-title>Opiate inhibition of sheep erythrocyte binding to T lymphocytes: reversal by naloxone and cyclic nucleotides</article-title><source>NIDA Res Monogr</source><year>1981</year><volume>34</volume><fpage>159</fpage><lpage>165</lpage><?supplied-pmid 6783926?><pub-id pub-id-type="pmid">6783926</pub-id></element-citation></ref><ref id="CR327"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLane</surname><given-names>VD</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Willis</surname><given-names>CL</given-names></name></person-group><article-title>Morphine increases hippocampal viral load and suppresses frontal lobe CCL5 expression in the LP-BM5 AIDS model</article-title><source>J Neuroimmunol</source><year>2014</year><volume>269</volume><fpage>44</fpage><lpage>51</lpage><?supplied-pmid 24629894?><pub-id pub-id-type="pmid">24629894</pub-id></element-citation></ref><ref id="CR328"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLane</surname><given-names>VD</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Leeming</surname><given-names>R</given-names></name><name><surname>Rau</surname><given-names>S</given-names></name><name><surname>Willis</surname><given-names>CL</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name></person-group><article-title>Morphine-potentiated cognitive deficits correlate to suppressed hippocampal iNOS RNA expression and an absent type 1 interferon response in LP-BM5 murine AIDS</article-title><source>J Neuroimmunol</source><year>2018</year><volume>319</volume><fpage>117</fpage><lpage>129</lpage><?supplied-pmid 29526406?><pub-id pub-id-type="pmid">29526406</pub-id></element-citation></ref><ref id="CR329"><mixed-citation publication-type="other">McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, Mohabbat Y, Moyer RA, Bohn LM, Coscia CJ (2008) Kappa opioids promote the proliferation of astrocytes via G&#x003b2;&#x003b3; and &#x003b2;-arrestin 2-dependent MAPK-mediated pathways. J Neurochem 107:1753&#x02013;1765</mixed-citation></ref><ref id="CR330"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPherson</surname><given-names>J</given-names></name><name><surname>Rivero</surname><given-names>G</given-names></name><name><surname>Baptist</surname><given-names>M</given-names></name><name><surname>Llorente</surname><given-names>J</given-names></name><name><surname>Al-Sabah</surname><given-names>S</given-names></name><name><surname>Krasel</surname><given-names>C</given-names></name><name><surname>Dewey</surname><given-names>WL</given-names></name><name><surname>Bailey</surname><given-names>CP</given-names></name><name><surname>Rosethorne</surname><given-names>EM</given-names></name><name><surname>Charlton</surname><given-names>SJ</given-names></name><name><surname>Henderson</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>E</given-names></name></person-group><article-title>Mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization</article-title><source>Mol Pharmacol</source><year>2010</year><volume>78</volume><fpage>756</fpage><lpage>766</lpage><?supplied-pmid 20647394?><pub-id pub-id-type="pmid">20647394</pub-id></element-citation></ref><ref id="CR331"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meemken</surname><given-names>L</given-names></name><name><surname>Hanhoff</surname><given-names>N</given-names></name><name><surname>Tseng</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>S</given-names></name><name><surname>Gillessen</surname><given-names>A</given-names></name></person-group><article-title>Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy</article-title><source>Ann Pharmacother</source><year>2015</year><volume>49</volume><fpage>796</fpage><lpage>807</lpage><?supplied-pmid 25902733?><pub-id pub-id-type="pmid">25902733</pub-id></element-citation></ref><ref id="CR332"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijerink</surname><given-names>H</given-names></name><name><surname>Wisaksana</surname><given-names>R</given-names></name><name><surname>Iskandar</surname><given-names>S</given-names></name><name><surname>den Heijer</surname><given-names>M</given-names></name><name><surname>van der Ven</surname><given-names>AJ</given-names></name><name><surname>Alisjahbana</surname><given-names>B</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name></person-group><article-title>Injecting drug use is associated with a more rapid CD4 cell decline among treatment naive HIV-positive patients in Indonesia</article-title><source>J Int AIDS Soc</source><year>2014</year><volume>17</volume><fpage>18844</fpage><?supplied-pmid 24388495?><pub-id pub-id-type="pmid">24388495</pub-id></element-citation></ref><ref id="CR333"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijerink</surname><given-names>H</given-names></name><name><surname>Indrati</surname><given-names>AR</given-names></name><name><surname>Soedarmo</surname><given-names>S</given-names></name><name><surname>Utami</surname><given-names>F</given-names></name><name><surname>de Jong</surname><given-names>CA</given-names></name><name><surname>Alisjahbana</surname><given-names>B</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Wisaksana</surname><given-names>R</given-names></name><name><surname>Van der Ven</surname><given-names>AJ</given-names></name></person-group><article-title>Heroin use in Indonesia is associated with higher expression of CCR5 on CD4+ cells and lower ex-vivo production of CCR5 ligands</article-title><source>AIDS</source><year>2015</year><volume>29</volume><fpage>385</fpage><lpage>388</lpage><?supplied-pmid 25834861?><pub-id pub-id-type="pmid">25834861</pub-id></element-citation></ref><ref id="CR334"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Sindberg</surname><given-names>GM</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>Disruption of gut homeostasis by opioids accelerates HIV disease progression</article-title><source>Front Microbiol</source><year>2015</year><volume>6</volume><fpage>643</fpage><?supplied-pmid 26167159?><pub-id pub-id-type="pmid">26167159</pub-id></element-citation></ref><ref id="CR335"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>UA</given-names></name><name><surname>Zanger</surname><given-names>UM</given-names></name></person-group><article-title>Molecular mechanisms of genetic polymorphisms of drug metabolism</article-title><source>Annu Rev Pharmacol Toxicol</source><year>1997</year><volume>37</volume><fpage>269</fpage><lpage>296</lpage><?supplied-pmid 9131254?><pub-id pub-id-type="pmid">9131254</pub-id></element-citation></ref><ref id="CR336"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>VJ</given-names></name><name><surname>Rubin</surname><given-names>LH</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>KM</given-names></name><name><surname>Cohen</surname><given-names>MH</given-names></name><name><surname>Golub</surname><given-names>ET</given-names></name><name><surname>Valcour</surname><given-names>V</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name><name><surname>Crystal</surname><given-names>H</given-names></name><name><surname>Anastos</surname><given-names>K</given-names></name><name><surname>Aouizerat</surname><given-names>BE</given-names></name><name><surname>Milam</surname><given-names>J</given-names></name><name><surname>Maki</surname><given-names>PM</given-names></name></person-group><article-title>HIV and recent illicit drug use interact to affect verbal memory in women</article-title><source>J Acquir Immune Defic Syndr</source><year>2013</year><volume>63</volume><fpage>67</fpage><lpage>76</lpage><?supplied-pmid 23392462?><pub-id pub-id-type="pmid">23392462</pub-id></element-citation></ref><ref id="CR337"><mixed-citation publication-type="other">Midde NM, Gomez AM, Zhu J (2012) HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. J NeuroImmune Pharmacol 7:629&#x02013;639</mixed-citation></ref><ref id="CR338"><mixed-citation publication-type="other">Midde NM, Yuan Y, Quizon PM, Sun WL, Huang X, Zhan CG, Zhu J (2015) Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. J NeuroImmune Pharmacol 10:122&#x02013;135</mixed-citation></ref><ref id="CR339"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirsattari</surname><given-names>SM</given-names></name><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Primary headaches with HIV infection</article-title><source>Headache</source><year>1999</year><volume>39</volume><fpage>3</fpage><lpage>10</lpage><?supplied-pmid 15613188?><pub-id pub-id-type="pmid">15613188</pub-id></element-citation></ref><ref id="CR340"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group><article-title>HIV-1 tat C phosphorylates VE-cadherin complex and increases human brain microvascular endothelial cell permeability</article-title><source>BMC Neurosci</source><year>2014</year><volume>15</volume><fpage>80</fpage><?supplied-pmid 24965120?><pub-id pub-id-type="pmid">24965120</pub-id></element-citation></ref><ref id="CR341"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>M</given-names></name><name><surname>Vetrivel</surname><given-names>S</given-names></name><name><surname>Siddappa</surname><given-names>NB</given-names></name><name><surname>Ranga</surname><given-names>U</given-names></name><name><surname>Seth</surname><given-names>P</given-names></name></person-group><article-title>Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C tat of human neurons: significance of dicysteine C30C31 motif</article-title><source>Ann Neurol</source><year>2008</year><volume>63</volume><fpage>366</fpage><lpage>376</lpage><?supplied-pmid 18074388?><pub-id pub-id-type="pmid">18074388</pub-id></element-citation></ref><ref id="CR342"><mixed-citation publication-type="other">Mishra M, Taneja M, Malik S, Khalique H, Seth P (2010) Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS. J NeuroVirol 16:355&#x02013;367</mixed-citation></ref><ref id="CR343"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moises</surname><given-names>HC</given-names></name><name><surname>Rusin</surname><given-names>KI</given-names></name><name><surname>Macdonald</surname><given-names>RL</given-names></name></person-group><article-title>Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons</article-title><source>J Neurosci</source><year>1994</year><volume>14</volume><fpage>5903</fpage><lpage>5916</lpage><?supplied-pmid 7931552?><pub-id pub-id-type="pmid">7931552</pub-id></element-citation></ref><ref id="CR344"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Dimsdale</surname><given-names>JE</given-names></name></person-group><article-title>Opioids, sleep, and cancer-related fatigue</article-title><source>Med Hypotheses</source><year>2002</year><volume>58</volume><fpage>77</fpage><lpage>82</lpage><?supplied-pmid 11863402?><pub-id pub-id-type="pmid">11863402</pub-id></element-citation></ref><ref id="CR345"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales Odia</surname><given-names>Y</given-names></name><name><surname>Jinka</surname><given-names>M</given-names></name><name><surname>Ziai</surname><given-names>WC</given-names></name></person-group><article-title>Severe leukoencephalopathy following acute oxycodone intoxication</article-title><source>Neurocrit Care</source><year>2010</year><volume>13</volume><fpage>93</fpage><lpage>97</lpage><?supplied-pmid 20440598?><pub-id pub-id-type="pmid">20440598</pub-id></element-citation></ref><ref id="CR346"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>MM</given-names></name><name><surname>Christie</surname><given-names>MJ</given-names></name></person-group><article-title>Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human</article-title><source>Br J Pharmacol</source><year>2011</year><volume>164</volume><fpage>1322</fpage><lpage>1334</lpage><?supplied-pmid 21434879?><pub-id pub-id-type="pmid">21434879</pub-id></element-citation></ref><ref id="CR347"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukandavire</surname><given-names>C</given-names></name><name><surname>Low</surname><given-names>A</given-names></name><name><surname>Mburu</surname><given-names>G</given-names></name><name><surname>Trickey</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>MT</given-names></name><name><surname>Davies</surname><given-names>CF</given-names></name><name><surname>French</surname><given-names>CE</given-names></name><name><surname>Looker</surname><given-names>KJ</given-names></name><name><surname>Rhodes</surname><given-names>T</given-names></name><name><surname>Platt</surname><given-names>L</given-names></name><name><surname>Guise</surname><given-names>A</given-names></name><name><surname>Hickman</surname><given-names>M</given-names></name><name><surname>Vickerman</surname><given-names>P</given-names></name></person-group><article-title>Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>1181</fpage><lpage>1190</lpage><?supplied-pmid 28323752?><pub-id pub-id-type="pmid">28323752</pub-id></element-citation></ref><ref id="CR348"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>UJ</given-names></name><name><surname>Truebner</surname><given-names>K</given-names></name><name><surname>Schiltz</surname><given-names>K</given-names></name><name><surname>Kuhn</surname><given-names>J</given-names></name><name><surname>Mawrin</surname><given-names>C</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name></person-group><article-title>Postmortem volumetric analysis of the nucleus accumbens in male heroin addicts: implications for deep brain stimulation</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2015</year><volume>265</volume><fpage>647</fpage><lpage>653</lpage><?supplied-pmid 26189034?><pub-id pub-id-type="pmid">26189034</pub-id></element-citation></ref><ref id="CR349"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>UJ</given-names></name><name><surname>Schiltz</surname><given-names>K</given-names></name><name><surname>Mawrin</surname><given-names>C</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Frodl</surname><given-names>T</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name><name><surname>Truebner</surname><given-names>K</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name></person-group><article-title>Total hypothalamic volume is reduced in postmortem brains of male heroin addicts</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2018</year><volume>268</volume><fpage>243</fpage><lpage>248</lpage><?supplied-pmid 28534187?><pub-id pub-id-type="pmid">28534187</pub-id></element-citation></ref><ref id="CR350"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>UJ</given-names></name><name><surname>Mawrin</surname><given-names>C</given-names></name><name><surname>Frodl</surname><given-names>T</given-names></name><name><surname>Dobrowolny</surname><given-names>H</given-names></name><name><surname>Busse</surname><given-names>S</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Bogerts</surname><given-names>B</given-names></name><name><surname>Truebner</surname><given-names>K</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name></person-group><article-title>Reduced volumes of the external and internal globus pallidus in male heroin addicts: a postmortem study</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2019</year><volume>269</volume><fpage>317</fpage><lpage>324</lpage><?supplied-pmid 30173319?><pub-id pub-id-type="pmid">30173319</pub-id></element-citation></ref><ref id="CR351"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>A</given-names></name><name><surname>Barbaro</surname><given-names>J</given-names></name><name><surname>Martinez-Aguado</surname><given-names>P</given-names></name><name><surname>Chilunda</surname><given-names>V</given-names></name><name><surname>Jaureguiberry-Bravo</surname><given-names>M</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>The effects of opioids on HIV Neuropathogenesis</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2445</fpage><?supplied-pmid 31681322?><pub-id pub-id-type="pmid">31681322</pub-id></element-citation></ref><ref id="CR352"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>H</given-names></name><name><surname>Chandra</surname><given-names>R</given-names></name><name><surname>Francis</surname><given-names>TC</given-names></name><name><surname>Dias</surname><given-names>C</given-names></name><name><surname>Cheer</surname><given-names>JF</given-names></name><name><surname>Lobo</surname><given-names>MK</given-names></name></person-group><article-title>Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress</article-title><source>Neuropsychopharmacology</source><year>2019</year><volume>44</volume><fpage>1876</fpage><lpage>1885</lpage><?supplied-pmid 31132785?><pub-id pub-id-type="pmid">31132785</pub-id></element-citation></ref><ref id="CR353"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandhu</surname><given-names>MS</given-names></name><name><surname>Naijil</surname><given-names>G</given-names></name><name><surname>Smijin</surname><given-names>S</given-names></name><name><surname>Jayanarayanan</surname><given-names>S</given-names></name><name><surname>Paulose</surname><given-names>CS</given-names></name></person-group><article-title>Opioid system functional regulation in neurological disease management</article-title><source>J Neurosci Res</source><year>2010</year><volume>88</volume><fpage>3215</fpage><lpage>3221</lpage><?supplied-pmid 20734417?><pub-id pub-id-type="pmid">20734417</pub-id></element-citation></ref><ref id="CR354"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narasipura</surname><given-names>SD</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Al-Harthi</surname><given-names>L</given-names></name></person-group><article-title>Epigenetic regulation of HIV-1 latency in astrocytes</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>3031</fpage><lpage>3038</lpage><?supplied-pmid 24352441?><pub-id pub-id-type="pmid">24352441</pub-id></element-citation></ref><ref id="CR355"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Miyatake</surname><given-names>M</given-names></name><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Shibasaki</surname><given-names>M</given-names></name><name><surname>Shindo</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Kuzumaki</surname><given-names>N</given-names></name><name><surname>Nagumo</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name></person-group><article-title>Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>2476</fpage><lpage>2488</lpage><?supplied-pmid 16407899?><pub-id pub-id-type="pmid">16407899</pub-id></element-citation></ref><ref id="CR356"><mixed-citation publication-type="other">Nash B, Meucci O (2014) Functions of the chemokine receptor CXCR in the central nervous system and its regulation by &#x003bc;-opioid receptors. Int Rev Neurobiol 118:105&#x02013;128</mixed-citation></ref><ref id="CR357"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Pathobiology of human immunodeficiency virus dementia</article-title><source>Semin Neurol</source><year>1999</year><volume>19</volume><fpage>113</fpage><lpage>127</lpage><?supplied-pmid 10718533?><pub-id pub-id-type="pmid">10718533</pub-id></element-citation></ref><ref id="CR358"><mixed-citation publication-type="other">Nath A (2015) Eradication of human immunodeficiency virus from brain reservoirs. J NeuroVirol 21:227&#x02013;234</mixed-citation></ref><ref id="CR359"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Booze</surname><given-names>RM</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Mactutus</surname><given-names>CF</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name><name><surname>Maragos</surname><given-names>WF</given-names></name><name><surname>Berger</surname><given-names>JR</given-names></name></person-group><article-title>Critical questions for neuroscientists in interactions of drugs of abuse and HIV infection</article-title><source>NeuroAIDS</source><year>1999</year><volume>2</volume><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="CR360"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Maragos</surname><given-names>W</given-names></name><name><surname>Booze</surname><given-names>R</given-names></name><name><surname>Mactutus</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Mattson</surname><given-names>M</given-names></name></person-group><article-title>Neurotoxicity and dysfunction of dopamine systems associated with AIDS dementia</article-title><source>Psychopharmacol</source><year>2000</year><volume>14</volume><fpage>222</fpage><lpage>227</lpage></element-citation></ref><ref id="CR361"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Maragos</surname><given-names>W</given-names></name><name><surname>Booze</surname><given-names>R</given-names></name><name><surname>Mactutus</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Mattson</surname><given-names>M</given-names></name></person-group><article-title>Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia</article-title><source>J Psychopharmacol</source><year>2000</year><volume>14</volume><fpage>222</fpage><lpage>227</lpage><?supplied-pmid 11106300?><pub-id pub-id-type="pmid">11106300</pub-id></element-citation></ref><ref id="CR362"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Wojna</surname><given-names>V</given-names></name><name><surname>Booze</surname><given-names>RM</given-names></name><name><surname>Maragos</surname><given-names>W</given-names></name><name><surname>Prendergast</surname><given-names>M</given-names></name><name><surname>Cass</surname><given-names>W</given-names></name><name><surname>Turchan</surname><given-names>JT</given-names></name></person-group><article-title>Molecular basis for interactions of HIV and drugs of abuse</article-title><source>J Acquir Immune Defic Syndr</source><year>2002</year><volume>31</volume><issue>Suppl 2</issue><fpage>S62</fpage><lpage>S69</lpage><?supplied-pmid 12394784?><pub-id pub-id-type="pmid">12394784</pub-id></element-citation></ref><ref id="CR363"><mixed-citation publication-type="other">NIDA (2020) COVID-19: Potential implications for individuals with substance use disorders. In: (Volkow ND, ed) Nora&#x02019;s Blog. National Institute on Drug Abuse (NIDA). 4/6/2020: <ext-link ext-link-type="uri" xlink:href="https://www.drugabuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications-individuals-substance-use-disorders">https://www.drugabuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications-individuals-substance-use-disorders</ext-link></mixed-citation></ref><ref id="CR364"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieminen</surname><given-names>TH</given-names></name><name><surname>Hagelberg</surname><given-names>NM</given-names></name><name><surname>Saari</surname><given-names>TI</given-names></name><name><surname>Neuvonen</surname><given-names>M</given-names></name><name><surname>Neuvonen</surname><given-names>PJ</given-names></name><name><surname>Laine</surname><given-names>K</given-names></name><name><surname>Olkkola</surname><given-names>KT</given-names></name></person-group><article-title>Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir</article-title><source>Eur J Clin Pharmacol</source><year>2010</year><volume>66</volume><fpage>977</fpage><lpage>985</lpage><?supplied-pmid 20697700?><pub-id pub-id-type="pmid">20697700</pub-id></element-citation></ref><ref id="CR365"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>F</given-names></name><name><surname>Marie</surname><given-names>N</given-names></name></person-group><article-title>Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine</article-title><source>Frontiers in psychiatry</source><year>2018</year><volume>9</volume><fpage>742</fpage><?supplied-pmid 30713510?><pub-id pub-id-type="pmid">30713510</pub-id></element-citation></ref><ref id="CR366"><mixed-citation publication-type="other">Noel RJ Jr, Kumar A (2006) Virus replication and disease progression inversely correlate with SIV Tat evolution in morphine-dependent and SIV/SHIV-infected Indian rhesus macaques. Virology 346:127&#x02013;138</mixed-citation></ref><ref id="CR367"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS</article-title><source>Virology</source><year>2007</year><volume>359</volume><fpage>397</fpage><lpage>404</lpage><?supplied-pmid 17064752?><pub-id pub-id-type="pmid">17064752</pub-id></element-citation></ref><ref id="CR368"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Toro-Bahamonde</surname><given-names>A</given-names></name><name><surname>Marrero-Otero</surname><given-names>Z</given-names></name><name><surname>Orsini</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>AS</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Lack of correlation between SIV-Nef evolution and rapid disease progression in morphine-dependent nonhuman primate model of AIDS</article-title><source>AIDS Res Hum Retrovir</source><year>2006</year><volume>22</volume><fpage>817</fpage><lpage>823</lpage><?supplied-pmid 16910840?><pub-id pub-id-type="pmid">16910840</pub-id></element-citation></ref><ref id="CR369"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Marrero-Otero</surname><given-names>Z</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Chompre-Gonzalez</surname><given-names>GS</given-names></name><name><surname>Verma</surname><given-names>AS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Correlation between SIV tat evolution and AIDS progression in cerebrospinal fluid of morphine-dependent and control macaques infected with SIV and SHIV</article-title><source>Virology</source><year>2006</year><volume>349</volume><fpage>440</fpage><lpage>452</lpage><?supplied-pmid 16643974?><pub-id pub-id-type="pmid">16643974</pub-id></element-citation></ref><ref id="CR370"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nosyk</surname><given-names>B</given-names></name><name><surname>Min</surname><given-names>JE</given-names></name><name><surname>Colley</surname><given-names>G</given-names></name><name><surname>Lima</surname><given-names>VD</given-names></name><name><surname>Yip</surname><given-names>B</given-names></name><name><surname>Milloy</surname><given-names>MJ</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Montaner</surname><given-names>JS</given-names></name></person-group><article-title>The causal effect of opioid substitution treatment on HAART medication refill adherence</article-title><source>AIDS</source><year>2015</year><volume>29</volume><fpage>965</fpage><lpage>973</lpage><?supplied-pmid 25915170?><pub-id pub-id-type="pmid">25915170</pub-id></element-citation></ref><ref id="CR371"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nottet</surname><given-names>HS</given-names></name><name><surname>Persidsky</surname><given-names>Y</given-names></name><name><surname>Sasseville</surname><given-names>VG</given-names></name><name><surname>Nukuna</surname><given-names>AN</given-names></name><name><surname>Bock</surname><given-names>P</given-names></name><name><surname>Zhai</surname><given-names>QH</given-names></name><name><surname>Sharer</surname><given-names>LR</given-names></name><name><surname>McComb</surname><given-names>RD</given-names></name><name><surname>Swindells</surname><given-names>S</given-names></name><name><surname>Soderland</surname><given-names>C</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name></person-group><article-title>Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain</article-title><source>J Immunol</source><year>1996</year><volume>156</volume><fpage>1284</fpage><lpage>1295</lpage><?supplied-pmid 8558009?><pub-id pub-id-type="pmid">8558009</pub-id></element-citation></ref><ref id="CR372"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novick</surname><given-names>DM</given-names></name><name><surname>Ochshorn</surname><given-names>M</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts</article-title><source>Adv Exp Med Biol</source><year>1991</year><volume>288</volume><fpage>159</fpage><lpage>170</lpage><?supplied-pmid 1950730?><pub-id pub-id-type="pmid">1950730</pub-id></element-citation></ref><ref id="CR373"><mixed-citation publication-type="other">Nukuzuma S, Kameoka M, Sugiura S, Nakamichi K, Nukuzuma C, Miyoshi I, Takegami T (2012) Exogenous human immunodeficiency virus-1 protein, Tat, enhances replication of JC virus efficiently in neuroblastoma cell lines. J Med Virol 84:555&#x02013;561</mixed-citation></ref><ref id="CR374"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehmichen</surname><given-names>M</given-names></name><name><surname>Meissner</surname><given-names>C</given-names></name><name><surname>Reiter</surname><given-names>A</given-names></name><name><surname>Birkholz</surname><given-names>M</given-names></name></person-group><article-title>Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse</article-title><source>Acta Neuropathol</source><year>1996</year><volume>91</volume><fpage>642</fpage><lpage>646</lpage><?supplied-pmid 8781664?><pub-id pub-id-type="pmid">8781664</pub-id></element-citation></ref><ref id="CR375"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Offiah</surname><given-names>C</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name></person-group><article-title>Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy</article-title><source>Clin Radiol</source><year>2008</year><volume>63</volume><fpage>146</fpage><lpage>152</lpage><?supplied-pmid 18194689?><pub-id pub-id-type="pmid">18194689</pub-id></element-citation></ref><ref id="CR376"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>YJ</given-names></name><name><surname>Brechtel</surname><given-names>CW</given-names></name><name><surname>Siviglia</surname><given-names>E</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Clemente</surname><given-names>A</given-names></name><name><surname>Harrop</surname><given-names>A</given-names></name><name><surname>McKercher</surname><given-names>S</given-names></name><name><surname>Kaul</surname><given-names>M</given-names></name><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group><article-title>HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest</article-title><source>Cell Stem Cell</source><year>2007</year><volume>1</volume><fpage>230</fpage><lpage>236</lpage><?supplied-pmid 18371353?><pub-id pub-id-type="pmid">18371353</pub-id></element-citation></ref><ref id="CR377"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallinger</surname><given-names>E</given-names></name><name><surname>Csaba</surname><given-names>G</given-names></name></person-group><article-title>A hormone map of human immune cells showing the presence of adrenocorticotropic hormone, triiodothyronine and endorphin in immunophenotyped white blood cells</article-title><source>Immunology</source><year>2008</year><volume>123</volume><fpage>584</fpage><lpage>589</lpage><?supplied-pmid 18005034?><pub-id pub-id-type="pmid">18005034</pub-id></element-citation></ref><ref id="CR378"><mixed-citation publication-type="other">Paris JJ, Liere P, Kim S, Mahdi F, Buchanan ME, Nass SR, Qrareya AN, Salahuddin MF, Pianos A, Fernandez N, Shariat-Madar Z, Knapp PE, Schumacher M, Hauser KF (2020) Pregnane steroidogenesis is altered by HIV-1 Tat and morphine: physiological allopregnanolone is protective against neurotoxic and psychomotor effects. Neurobiol Stress 12:100211</mixed-citation></ref><ref id="CR379"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname><given-names>GW</given-names></name></person-group><article-title>Multiple opiate receptors: deja vu all over again</article-title><source>Neuropharmacology</source><year>2004</year><volume>47</volume><issue>Suppl 1</issue><fpage>312</fpage><lpage>323</lpage><?supplied-pmid 15464147?><pub-id pub-id-type="pmid">15464147</pub-id></element-citation></ref><ref id="CR380"><mixed-citation publication-type="other">Pasternak GW (2014) Opioids and their receptors: are we there yet? Neuropharmacology 76 Pt B:198-203</mixed-citation></ref><ref id="CR381"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Pan</surname><given-names>YX</given-names></name></person-group><article-title>Mu opioids and their receptors: evolution of a concept</article-title><source>Pharmacol Rev</source><year>2013</year><volume>65</volume><fpage>1257</fpage><lpage>1317</lpage><?supplied-pmid 24076545?><pub-id pub-id-type="pmid">24076545</pub-id></element-citation></ref><ref id="CR382"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Kolesnikov</surname><given-names>YA</given-names></name><name><surname>Babey</surname><given-names>AM</given-names></name></person-group><article-title>Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance</article-title><source>Neuropsychopharmacology</source><year>1995</year><volume>13</volume><fpage>309</fpage><lpage>313</lpage><?supplied-pmid 8747755?><pub-id pub-id-type="pmid">8747755</pub-id></element-citation></ref><ref id="CR383"><mixed-citation publication-type="other">Patel S, Leibrand CR, Palasuberniam P, Couraud PO, Weksler B, Jahr FM, McClay JL, Hauser KF, McRae M (2017) Effects of HIV-1 Tat and methamphetamine on blood-brain barrier integrity and function in vitro. Antimicrob Agents Chemother 61:e01307-e1317</mixed-citation></ref><ref id="CR384"><mixed-citation publication-type="other">Patel SH, Ismaiel OA, Mylott WR Jr, Yuan M, McClay JL, Paris JJ, Hauser KF, McRae M (2019) Cell-type specific differences in antiretroviral penetration and the effects of HIV-1 Tat and morphine among primary human brain endothelial cells, astrocytes, pericytes, and microglia. Neurosci Lett 712:134475</mixed-citation></ref><ref id="CR385"><mixed-citation publication-type="other">Pello OM, Duthey B, Garcia-Bernal D, Rodriguez-Frade JM, Stein JV, Teixido J, Martinez C, Mellado M (2006) Opioids trigger &#x003b1;<sub>5</sub>&#x003b2;<sub>2</sub> integrin-mediated monocyte adhesion. J Immunol 176:1675&#x02013;1685</mixed-citation></ref><ref id="CR386"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendyala</surname><given-names>G</given-names></name><name><surname>Periyasamy</surname><given-names>P</given-names></name><name><surname>Callen</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>HS</given-names></name><name><surname>Lisco</surname><given-names>SJ</given-names></name><name><surname>Buch</surname><given-names>SJ</given-names></name></person-group><article-title>Chronic SIV and morphine treatment increases heat shock protein 5 expression at the synapse</article-title><source>J Neuro-Oncol</source><year>2015</year><volume>21</volume><fpage>592</fpage><lpage>598</lpage></element-citation></ref><ref id="CR387"><mixed-citation publication-type="other">Peng H, Whitney N, Wu Y, Tian C, Dou H, Zhou Y, Zheng J (2008) HIV-1-infected and/or immune-activated macrophage-secreted TNF-&#x003b1; affects human fetal cortical neural progenitor cell proliferation and differentiation. Glia 56:903&#x02013;916</mixed-citation></ref><ref id="CR388"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>B</given-names></name><name><surname>Lan</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>HIV-1-infected and immune-activated macrophages induce astrocytic differentiation of human cortical neural progenitor cells via the STAT3 pathway</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e19439</fpage><?supplied-pmid 21637744?><pub-id pub-id-type="pmid">21637744</pub-id></element-citation></ref><ref id="CR389"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Casanova</surname><given-names>A</given-names></name><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Rivera-Amill</surname><given-names>V</given-names></name><name><surname>Husain</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Morphine-mediated deterioration of oxidative stress leads to rapid disease progression in SIV/SHIV-infected macaques</article-title><source>AIDS Res Hum Retrovir</source><year>2007</year><volume>23</volume><fpage>1004</fpage><lpage>1007</lpage><?supplied-pmid 17725417?><pub-id pub-id-type="pmid">17725417</pub-id></element-citation></ref><ref id="CR390"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Casanova</surname><given-names>A</given-names></name><name><surname>Husain</surname><given-names>K</given-names></name><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Rivera-Amill</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Interaction of SIV/SHIV infection and morphine on plasma oxidant/antioxidant balance in macaque</article-title><source>Mol Cell Biochem</source><year>2008</year><volume>308</volume><fpage>169</fpage><lpage>175</lpage><?supplied-pmid 17934700?><pub-id pub-id-type="pmid">17934700</pub-id></element-citation></ref><ref id="CR391"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>229</fpage><lpage>239</lpage><?supplied-pmid 27468059?><pub-id pub-id-type="pmid">27468059</pub-id></element-citation></ref><ref id="CR392"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Sharp</surname><given-names>BM</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Portoghese</surname><given-names>PS</given-names></name><name><surname>Sannerud</surname><given-names>K</given-names></name><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures</article-title><source>AIDS</source><year>1990</year><volume>4</volume><fpage>869</fpage><lpage>873</lpage><?supplied-pmid 2174676?><pub-id pub-id-type="pmid">2174676</pub-id></element-citation></ref><ref id="CR393"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Schoolov</surname><given-names>Y</given-names></name><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name><name><surname>Chao</surname><given-names>CC</given-names></name></person-group><article-title>Microglial cell upregulation of HIV-1 expression in the chronically infected promonocytic cell line U1: the role of tumor necrosis factor-alpha</article-title><source>J Neuroimmunol</source><year>1992</year><volume>41</volume><fpage>81</fpage><lpage>87</lpage><?supplied-pmid 1460095?><pub-id pub-id-type="pmid">1460095</pub-id></element-citation></ref><ref id="CR394"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Schut</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name><name><surname>Chao</surname><given-names>CC</given-names></name></person-group><article-title>Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection</article-title><source>Adv Exp Med Biol</source><year>1993</year><volume>335</volume><fpage>181</fpage><lpage>188</lpage><?supplied-pmid 8237594?><pub-id pub-id-type="pmid">8237594</pub-id></element-citation></ref><ref id="CR395"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Molitor</surname><given-names>TW</given-names></name><name><surname>Chao</surname><given-names>CC</given-names></name></person-group><article-title>The opioid-cytokine connection</article-title><source>J Neuroimmunol</source><year>1998</year><volume>83</volume><fpage>63</fpage><lpage>69</lpage><?supplied-pmid 9610674?><pub-id pub-id-type="pmid">9610674</pub-id></element-citation></ref><ref id="CR396"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Lokensgard</surname><given-names>J</given-names></name><name><surname>Portoghese</surname><given-names>PS</given-names></name><name><surname>Chao</surname><given-names>CC</given-names></name></person-group><article-title>Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor</article-title><source>Neuropharmacology</source><year>1999</year><volume>38</volume><fpage>273</fpage><lpage>278</lpage><?supplied-pmid 10218868?><pub-id pub-id-type="pmid">10218868</pub-id></element-citation></ref><ref id="CR397"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettes</surname><given-names>T</given-names></name><name><surname>Wood</surname><given-names>E</given-names></name><name><surname>Guillemi</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name><name><surname>Kerr</surname><given-names>T</given-names></name></person-group><article-title>Methadone use among HIV-positive injection drug users in a Canadian setting</article-title><source>J Subst Abus Treat</source><year>2010</year><volume>39</volume><fpage>174</fpage><lpage>179</lpage></element-citation></ref><ref id="CR398"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pezawas</surname><given-names>LM</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Diamant</surname><given-names>K</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Schindler</surname><given-names>SD</given-names></name><name><surname>Thurnher</surname><given-names>M</given-names></name><name><surname>Ploechl</surname><given-names>W</given-names></name><name><surname>Eder</surname><given-names>H</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name></person-group><article-title>Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements</article-title><source>Psychiatry Res</source><year>1998</year><volume>83</volume><fpage>139</fpage><lpage>147</lpage><?supplied-pmid 9849723?><pub-id pub-id-type="pmid">9849723</pub-id></element-citation></ref><ref id="CR399"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitcher</surname><given-names>J</given-names></name><name><surname>Abt</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>R</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Graziano</surname><given-names>A</given-names></name><name><surname>Festa</surname><given-names>L</given-names></name><name><surname>Kutzler</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name><name><surname>Fischer-Smith</surname><given-names>T</given-names></name><name><surname>Rappaport</surname><given-names>J</given-names></name><name><surname>Meucci</surname><given-names>O</given-names></name></person-group><article-title>Neuronal ferritin heavy chain and drug abuse affect HIV-associated cognitive dysfunction</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>656</fpage><lpage>669</lpage><?supplied-pmid 24401274?><pub-id pub-id-type="pmid">24401274</pub-id></element-citation></ref><ref id="CR400"><mixed-citation publication-type="other">Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Hickman M (2016) Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev 2016:CD012021</mixed-citation></ref><ref id="CR401"><mixed-citation publication-type="other">Plotnikoff NP (1988) Opioids: immunomodulators. A proposed role in cancer and aging. Ann N Y Acad Sci 521:312-322</mixed-citation></ref><ref id="CR402"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podhaizer</surname><given-names>EM</given-names></name><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Fitting</surname><given-names>S</given-names></name><name><surname>Samano</surname><given-names>KL</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Morphine and gp120 toxic interactions in striatal neurons are dependent on HIV-1 strain</article-title><source>J NeuroImmune Pharmacol</source><year>2012</year><volume>7</volume><fpage>877</fpage><lpage>891</lpage><?supplied-pmid 22101471?><pub-id pub-id-type="pmid">22101471</pub-id></element-citation></ref><ref id="CR403"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polli</surname><given-names>JW</given-names></name><name><surname>Jarrett</surname><given-names>JL</given-names></name><name><surname>Studenberg</surname><given-names>SD</given-names></name><name><surname>Humphreys</surname><given-names>JE</given-names></name><name><surname>Dennis</surname><given-names>SW</given-names></name><name><surname>Brouwer</surname><given-names>KR</given-names></name><name><surname>Woolley</surname><given-names>JL</given-names></name></person-group><article-title>Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor</article-title><source>Pharm Res</source><year>1999</year><volume>16</volume><fpage>1206</fpage><lpage>1212</lpage><?supplied-pmid 10468021?><pub-id pub-id-type="pmid">10468021</pub-id></element-citation></ref><ref id="CR404"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>RW</given-names></name><name><surname>Brew</surname><given-names>B</given-names></name><name><surname>Sidtis</surname><given-names>J</given-names></name><name><surname>Rosenblum</surname><given-names>M</given-names></name><name><surname>Scheck</surname><given-names>AC</given-names></name><name><surname>Cleary</surname><given-names>P</given-names></name></person-group><article-title>The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex</article-title><source>Science</source><year>1988</year><volume>239</volume><fpage>586</fpage><lpage>592</lpage><?supplied-pmid 3277272?><pub-id pub-id-type="pmid">3277272</pub-id></element-citation></ref><ref id="CR405"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Protass</surname><given-names>LM</given-names></name></person-group><article-title>Delayed postanoxic encephalopathy after heroin use</article-title><source>Ann Intern Med</source><year>1971</year><volume>74</volume><fpage>738</fpage><lpage>739</lpage><?supplied-pmid 5559439?><pub-id pub-id-type="pmid">5559439</pub-id></element-citation></ref><ref id="CR406"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudnikov</surname><given-names>D</given-names></name><name><surname>Randesi</surname><given-names>M</given-names></name><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Crystal</surname><given-names>H</given-names></name><name><surname>Dorn</surname><given-names>M</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><fpage>1745</fpage><lpage>1756</lpage><?supplied-pmid 22457278?><pub-id pub-id-type="pmid">22457278</pub-id></element-citation></ref><ref id="CR407"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudnikov</surname><given-names>D</given-names></name><name><surname>Randesi</surname><given-names>M</given-names></name><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Yuferov</surname><given-names>V</given-names></name><name><surname>Crystal</surname><given-names>H</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history</article-title><source>J Acquir Immune Defic Syndr</source><year>2013</year><volume>63</volume><fpage>17</fpage><lpage>26</lpage><?supplied-pmid 23392455?><pub-id pub-id-type="pmid">23392455</pub-id></element-citation></ref><ref id="CR408"><mixed-citation publication-type="other">Puehler W, Rittner HL, Mousa SA, Brack A, Krause H, Stein C, Schafer M (2006) Interleukin-1 beta contributes to the upregulation of kappa opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation. Neuroscience 141:989&#x02013;998</mixed-citation></ref><ref id="CR409"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>V</given-names></name><name><surname>Rapaka</surname><given-names>RS</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name><name><surname>Shurtleff</surname><given-names>D</given-names></name></person-group><article-title>Do opioids activate latent HIV-1 by down-regulating anti-HIV microRNAs?</article-title><source>J NeuroImmune Pharmacol</source><year>2012</year><volume>7</volume><fpage>519</fpage><lpage>523</lpage><?supplied-pmid 22527633?><pub-id pub-id-type="pmid">22527633</pub-id></element-citation></ref><ref id="CR410"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putatunda</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Barbe</surname><given-names>MF</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name></person-group><article-title>Adult neurogenic deficits in HIV-1 Tg26 transgenic mice</article-title><source>J Neuroinflammation</source><year>2018</year><volume>15</volume><fpage>287</fpage><?supplied-pmid 30314515?><pub-id pub-id-type="pmid">30314515</pub-id></element-citation></ref><ref id="CR411"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putatunda</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>WZ</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name></person-group><article-title>HIV-1 and compromised adult neurogenesis: emerging evidence for a new paradigm of HAND persistence</article-title><source>AIDS Rev</source><year>2019</year><volume>21</volume><fpage>11</fpage><lpage>22</lpage><?supplied-pmid 30899112?><pub-id pub-id-type="pmid">30899112</pub-id></element-citation></ref><ref id="CR412"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Zhuo</surname><given-names>F</given-names></name></person-group><article-title>Progressive white matter microstructure damage in male chronic heroin dependent individuals: a DTI and TBSS study</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e63212</fpage><?supplied-pmid 23650554?><pub-id pub-id-type="pmid">23650554</pub-id></element-citation></ref><ref id="CR413"><mixed-citation publication-type="other">Qureshi A, Lee-Chiong T, Jr. (2004) Medications and their effects on sleep. The medical clinics of North America 88:751&#x02013;766</mixed-citation></ref><ref id="CR414"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radja</surname><given-names>F</given-names></name><name><surname>Kay</surname><given-names>DG</given-names></name><name><surname>Albrecht</surname><given-names>S</given-names></name><name><surname>Jolicoeur</surname><given-names>P</given-names></name></person-group><article-title>Oligodendrocyte-specific expression of human immunodeficiency virus type 1 Nef in transgenic mice leads to vacuolar myelopathy and alters oligodendrocyte phenotype in vitro</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>11745</fpage><lpage>11753</lpage><?supplied-pmid 14557659?><pub-id pub-id-type="pmid">14557659</pub-id></element-citation></ref><ref id="CR415"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragin</surname><given-names>AB</given-names></name><name><surname>Storey</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>BA</given-names></name><name><surname>Epstein</surname><given-names>LG</given-names></name><name><surname>Edelman</surname><given-names>RR</given-names></name></person-group><article-title>Whole brain diffusion tensor imaging in HIV-associated cognitive impairment</article-title><source>AJNR Am J Neuroradiol</source><year>2004</year><volume>25</volume><fpage>195</fpage><lpage>200</lpage><?supplied-pmid 14970017?><pub-id pub-id-type="pmid">14970017</pub-id></element-citation></ref><ref id="CR416"><mixed-citation publication-type="other">Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LG (2005) Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus. J Neurovirol 11(3):292&#x02013;298</mixed-citation></ref><ref id="CR417"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramage</surname><given-names>SN</given-names></name><name><surname>Anthony</surname><given-names>IC</given-names></name><name><surname>Carnie</surname><given-names>FW</given-names></name><name><surname>Busuttil</surname><given-names>A</given-names></name><name><surname>Robertson</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name></person-group><article-title>Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers</article-title><source>Neuropathol Appl Neurobiol</source><year>2005</year><volume>31</volume><fpage>439</fpage><lpage>448</lpage><?supplied-pmid 16008828?><pub-id pub-id-type="pmid">16008828</pub-id></element-citation></ref><ref id="CR418"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranga</surname><given-names>U</given-names></name><name><surname>Shankarappa</surname><given-names>R</given-names></name><name><surname>Siddappa</surname><given-names>NB</given-names></name><name><surname>Ramakrishna</surname><given-names>L</given-names></name><name><surname>Nagendran</surname><given-names>R</given-names></name><name><surname>Mahalingam</surname><given-names>M</given-names></name><name><surname>Mahadevan</surname><given-names>A</given-names></name><name><surname>Jayasuryan</surname><given-names>N</given-names></name><name><surname>Satishchandra</surname><given-names>P</given-names></name><name><surname>Shankar</surname><given-names>SK</given-names></name><name><surname>Prasad</surname><given-names>VR</given-names></name></person-group><article-title>Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>2586</fpage><lpage>2590</lpage><?supplied-pmid 14963162?><pub-id pub-id-type="pmid">14963162</pub-id></element-citation></ref><ref id="CR419"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>VR</given-names></name><name><surname>Sas</surname><given-names>AR</given-names></name><name><surname>Eugenin</surname><given-names>EA</given-names></name><name><surname>Siddappa</surname><given-names>NB</given-names></name><name><surname>Bimonte-Nelson</surname><given-names>H</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name><name><surname>Ranga</surname><given-names>U</given-names></name><name><surname>Tyor</surname><given-names>WR</given-names></name><name><surname>Prasad</surname><given-names>VR</given-names></name></person-group><article-title>HIV-1 clade-specific differences in the induction of neuropathogenesis</article-title><source>J Neurosci</source><year>2008</year><volume>28</volume><fpage>10010</fpage><lpage>10016</lpage><?supplied-pmid 18829958?><pub-id pub-id-type="pmid">18829958</pub-id></element-citation></ref><ref id="CR420"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>VR</given-names></name><name><surname>Neogi</surname><given-names>U</given-names></name><name><surname>Talboom</surname><given-names>JS</given-names></name><name><surname>Padilla</surname><given-names>L</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Fritz-French</surname><given-names>C</given-names></name><name><surname>Gonzalez-Ramirez</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>C</given-names></name><name><surname>Ruprecht</surname><given-names>RM</given-names></name><name><surname>Ranga</surname><given-names>U</given-names></name><name><surname>Azim</surname><given-names>T</given-names></name><name><surname>Joska</surname><given-names>J</given-names></name><name><surname>Eugenin</surname><given-names>E</given-names></name><name><surname>Shet</surname><given-names>A</given-names></name><name><surname>Bimonte-Nelson</surname><given-names>H</given-names></name><name><surname>Tyor</surname><given-names>WR</given-names></name><name><surname>Prasad</surname><given-names>VR</given-names></name></person-group><article-title>Clade C HIV-1 isolates circulating in southern Africa exhibit a greater frequency of dicysteine motif-containing tat variants than those in Southeast Asia and cause increased neurovirulence</article-title><source>Retrovirology</source><year>2013</year><volume>10</volume><fpage>61</fpage><?supplied-pmid 23758766?><pub-id pub-id-type="pmid">23758766</pub-id></element-citation></ref><ref id="CR421"><mixed-citation publication-type="other">Rappaport J, Volsky DJ (2015) Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment. J Neurovirol 21(3):235&#x02013;241</mixed-citation></ref><ref id="CR422"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PV</given-names></name><name><surname>Pilakka-Kanthikeel</surname><given-names>S</given-names></name><name><surname>Saxena</surname><given-names>SK</given-names></name><name><surname>Saiyed</surname><given-names>Z</given-names></name><name><surname>Nair</surname><given-names>MP</given-names></name></person-group><article-title>Interactive effects of morphine on HIV infection: role in HIV-associated neurocognitive disorder</article-title><source>AIDS research and treatment</source><year>2012</year><volume>2012</volume><fpage>953678</fpage><?supplied-pmid 22666564?><pub-id pub-id-type="pmid">22666564</pub-id></element-citation></ref><ref id="CR423"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>PM</given-names></name><name><surname>Dave</surname><given-names>RS</given-names></name><name><surname>Datta</surname><given-names>PK</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name></person-group><article-title>Epigenetics of &#x000b5;-opioid receptors: intersection with HIV-1 infection of the central nervous system</article-title><source>J Cell Physiol</source><year>2012</year><volume>227</volume><fpage>2832</fpage><lpage>2841</lpage><?supplied-pmid 22034138?><pub-id pub-id-type="pmid">22034138</pub-id></element-citation></ref><ref id="CR424"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittner</surname><given-names>HL</given-names></name><name><surname>Brack</surname><given-names>A</given-names></name><name><surname>Machelska</surname><given-names>H</given-names></name><name><surname>Mousa</surname><given-names>SA</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Schafer</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>C</given-names></name></person-group><article-title>Opioid peptide-expressing leukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain</article-title><source>Anesthesiology</source><year>2001</year><volume>95</volume><fpage>500</fpage><lpage>508</lpage><?supplied-pmid 11506126?><pub-id pub-id-type="pmid">11506126</pub-id></element-citation></ref><ref id="CR425"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittner</surname><given-names>HL</given-names></name><name><surname>Brack</surname><given-names>A</given-names></name><name><surname>Stein</surname><given-names>C</given-names></name></person-group><article-title>Pain and the immune system</article-title><source>Br J Anaesth</source><year>2008</year><volume>101</volume><fpage>40</fpage><lpage>44</lpage><?supplied-pmid 18397920?><pub-id pub-id-type="pmid">18397920</pub-id></element-citation></ref><ref id="CR426"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>I</given-names></name><name><surname>Garcia</surname><given-names>Y</given-names></name><name><surname>Gangwani</surname><given-names>MR</given-names></name><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Maldonado</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Rivera-Amill</surname><given-names>V</given-names></name></person-group><article-title>Identification and molecular characterization of SIV Vpr R50G mutation associated with long term survival in SIV-infected morphine dependent and control macaques</article-title><source>Virology</source><year>2013</year><volume>446</volume><fpage>144</fpage><lpage>151</lpage><?supplied-pmid 24074576?><pub-id pub-id-type="pmid">24074576</pub-id></element-citation></ref><ref id="CR427"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera-Amill</surname><given-names>V</given-names></name><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Orsini</surname><given-names>S</given-names></name><name><surname>Tirado</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>JM</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV</article-title><source>Virology</source><year>2007</year><volume>358</volume><fpage>373</fpage><lpage>383</lpage><?supplied-pmid 17011009?><pub-id pub-id-type="pmid">17011009</pub-id></element-citation></ref><ref id="CR428"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera-Amill</surname><given-names>V</given-names></name><name><surname>Silverstein</surname><given-names>PS</given-names></name><name><surname>Noel</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Morphine and rapid disease progression in nonhuman primate model of AIDS: inverse correlation between disease progression and virus evolution</article-title><source>J NeuroImmune Pharmacol</source><year>2010</year><volume>5</volume><fpage>122</fpage><lpage>132</lpage><?supplied-pmid 20013315?><pub-id pub-id-type="pmid">20013315</pub-id></element-citation></ref><ref id="CR429"><mixed-citation publication-type="other">Rivera-Amill V, Noel RJ Jr, Garcia Y, Rivera I, Iszard M, Buch S, Kumar A (2010b) Accelerated evolution of SIV <italic>env</italic> within the cerebral compartment in the setting of morphine-dependent rapid disease progression. Virology 398:201&#x02013;207</mixed-citation></ref><ref id="CR430"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>D</given-names></name><name><surname>Wolfarth</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>C</given-names></name><name><surname>Pehrson</surname><given-names>AL</given-names></name></person-group><article-title>Frontal cortex dysfunction as a target for remediation in opiate use disorder: role in cognitive dysfunction and disordered reward systems</article-title><source>Prog Brain Res</source><year>2018</year><volume>239</volume><fpage>179</fpage><lpage>227</lpage><?supplied-pmid 30314567?><pub-id pub-id-type="pmid">30314567</pub-id></element-citation></ref><ref id="CR431"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson-Papp</surname><given-names>J</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Vaida</surname><given-names>F</given-names></name><name><surname>Fitzsimons</surname><given-names>C</given-names></name><name><surname>Simpson</surname><given-names>DM</given-names></name><name><surname>Elliott</surname><given-names>KJ</given-names></name><name><surname>Al-Lozi</surname><given-names>M</given-names></name><name><surname>Gelman</surname><given-names>BB</given-names></name><name><surname>Clifford</surname><given-names>D</given-names></name><name><surname>Marra</surname><given-names>CM</given-names></name><name><surname>McCutchan</surname><given-names>JA</given-names></name><name><surname>Atkinson</surname><given-names>JH</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name></person-group><article-title>Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy</article-title><source>Pain</source><year>2010</year><volume>151</volume><fpage>732</fpage><lpage>736</lpage><?supplied-pmid 20851521?><pub-id pub-id-type="pmid">20851521</pub-id></element-citation></ref><ref id="CR432"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez Salgado</surname><given-names>D</given-names></name><name><surname>Rodriguez Alvarez</surname><given-names>M</given-names></name><name><surname>Seoane Pesqueira</surname><given-names>G</given-names></name></person-group><article-title>Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users</article-title><source>Cogn Behav Neurol</source><year>2006</year><volume>19</volume><fpage>95</fpage><lpage>104</lpage><?supplied-pmid 16783132?><pub-id pub-id-type="pmid">16783132</pub-id></element-citation></ref><ref id="CR433"><mixed-citation publication-type="other">Rodriguez M, Lapierre J, Ojha CR, Estrada-Bueno H, Dever SM, Gewirtz DA, Kashanchi F, El-Hage N (2017) Importance of autophagy in mediating human immunodeficiency virus (HIV) and morphine-induced metabolic dysfunction and inflammation in human astrocytes. Viruses 9:201</mixed-citation></ref><ref id="CR434"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name></person-group><article-title>Opioid G protein-coupled receptors: signals at the crossroads of inflammation</article-title><source>Trends Immunol</source><year>2003</year><volume>24</volume><fpage>116</fpage><lpage>121</lpage><?supplied-pmid 12615205?><pub-id pub-id-type="pmid">12615205</pub-id></element-citation></ref><ref id="CR435"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>TJ</given-names></name><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Howard</surname><given-names>OM</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name></person-group><article-title>Bidirectional heterologous desensitization of opioid and chemokine receptors</article-title><source>Ann N Y Acad Sci</source><year>2000</year><volume>917</volume><fpage>19</fpage><lpage>28</lpage><?supplied-pmid 11268344?><pub-id pub-id-type="pmid">11268344</pub-id></element-citation></ref><ref id="CR436"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenaigner</surname><given-names>I</given-names></name><name><surname>Kramer</surname><given-names>S</given-names></name><name><surname>Ziegler</surname><given-names>M</given-names></name><name><surname>Wolff</surname><given-names>H</given-names></name><name><surname>Kleinschmidt</surname><given-names>A</given-names></name><name><surname>Brack-Werner</surname><given-names>R</given-names></name></person-group><article-title>Long-term HIV-1 infection of neural progenitor populations</article-title><source>AIDS</source><year>2007</year><volume>21</volume><fpage>2271</fpage><lpage>2281</lpage><?supplied-pmid 18090275?><pub-id pub-id-type="pmid">18090275</pub-id></element-citation></ref><ref id="CR437"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouveix</surname><given-names>B</given-names></name></person-group><article-title>Opiates and immune function. Consequences on infectious diseases with special reference to AIDS</article-title><source>Therapie</source><year>1992</year><volume>47</volume><fpage>503</fpage><lpage>512</lpage><?supplied-pmid 1301643?><pub-id pub-id-type="pmid">1301643</pub-id></element-citation></ref><ref id="CR438"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kelschenbach</surname><given-names>J</given-names></name><name><surname>Koodie</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name></person-group><article-title>Modulation of immune function by morphine: implications for susceptibility to infection</article-title><source>J NeuroImmune Pharmacol</source><year>2006</year><volume>1</volume><fpage>77</fpage><lpage>89</lpage><?supplied-pmid 18040793?><pub-id pub-id-type="pmid">18040793</pub-id></element-citation></ref><ref id="CR439"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royal</surname><given-names>W</given-names><suffix>3rd</suffix></name><name><surname>Updike</surname><given-names>M</given-names></name><name><surname>Selnes</surname><given-names>OA</given-names></name><name><surname>Proctor</surname><given-names>TV</given-names></name><name><surname>Nance-Sproson</surname><given-names>L</given-names></name><name><surname>Solomon</surname><given-names>L</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Cornblath</surname><given-names>DR</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group><article-title>HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>1905</fpage><lpage>1910</lpage><?supplied-pmid 1745346?><pub-id pub-id-type="pmid">1745346</pub-id></element-citation></ref><ref id="CR440"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>LH</given-names></name><name><surname>Radtke</surname><given-names>KK</given-names></name><name><surname>Eum</surname><given-names>S</given-names></name><name><surname>Tamraz</surname><given-names>B</given-names></name><name><surname>Kumanan</surname><given-names>KN</given-names></name><name><surname>Springer</surname><given-names>G</given-names></name><name><surname>Maki</surname><given-names>PM</given-names></name><name><surname>Anastos</surname><given-names>K</given-names></name><name><surname>Merenstein</surname><given-names>D</given-names></name><name><surname>Karim</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>KM</given-names></name><name><surname>Gustafson</surname><given-names>D</given-names></name><name><surname>Greenblatt</surname><given-names>RM</given-names></name><name><surname>Bishop</surname><given-names>JR</given-names></name></person-group><article-title>Cognitive burden of common non-antiretroviral medications in HIV-infected women</article-title><source>J Acquir Immune Defic Syndr</source><year>2018</year><volume>79</volume><fpage>83</fpage><lpage>91</lpage><?supplied-pmid 29781879?><pub-id pub-id-type="pmid">29781879</pub-id></element-citation></ref><ref id="CR441"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>RA</given-names></name><name><surname>Chojnacki</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>DM</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Do</surname><given-names>T</given-names></name><name><surname>Eggeling</surname><given-names>C</given-names></name><name><surname>Padilla-Parra</surname><given-names>S</given-names></name><name><surname>Sattentau</surname><given-names>QJ</given-names></name></person-group><article-title>Astrocytes resist HIV-1 fusion but engulf infected macrophage material</article-title><source>Cell Rep</source><year>2017</year><volume>18</volume><fpage>1473</fpage><lpage>1483</lpage><?supplied-pmid 28178524?><pub-id pub-id-type="pmid">28178524</pub-id></element-citation></ref><ref id="CR442"><mixed-citation publication-type="other">Ruzicka BB, Akil H (1997) The interleukin-1&#x003b2;-mediated regulation of proenkephalin and opioid receptor messenger RNA in primary astrocyte-enriched cultures. Neuroscience 79:517&#x02013;524</mixed-citation></ref><ref id="CR443"><mixed-citation publication-type="other">Ruzicka BB, Fox CA, Thompson RC, Meng F, Watson SJ, Akil H (1995) Primary astroglial cultures derived from several rat brain regions differentially express &#x003bc;, &#x003b4;, and &#x003ba; opioid receptor mRNA. Brain Res Mol Brain Res 34:209&#x02013;220</mixed-citation></ref><ref id="CR444"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>LA</given-names></name><name><surname>Brester</surname><given-names>M</given-names></name><name><surname>Bohac</surname><given-names>D</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>Up-regulation of soluble tumor necrosis factor receptor two in plasma of HIV-seropositive individuals who use opiates</article-title><source>AIDS Res Hum Retrovir</source><year>2004</year><volume>20</volume><fpage>41</fpage><lpage>45</lpage><?supplied-pmid 15000697?><pub-id pub-id-type="pmid">15000697</pub-id></element-citation></ref><ref id="CR445"><mixed-citation publication-type="other">Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford DB, Laeyendecker O, Quinn TC (2009) HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 49:780&#x02013;786</mixed-citation></ref><ref id="CR446"><mixed-citation publication-type="other">Salahuddin MF, Qrareya AN, Mahdi F, Jackson D, Foster M, Vujanovic T, Box JG, Paris JJ (2020) Combined HIV-1 Tat and oxycodone activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor, affective, and cognitive dysfunction in female mice. Horm Behav 119:104649</mixed-citation></ref><ref id="CR447"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvemini</surname><given-names>D</given-names></name></person-group><article-title>Peroxynitrite and opiate antinociceptive tolerance: a painful reality</article-title><source>Arch Biochem Biophys</source><year>2009</year><volume>484</volume><fpage>238</fpage><lpage>244</lpage><?supplied-pmid 19017525?><pub-id pub-id-type="pmid">19017525</pub-id></element-citation></ref><ref id="CR448"><mixed-citation publication-type="other">Samikkannu T, Agudelo M, Gandhi N, Reddy PV, Saiyed ZM, Nwankwo D, Nair MP (2011) Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS. J Neurovirol 17:230&#x02013;238</mixed-citation></ref><ref id="CR449"><mixed-citation publication-type="other">Samoshkin A, Convertino M, Viet CT, Wieskopf JS, Kambur O, Marcovitz J, Patel P, Stone LS, Kalso E, Mogil JS, Schmidt BL, Maixner W, Dokholyan NV, Diatchenko L (2015) Structural and functional interactions between six-transmembrane &#x003bc;-opioid receptors and &#x003b2;2-adrenoreceptors modulate opioid signaling. Sci Rep 5:18198</mixed-citation></ref><ref id="CR450"><mixed-citation publication-type="other">Samuels EA, Clark SA, Wunsch C, Keeler LAJ, Reddy N, Vanjani R, Wightman RS (2020) Innovation during COVID-19: improving addiction treatment access. J Addict Med 14:e8&#x02013;e9. 10.1097/ADM.0000000000000685</mixed-citation></ref><ref id="CR451"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>ES</given-names></name><name><surname>Bigbee</surname><given-names>JW</given-names></name><name><surname>Fobbs</surname><given-names>W</given-names></name><name><surname>Robinson</surname><given-names>SE</given-names></name><name><surname>Sato-Bigbee</surname><given-names>C</given-names></name></person-group><article-title>Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain</article-title><source>Glia</source><year>2008</year><volume>56</volume><fpage>1017</fpage><lpage>1027</lpage><?supplied-pmid 18381654?><pub-id pub-id-type="pmid">18381654</pub-id></element-citation></ref><ref id="CR452"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkisyan</surname><given-names>D</given-names></name><name><surname>Hussain</surname><given-names>MZ</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Kononenko</surname><given-names>O</given-names></name><name><surname>Bazov</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Yamskova</surname><given-names>O</given-names></name><name><surname>Krishtal</surname><given-names>O</given-names></name><name><surname>Karpyak</surname><given-names>VM</given-names></name><name><surname>Yakovleva</surname><given-names>T</given-names></name><name><surname>Bakalkin</surname><given-names>G</given-names></name></person-group><article-title>Downregulation of the endogenous opioid peptides in the dorsal striatum of human alcoholics</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>9</volume><fpage>187</fpage><?supplied-pmid 26029055?><pub-id pub-id-type="pmid">26029055</pub-id></element-citation></ref><ref id="CR453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauriyal</surname><given-names>DS</given-names></name><name><surname>Jaggi</surname><given-names>AS</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Extending pharmacological spectrum of opioids beyond analgesia: multifunctional aspects in different pathophysiological states</article-title><source>Neuropeptides</source><year>2011</year><volume>45</volume><fpage>175</fpage><lpage>188</lpage><?supplied-pmid 21208657?><pub-id pub-id-type="pmid">21208657</pub-id></element-citation></ref><ref id="CR454"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saylor</surname><given-names>D</given-names></name><name><surname>Dickens</surname><given-names>AM</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>Haughey</surname><given-names>N</given-names></name><name><surname>Slusher</surname><given-names>B</given-names></name><name><surname>Pletnikov</surname><given-names>M</given-names></name><name><surname>Mankowski</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Volsky</surname><given-names>DJ</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name></person-group><article-title>HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><fpage>234</fpage><lpage>248</lpage><?supplied-pmid 26965674?><pub-id pub-id-type="pmid">26965674</pub-id></element-citation></ref><ref id="CR455"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmaal</surname><given-names>L</given-names></name><name><surname>van Velzen</surname><given-names>LS</given-names></name></person-group><article-title>Deficits in white matter microstructure in Major depressive disorder: cause, consequence, or correlate?</article-title><source>Biol Psychiatry</source><year>2019</year><volume>86</volume><fpage>734</fpage><lpage>735</lpage><?supplied-pmid 31648680?><pub-id pub-id-type="pmid">31648680</pub-id></element-citation></ref><ref id="CR456"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>L</given-names></name><name><surname>Seth</surname><given-names>P</given-names></name><name><surname>Kariisa</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>N</given-names></name><name><surname>Baldwin</surname><given-names>G</given-names></name></person-group><article-title>Drug and opioid-involved overdose deaths - United States, 2013-2017</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2018</year><volume>67</volume><fpage>1419</fpage><lpage>1427</lpage><?supplied-pmid 30605448?><pub-id pub-id-type="pmid">30605448</pub-id></element-citation></ref><ref id="CR457"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name></person-group><article-title>Neural progenitors and HIV-1-associated central nervous system disease in adults and children</article-title><source>Curr HIV Res</source><year>2006</year><volume>4</volume><fpage>319</fpage><lpage>327</lpage><?supplied-pmid 16842084?><pub-id pub-id-type="pmid">16842084</pub-id></element-citation></ref><ref id="CR458"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Civitello</surname><given-names>L</given-names></name><name><surname>Dunn-Pirio</surname><given-names>A</given-names></name><name><surname>Ryschkewitsch</surname><given-names>S</given-names></name><name><surname>Berry</surname><given-names>E</given-names></name><name><surname>Cavert</surname><given-names>W</given-names></name><name><surname>Kinzel</surname><given-names>N</given-names></name><name><surname>Lawrence</surname><given-names>DM</given-names></name><name><surname>Hazra</surname><given-names>R</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name></person-group><article-title>Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue</article-title><source>J Neuro-Oncol</source><year>2007</year><volume>13</volume><fpage>274</fpage><lpage>283</lpage></element-citation></ref><ref id="CR459"><mixed-citation publication-type="other">Secretary &#x02013; United States Department of Health and Human Services (2017) Determination that a public health emergency exists. <ext-link ext-link-type="uri" xlink:href="https://www.hhs.gov/sites/default/files/opioid%20PHE%20Declaration-no-sig.pdf">https://www.hhs.gov/sites/default/files/opioid%20PHE%20Declaration-no-sig.pdf</ext-link></mixed-citation></ref><ref id="CR460"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>RA</given-names></name><name><surname>Pryce</surname><given-names>KD</given-names></name><name><surname>Zachariou</surname><given-names>V</given-names></name></person-group><article-title>The mesolimbic dopamine system in chronic pain and associated affective comorbidities</article-title><source>Biol Psychiatry</source><year>2020</year><volume>87</volume><fpage>64</fpage><lpage>73</lpage><?supplied-pmid 31806085?><pub-id pub-id-type="pmid">31806085</pub-id></element-citation></ref><ref id="CR461"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>HS</given-names></name><name><surname>Ali</surname><given-names>SF</given-names></name></person-group><article-title>Alterations in blood-brain barrier function by morphine and methamphetamine</article-title><source>Ann N Y Acad Sci</source><year>2006</year><volume>1074</volume><fpage>198</fpage><lpage>224</lpage><?supplied-pmid 17105918?><pub-id pub-id-type="pmid">17105918</pub-id></element-citation></ref><ref id="CR462"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Klee</surname><given-names>WA</given-names></name><name><surname>Nirenberg</surname><given-names>M</given-names></name></person-group><article-title>Opiate-dependent modulation of adenylate cyclase</article-title><source>Proc Natl Acad Sci U S A</source><year>1977</year><volume>74</volume><fpage>3365</fpage><lpage>3369</lpage><?supplied-pmid 269396?><pub-id pub-id-type="pmid">269396</pub-id></element-citation></ref><ref id="CR463"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>WS</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Gekker</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>PK</given-names></name><name><surname>Chao</surname><given-names>CC</given-names></name></person-group><article-title>Immunomodulatory role of opioids in the central nervous system</article-title><source>Arch Immunol Ther Exp</source><year>1997</year><volume>45</volume><fpage>359</fpage><lpage>366</lpage></element-citation></ref><ref id="CR464"><mixed-citation publication-type="other">Sheng WS, Hu S, Lokensgard JR, Peterson PK (2003) U50,488 inhibits HIV-1 Tat-induced monocyte chemoattractant protein-1 (CCL2) production by human astrocytes. Biochem Pharmacol 65:9&#x02013;14</mixed-citation></ref><ref id="CR465"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinoda</surname><given-names>H</given-names></name><name><surname>Marini</surname><given-names>AM</given-names></name><name><surname>Cosi</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>JP</given-names></name></person-group><article-title>Brain region and gene specificity of neuropeptide gene expression in cultured astrocytes</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>415</fpage><lpage>417</lpage><?supplied-pmid 2569236?><pub-id pub-id-type="pmid">2569236</pub-id></element-citation></ref><ref id="CR466"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrot</surname><given-names>S</given-names></name><name><surname>Poretti</surname><given-names>A</given-names></name><name><surname>Tucker</surname><given-names>EW</given-names></name><name><surname>Soares</surname><given-names>BP</given-names></name><name><surname>Huisman</surname><given-names>TA</given-names></name></person-group><article-title>Acute brain injury following illicit drug abuse in adolescent and young adult patients: spectrum of neuroimaging findings</article-title><source>Neuroradiol J</source><year>2017</year><volume>30</volume><fpage>144</fpage><lpage>150</lpage><?supplied-pmid 28424016?><pub-id pub-id-type="pmid">28424016</pub-id></element-citation></ref><ref id="CR467"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>CH</given-names></name><name><surname>O'Dowd</surname><given-names>MA</given-names></name><name><surname>Chartock</surname><given-names>P</given-names></name><name><surname>Schoenbaum</surname><given-names>EE</given-names></name><name><surname>Friedland</surname><given-names>G</given-names></name><name><surname>Hartel</surname><given-names>D</given-names></name><name><surname>McKegney</surname><given-names>FP</given-names></name></person-group><article-title>A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients</article-title><source>Gen Hosp Psychiatry</source><year>1993</year><volume>15</volume><fpage>351</fpage><lpage>359</lpage><?supplied-pmid 8112557?><pub-id pub-id-type="pmid">8112557</pub-id></element-citation></ref><ref id="CR468"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>BF</given-names></name></person-group><article-title>Diverse characteristics of addiction necessitate multiple preclinical models</article-title><source>Biol Psychiatry</source><year>2019</year><volume>86</volume><fpage>e43</fpage><lpage>e45</lpage><?supplied-pmid 31668223?><pub-id pub-id-type="pmid">31668223</pub-id></element-citation></ref><ref id="CR469"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>KK</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name></person-group><article-title>Host genetic determinants of human immunodeficiency virus infection and disease progression in children</article-title><source>Pediatr Res</source><year>2009</year><volume>65</volume><fpage>55R</fpage><lpage>63R</lpage><?supplied-pmid 19190524?><pub-id pub-id-type="pmid">19190524</pub-id></element-citation></ref><ref id="CR470"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjogren</surname><given-names>P</given-names></name><name><surname>Thomsen</surname><given-names>AB</given-names></name><name><surname>Olsen</surname><given-names>AK</given-names></name></person-group><article-title>Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy</article-title><source>J Pain Symptom Manag</source><year>2000</year><volume>19</volume><fpage>100</fpage><lpage>108</lpage></element-citation></ref><ref id="CR471"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JE</given-names></name><name><surname>Co</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>ME</given-names></name><name><surname>Lane</surname><given-names>JD</given-names></name></person-group><article-title>Brain neurotransmitter turnover correlated with morphine-seeking behavior of rats</article-title><source>Pharmacol Biochem Behav</source><year>1982</year><volume>16</volume><fpage>509</fpage><lpage>519</lpage><?supplied-pmid 6123120?><pub-id pub-id-type="pmid">6123120</pub-id></element-citation></ref><ref id="CR472"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JE</given-names></name><name><surname>Co</surname><given-names>C</given-names></name><name><surname>Lane</surname><given-names>JD</given-names></name></person-group><article-title>Limbic acetylcholine turnover rates correlated with rat morphine-seeking behaviors</article-title><source>Pharmacol Biochem Behav</source><year>1984</year><volume>20</volume><fpage>429</fpage><lpage>442</lpage><?supplied-pmid 6538688?><pub-id pub-id-type="pmid">6538688</pub-id></element-citation></ref><ref id="CR473"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MW</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Winkler</surname><given-names>C</given-names></name><name><surname>Huttley</surname><given-names>GA</given-names></name><name><surname>Lomb</surname><given-names>DA</given-names></name><name><surname>Goedert</surname><given-names>JJ</given-names></name><name><surname>O'Brien</surname><given-names>TR</given-names></name><name><surname>Jacobson</surname><given-names>LP</given-names></name><name><surname>Kaslow</surname><given-names>R</given-names></name><name><surname>Buchbinder</surname><given-names>S</given-names></name><name><surname>Vittinghoff</surname><given-names>E</given-names></name><name><surname>Vlahov</surname><given-names>D</given-names></name><name><surname>Hoots</surname><given-names>K</given-names></name><name><surname>Hilgartner</surname><given-names>MW</given-names></name><name><surname>O'Brien</surname><given-names>SJ</given-names></name></person-group><article-title>Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco City Cohort (SFCC), ALIVE study</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>959</fpage><lpage>965</lpage><?supplied-pmid 9252328?><pub-id pub-id-type="pmid">9252328</pub-id></element-citation></ref><ref id="CR474"><mixed-citation publication-type="other">Smith DB, Simmonds P, Bell JE (2014) Brain viral burden, neuroinflammation and neurodegeneration in HAART-treated HIV positive injecting drug users. J Neurovirol 20:28&#x02013;38</mixed-citation></ref><ref id="CR475"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solbrig</surname><given-names>MV</given-names></name><name><surname>Koob</surname><given-names>GF</given-names></name></person-group><article-title>Epilepsy, CNS viral injury and dynorphin</article-title><source>Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><fpage>98</fpage><lpage>104</lpage><?supplied-pmid 15102496?><pub-id pub-id-type="pmid">15102496</pub-id></element-citation></ref><ref id="CR476"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Rahim</surname><given-names>RT</given-names></name><name><surname>Davey</surname><given-names>PC</given-names></name><name><surname>Bednar</surname><given-names>F</given-names></name><name><surname>Bardi</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name></person-group><article-title>Protein kinase C&#x003b6; mediates &#x000b5;-opioid receptor-induced cross-desensitization of chemokine receptor CCR5</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>20354</fpage><lpage>20365</lpage><?supplied-pmid 21454526?><pub-id pub-id-type="pmid">21454526</pub-id></element-citation></ref><ref id="CR477"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrell</surname><given-names>ME</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Ligand-gated purinergic receptors regulate HIV-1 tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures</article-title><source>J NeuroImmune Pharmacol</source><year>2014</year><volume>9</volume><fpage>233</fpage><lpage>244</lpage><?supplied-pmid 24158495?><pub-id pub-id-type="pmid">24158495</pub-id></element-citation></ref><ref id="CR478"><mixed-citation publication-type="other">Spruce BA, Curtis R, Wilkin GP, Glover DM (1990) A neuropeptide precursor in cerebellum: proenkephalin exists in subpopulations of both neurons and astrocytes. EMBO J 9(6):1787&#x02013;1795</mixed-citation></ref><ref id="CR479"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squinto</surname><given-names>SP</given-names></name><name><surname>Mondal</surname><given-names>D</given-names></name><name><surname>Block</surname><given-names>AL</given-names></name><name><surname>Prakash</surname><given-names>O</given-names></name></person-group><article-title>Morphine-induced transactivation of HIV-1 LTR in human neuroblastoma cells</article-title><source>AIDS Res Hum Retrovir</source><year>1990</year><volume>6</volume><fpage>1163</fpage><lpage>1168</lpage><?supplied-pmid 2252636?><pub-id pub-id-type="pmid">2252636</pub-id></element-citation></ref><ref id="CR480"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Szabo</surname><given-names>I</given-names></name><name><surname>Bednar</surname><given-names>F</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name></person-group><article-title>Interactions between opioid and chemokine receptors: heterologous desensitization</article-title><source>Cytokine Growth Factor Rev</source><year>2002</year><volume>13</volume><fpage>209</fpage><lpage>222</lpage><?supplied-pmid 12486875?><pub-id pub-id-type="pmid">12486875</pub-id></element-citation></ref><ref id="CR481"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Henderson</surname><given-names>EE</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name></person-group><article-title>Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication</article-title><source>Virology</source><year>2003</year><volume>309</volume><fpage>99</fpage><lpage>107</lpage><?supplied-pmid 12726730?><pub-id pub-id-type="pmid">12726730</pub-id></element-citation></ref><ref id="CR482"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>C</given-names></name><name><surname>Schafer</surname><given-names>M</given-names></name><name><surname>Machelska</surname><given-names>H</given-names></name></person-group><article-title>Attacking pain at its source: new perspectives on opioids</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>1003</fpage><lpage>1008</lpage><?supplied-pmid 12894165?><pub-id pub-id-type="pmid">12894165</pub-id></element-citation></ref><ref id="CR483"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>CW</given-names></name><name><surname>Aravind</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>RL</given-names></name></person-group><article-title>Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4</article-title><source>Br J Pharmacol</source><year>2013</year><volume>168</volume><fpage>1421</fpage><lpage>1429</lpage><?supplied-pmid 23083095?><pub-id pub-id-type="pmid">23083095</pub-id></element-citation></ref><ref id="CR484"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro</article-title><source>J Neurosci Res</source><year>1991</year><volume>29</volume><fpage>538</fpage><lpage>548</lpage><?supplied-pmid 1665190?><pub-id pub-id-type="pmid">1665190</pub-id></element-citation></ref><ref id="CR485"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Opiates selectively increase intracellular calcium in developing type-1 astrocytes: role of calcium in morphine-induced morphologic differentiation</article-title><source>Brain Res Dev Brain Res</source><year>1993</year><volume>76</volume><fpage>189</fpage><lpage>196</lpage><?supplied-pmid 8149585?><pub-id pub-id-type="pmid">8149585</pub-id></element-citation></ref><ref id="CR486"><mixed-citation publication-type="other">Stiene-Martin A, Zhou R, Hauser KF (1998) Regional, developmental, and cell cycle-dependent differences in &#x003bc;, &#x003b4;, and &#x003ba;-opioid receptor expression among cultured mouse astrocytes. Glia 22:249&#x02013;259</mixed-citation></ref><ref id="CR487"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiene-Martin</surname><given-names>A</given-names></name><name><surname>Knapp</surname><given-names>PE</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Gurwell</surname><given-names>JA</given-names></name><name><surname>Ryan</surname><given-names>S</given-names></name><name><surname>Thornton</surname><given-names>SR</given-names></name><name><surname>Smith</surname><given-names>FL</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo</article-title><source>Glia</source><year>2001</year><volume>36</volume><fpage>78</fpage><lpage>88</lpage><?supplied-pmid 11571786?><pub-id pub-id-type="pmid">11571786</pub-id></element-citation></ref><ref id="CR488"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strathdee</surname><given-names>SA</given-names></name><name><surname>Beyrer</surname><given-names>C</given-names></name></person-group><article-title>Threading the needle--how to stop the HIV outbreak in rural Indiana</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>397</fpage><lpage>399</lpage><?supplied-pmid 26106947?><pub-id pub-id-type="pmid">26106947</pub-id></element-citation></ref><ref id="CR489"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strazza</surname><given-names>M</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Alexaki</surname><given-names>A</given-names></name><name><surname>Passic</surname><given-names>SR</given-names></name><name><surname>Meucci</surname><given-names>O</given-names></name><name><surname>Pirrone</surname><given-names>V</given-names></name><name><surname>Wigdahl</surname><given-names>B</given-names></name><name><surname>Nonnemacher</surname><given-names>MR</given-names></name></person-group><article-title>Effect of mu-opioid agonist DAMGO on surface CXCR4 and HIV-1 replication in TF-1 human bone marrow progenitor cells</article-title><source>BMC research notes</source><year>2014</year><volume>7</volume><fpage>752</fpage><?supplied-pmid 25338959?><pub-id pub-id-type="pmid">25338959</pub-id></element-citation></ref><ref id="CR490"><mixed-citation publication-type="other">Strazza M, Pirrone V, Wigdahl B, Dampier W, Lin W, Feng R, Maubert ME, Weksler B, Romero IA, Couraud PO, Nonnemacher MR (2016) Prolonged morphine exposure induces increased firm adhesion in an in vitro model of the blood-brain barrier. International journal of molecular sciences 17:916</mixed-citation></ref><ref id="CR491"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbe-Drger</surname><given-names>B</given-names></name><name><surname>Deppe</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>S</given-names></name><name><surname>Keller</surname><given-names>SS</given-names></name><name><surname>Kugel</surname><given-names>H</given-names></name><name><surname>Gregor</surname><given-names>N</given-names></name><name><surname>Evers</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Ringelstein</surname><given-names>EB</given-names></name><name><surname>Arendt</surname><given-names>G</given-names></name><name><surname>Knecht</surname><given-names>S</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name><name><surname>German Competence Network</surname><given-names>HA</given-names></name></person-group><article-title>Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study</article-title><source>BMC Neurol</source><year>2012</year><volume>12</volume><fpage>23</fpage><?supplied-pmid 22548835?><pub-id pub-id-type="pmid">22548835</pub-id></element-citation></ref><ref id="CR492"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturdevant</surname><given-names>CB</given-names></name><name><surname>Joseph</surname><given-names>SB</given-names></name><name><surname>Schnell</surname><given-names>G</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name><name><surname>Swanstrom</surname><given-names>R</given-names></name><name><surname>Spudich</surname><given-names>S</given-names></name></person-group><article-title>Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection</article-title><source>PLoS Pathog</source><year>2015</year><volume>11</volume><fpage>e1004720</fpage><?supplied-pmid 25811757?><pub-id pub-id-type="pmid">25811757</pub-id></element-citation></ref><ref id="CR493"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundar</surname><given-names>KS</given-names></name><name><surname>Kamaraju</surname><given-names>LS</given-names></name><name><surname>Dingfelder</surname><given-names>J</given-names></name><name><surname>McMahon</surname><given-names>J</given-names></name><name><surname>Gollapudi</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>WH</given-names></name><name><surname>Kong</surname><given-names>LY</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name><name><surname>Weiss</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name></person-group><article-title>&#x003b2;-Endorphin enhances the replication of neurotropic human immunodeficiency virus in fetal perivascular microglia</article-title><source>J Neuroimmunol</source><year>1995</year><volume>61</volume><fpage>97</fpage><lpage>104</lpage><?supplied-pmid 7560019?><pub-id pub-id-type="pmid">7560019</pub-id></element-citation></ref><ref id="CR494"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suomivuori</surname><given-names>CM</given-names></name><name><surname>Latorraca</surname><given-names>NR</given-names></name><name><surname>Wingler</surname><given-names>LM</given-names></name><name><surname>Eismann</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>MC</given-names></name><name><surname>Kleinhenz</surname><given-names>ALW</given-names></name><name><surname>Skiba</surname><given-names>MA</given-names></name><name><surname>Staus</surname><given-names>DP</given-names></name><name><surname>Kruse</surname><given-names>AC</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name></person-group><article-title>Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>881</fpage><lpage>887</lpage><?supplied-pmid 32079767?><pub-id pub-id-type="pmid">32079767</pub-id></element-citation></ref><ref id="CR495"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Chuang</surname><given-names>LF</given-names></name><name><surname>Yau</surname><given-names>P</given-names></name><name><surname>Doi</surname><given-names>RH</given-names></name><name><surname>Chuang</surname><given-names>RY</given-names></name></person-group><article-title>Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells</article-title><source>Exp Cell Res</source><year>2002</year><volume>280</volume><fpage>192</fpage><lpage>200</lpage><?supplied-pmid 12413885?><pub-id pub-id-type="pmid">12413885</pub-id></element-citation></ref><ref id="CR496"><mixed-citation publication-type="other">Suzuki M, El-Hage N, Zou S, Hahn YK, Sorrell ME, Sturgill JL, Conrad DH, Knapp PE, Hauser KF (2011) Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener 6:78</mixed-citation></ref><ref id="CR497"><mixed-citation publication-type="other">Swan N (1997) CDC report highlights link between drug abuse and spread of HIV. In: NIDA notes (AIDS research), 2 edition: NIDA <ext-link ext-link-type="uri" xlink:href="https://archives.drugabuse.gov/news-events/nida-notes/1997/04/cdc-report-highlights-link-between-drug-abuse-spread-hiv">https://archives.drugabuse.gov/news-events/nida-notes/1997/04/cdc-report-highlights-link-between-drug-abuse-spread-hiv</ext-link></mixed-citation></ref><ref id="CR498"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>I</given-names></name><name><surname>Wetzel</surname><given-names>MA</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Steele</surname><given-names>AD</given-names></name><name><surname>Kaminsky</surname><given-names>DE</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Liu-Chen</surname><given-names>LY</given-names></name><name><surname>Bednar</surname><given-names>F</given-names></name><name><surname>Henderson</surname><given-names>EE</given-names></name><name><surname>Howard</surname><given-names>OM</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name><name><surname>Rogers</surname><given-names>TJ</given-names></name></person-group><article-title>Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization</article-title><source>J Leukoc Biol</source><year>2003</year><volume>74</volume><fpage>1074</fpage><lpage>1082</lpage><?supplied-pmid 12972507?><pub-id pub-id-type="pmid">12972507</pub-id></element-citation></ref><ref id="CR499"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>CY</given-names></name><name><surname>Tang</surname><given-names>NL</given-names></name><name><surname>Lee</surname><given-names>DT</given-names></name><name><surname>Stadlin</surname><given-names>A</given-names></name></person-group><article-title>Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts</article-title><source>Neuroreport</source><year>2001</year><volume>12</volume><fpage>1103</fpage><lpage>1106</lpage><?supplied-pmid 11338173?><pub-id pub-id-type="pmid">11338173</pub-id></element-citation></ref><ref id="CR500"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Kashiwagi</surname><given-names>Y</given-names></name><name><surname>Patin</surname><given-names>DJ</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name></person-group><article-title>Spinal bromodomain-containing protein 4 contributes to neuropathic pain induced by HIV glycoprotein 120 with morphine in rats</article-title><source>Neuroreport</source><year>2018</year><volume>29</volume><fpage>441</fpage><lpage>446</lpage><?supplied-pmid 29465625?><pub-id pub-id-type="pmid">29465625</pub-id></element-citation></ref><ref id="CR501"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>S</given-names></name></person-group><article-title>Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV</article-title><source>Curr Opin HIV AIDS</source><year>2010</year><volume>5</volume><fpage>335</fpage><lpage>343</lpage><?supplied-pmid 20543610?><pub-id pub-id-type="pmid">20543610</pub-id></element-citation></ref><ref id="CR502"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Sobieszczyk</surname><given-names>ME</given-names></name><name><surname>McCutchan</surname><given-names>FE</given-names></name><name><surname>Hammer</surname><given-names>SM</given-names></name></person-group><article-title>The challenge of HIV-1 subtype diversity</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1590</fpage><lpage>1602</lpage><?supplied-pmid 18403767?><pub-id pub-id-type="pmid">18403767</pub-id></element-citation></ref><ref id="CR503"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terashvili</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>HE</given-names></name><name><surname>Schwasinger</surname><given-names>ET</given-names></name><name><surname>Hung</surname><given-names>KC</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name><name><surname>Tseng</surname><given-names>LF</given-names></name></person-group><article-title>(+)-morphine attenuates the (&#x02212;)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated dopamine increase in the posterior nucleus accumbens of the rat</article-title><source>Eur J Pharmacol</source><year>2008</year><volume>587</volume><fpage>147</fpage><lpage>154</lpage><?supplied-pmid 18448094?><pub-id pub-id-type="pmid">18448094</pub-id></element-citation></ref><ref id="CR504"><mixed-citation publication-type="other">Theberge FR, Li X, Kambhampati S, Pickens CL, St Laurent R, Bossert JM, Baumann MH, Hutchinson MR, Rice KC, Watkins LR, Shaham Y (2013) Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry 73:729&#x02013;737</mixed-citation></ref><ref id="CR505"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AR</given-names></name></person-group><article-title>Opioids and their proper use as analgesics in the management of head and neck cancer patients</article-title><source>Am J Otolaryngol</source><year>2000</year><volume>21</volume><fpage>244</fpage><lpage>254</lpage><?supplied-pmid 10937910?><pub-id pub-id-type="pmid">10937910</pub-id></element-citation></ref><ref id="CR506"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>GL</given-names></name><name><surname>Kelly</surname><given-names>E</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name><name><surname>Canals</surname><given-names>M</given-names></name></person-group><article-title>Novel GPCR paradigms at the mu-opioid receptor</article-title><source>Br J Pharmacol</source><year>2015</year><volume>172</volume><fpage>287</fpage><lpage>296</lpage><?supplied-pmid 24460711?><pub-id pub-id-type="pmid">24460711</pub-id></element-citation></ref><ref id="CR507"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>GS</given-names></name><name><surname>Simmonds</surname><given-names>P</given-names></name><name><surname>Busuttil</surname><given-names>A</given-names></name><name><surname>Chiswick</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>JE</given-names></name></person-group><article-title>Upregulation of microglia in drug users with and without pre-symptomatic HIV infection</article-title><source>Neuropathol Appl Neurobiol</source><year>1999</year><volume>25</volume><fpage>369</fpage><lpage>379</lpage><?supplied-pmid 10564526?><pub-id pub-id-type="pmid">10564526</pub-id></element-citation></ref><ref id="CR508"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornatore</surname><given-names>C</given-names></name><name><surname>Meyers</surname><given-names>K</given-names></name><name><surname>Atwood</surname><given-names>W</given-names></name><name><surname>Conant</surname><given-names>K</given-names></name><name><surname>Major</surname><given-names>E</given-names></name></person-group><article-title>Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes</article-title><source>J Virol</source><year>1994</year><volume>68</volume><fpage>93</fpage><lpage>102</lpage><?supplied-pmid 8254781?><pub-id pub-id-type="pmid">8254781</pub-id></element-citation></ref><ref id="CR509"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Munoz</surname><given-names>J</given-names></name><name><surname>Stockton</surname><given-names>P</given-names></name><name><surname>Tacoronte</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>B</given-names></name><name><surname>Maronpot</surname><given-names>RR</given-names></name><name><surname>Petito</surname><given-names>CK</given-names></name></person-group><article-title>Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection</article-title><source>J Neuropathol Exp Neurol</source><year>2001</year><volume>60</volume><fpage>885</fpage><lpage>892</lpage><?supplied-pmid 11556545?><pub-id pub-id-type="pmid">11556545</pub-id></element-citation></ref><ref id="CR510"><mixed-citation publication-type="other">Tran PB, Miller RJ (2005) HIV-1, chemokines and neurogenesis. Neurotox Res 8:149&#x02013;158</mixed-citation></ref><ref id="CR511"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trescot</surname><given-names>AM</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>H</given-names></name></person-group><article-title>Opioid pharmacology</article-title><source>Pain Physician</source><year>2008</year><volume>11</volume><fpage>S133</fpage><lpage>S153</lpage><?supplied-pmid 18443637?><pub-id pub-id-type="pmid">18443637</pub-id></element-citation></ref><ref id="CR512"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tryoen-Toth</surname><given-names>P</given-names></name><name><surname>Gaveriaux-Ruff</surname><given-names>C</given-names></name><name><surname>Labourdette</surname><given-names>G</given-names></name></person-group><article-title>Down-regulation of mu-opioid receptor expression in rat oligodendrocytes during their development in vitro</article-title><source>J Neurosci Res</source><year>2000</year><volume>60</volume><fpage>10</fpage><lpage>20</lpage><?supplied-pmid 10723064?><pub-id pub-id-type="pmid">10723064</pub-id></element-citation></ref><ref id="CR513"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchan-Cholewo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gartner</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>R</given-names></name><name><surname>Jie</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Chauhan</surname><given-names>A</given-names></name><name><surname>Haughey</surname><given-names>N</given-names></name><name><surname>Cutler</surname><given-names>R</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Pardo</surname><given-names>C</given-names></name><name><surname>Conant</surname><given-names>K</given-names></name><name><surname>Sacktor</surname><given-names>N</given-names></name><name><surname>McArthur</surname><given-names>JC</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Gairola</surname><given-names>C</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl</article-title><source>Neurobiol Dis</source><year>2006</year><volume>23</volume><fpage>109</fpage><lpage>119</lpage><?supplied-pmid 16697650?><pub-id pub-id-type="pmid">16697650</pub-id></element-citation></ref><ref id="CR514"><mixed-citation publication-type="other">Turchan-Cholewo J, Dimayuga FO, Ding Q, Keller JN, Hauser KF, Knapp PE, Bruce-Keller AJ (2008) Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 86:2100&#x02013;2110</mixed-citation></ref><ref id="CR515"><mixed-citation publication-type="other">Turchan-Cholewo J, Dimayuga FO, Gupta S, Keller JN, Knapp PE, Hauser KF, Bruce-Keller AJ (2009) Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 108:202&#x02013;215</mixed-citation></ref><ref id="CR516"><mixed-citation publication-type="other">Tyor W, Fritz-French C, Nath A (2013) Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neurovirol 19:515&#x02013;522</mixed-citation></ref><ref id="CR517"><mixed-citation publication-type="other">UNODC (2019a) Executive summary: Conclusions and policy implications. United Nations Office on Drugs and Crime (UNODC). <ext-link ext-link-type="uri" xlink:href="https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_1_EXECUTIVE_SUMMARY.pdf">https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_1_EXECUTIVE_SUMMARY.pdf</ext-link></mixed-citation></ref><ref id="CR518"><mixed-citation publication-type="other">UNODC (2019b). Depressants. United Nations Office on Drugs and Crime (UNODC). <ext-link ext-link-type="uri" xlink:href="https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_3_DEPRESSANTS.pdf">https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_3_DEPRESSANTS.pdf</ext-link></mixed-citation></ref><ref id="CR519"><mixed-citation publication-type="other">UNODC (2019c). Global overview of drug demand and supply. United Nations Office on Drugs and Crime (UNODC). <ext-link ext-link-type="uri" xlink:href="https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_DRUG_DEMAND.pdf">https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_DRUG_DEMAND.pdf</ext-link></mixed-citation></ref><ref id="CR520"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhyay</surname><given-names>J</given-names></name><name><surname>Maleki</surname><given-names>N</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Elman</surname><given-names>I</given-names></name><name><surname>Rudrauf</surname><given-names>D</given-names></name><name><surname>Knudsen</surname><given-names>J</given-names></name><name><surname>Wallin</surname><given-names>D</given-names></name><name><surname>Pendse</surname><given-names>G</given-names></name><name><surname>McDonald</surname><given-names>L</given-names></name><name><surname>Griffin</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Nutile</surname><given-names>L</given-names></name><name><surname>Renshaw</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Becerra</surname><given-names>L</given-names></name><name><surname>Borsook</surname><given-names>D</given-names></name></person-group><article-title>Alterations in brain structure and functional connectivity in prescription opioid-dependent patients</article-title><source>Brain</source><year>2010</year><volume>133</volume><fpage>2098</fpage><lpage>2114</lpage><?supplied-pmid 20558415?><pub-id pub-id-type="pmid">20558415</pub-id></element-citation></ref><ref id="CR521"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>NK</given-names></name><name><surname>Ribeiro</surname><given-names>RM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Modeling the effects of morphine on simian immunodeficiency virus dynamics</article-title><source>PLoS Comput Biol</source><year>2016</year><volume>12</volume><fpage>e1005127</fpage><?supplied-pmid 27668463?><pub-id pub-id-type="pmid">27668463</pub-id></element-citation></ref><ref id="CR522"><mixed-citation publication-type="other">van Rij RP, Portegies P, Hallaby T, Lange JM, Visser J, de Roda Husman AM, van 't Wout AB, Schuitemaker H (1999) Reduced prevalence of the CCR5 &#x00394;32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis 180:854&#x02013;857</mixed-citation></ref><ref id="CR523"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veenhuis</surname><given-names>RT</given-names></name><name><surname>Clements</surname><given-names>JE</given-names></name><name><surname>Gama</surname><given-names>L</given-names></name></person-group><article-title>HIV eradication strategies: implications for the central nervous system</article-title><source>Curr HIV/AIDS Rep</source><year>2019</year><volume>16</volume><fpage>96</fpage><lpage>104</lpage><?supplied-pmid 30734905?><pub-id pub-id-type="pmid">30734905</pub-id></element-citation></ref><ref id="CR524"><mixed-citation publication-type="other">Venkatesan A, Nath A, Ming GL, Song H (2007) Adult hippocampal neurogenesis: regulation by HIV and drugs of abuse. Cellular and molecular life sciences 64:2120&#x02013;2132</mixed-citation></ref><ref id="CR525"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venuto</surname><given-names>CS</given-names></name><name><surname>Mollan</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Daar</surname><given-names>ES</given-names></name><name><surname>Sax</surname><given-names>PE</given-names></name><name><surname>Fischl</surname><given-names>M</given-names></name><name><surname>Collier</surname><given-names>AC</given-names></name><name><surname>Smith</surname><given-names>KY</given-names></name><name><surname>Tierney</surname><given-names>C</given-names></name><name><surname>Morse</surname><given-names>GD</given-names></name></person-group><article-title>Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group study A5202</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><fpage>3300</fpage><lpage>3310</lpage><?supplied-pmid 25159623?><pub-id pub-id-type="pmid">25159623</pub-id></element-citation></ref><ref id="CR526"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestal-Laborde</surname><given-names>AA</given-names></name><name><surname>Eschenroeder</surname><given-names>AC</given-names></name><name><surname>Bigbee</surname><given-names>JW</given-names></name><name><surname>Robinson</surname><given-names>SE</given-names></name><name><surname>Sato-Bigbee</surname><given-names>C</given-names></name></person-group><article-title>The opioid system and brain development: effects of methadone on the oligodendrocyte lineage and the early stages of myelination</article-title><source>Dev Neurosci</source><year>2014</year><volume>36</volume><fpage>409</fpage><lpage>421</lpage><?supplied-pmid 25138998?><pub-id pub-id-type="pmid">25138998</pub-id></element-citation></ref><ref id="CR527"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilijn</surname><given-names>MH</given-names></name><name><surname>Vaysse</surname><given-names>PJ</given-names></name><name><surname>Zukin</surname><given-names>RS</given-names></name><name><surname>Kessler</surname><given-names>JA</given-names></name></person-group><article-title>Expression of preproenkephalin mRNA by cultured astrocytes and neurons</article-title><source>Proc Natl Acad Sci U S A</source><year>1988</year><volume>85</volume><fpage>6551</fpage><lpage>6555</lpage><?supplied-pmid 3413111?><pub-id pub-id-type="pmid">3413111</pub-id></element-citation></ref><ref id="CR528"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Violin</surname><given-names>JD</given-names></name><name><surname>Crombie</surname><given-names>AL</given-names></name><name><surname>Soergel</surname><given-names>DG</given-names></name><name><surname>Lark</surname><given-names>MW</given-names></name></person-group><article-title>Biased ligands at G-protein-coupled receptors: promise and progress</article-title><source>Trends Pharmacol Sci</source><year>2014</year><volume>35</volume><fpage>308</fpage><lpage>316</lpage><?supplied-pmid 24878326?><pub-id pub-id-type="pmid">24878326</pub-id></element-citation></ref><ref id="CR529"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Morales</surname><given-names>M</given-names></name></person-group><article-title>The brain on drugs: from reward to addiction</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>712</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">26276628</pub-id></element-citation></ref><ref id="CR530"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Frieden</surname><given-names>TR</given-names></name><name><surname>Hyde</surname><given-names>PS</given-names></name><name><surname>Cha</surname><given-names>SS</given-names></name></person-group><article-title>Medication-assisted therapies--tackling the opioid-overdose epidemic</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>2063</fpage><lpage>2066</lpage><?supplied-pmid 24758595?><pub-id pub-id-type="pmid">24758595</pub-id></element-citation></ref><ref id="CR531"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>C</given-names></name><name><surname>Van Uum</surname><given-names>SH</given-names></name><name><surname>O'Dell</surname><given-names>LE</given-names></name><name><surname>Lutfy</surname><given-names>K</given-names></name><name><surname>Friedman</surname><given-names>TC</given-names></name></person-group><article-title>The effects of opioids and opioid analogs on animal and human endocrine systems</article-title><source>Endocr Rev</source><year>2010</year><volume>31</volume><fpage>98</fpage><lpage>132</lpage><?supplied-pmid 19903933?><pub-id pub-id-type="pmid">19903933</pub-id></element-citation></ref><ref id="CR532"><mixed-citation publication-type="other">Wakeman SE, Green TC, Rich J (2020) An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med 26(6):819&#x02013;820</mixed-citation></ref><ref id="CR533"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>DR</given-names></name><name><surname>Dodson</surname><given-names>SL</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Booze</surname><given-names>RM</given-names></name></person-group><article-title>Delta opioid agonists attenuate TAT(1-72)-induced oxidative stress in SK-N-SH cells</article-title><source>Neurotoxicology</source><year>2006</year><volume>27</volume><fpage>101</fpage><lpage>107</lpage><?supplied-pmid 16168488?><pub-id pub-id-type="pmid">16168488</pub-id></element-citation></ref><ref id="CR534"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>SL</given-names></name><name><surname>Preston</surname><given-names>KL</given-names></name><name><surname>Stitzer</surname><given-names>ML</given-names></name><name><surname>Cone</surname><given-names>EJ</given-names></name><name><surname>Bigelow</surname><given-names>GE</given-names></name></person-group><article-title>Clinical pharmacology of buprenorphine: ceiling effects at high doses</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>55</volume><fpage>569</fpage><lpage>580</lpage><?supplied-pmid 8181201?><pub-id pub-id-type="pmid">8181201</pub-id></element-citation></ref><ref id="CR535"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Ernst</surname><given-names>T</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name></person-group><article-title>Decreased brain dopaminergic transporters in HIV-associated dementia patients</article-title><source>Brain</source><year>2004</year><volume>127</volume><fpage>2452</fpage><lpage>2458</lpage><?supplied-pmid 15319273?><pub-id pub-id-type="pmid">15319273</pub-id></element-citation></ref><ref id="CR536"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Loram</surname><given-names>LC</given-names></name><name><surname>Ramos</surname><given-names>K</given-names></name><name><surname>de Jesus</surname><given-names>AJ</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>A</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Morphine activates neuroinflammation in a manner parallel to endotoxin</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><fpage>6325</fpage><lpage>6330</lpage><?supplied-pmid 22474354?><pub-id pub-id-type="pmid">22474354</pub-id></element-citation></ref><ref id="CR537"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name></person-group><article-title>Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e21707</fpage><?supplied-pmid 21738771?><pub-id pub-id-type="pmid">21738771</pub-id></element-citation></ref><ref id="CR538"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>PJ</given-names></name><name><surname>Remski</surname><given-names>K</given-names></name></person-group><article-title>Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds</article-title><source>J Neurosci Rural Pract</source><year>2012</year><volume>3</volume><fpage>45</fpage><lpage>50</lpage><?supplied-pmid 22346191?><pub-id pub-id-type="pmid">22346191</pub-id></element-citation></ref><ref id="CR539"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DW</given-names></name><name><surname>Calderon</surname><given-names>TM</given-names></name><name><surname>Lopez</surname><given-names>L</given-names></name><name><surname>Carvallo-Torres</surname><given-names>L</given-names></name><name><surname>Gaskill</surname><given-names>PJ</given-names></name><name><surname>Eugenin</surname><given-names>EA</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e69270</fpage><?supplied-pmid 23922698?><pub-id pub-id-type="pmid">23922698</pub-id></element-citation></ref><ref id="CR540"><mixed-citation publication-type="other">Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013b) Regulation of &#x003bc;-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223&#x02013;254</mixed-citation></ref><ref id="CR541"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DW</given-names></name><name><surname>Veenstra</surname><given-names>M</given-names></name><name><surname>Gaskill</surname><given-names>PJ</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Calderon</surname><given-names>TM</given-names></name><name><surname>Berman</surname><given-names>JW</given-names></name></person-group><article-title>Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders</article-title><source>Curr HIV Res</source><year>2014</year><volume>12</volume><fpage>85</fpage><lpage>96</lpage><?supplied-pmid 24862333?><pub-id pub-id-type="pmid">24862333</pub-id></element-citation></ref><ref id="CR542"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE study, hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco City Cohort (SFCC)</article-title><source>Science</source><year>1998</year><volume>279</volume><fpage>389</fpage><lpage>393</lpage><?supplied-pmid 9430590?><pub-id pub-id-type="pmid">9430590</pub-id></element-citation></ref><ref id="CR543"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlschlaeger</surname><given-names>J</given-names></name><name><surname>Wenger</surname><given-names>E</given-names></name><name><surname>Mehraein</surname><given-names>P</given-names></name><name><surname>Weis</surname><given-names>S</given-names></name></person-group><article-title>White matter changes in HIV-1 infected brains: a combined gross anatomical and ultrastructural morphometric investigation of the corpus callosum</article-title><source>Clin Neurol Neurosurg</source><year>2009</year><volume>111</volume><fpage>422</fpage><lpage>429</lpage><?supplied-pmid 19185416?><pub-id pub-id-type="pmid">19185416</pub-id></element-citation></ref><ref id="CR544"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollman</surname><given-names>SC</given-names></name><name><surname>Hauson</surname><given-names>AO</given-names></name><name><surname>Hall</surname><given-names>MG</given-names></name><name><surname>Connors</surname><given-names>EJ</given-names></name><name><surname>Allen</surname><given-names>KE</given-names></name><name><surname>Stern</surname><given-names>MJ</given-names></name><name><surname>Stephan</surname><given-names>RA</given-names></name><name><surname>Kimmel</surname><given-names>CL</given-names></name><name><surname>Sarkissians</surname><given-names>S</given-names></name><name><surname>Barlet</surname><given-names>BD</given-names></name><name><surname>Flora-Tostado</surname><given-names>C</given-names></name></person-group><article-title>Neuropsychological functioning in opioid use disorder: a research synthesis and meta-analysis</article-title><source>Am J Drug Alcohol Abuse</source><year>2019</year><volume>45</volume><fpage>11</fpage><lpage>25</lpage><?supplied-pmid 30359116?><pub-id pub-id-type="pmid">30359116</pub-id></element-citation></ref><ref id="CR545"><mixed-citation publication-type="other">Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW (2000) Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 6(Suppl 1):S82&#x02013;S85</mixed-citation></ref><ref id="CR546"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Storey</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>BA</given-names></name><name><surname>Epstein</surname><given-names>LG</given-names></name><name><surname>Edelman</surname><given-names>RR</given-names></name><name><surname>Ragin</surname><given-names>AB</given-names></name></person-group><article-title>Diffusion alterations in corpus callosum of patients with HIV</article-title><source>AJNR Am J Neuroradiol</source><year>2006</year><volume>27</volume><fpage>656</fpage><lpage>660</lpage><?supplied-pmid 16552012?><pub-id pub-id-type="pmid">16552012</pub-id></element-citation></ref><ref id="CR547"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HY</given-names></name><name><surname>Tang</surname><given-names>XQ</given-names></name><name><surname>Mao</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>YX</given-names></name></person-group><article-title>Autocrine Interleukin-10 mediates glucagon-like Peptide-1 receptor-induced spinal microglial &#x003b2;-endorphin expression</article-title><source>J Neurosci</source><year>2017</year><volume>37</volume><fpage>11701</fpage><lpage>11714</lpage><?supplied-pmid 29084866?><pub-id pub-id-type="pmid">29084866</pub-id></element-citation></ref><ref id="CR548"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wybran</surname><given-names>J</given-names></name><name><surname>Appelboom</surname><given-names>T</given-names></name><name><surname>Famaey</surname><given-names>JP</given-names></name><name><surname>Govaerts</surname><given-names>A</given-names></name></person-group><article-title>Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes</article-title><source>J Immunol</source><year>1979</year><volume>123</volume><fpage>1068</fpage><lpage>1070</lpage><?supplied-pmid 224107?><pub-id pub-id-type="pmid">224107</pub-id></element-citation></ref><ref id="CR549"><mixed-citation publication-type="other">Xu C, Fitting S (2016) Inhibition of GABAergic neurotransmission by HIV-1 Tat and opioid treatment in the striatum involves &#x003bc;-opioid receptors. Front Neurosci 10:497</mixed-citation></ref><ref id="CR550"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>HIV-1 tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9</article-title><source>Brain Res</source><year>2012</year><volume>1436</volume><fpage>13</fpage><lpage>19</lpage><?supplied-pmid 22197032?><pub-id pub-id-type="pmid">22197032</pub-id></element-citation></ref><ref id="CR551"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Bolan</surname><given-names>E</given-names></name><name><surname>Gilbert</surname><given-names>AK</given-names></name><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Pan</surname><given-names>YX</given-names></name></person-group><article-title>Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1P</article-title><source>Synapse</source><year>2014</year><volume>68</volume><fpage>144</fpage><lpage>152</lpage><?supplied-pmid 24375714?><pub-id pub-id-type="pmid">24375714</pub-id></element-citation></ref><ref id="CR552"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>YX</given-names></name></person-group><article-title>A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene <italic>OPRM1</italic> via hnRNPH interactions</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>11048</fpage><lpage>11066</lpage><?supplied-pmid 25122903?><pub-id pub-id-type="pmid">25122903</pub-id></element-citation></ref><ref id="CR553"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>AH</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>CD</given-names></name></person-group><article-title>Exogenous brain-derived neurotrophic factor attenuates cognitive impairment induced by okadaic acid in a rat model of Alzheimer's disease</article-title><source>Neural Regen Res</source><year>2018</year><volume>13</volume><fpage>2173</fpage><lpage>2181</lpage><?supplied-pmid 30323150?><pub-id pub-id-type="pmid">30323150</pub-id></element-citation></ref><ref id="CR554"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>GB</given-names></name><name><surname>Shi</surname><given-names>DP</given-names></name><name><surname>Xu</surname><given-names>JL</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name></person-group><article-title>Initial study of magnetic resonance diffusion tensor imaging in brain white matter of early AIDS patients</article-title><source>Chin Med J</source><year>2013</year><volume>126</volume><fpage>2720</fpage><lpage>2724</lpage><?supplied-pmid 23876903?><pub-id pub-id-type="pmid">23876903</pub-id></element-citation></ref><ref id="CR555"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousif</surname><given-names>S</given-names></name><name><surname>Saubamea</surname><given-names>B</given-names></name><name><surname>Cisternino</surname><given-names>S</given-names></name><name><surname>Marie-Claire</surname><given-names>C</given-names></name><name><surname>Dauchy</surname><given-names>S</given-names></name><name><surname>Scherrmann</surname><given-names>JM</given-names></name><name><surname>Decleves</surname><given-names>X</given-names></name></person-group><article-title>Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein</article-title><source>J Neurochem</source><year>2008</year><volume>107</volume><fpage>647</fpage><lpage>657</lpage><?supplied-pmid 18761714?><pub-id pub-id-type="pmid">18761714</pub-id></element-citation></ref><ref id="CR556"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousif</surname><given-names>S</given-names></name><name><surname>Chaves</surname><given-names>C</given-names></name><name><surname>Potin</surname><given-names>S</given-names></name><name><surname>Margaill</surname><given-names>I</given-names></name><name><surname>Scherrmann</surname><given-names>JM</given-names></name><name><surname>Decleves</surname><given-names>X</given-names></name></person-group><article-title>Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation</article-title><source>J Neurochem</source><year>2012</year><volume>123</volume><fpage>491</fpage><lpage>503</lpage><?supplied-pmid 22845665?><pub-id pub-id-type="pmid">22845665</pub-id></element-citation></ref><ref id="CR557"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Arnatt</surname><given-names>CK</given-names></name><name><surname>El-Hage</surname><given-names>N</given-names></name><name><surname>Dever</surname><given-names>SM</given-names></name><name><surname>Jacob</surname><given-names>JC</given-names></name><name><surname>Selley</surname><given-names>DE</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>A bivalent ligand targeting the putative &#x003bc; opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities</article-title><source>MedChemComm</source><year>2013</year><volume>4</volume><fpage>847</fpage><lpage>851</lpage><?supplied-pmid 23682308?><pub-id pub-id-type="pmid">23682308</pub-id></element-citation></ref><ref id="CR558"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuferov</surname><given-names>V</given-names></name><name><surname>Butelman</surname><given-names>ER</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Morgello</surname><given-names>S</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Neurocognitive and neuroinflammatory correlates of PDYN and OPRK1 mRNA expression in the anterior cingulate in postmortem brain of HIV-infected subjects</article-title><source>J Neuroinflammation</source><year>2014</year><volume>11</volume><fpage>5</fpage><?supplied-pmid 24405578?><pub-id pub-id-type="pmid">24405578</pub-id></element-citation></ref><ref id="CR559"><mixed-citation publication-type="other">Zhu C, Han Q, Samoshkin A, Convertino M, Linton A, Faison EM, Ji RR, Diatchenko L, Dokholyan NV (2019) Stabilization of &#x003bc;-opioid receptor facilitates its cellular translocation and signaling. Proteins 87:878&#x02013;884</mixed-citation></ref><ref id="CR560"><mixed-citation publication-type="other">Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE (2011) Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at &#x003bc;-opioid receptor-expressing glia. Brain 134:3613&#x02013;3628</mixed-citation></ref><ref id="CR561"><mixed-citation publication-type="other">Zou S, Fuss B, Fitting S, Hahn YK, Hauser KF, Knapp PE (2015) Oligodendrocytes are targets of HIV-1 Tat: NMDA and AMPA receptor-mediated effects on survival and development. J Neurosci 35:11384&#x02013;11398</mixed-citation></ref><ref id="CR562"><mixed-citation publication-type="other">Zou S, Balinang JM, Paris JJ, Hauser KF, Fuss B, Knapp PE (2019) Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKII&#x003b2;-GSK3&#x003b2; interactions. J Neurochem 149:98&#x02013;110</mixed-citation></ref><ref id="CR563"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zubieta</surname><given-names>JK</given-names></name><name><surname>Smith</surname><given-names>YR</given-names></name><name><surname>Bueller</surname><given-names>JA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Kilbourn</surname><given-names>MR</given-names></name><name><surname>Jewett</surname><given-names>DM</given-names></name><name><surname>Meyer</surname><given-names>CR</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Stohler</surname><given-names>CS</given-names></name></person-group><article-title>Mu-opioid receptor-mediated antinociceptive responses differ in men and women</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><fpage>5100</fpage><lpage>5107</lpage><?supplied-pmid 12077205?><pub-id pub-id-type="pmid">12077205</pub-id></element-citation></ref></ref-list></back></article>